<!doctype html>
<html>
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width,initial-scale=1,viewport-fit=cover">
  <title>APEX & Trust Prototype</title>
  <link rel="stylesheet" href="../../apex_trust_panel.css">
  <style>
    @keyframes ticker {
      0% { transform: translateX(0); }
      100% { transform: translateX(-50%); }
    }
    @media (max-width: 768px) {
      #scorecard-ticker { animation: ticker 15s linear infinite; }
    }
  </style>
</head>
<body>
  <!-- CONSOLIDATED STICKY HEADER BLOCK -->
  <div style="position: sticky; top: 0; z-index: 9999; margin: 0; padding: 0; width: 100%; overflow: hidden;">
    
    <!-- Page Header -->
    <div style="background: rgb(26, 35, 54); padding: 0.3rem 1.5rem; margin: 0; border-bottom: 1px solid rgba(10, 132, 255, 0.2);">
      <div style="display: flex; align-items: center; gap: 16px;">
        <div style="font-size: 18px; font-weight: 700; color: white;">üî•APEX Intelligence Terminal</div>
      </div>
    </div>

    <!-- Stock Info Header -->
    <div id="stock-info-header" style="margin: 0; padding: 0;">
      <!-- COMPANY INFO HEADER -->
      <div style="display: flex; align-items: center; justify-content: space-between; gap: 0.75rem; background: rgb(26, 35, 54); box-shadow: 0 2px 8px rgba(0,0,0,0.3); border-bottom: 1px solid rgba(10, 132, 255, 0.4); padding: 0.6rem 1.5rem; margin: 0; width: 100%; position: relative; border-radius: 8px 8px 0 0;">
        <div style="display: flex; align-items: center; justify-content: space-between; gap: 0.6rem; width: 100%; overflow: hidden;">
          <!-- Ticker & Company Name (Left) -->
          <div style="flex: 1 1 auto; min-width: 100px; max-width: 180px;">
            <div id="header-ticker" style="color: white; font-size: 0.95rem; font-weight: 800; letter-spacing: 0.5px;">--</div>
            <div id="header-company" style="color: rgba(255,255,255,0.6); font-size: 0.65rem; line-height: 1; margin-top: 1px; white-space: nowrap; overflow: hidden; text-overflow: ellipsis;">--</div>
          </div>
          
          <!-- Key Metrics (Center) - 3 columns -->
          <div style="display: flex; gap: 0.5rem; align-items: center; flex: 2 1 auto; overflow: hidden;">
            <!-- Current Price (with currency) -->
            <div style="text-align: center; min-width: 60px; flex-shrink: 0;">
              <div style="color: rgba(255,255,255,0.5); font-size: 0.6rem; text-transform: uppercase; letter-spacing: 0.3px; line-height: 1;">
                Price <span id="header-currency" style="color: #f59e0b; font-size: 0.5rem; font-weight: 600;">--</span>
              </div>
              <div id="header-price" style="color: white; font-size: 0.85rem; font-weight: 800; line-height: 1.1; margin-top: 1px;">--</div>
            </div>
            
            <!-- Market Cap -->
            <div style="text-align: center; min-width: 55px; flex-shrink: 0;">
              <div style="color: rgba(255,255,255,0.5); font-size: 0.6rem; text-transform: uppercase; letter-spacing: 0.3px; line-height: 1;">Cap</div>
              <div id="header-mcap" style="color: #10b981; font-size: 0.85rem; font-weight: 800; line-height: 1.1; margin-top: 1px;">--</div>
            </div>
            
            <!-- Exchange (combined Market + Exchange) -->
            <div style="text-align: center; min-width: 60px; flex-shrink: 0;">
              <div style="color: rgba(255,255,255,0.5); font-size: 0.6rem; text-transform: uppercase; letter-spacing: 0.3px; line-height: 1;">Exchange</div>
              <div id="header-exchange" style="font-size: 0.75rem; font-weight: 700; line-height: 1.1; margin-top: 1px;">--</div>
            </div>
          </div>
        </div>
      </div>
      
      <!-- Details Row -->
      <div style="display: flex; gap: 1.5rem; font-size: 0.65rem; background: rgb(26, 35, 54); box-shadow: 0 2px 6px rgba(0,0,0,0.2); border-bottom: 1px solid rgba(10, 132, 255, 0.2); padding: 0.35rem 1.5rem 0.4rem 1.5rem; margin: 0; text-align: left; border-radius: 0 0 8px 8px;">
        <div style="display: flex; align-items: center; gap: 0.4rem; min-width: 100px;">
          <span style="color: #667eea; font-size: 0.6rem; text-transform: uppercase; letter-spacing: 0.4px; font-weight: 500; flex-shrink: 0;">Sector:</span>
          <span id="header-sector" style="color: white; font-weight: 700; font-size: 0.7rem; white-space: nowrap; overflow: hidden; text-overflow: ellipsis;">--</span>
        </div>
        <div style="display: flex; align-items: center; gap: 0.4rem; flex: 1; overflow: hidden;">
          <span style="color: #667eea; font-size: 0.6rem; text-transform: uppercase; letter-spacing: 0.4px; font-weight: 500; flex-shrink: 0;">Ind:</span>
          <span id="header-industry" style="color: white; font-weight: 700; font-size: 0.7rem; white-space: nowrap; overflow: hidden; text-overflow: ellipsis;">--</span>
        </div>
      </div>
    </div>

    <!-- Bloomberg Scorecard Ticker -->
    <div style="background: rgb(26, 35, 54); border-left: 3px solid #0a84ff; padding: 0.5rem 0; margin: 0; font-family: 'Courier New', monospace; font-size: 13px; letter-spacing: 0.5px; box-shadow: 0 2px 4px rgba(0,0,0,0.2); overflow: hidden; width: 100%;">
      <div id="scorecard-ticker" style="display: flex; white-space: nowrap; animation: ticker 20s linear infinite; width: max-content;">
        <div class="ticker-content" style="display: flex; align-items: center; gap: 1.5rem; padding: 0 1.5rem; flex-shrink: 0;">
          <span style="color: rgba(255,255,255,0.6); font-size: 11px; text-transform: uppercase; font-weight: 600;">SCORECARD</span>
          <span id="scorecard-apex" style="background: #10b981; color: white; padding: 6px 12px; border-radius: 6px; font-weight: 700; font-size: 13px;">APEX SCORE:--</span>
          <span id="scorecard-setup" style="color: #3B82F6; font-weight: 700;">SETUP:--</span>
          <span id="scorecard-trust" style="color: #8B5CF6; font-weight: 700;">TRUST:--</span>
          <span id="scorecard-panic" style="color: #EF4444; font-weight: 700;">PANIC:--</span>
          <span id="scorecard-comp" style="color: #F59E0B; font-weight: 700;">COMPRESSION:--</span>
          <span style="color: rgba(255,255,255,0.3); font-weight: 400;">‚îÇ</span>
          <span id="scorecard-timing" style="color: #3b82f6; font-weight: 700;">TIMING:--</span>
          <span style="color: rgba(255,255,255,0.3); font-weight: 400;">‚îÇ</span>
          <span id="scorecard-action" style="color: #ef4444; font-weight: 700;">ACTION:--</span>
        </div>
      </div>
    </div>
  </div>

  <div class="container">
    <!-- Narrative Section Header -->
    <div style="display: flex; align-items: center; gap: 12px; margin: 20px 0 12px 0;">
      <svg width="20" height="20" viewBox="0 0 20 20" fill="none" style="flex-shrink: 0;">
        <rect x="2" y="4" width="16" height="12" stroke="#10B981" stroke-width="1.5" fill="none" rx="2"/>
        <line x1="5" y1="4" x2="5" y2="2" stroke="#10B981" stroke-width="1.5" stroke-linecap="round"/>
        <line x1="15" y1="4" x2="15" y2="2" stroke="#10B981" stroke-width="1.5" stroke-linecap="round"/>
        <line x1="2" y1="7" x2="18" y2="7" stroke="#10B981" stroke-width="1.5"/>
        <circle cx="8" cy="11" r="1.2" fill="#10B981"/>
        <circle cx="12" cy="11" r="1.2" fill="#10B981"/>
        <circle cx="16" cy="11" r="1.2" fill="#10B981"/>
      </svg>
      <span style="color: #10B981; font-weight: 700; font-size: 13px; text-transform: uppercase; letter-spacing: 0.8px;">Company in 30 Seconds</span>
    </div>

    <!-- Narrative Card Stack -->
    <div class="card-stack" id="narrative-stack" style="position: relative; min-height: 180px; overflow: visible; touch-action: pan-y; user-select: none; margin-bottom: 30px;">
      <!-- Card 1: What They Do -->
      <div class="card component-card stack-card narrative-card" data-index="0" style="transition: 0.3s cubic-bezier(0.4, 0, 0.2, 1); transform: translateX(0%) scale(1); opacity: 1; pointer-events: auto; z-index: 10;">
        <div class="panel-header" style="padding:12px;border-bottom:1px solid rgba(16,185,129,0.1);display:flex;align-items:center;gap:10px">
          <svg width="18" height="18" viewBox="0 0 16 16" fill="none" style="flex-shrink:0">
            <rect x="3" y="3" width="10" height="10" stroke="#10B981" stroke-width="1.5" fill="none" rx="1"/>
            <path d="M6 3 L6 1 M10 3 L10 1 M3 6 L13 6" stroke="#10B981" stroke-width="1.5" stroke-linecap="round"/>
            <circle cx="8" cy="9" r="1.5" fill="#10B981"/>
          </svg>
          <div class="card-title" style="font-size:16px;font-weight:800;color:#10B981">What They Do <span class="info-icon" data-field="what" data-tooltip="Company business model and core operations" style="cursor:pointer;opacity:0.6;font-size:14px;transition:all 0.2s ease" onmouseenter="this.style.opacity='1'" onmouseleave="this.style.opacity='0.6'" onclick="showTooltipPopover(event, 'Company business model and core operations')">‚ìò</span></div>
        </div>
        <div style="padding:12px">
          <span id="company-what" style="color: #e5e7eb; line-height: 1.6; font-size: 12px;">--</span>
        </div>
      </div>

      <!-- Card 2: Why It Matters -->
      <div class="card component-card stack-card narrative-card" data-index="1" style="transition: 0.3s cubic-bezier(0.4, 0, 0.2, 1); transform: translateX(100%) scale(0.95); opacity: 0; pointer-events: none; z-index: 5;">
        <div class="panel-header" style="padding:12px;border-bottom:1px solid rgba(16,185,129,0.1);display:flex;align-items:center;gap:10px">
          <svg width="18" height="18" viewBox="0 0 16 16" fill="none" style="flex-shrink:0">
            <circle cx="8" cy="8" r="6" stroke="#10B981" stroke-width="1.5" fill="none"/>
            <circle cx="8" cy="8" r="2" fill="#10B981"/>
            <path d="M8 2 L8 6 M8 10 L8 14 M2 8 L6 8 M10 8 L14 8" stroke="#10B981" stroke-width="1.5" stroke-linecap="round"/>
          </svg>
          <div class="card-title" style="font-size:16px;font-weight:800;color:#10B981">Why It Matters <span class="info-icon" data-field="why" data-tooltip="Market significance and investment thesis" style="cursor:pointer;opacity:0.6;font-size:14px;transition:all 0.2s ease" onmouseenter="this.style.opacity='1'" onmouseleave="this.style.opacity='0.6'" onclick="showTooltipPopover(event, 'Market significance and investment thesis')">‚ìò</span></div>
        </div>
        <div style="padding:12px">
          <span id="company-why" style="color: #e5e7eb; line-height: 1.6; font-size: 12px;">--</span>
        </div>
      </div>

      <!-- Card 3: Current State -->
      <div class="card component-card stack-card narrative-card" data-index="2" style="transition: 0.3s cubic-bezier(0.4, 0, 0.2, 1); transform: translateX(100%) scale(0.95); opacity: 0; pointer-events: none; z-index: 5;">
        <div class="panel-header" style="padding:12px;border-bottom:1px solid rgba(16,185,129,0.1);display:flex;align-items:center;gap:10px">
          <svg width="18" height="18" viewBox="0 0 16 16" fill="none" style="flex-shrink:0">
            <path d="M2 12 L5 9 L8 11 L14 4" stroke="#10B981" stroke-width="1.5" stroke-linecap="round" stroke-linejoin="round" fill="none"/>
            <circle cx="5" cy="9" r="1.5" fill="#10B981"/>
            <circle cx="8" cy="11" r="1.5" fill="#10B981"/>
            <circle cx="14" cy="4" r="1.5" fill="#10B981"/>
          </svg>
          <div class="card-title" style="font-size:16px;font-weight:800;color:#10B981">Current State <span class="info-icon" data-field="state" data-tooltip="Latest company situation and metrics" style="cursor:pointer;opacity:0.6;font-size:14px;transition:all 0.2s ease" onmouseenter="this.style.opacity='1'" onmouseleave="this.style.opacity='0.6'" onclick="showTooltipPopover(event, 'Latest company situation and metrics')">‚ìò</span></div>
        </div>
        <div style="padding:12px">
          <span id="company-state" style="color: #e5e7eb; line-height: 1.6; font-size: 12px;">--</span>
        </div>
      </div>

      <!-- Narrative Stack Navigation -->
      <div class="stack-nav" style="bottom: -35px;">
        <div class="stack-dots">
          <span class="stack-dot narrative-dot" data-index="0"></span>
          <span class="stack-dot narrative-dot" data-index="1"></span>
          <span class="stack-dot narrative-dot" data-index="2"></span>
        </div>
        <div class="stack-label" style="color: #10B981;">Company</div>
      </div>
    </div>

    <!-- Scorecard Breakdown Section Header -->
    <div style="display: flex; align-items: center; gap: 12px; margin: 20px 0 12px 0;">
      <svg width="20" height="20" viewBox="0 0 20 20" fill="none" style="flex-shrink: 0;">
        <rect x="2" y="6" width="3" height="12" rx="1" stroke="#fff" stroke-width="1.5" fill="none"/>
        <rect x="7" y="3" width="3" height="15" rx="1" stroke="#fff" stroke-width="1.5" fill="none"/>
        <rect x="12" y="8" width="3" height="10" rx="1" stroke="#fff" stroke-width="1.5" fill="none"/>
        <rect x="17" y="5" width="1" height="13" rx="0.5" stroke="#fff" stroke-width="1.5" fill="none"/>
        <circle cx="10" cy="1" r="1.5" fill="#fff"/>
      </svg>
      <span style="color: #fff; font-weight: 700; font-size: 13px; text-transform: uppercase; letter-spacing: 0.8px;">Scorecard Breakdown</span>
    </div>

    <!-- Main swipeable cards -->
    <div id="component-grid"></div>

    <!-- Bloomberg Phase 2: Collapsible Sections -->
    <div class="bloomberg-sections" style="margin-top: 20px;">
      <!-- CrashDash Intelligence -->
      <div class="bloomberg-section" style="background: rgb(26, 35, 54); border: 1px solid #374151; border-radius: 8px; margin-bottom: 12px; overflow: hidden;">
        <div class="section-header" onclick="toggleSection('crashdash')" style="padding: 12px 16px; cursor: pointer; display: flex; justify-content: space-between; align-items: center; background: rgba(59, 130, 246, 0.1); border-bottom: 1px solid #374151;">
          <div style="display: flex; align-items: center; gap: 12px;">
            <span id="crashdash-arrow" style="color: #3b82f6; font-size: 16px; transition: transform 0.2s;">‚ñ∂</span>
            <span style="font-family: 'Courier New', monospace; font-size: 13px; font-weight: 700; color: #3b82f6; text-transform: uppercase; letter-spacing: 0.5px;">CrashDash Intelligence</span>
          </div>
          <span style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.5);">INDUSTRY PATTERNS ¬∑ RECOVERY PATHS</span>
        </div>
        <div id="crashdash-content" class="section-content" style="display: none; padding: 16px; font-family: 'Courier New', monospace; font-size: 12px; line-height: 1.6;">
          <div id="crashdash-data">Loading...</div>
        </div>
      </div>

      <!-- Catalyst Pipeline -->
      <div class="bloomberg-section" style="background: rgb(26, 35, 54); border: 1px solid #374151; border-radius: 8px; margin-bottom: 12px; overflow: hidden;">
        <div class="section-header" onclick="toggleSection('catalyst')" style="padding: 12px 16px; cursor: pointer; display: flex; justify-content: space-between; align-items: center; background: rgba(16, 185, 129, 0.1); border-bottom: 1px solid #374151;">
          <div style="display: flex; align-items: center; gap: 12px;">
            <span id="catalyst-arrow" style="color: #10b981; font-size: 16px; transition: transform 0.2s;">‚ñ∂</span>
            <span style="font-family: 'Courier New', monospace; font-size: 13px; font-weight: 700; color: #10b981; text-transform: uppercase; letter-spacing: 0.5px;">Catalyst Pipeline</span>
          </div>
          <span style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.5);">UPCOMING EVENTS ¬∑ TIMELINE</span>
        </div>
        <div id="catalyst-content" class="section-content" style="display: none; padding: 16px; font-family: 'Courier New', monospace; font-size: 12px; line-height: 1.6;">
          <div id="catalyst-data">Loading...</div>
        </div>
      </div>

      <!-- Market Tape -->
      <div class="bloomberg-section" style="background: rgb(26, 35, 54); border: 1px solid #374151; border-radius: 8px; margin-bottom: 12px; overflow: hidden;">
        <div class="section-header" onclick="toggleSection('market')" style="padding: 12px 16px; cursor: pointer; display: flex; justify-content: space-between; align-items: center; background: rgba(245, 158, 11, 0.1); border-bottom: 1px solid #374151;">
          <div style="display: flex; align-items: center; gap: 12px;">
            <span id="market-arrow" style="color: #f59e0b; font-size: 16px; transition: transform 0.2s;">‚ñ∂</span>
            <span style="font-family: 'Courier New', monospace; font-size: 13px; font-weight: 700; color: #f59e0b; text-transform: uppercase; letter-spacing: 0.5px;">Market Tape</span>
          </div>
          <span style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.5);">SOCIAL SENTIMENT ¬∑ TRENDS</span>
        </div>
        <div id="market-content" class="section-content" style="display: none; padding: 16px; font-family: 'Courier New', monospace; font-size: 12px; line-height: 1.6;">
          <div id="market-data">Loading...</div>
        </div>
      </div>

      <!-- Investment Decision -->
      <div class="bloomberg-section" style="background: rgb(26, 35, 54); border: 1px solid #374151; border-radius: 8px; margin-bottom: 12px; overflow: hidden;">
        <div class="section-header" onclick="toggleSection('decision')" style="padding: 12px 16px; cursor: pointer; display: flex; justify-content: space-between; align-items: center; background: rgba(239, 68, 68, 0.1); border-bottom: 1px solid #374151;">
          <div style="display: flex; align-items: center; gap: 12px;">
            <span id="decision-arrow" style="color: #ef4444; font-size: 16px; transition: transform 0.2s;">‚ñ∂</span>
            <span style="font-family: 'Courier New', monospace; font-size: 13px; font-weight: 700; color: #ef4444; text-transform: uppercase; letter-spacing: 0.5px;">Investment Decision</span>
          </div>
          <span id="decision-status" style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.5);">ANALYSIS ¬∑ ACTION</span>
        </div>
        <div id="decision-content" class="section-content" style="display: none; padding: 16px; font-family: 'Courier New', monospace; font-size: 12px; line-height: 1.6;">
          <div id="decision-data">Loading...</div>
        </div>
      </div>

      <!-- Top 5 Recent RNS -->
      <div class="bloomberg-section" style="background: rgb(26, 35, 54); border: 1px solid #374151; border-radius: 8px; margin-bottom: 12px; overflow: hidden;">
        <div class="section-header" onclick="toggleSection('rns')" style="padding: 12px 16px; cursor: pointer; display: flex; justify-content: space-between; align-items: center; background: rgba(6, 182, 212, 0.1); border-bottom: 1px solid #374151;">
          <div style="display: flex; align-items: center; gap: 12px;">
            <span id="rns-arrow" style="color: #06b6d4; font-size: 16px; transition: transform 0.2s;">‚ñ∂</span>
            <span style="font-family: 'Courier New', monospace; font-size: 13px; font-weight: 700; color: #06b6d4; text-transform: uppercase; letter-spacing: 0.5px;">Top 5 Recent RNS</span>
          </div>
          <span style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.5);">REGULATORY NEWS ¬∑ ANNOUNCEMENTS</span>
        </div>
        <div id="rns-content" class="section-content" style="display: none; padding: 16px; font-family: 'Courier New', monospace; font-size: 12px; line-height: 1.6;">
          <div id="rns-data">Loading...</div>
        </div>
      </div>
    </div>

    <!-- Bloomberg Terminal Footer (Collapsible) -->
    <div id="footer-container" style="margin-top: 40px; background: linear-gradient(180deg, #0a1628 0%, #020617 100%); border: 1px solid #1e293b; border-radius: 12px; overflow: hidden; box-shadow: 0 20px 50px rgba(0,0,0,0.5);">
        <!-- Header Bar (Always Visible) -->
        <div style="background: rgba(59, 130, 246, 0.08); border-bottom: 1px solid rgba(59, 130, 246, 0.2); padding: 12px 16px; cursor: pointer;" onclick="toggleFooter()">
            <div style="display: flex; align-items: center; justify-content: space-between; gap: 8px; width: 100%;">
                <div style="display: flex; align-items: center; gap: 8px; flex: 1; min-width: 0; overflow: hidden;">
                    <div style="width: 8px; height: 8px; background: #3b82f6; border-radius: 50%; box-shadow: 0 0 12px rgba(59, 130, 246, 0.6); flex-shrink: 0;"></div>
                    <span style="font-family: 'Courier New', monospace; font-size: 12px; font-weight: 700; color: #3b82f6; text-transform: uppercase; letter-spacing: 0.5px; white-space: nowrap; overflow: hidden; text-overflow: ellipsis;">APEX Intelligence Terminal</span>
                    <span id="footer-toggle-icon" style="font-size: 14px; color: #3b82f6; transition: transform 0.3s ease; flex-shrink: 0; margin-left: auto;">‚ñº</span>
                </div>
            </div>
            <div style="font-family: 'Courier New', monospace; font-size: 9px; color: rgba(255, 255, 255, 0.4); letter-spacing: 0.3px; margin-top: 6px; overflow: hidden;">
                GENERATED: <span style="color: #06b6d4;" id="footerDate"></span> ‚Ä¢ SESSION: <span style="color: #10b981;">LIVE</span>
            </div>
        </div>
        
        <!-- Collapsible Content Section -->
        <div id="footer-content" style="display: none;">
            <!-- Content Grid -->
            <div style="padding: 24px; display: grid; grid-template-columns: 1fr 1fr; gap: 24px;">
                <!-- Left Column -->
                <div style="display: flex; flex-direction: column; gap: 20px;">
                    <!-- System Information -->
                    <div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; font-weight: 700; color: #3b82f6; margin-bottom: 8px; text-transform: uppercase; letter-spacing: 1px;">System Information</div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; color: rgba(255, 255, 255, 0.7); display: flex; gap: 16px; flex-wrap: wrap; align-items: center;">
                            <span><span style="color: rgba(255, 255, 255, 0.4);">VERSION:</span> <span style="color: #06b6d4; font-weight: 700;">APEX v5.0</span></span>
                            <span style="color: rgba(255, 255, 255, 0.2);">‚Ä¢</span>
                            <span><span style="color: rgba(255, 255, 255, 0.4);">ENGINE:</span> <span style="color: #10b981;">CrashDash Intelligence</span></span>
                            <span style="color: rgba(255, 255, 255, 0.2);">‚Ä¢</span>
                            <span><span style="color: rgba(255, 255, 255, 0.4);">COVERAGE:</span> <span style="color: #a855f7;">LSE AIM Micro-Caps</span></span>
                            <span style="color: rgba(255, 255, 255, 0.2);">‚Ä¢</span>
                            <span><span style="color: rgba(255, 255, 255, 0.4);">SOURCES:</span> <span style="color: #ef4444;">RNS ‚Ä¢ Social ‚Ä¢ Trends</span></span>
                        </div>
                    </div>
                    
                    <!-- Risk Disclosure -->
                    <div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; font-weight: 700; color: #ef4444; margin-bottom: 12px; text-transform: uppercase; letter-spacing: 1px;">Risk Disclosure</div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; color: rgba(255, 255, 255, 0.5); line-height: 1.6;">
                            This analysis is provided for informational purposes only and does not constitute financial advice. AIM micro-cap securities carry significant volatility and liquidity risks. Past performance does not guarantee future results. Always conduct your own due diligence and consult with a qualified financial advisor before making investment decisions.
                        </div>
                    </div>
                </div>
                
                <!-- Right Column -->
                <div style="display: flex; flex-direction: column; gap: 20px;">
                    <!-- Platform Overview -->
                    <div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; font-weight: 700; color: #10b981; margin-bottom: 12px; text-transform: uppercase; letter-spacing: 1px;">Platform Overview</div>
                        <div style="font-family: 'Courier New', monospace; font-size: 11px; color: rgba(255, 255, 255, 0.7); line-height: 1.6;">
                            APEX Intelligence Terminal combines technical analysis, sentiment tracking, and regulatory news monitoring to identify high-probability contrarian setups in distressed micro-cap equities. Our proprietary scoring system evaluates setup quality, panic intensity, and compression patterns to surface opportunities before institutional recognition.
                        </div>
                    </div>
                    
                    <!-- Target Users -->
                    <div>
                        <div style="font-family: 'Courier New', monospace; font-size: 10px; font-weight: 700; color: #a855f7; margin-bottom: 12px; text-transform: uppercase; letter-spacing: 1px;">Target Users</div>
                        <div style="display: flex; flex-wrap: wrap; gap: 8px;">
                            <span style="font-family: 'Courier New', monospace; font-size: 10px; padding: 6px 12px; background: rgba(168, 85, 247, 0.1); border: 1px solid rgba(168, 85, 247, 0.3); border-radius: 4px; color: #a855f7; font-weight: 600;">PROP TRADERS</span>
                            <span style="font-family: 'Courier New', monospace; font-size: 10px; padding: 6px 12px; background: rgba(59, 130, 246, 0.1); border: 1px solid rgba(59, 130, 246, 0.3); border-radius: 4px; color: #3b82f6; font-weight: 600;">HEDGE FUNDS</span>
                            <span style="font-family: 'Courier New', monospace; font-size: 10px; padding: 6px 12px; background: rgba(16, 185, 129, 0.1); border: 1px solid rgba(16, 185, 129, 0.3); border-radius: 4px; color: #10b981; font-weight: 600;">QUANT TEAMS</span>
                            <span style="font-family: 'Courier New', monospace; font-size: 10px; padding: 6px 12px; background: rgba(239, 68, 68, 0.1); border: 1px solid rgba(239, 68, 68, 0.3); border-radius: 4px; color: #ef4444; font-weight: 600;">RESEARCH DESKS</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Bottom Bar -->
            <div style="background: rgba(2, 6, 23, 0.6); border-top: 1px solid rgba(59, 130, 246, 0.15); padding: 12px 24px;">
                <div style="display: flex; align-items: center; justify-content: space-between; flex-wrap: wrap; gap: 12px; font-family: 'Courier New', monospace; font-size: 10px;">
                    <div style="color: rgba(255, 255, 255, 0.4);">¬© 2026 APEX Intelligence ‚Ä¢ All Rights Reserved</div>
                    <div style="display: flex; align-items: center; gap: 20px; color: rgba(255, 255, 255, 0.5);">
                        <span>STATUS: <span style="color: #10b981; font-weight: 700;">‚óè OPERATIONAL</span></span>
                        <span>LATENCY: <span style="color: #06b6d4; font-weight: 700;">12ms</span></span>
                        <span>BUILD: <span style="color: #a855f7; font-weight: 700;">5.0.2</span></span>
                    </div>
                </div>
            </div>
        </div>
    </div>
    
    <script>
        function toggleFooter() {
            const content = document.getElementById('footer-content');
            const icon = document.getElementById('footer-toggle-icon');
            
            if (content.style.display === 'none') {
                content.style.display = 'block';
                icon.style.transform = 'rotate(180deg)';
            } else {
                content.style.display = 'none';
                icon.style.transform = 'rotate(0deg)';
            }
        }

        // Mobile-friendly tooltip popover
        function showTooltipPopover(event, tooltipText) {
            event.stopPropagation();
            
            // Close any existing popover
            const existing = document.getElementById('tooltip-popover');
            if (existing) existing.remove();
            
            // Create popover
            const popover = document.createElement('div');
            popover.id = 'tooltip-popover';
            popover.style.cssText = 'position:fixed;background:rgba(20,25,40,0.98);color:#e5e7eb;padding:10px 14px;border-radius:6px;font-size:12px;line-height:1.4;max-width:250px;border:1px solid rgba(16,185,129,0.3);z-index:10000;box-shadow:0 4px 12px rgba(0,0,0,0.4);backdrop-filter:blur(8px);word-wrap:break-word';
            popover.textContent = tooltipText;
            document.body.appendChild(popover);
            
            // Position near clicked element
            const rect = event.target.getBoundingClientRect();
            popover.style.left = Math.min(rect.left, window.innerWidth - 270) + 'px';
            popover.style.top = (rect.bottom + 8) + 'px';
            
            // Close on outside click
            setTimeout(() => {
                document.addEventListener('click', closeTooltip, { once: true });
            }, 0);
        }

        function closeTooltip() {
            const popover = document.getElementById('tooltip-popover');
            if (popover) popover.remove();
        }
    </script>
  </div>
  
  <!-- Mobile Responsive Styles -->
  <style>
    @media(max-width:768px){
        body{padding:10px!important}
        .container{max-width:100%!important}
        #footer-container{margin-top:20px!important}
        div[style*="grid-template-columns: 1fr 1fr"]{grid-template-columns:1fr!important;gap:12px!important}
        div[style*="grid-template-columns: repeat(4"]{grid-template-columns:repeat(2,1fr)!important;gap:10px!important}
        div[style*="padding: 24px"]{padding:16px!important}
        div[style*="padding: 12px 16px"]{padding:10px 12px!important}
        div[style*="gap: 20px"]{gap:14px!important}
        div[style*="font-size: 11px"]{font-size:10px!important}
        div[style*="font-size: 12px"]{font-size:11px!important}
        div[style*="font-size: 13px"]{font-size:12px!important}
    }
    @media(max-width:480px){
        body{padding:6px!important}
        .container{padding:0!important;margin:0!important}
        #footer-container{margin-top:16px!important;margin-left:6px!important;margin-right:6px!important}
        #footer-container > div:first-child{padding:8px 10px!important}
        div[style*="grid-template-columns: 1fr 1fr"]{grid-template-columns:1fr!important;gap:8px!important}
        div[style*="grid-template-columns: repeat(4"]{grid-template-columns:1fr!important;gap:6px!important;padding:8px 10px!important}
        div[style*="grid-template-columns: repeat(2"]{grid-template-columns:1fr!important;gap:6px!important}
        div[style*="padding: 24px"]{padding:10px!important}
        div[style*="padding: 12px 16px"]{padding:8px 10px!important}
        div[style*="padding: 14px 16px"]{padding:8px 10px!important}
        div[style*="padding: 18px"]{padding:10px!important}
        div[style*="gap: 20px"]{gap:8px!important}
        div[style*="gap: 30px"]{gap:10px!important}
        div[style*="gap: 24px"]{gap:10px!important}
        div[style*="gap: 16px"]{gap:6px!important}
        div[style*="gap: 12px"]{gap:6px!important}
        div[style*="gap: 8px"]{gap:4px!important}
        div[style*="font-size: 9px"]{font-size:8px!important}
        div[style*="font-size: 10px"]{font-size:8px!important}
        div[style*="font-size: 11px"]{font-size:9px!important}
        div[style*="font-size: 12px"]{font-size:10px!important}
        div[style*="font-size: 13px"]{font-size:11px!important}
        div[style*="padding: 6px 12px"]{padding:4px 6px!important;font-size:7px!important}
        div[style*="line-height: 1.8"]{line-height:1.4!important}
        div[style*="line-height: 1.6"]{line-height:1.3!important}
        div[style*="line-height: 1.5"]{line-height:1.2!important}
        /* Footer system info on mobile - stack vertically and shrink */
        div[style*="display: flex; gap: 16px; flex-wrap: wrap; align-items: center"] {
          flex-direction: column!important;
          align-items: flex-start!important;
          gap: 4px!important;
          font-size: 7px!important;
        }
    }
  </style>
  
  <script>window.__APEX_PROFILE = {
  "analysis_mode": "HISTORICAL_ONLY",
  "symbol": "ROQ.L",
  "generated_at": "2026-02-11T23:07:49.106217Z",
  "top_card": {
    "ticker": "ROQ.L",
    "company_name": "Roquefort Therapeutics plc",
    "sector": "Healthcare",
    "market_cap_gbp": 1800989,
    "days_active": 167,
    "apex_score_100": 50,
    "confidence_score_100": 40,
    "ai_final_score_25": 11,
    "ai_strength": "MODERATE",
    "timing_regime": "TOO_EARLY",
    "action": "WATCH",
    "thesis_one_liner": "WATCH - TOO_EARLY timing with 50/100 opportunity score"
  },
  "enrichment": {
    "company_info": {
      "name": "Roquefort Therapeutics plc",
      "sector": "Healthcare",
      "industry": "Biotechnology",
      "exchange": "LSE",
      "market": "MAIN",
      "currency": "GBP",
      "risk_tier": "Low Risk",
      "current_market_cap": 1800989,
      "current_close_price": 1.1
    },
    "basics": {
      "ticker": "ROQ.L",
      "current_price": 1.1,
      "ath": 850.0,
      "atl": 1.0,
      "ath_date": "2021-03-23",
      "atl_date": "2026-02-03",
      "week_52_high": 3.0,
      "week_52_low": 1.0,
      "week_52_high_date": "2025-03-10",
      "week_52_low_date": "2026-02-03",
      "drawdown_from_ath_pct": 99.87,
      "data_start": "2021-03-22",
      "data_end": "2026-02-11",
      "total_bars": 1089
    },
    "latest_signal": {
      "date": "2025-08-28",
      "scan_date": "2026-01-26",
      "signal_type": "CRASH ZONE BOTTOM",
      "signal_color": "YELLOW",
      "price": 1.3,
      "drawdown_pct": 80.81,
      "ai_score": 9.0,
      "rsi": 11.1,
      "cycle_position": 0.2718,
      "holding_period_days": 167,
      "current_pnl_pct": -15.38,
      "rally_state": "accumulating",
      "distance_from_high_pct": -53.77,
      "Rally_Count": 1,
      "days_since_last_high": 17,
      "last_high_date": "2026-01-09",
      "lock_in_reached": true,
      "lock_in_date": "2025-11-27",
      "best_rally_pct": 103.85
    },
    "best_historical_signal": {
      "signal_date": "2025-08-22",
      "signal_type": "CRASH ZONE BOTTOM",
      "signal_color": "YELLOW",
      "entry_price": 1.25,
      "peak_price": 3.0,
      "peak_date": "2025-11-27",
      "rally_pct": 140.0,
      "days_to_peak": 97,
      "ai_score": 8.0
    },
    "all_historical_signals": [
      {
        "signal_id": "ROQ.L_2025-02-27",
        "signal_date": "2025-02-27",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.7,
        "current_price": 1.225,
        "current_return_pct": -27.94,
        "best_rally_pct": 55.88,
        "best_rally_date": "2025-11-27",
        "rally_state": "accumulating",
        "Rally_Count": 6,
        "distance_from_high_pct": -53.77,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 333,
        "status": "historical"
      },
      {
        "signal_id": "ROQ.L_2025-06-19",
        "signal_date": "2025-06-19",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.35,
        "current_price": 1.225,
        "current_return_pct": -9.26,
        "best_rally_pct": 96.3,
        "best_rally_date": "2025-11-27",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -53.77,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 221,
        "status": "historical"
      },
      {
        "signal_id": "ROQ.L_2025-08-22",
        "signal_date": "2025-08-22",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.25,
        "current_price": 1.225,
        "current_return_pct": -2.0,
        "best_rally_pct": 112.0,
        "best_rally_date": "2025-11-27",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -53.77,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 157,
        "status": "historical"
      },
      {
        "signal_id": "ROQ.L_2025-08-27",
        "signal_date": "2025-08-27",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.3,
        "current_price": 1.225,
        "current_return_pct": -5.77,
        "best_rally_pct": 103.85,
        "best_rally_date": "2025-11-27",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -53.77,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 152,
        "status": "historical"
      },
      {
        "signal_id": "ROQ.L_2025-08-28",
        "signal_date": "2025-08-28",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.3,
        "current_price": 1.225,
        "current_return_pct": -5.77,
        "best_rally_pct": 103.85,
        "best_rally_date": "2025-11-27",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -53.77,
        "days_since_last_high": 17,
        "lock_in_reached": true,
        "age_days": 151,
        "status": "historical"
      }
    ],
    "stats": {
      "total_signals": 5,
      "win_rate_pct": 100.0,
      "avg_rally_pct": 120.05,
      "median_rally_pct": 130.77,
      "best_rally_pct": 140.0,
      "worst_rally_pct": 76.47
    },
    "splits": [
      {
        "date": "2021-03-24",
        "ratio": "1:20",
        "ratio_value": 100.0
      }
    ],
    "split_risk": {
      "split_detected": false,
      "risk_level": "NONE",
      "confidence": "HIGH"
    },
    "data_quality": {
      "price_reliability": "RELIABLE",
      "pnl_reliability": "RELIABLE",
      "overall_confidence": "HIGH"
    },
    "risk_flags": [
      "HAS_REVERSE_SPLIT",
      "EXTREME_DRAWDOWN"
    ],
    "last_updated": "2026-02-11 20:06:50 UTC",
    "volatility": {
      "atr_normalized": 8.89,
      "stddev_20d": 0.0
    },
    "trends": {
      "intelligence_signal": "ACCUMULATION"
    }
  },
  "decision_summary": {
    "why_it_matters": [
      "APEX 50/100 indicates strong opportunity quality",
      "Timing regime: TOO_EARLY",
      "Historical profile: 1 rallies, 104% best run"
    ],
    "main_risk": "Confidence 40/100 - full data loaded",
    "watch_next": [
      "RNS catalysts (funding/operational updates)",
      "Volume expansion confirmation",
      "Timing regime change signals"
    ]
  },
  "triangulation": {
    "rns": {
      "has_data": true,
      "ticker": "ROQ.L",
      "latest": [
        {
          "title": "Research Note Published",
          "announcement_date": "15th Jan 2026",
          "release_time": "7:00 am",
          "source": "RNS-R",
          "content": "15 Jan 2026 07:00\nRNS Number : 9354O\nRoquefort Therapeutics PLC\n15 January 2026\n15 January 2026\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nResearch Note Published\nRoquefort\nTherapeutics\nplc (\nLSE:ROQ\n), the Main Market listed biotech company, announces that a new research note regarding the Company's proposed transaction with Coiled Therapeutics, Inc. and A2A Pharmaceuticals, Inc., as first announced on 8 September 2025, has been published by its broker SP Angel Corporate Finance LLP.\nIt can be accessed by the following link:\nhttps://www.roquefortplc.com/analyst-research\nENDS\nEnquiries:\nRoquefort Therapeutics plc\n+44 (0)20 3918 8633\nStephen West (Chairman) / Dr Darrin Disley (Interim MD)\nSP Angel Corporate Finance LLP (Broker to the Company)\nDavid Hignell / Vadim Alexandre / Devik Mehta\n+44 (0)20 3470 0470\nShard Capital Partners LLP (Broker to the Company)\nDamon Heath\n+44 (0)20 4530 6926\nBurson Buchanan (Public Relations)\nBen Romney / Jamie Hooper\n+44 (0)20 7466 5000\nLEI: \u200e254900P4SISIWOR9RH34\nFor further information on Roquefort Therapeutics, please\nvisit\nwww.roquefortplc.com\nAbout Coiled Therapeutics Inc. (\"Coiled USA\")\nCoiled USA is a clinical stage oncology company and is a spin-out of A2A Pharmaceuticals, Inc. Coiled USA holds the exclusive worldwide rights to AO-252, a novel, brain-penetrant small molecule inhibitor designed to disrupt TACC3 protein-protein interactions.\nCoiled USA has advanced the AO-252 program through pre-clinical development and IND approval and commenced Phase I trials in the USA (trials ID: NCT06136884). Coiled USA is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments.\nAbout A2A Pharmaceuticals, Inc. (\"A2A Pharmaceuticals\")\nA2A Pharmaceuticals is a private, well-funded company that uses proprietary computational systems, including generative AI with its SCULPT\u2122 platform to accelerate the development of novel drug alternatives for life threatening diseases like cancer. This enables a more efficient process than traditional trial and error approaches to drug discovery.\nA2A Pharmaceuticals aims to develop therapies to early clinical stages and then spin them out into standalone entities to progress them through clinical development. In 2018, A2A Pharmaceuticals spun out its MLL-Menin program to Biomea Fusion, Inc. (\"Biomea Fusion\"), a company that completed an IPO on Nasdaq in 2021 raising US$153 million and listing with a market capitalisation of US$464 million. Post-IPO Biomea Fusion's market capitalisation reached a peak of over US$1 billion.\nFurther information on A2A Pharmaceuticals can be found at:\nhttps://www.a2apharma.com/\nThis information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNRASFUFMLEMSEEF",
          "rns_number": "RNS Number : 9354O"
        },
        {
          "title": "Clinical Trial & License Agreement Update",
          "announcement_date": "12th Dec 2025",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "12 Dec 2025 07:00\nRNS Number : 2919L\nRoquefort Therapeutics PLC\n12 December 2025\n12 December 2025\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nClinical Trial & License Agreement Update\nRoquefort\nTherapeutics\nplc (\nLSE:ROQ\n), the Main Market listed biotech company, announces that the binding exclusive license agreement with Coiled Therapeutics, Inc. (\"Coiled USA\") and A2A Pharmaceuticals, Inc. (\"A2A Pharma\") regarding the worldwide exclusive rights to AO-252 (the \"AO-252 License Agreement\") announced on 18 November 2025 has been amended and includes an extension to the long stop date from 31 January 2026 to 16 March 2026. In addition, the Company provides an update on the progress of the Phase I clinical trial which is currently underway in USA.\nClinical Stage Progress\nCoiled USA recently received approval for a protocol amendment to expand the inclusion criteria for its Phase I clinical trial for AO-252 to encompass all solid tumours, including patients with or without brain metastases.\nFollowing this successful protocol amendment, together with encouraging safety signals, Coiled USA has strategically prioritised prostate cancer as its primary indication for clinical trials, with the first patient with metastatic castration-resistant prostate cancer being enrolled and dosed in November 2025 within the active Cohort 4b dose level.\nThe decision by Coiled USA to\nprioritise prostate cancer as its primary indication for clinical trials is supported by positive feedback from potential pharmaceutical partners and investors, and is also underpinned by compelling pre-clinical data across multiple distinct models:\n\u00b7\nVCaP Xenografts (AR-positive, ETS-fusion)\n: demonstrated 100% complete response/partial response (\"CR+PR\") with complete regressions observed;\n\u00b7\nAR-independent Cell Lines\n: significant tumour growth inhibition (\"TGI\") of 60% was observed in androgen receptor (\"AR\") independent models;\n\u00b7\n22Rv1 Models (AR-resistant)\n: demonstrated 90% TGI; and\n\u00b7\nMechanism\n: importantly, efficacy was observed to be independent of androgen signalling, suggesting broad potential utility in resistant disease.\nCoiled USA is currently enrolling additional patients in Cohort 4b, the best of six cohort dose levels where the strongest clinical benefit has been observed to date. In addition, Coiled USA has initiated a food effect cohort study using the Cohort 4b dose to optimise exposure based on clear PK/PD modelling.\nThe commercial interest in oral targeted therapies for multiple types of solid tumours, including prostate cancer, was recently demonstrated by the announcement on 17 November 2025 by Johnson & Johnson that it was acquiring Halda Therapeutics OpCo, Inc (\"Halda\") for US$3.05 billion in cash. Prior to the acquisition, Halda's Phase I/II clinical trial had demonstrated impressive preliminary efficacy and a strong early safety profile in prostate cancer.\nLicense Extension\nCompletion of the AO-252 License Agreement is conditional on\ninter alia\nthe Company's enlarged ordinary share capital being admitted to trading on the AIM market (\"Admission\") no later than 31 January 2026 (the \"Longstop Date\"). The Company and its advisers are currently progressing key documents relating to the Transaction (defined below), including an AIM Admission Document which will be published in due course.\nDue to the impact of the forthcoming holiday season, it is unlikely that Admission will occur prior to 31 January 2026 and therefore the parties to the AO-252 License Agreement have agreed to extend the Longstop Date to 16 March 2026 in return for an amendment to certain commercial terms (refer below). The extension to the Longstop Date will also provide additional time for data readouts from the clinical trial.\nAmendment to Commercial Terms\nIn return for agreeing to extend the Longstop Date, the parties to the AO-252 License Agreement have agreed to amend the following commercial terms in the agreement:\n1.\nThe upfront consideration amount has been increased to \u00a331,875,000\nto be satisfied by the issue of ordinary shares in the capital of the Company (\"Ordinary Shares\") to the shareholders of Coiled USA (the \"Consideration Shares\") at an effective price of 1.7 pence per share, subject to the satisfaction of certain conditions, including Admission (the \"Transaction\");\n2. The total number of additional Ordinary Shares to be issued to A2A Pharma should certain market capitalisation targets be met for a period of 30 consecutive days (the \"Deferred Consideration Shares\") has been amended to the following:\na. Market capitalisation of the Company being greater than or equal to \u00a360 million: 250 million Deferred Consideration Shares;\nb. Market capitalisation of the Company being greater than or equal to \u00a390 million: a further 250 million Deferred Consideration Shares; and\nc. Market capitalisation of the Company being greater than or equal to \u00a3120 million: a further 250 million Deferred Consideration Shares.\nThe Board believes that the modest increase in the number of Consideration Shares and Deferred Consideration Shares is justified given the significant progress Coiled USA has made with the current Phase I clinical trial.\nStephen West, Roquefort Therapeutics Chairman commented:\n\"We are pleased with Coiled USA's strategic decision to prioritise prostate cancer as the primary indication for AO-252, a move that is supported by both compelling pre-clinical data and positive feedback from potential pharmaceutical partners and investors. This pivot, combined with the enrolment of the first prostate cancer patient in Cohort 4b, represents an exciting move for the Transaction. The recent acquisition of Halda Therapeutics by Johnson & Johnson shows the significant commercial appetite for novel oral therapies in prostate cancer and underscores the potential value that could be unlocked through our Transaction. With clear market validation and encouraging early clinical signals, we believe we are well positioned to deliver value for our shareholders.\"\nDr Sridhar Vempati, proposed CEO post Admission commented:\n\"Dosing the first prostate cancer patients in Cohort 4b marks a major clinical and scientific step forward. The dose-escalation work has identified this cohort as the level where we see the most meaningful activity, including tumour reduction. Given the specific properties of AO-252, we see a clear opportunity to further optimise exposure through the upcoming food effect study. This targeted approach ensures we are maximising the drug's bioavailability as we advance the program. Extending the closing deadline for our Transaction to 16 March 2026 reflects our shared confidence in delivering significant value from the AO-252 program.\"\nRegulatory Information\nThis Announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\").\nENDS\nEnquiries:\nRoquefort Therapeutics plc\n+44 (0)20 3918 8633\nStephen West (Chairman) / Dr Darrin Disley (Interim MD)\nSP Angel Corporate Finance LLP (Broker to the Company)\nDavid Hignell / Vadim Alexandre / Devik Mehta\n+44 (0)20 3470 0470\nShard Capital Partners LLP (Broker to the Company)\nDamon Heath\n+44 (0)20 4530 6926\nCPS Capital Group (Broker to A2A Pharma & Coiled USA)\nJason Peterson / David Valentino\n+61 (0)8 9223 2222\nBurson Buchanan (Public Relations)\nBen Romney / Jamie Hooper\n+44 (0)20 7466 5000\nLEI: \u200e254900P4SISIWOR9RH34\nFor further information on Roquefort Therapeutics, please\nvisit\nwww.roquefortplc.com\nAbout Coiled USA\nCoiled USA is a clinical stage oncology company and is a spin-out of A2A Pharmaceuticals, Inc. Coiled USA holds the exclusive worldwide rights to AO-252, a novel, brain-penetrant small molecule inhibitor designed to disrupt TACC3 protein-protein interactions.\nCoiled USA has advanced the AO-252 program through pre-clinical development and IND approval and commenced Phase I trials in the USA (trials ID: NCT06136884). Coiled USA is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments.\nAbout A2A Pharmaceuticals\nA2A Pharmaceuticals is a private, well-funded company that uses proprietary computational systems, including generative AI with its SCULPT\u2122 platform to accelerate the development of novel drug alternatives for life threatening diseases like cancer. This enables a more efficient process than traditional trial and error approaches to drug discovery.\nA2A Pharmaceuticals aims to develop therapies to early clinical stages and then spin them out into standalone entities to progress them through clinical development. In 2018, A2A Pharmaceuticals spun out its MLL-Menin program to Biomea Fusion, Inc. (\"Biomea Fusion\"), a company that completed an IPO on Nasdaq in 2021 raising US$153 million and listing with a market capitalisation of US$464 million. Post-IPO Biomea Fusion's market capitalisation reached a peak of over US$1 billion.\nFurther information on A2A Pharmaceuticals can be found at:\nhttps://www.a2apharma.com/\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nAGRUAAURVBUUAUA",
          "rns_number": "RNS Number : 2919L"
        },
        {
          "title": "Conversion of CLNs",
          "announcement_date": "9th Dec 2025",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "9 Dec 2025 07:00\nRNS Number : 7191K\nRoquefort Therapeutics PLC\n09 December 2025\n9 December 2025\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nConversion of CLNs\nRoquefort Therapeutics (LSE:ROQ),\nthe Main Market listed biotech company\n, announces that\nthe Company has received notices, in two tranches, to convert a total face value of \u00a380,000 convertible loan notes (the \"CLNs\") resulting in the issue of 6,282,264 new ordinary shares in the Company (the \"CLN Shares\").\nIn accordance with the terms of the CLNs, which were issued and announced on 23 May 2024, all accrued interest on the CLNs at a rate of 12.5% per annum is included in the conversion into the Company's ordinary shares of \u00a30.01 each (\"Ordinary Shares\"). The conversion price of the first tranche of the CLNs representing a face value of \u00a330,000 is 1.81p and the conversion price of the second tranche of the CLNs representing a face value of \u00a350,000 is 1.29p. The conversion price is calculated as being 90% of the price equal to the 10-day volume-weighted average price calculated backwards from the date, which is three business days prior to the notice of conversion given to the Company.\nFollowing conversion of these CLNs, the Company has CLNs with a face value of \u00a3257,894 outstanding.\nAdmission and Total Voting Rights\nApplication will be made for the CLN Shares to be admitted to trading on the London Stock Exchange's Main Market for listed securities, which is expected to occur on or around 16 December 2025 (\"Admission\"). The CLN Shares will rank\npari passu\nin all respects with the Company's existing Ordinary Shares.\nFollowing Admission, the Company's issued share capital will comprise 163,726,294 Ordinary Shares in issue, with each share carrying the right to one vote. The Company does not hold any Ordinary Shares in treasury. The figure of 163,726,294 Ordinary Shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or of a change to their interest in the Company under the FCA's Disclosure and Transparency Rules.\nRegulatory Information\nThis Announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\").\nENDS\nEnquiries:\nRoquefort Therapeutics plc\n+44 (0)20 3918 8633\nStephen West (Chairman) / Dr Darrin Disley (Interim MD)\nSP Angel Corporate Finance LLP (Broker to the Company)\nDavid Hignell / Vadim Alexandre / Devik Mehta\n+44 (0)20 3470 0470\nShard Capital Partners LLP (Broker to the Company)\nDamon Heath\n+44 (0)20 4530 6926\nBurson Buchanan (Public Relations)\nBen Romney / Jamie Hooper\n+44 (0)20 7466 5000\nLEI: \u200e254900P4SISIWOR9RH34\nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ) is focused on completing the\nproposed transaction with A2A Pharmaceuticals, Inc. and Coiled Therapeutics, Inc. which will result in the Company acquiring the exclusive licence rights to AO-252, a novel first-in-class, first-in-human new drug alternative targeting the TACC3 protein for the treatment of certain cancers, initially announced by the Company on 8 September 2025.\nFor further information on Roquefort Therapeutics, please\nvisit\nwww.roquefortplc.com\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nCONUPGAPPUPAGMR",
          "rns_number": "RNS Number : 7191K"
        },
        {
          "title": "Ex-Entitlement Date - Unlisted RNV Shares",
          "announcement_date": "1st Dec 2025",
          "release_time": "10:35 am",
          "source": "RNS",
          "content": "1 Dec 2025 10:35\nRNS Number : 6886J\nRoquefort Therapeutics PLC\n01 December 2025\n1 December 2025\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nEx-Entitlement Date - Unlisted Redeemable Non-Voting Shares\nRoquefort Therapeutics (LSE:ROQ),\nthe Main Market listed biotech company\n, announces that further to the Company's announcement earlier today confirming that the record date for determining entitlement to the Unlisted Redeemable Non-Voting Shares (\"Unlisted RNV Shares\") has now passed, its ordinary shares will be marked ex-entitlement in respect of the Unlisted RNV Shares with effect from the commencement of trading today, 1 December 2025.\nAccordingly, all holders of ordinary shares and convertible loan notes who were on the Company's register as at close of business on 28 November 2025 will be eligible to receive the Unlisted RNV Shares. In addition, anyone who purchased ordinary shares on Friday, 28 November 2025 will also be eligible to receive the Unlisted RNV Shares.\nA detailed timetable for the crediting of the Unlisted RNV Shares to eligible shareholders, together with full details of the entitlement ratio and the exact number of Unlisted RNV Shares to be issued, will be set out in a further announcement to be made in due course.\nRegulatory Information\nThis Announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\").\nENDS\nEnquiries:\nRoquefort Therapeutics plc\n+44 (0)20 3918 8633\nStephen West (Chairman) / Dr Darrin Disley (Interim MD)\nSP Angel Corporate Finance LLP (Broker to the Company)\nDavid Hignell / Vadim Alexandre / Devik Mehta\n+44 (0)20 3470 0470\nShard Capital Partners LLP (Broker to the Company)\nDamon Heath\n+44 (0)20 4530 6926\nBurson Buchanan (Public Relations)\nBen Romney / Jamie Hooper\n+44 (0)20 7466 5000\nLEI: \u200e254900P4SISIWOR9RH34\nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ) is focused on completing the\nproposed transaction with A2A Pharmaceuticals, Inc. and Coiled Therapeutics, Inc. which will result in the Company acquiring the exclusive licence rights to AO-252, a novel first-in-class, first-in-human new drug alternative targeting the TACC3 protein for the treatment of certain cancers, initially announced by the Company on 8 September 2025.\nFor further information on Roquefort Therapeutics, please\nvisit\nwww.roquefortplc.com\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nFURUAORRVOUURAA",
          "rns_number": "RNS Number : 6886J"
        },
        {
          "title": "Determination of Record Date and Entitlement",
          "announcement_date": "1st Dec 2025",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "1 Dec 2025 07:00\nRNS Number : 5583J\nRoquefort Therapeutics PLC\n01 December 2025\n1 December 2025\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nDetermination of Record Date and Entitlement\nRoquefort Therapeutics (LSE:ROQ),\nthe Main Market listed biotech company\n, announces that, following the announcement on 3 November 2025 regarding the proposed issue of new unlisted redeemable non-voting shares (\"Unlisted RNV Shares\"), the Company confirms that the record date for determining entitlement to the Unlisted RNV Shares has now passed.\nHolders of ordinary shares and convertible loan notes who were on the Company's registers as at close of business on 30 November 2025 (the \"Record Date\") will be entitled to receive Unlisted RNV Shares.\nThe Unlisted RNV Shares will carry the right to all future commercial benefits arising from the Company's Midkine Investments portfolio, with the ultimate intention of facilitating an\nin-specie\ndistribution of the Midkine Investments shares to the holders of Unlisted RNV Shares when the Company's balance sheet permits such a distribution in accordance with the Companies Act 2006.\nFull details of the entitlement ratio, the exact number of Unlisted RNV Shares to be issued, the crediting process and the anticipated timetable will be set out in a further announcement to be made in due course.\nRegulatory Information\nThis Announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\").\nENDS\nEnquiries:\nRoquefort Therapeutics plc\n+44 (0)20 3918 8633\nStephen West (Chairman) / Dr Darrin Disley (Interim MD)\nSP Angel Corporate Finance LLP (Broker to the Company)\nDavid Hignell / Vadim Alexandre / Devik Mehta\n+44 (0)20 3470 0470\nShard Capital Partners LLP (Broker to the Company)\nDamon Heath\n+44 (0)20 4530 6926\nBurson Buchanan (Public Relations)\nBen Romney / Jamie Hooper\n+44 (0)20 7466 5000\nLEI: \u200e254900P4SISIWOR9RH34\nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ) is focused on completing the\nproposed transaction with A2A Pharmaceuticals, Inc. and Coiled Therapeutics, Inc. which will result in the Company acquiring the exclusive licence rights to AO-252, a novel first-in-class, first-in-human new drug alternative targeting the TACC3 protein for the treatment of certain cancers, initially announced by the Company on 8 September 2025.\nFor further information on Roquefort Therapeutics, please\nvisit\nwww.roquefortplc.com\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCFLFSRLTLIVIE",
          "rns_number": "RNS Number : 5583J"
        }
      ],
      "themes": [
        "drilling",
        "operations"
      ]
    },
    "social": {
      "has_data": true,
      "buzz_level": "HIGH",
      "post_count": 915,
      "sentiment_breakdown": {
        "positive": 0.0,
        "neutral": 100.0,
        "negative": 0.0
      }
    },
    "trends": {
      "has_data": true,
      "current_interest": 0,
      "momentum_score": 0,
      "trend_direction": "flat",
      "intelligence_signal": "ACCUMULATION"
    },
    "volatility": {
      "atr_normalized": 8.89,
      "stddev_20d": 0.0
    },
    "risk_flags": {
      "split_risk_level": "NONE",
      "halt_risk": "NONE",
      "penny_stock_risk": "NONE"
    },
    "all_events": [
      {
        "event_id": "RNS-15th Jan 2026-research",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.255855Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Research Note Published",
          "category": "RNS-R",
          "url": "https://www.lse.co.uk/rns/ROQ/research-note-published-ndu4we2cbhzx1is.html",
          "rns_number": "RNS Number : 9354O",
          "full_content": "15 Jan 2026 07:00\nRNS Number : 9354O\nRoquefort Therapeutics PLC\n15 January 2026\n15 January 2026\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nResearch Note Published\nRoquefort\nTherapeutics\nplc (\nLSE:ROQ\n), the Main Market listed biotech company, announces that a new research note regarding the Company's proposed transaction with Coiled Therapeutics, Inc. and A2A Pharmaceuticals, Inc., as first announced on 8 September 2025, has been published by its broker SP Angel Corporate Finance LLP.\nIt can be accessed by the following link:\nhttps://www.roquefortplc.com/analyst-research\nENDS\nEnquiries:\nRoquefort Therapeutics plc\n+44 (0)20 3918 8633\nStephen West (Chairman) / Dr Darrin Disley (Interim MD)\nSP Angel Corporate Finance LLP (Broker to the Company)\nDavid Hignell / Vadim Alexandre / Devik Mehta\n+44 (0)20 3470 0470\nShard Capital Partners LLP (Broker to the Company)\nDamon Heath\n+44 (0)20 4530 6926\nBurson Buchanan (Public Relations)\nBen Romney / Jamie Hooper\n+44 (0)20 7466 5000\nLEI: \u200e254900P4SISIWOR9RH34\nFor further information on Roquefort Therapeutics, please\nvisit\nwww.roquefortplc.com\nAbout Coiled Therapeutics Inc. (\"Coiled USA\")\nCoiled USA is a clinical stage oncology company and is a spin-out of A2A Pharmaceuticals, Inc. Coiled USA holds the exclusive worldwide rights to AO-252, a novel, brain-penetrant small molecule inhibitor designed to disrupt TACC3 protein-protein interactions.\nCoiled USA has advanced the AO-252 program through pre-clinical development and IND approval and commenced Phase I trials in the USA (trials ID: NCT06136884). Coiled USA is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments.\nAbout A2A Pharmaceuticals, Inc. (\"A2A Pharmaceuticals\")\nA2A Pharmaceuticals is a private, well-funded company that uses proprietary computational systems, including generative AI with its SCULPT\u2122 platform to accelerate the development of novel drug alternatives for life threatening diseases like cancer. This enables a more efficient process than traditional trial and error approaches to drug discovery.\nA2A Pharmaceuticals aims to develop therapies to early clinical stages and then spin them out into standalone entities to progress them through clinical development. In 2018, A2A Pharmaceuticals spun out its MLL-Menin program to Biomea Fusion, Inc. (\"Biomea Fusion\"), a company that completed an IPO on Nasdaq in 2021 raising US$153 million and listing with a market capitalisation of US$464 million. Post-IPO Biomea Fusion's market capitalisation reached a peak of over US$1 billion.\nFurther information on A2A Pharmaceuticals can be found at:\nhttps://www.a2apharma.com/\nThis information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNRASFUFMLEMSEEF",
          "content_length": 3416
        },
        "ingested_at": "2026-01-16T22:42:51.255898Z"
      },
      {
        "event_id": "RNS-12th Dec 2025-clinical",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.255919Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Clinical Trial & License Agreement Update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/clinical-trial-license-agreement-update-a0v4fpahdw8rdwz.html",
          "rns_number": "RNS Number : 2919L",
          "full_content": "12 Dec 2025 07:00\nRNS Number : 2919L\nRoquefort Therapeutics PLC\n12 December 2025\n12 December 2025\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nClinical Trial & License Agreement Update\nRoquefort\nTherapeutics\nplc (\nLSE:ROQ\n), the Main Market listed biotech company, announces that the binding exclusive license agreement with Coiled Therapeutics, Inc. (\"Coiled USA\") and A2A Pharmaceuticals, Inc. (\"A2A Pharma\") regarding the worldwide exclusive rights to AO-252 (the \"AO-252 License Agreement\") announced on 18 November 2025 has been amended and includes an extension to the long stop date from 31 January 2026 to 16 March 2026. In addition, the Company provides an update on the progress of the Phase I clinical trial which is currently underway in USA.\nClinical Stage Progress\nCoiled USA recently received approval for a protocol amendment to expand the inclusion criteria for its Phase I clinical trial for AO-252 to encompass all solid tumours, including patients with or without brain metastases.\nFollowing this successful protocol amendment, together with encouraging safety signals, Coiled USA has strategically prioritised prostate cancer as its primary indication for clinical trials, with the first patient with metastatic castration-resistant prostate cancer being enrolled and dosed in November 2025 within the active Cohort 4b dose level.\nThe decision by Coiled USA to\nprioritise prostate cancer as its primary indication for clinical trials is supported by positive feedback from potential pharmaceutical partners and investors, and is also underpinned by compelling pre-clinical data across multiple distinct models:\n\u00b7\nVCaP Xenografts (AR-positive, ETS-fusion)\n: demonstrated 100% complete response/partial response (\"CR+PR\") with complete regressions observed;\n\u00b7\nAR-independent Cell Lines\n: significant tumour growth inhibition (\"TGI\") of 60% was observed in androgen receptor (\"AR\") independent models;\n\u00b7\n22Rv1 Models (AR-resistant)\n: demonstrated 90% TGI; and\n\u00b7\nMechanism\n: importantly, efficacy was observed to be independent of androgen signalling, suggesting broad potential utility in resistant disease.\nCoiled USA is currently enrolling additional patients in Cohort 4b, the best of six cohort dose levels where the strongest clinical benefit has been observed to date. In addition, Coiled USA has initiated a food effect cohort study using the Cohort 4b dose to optimise exposure based on clear PK/PD modelling.\nThe commercial interest in oral targeted therapies for multiple types of solid tumours, including prostate cancer, was recently demonstrated by the announcement on 17 November 2025 by Johnson & Johnson that it was acquiring Halda Therapeutics OpCo, Inc (\"Halda\") for US$3.05 billion in cash. Prior to the acquisition, Halda's Phase I/II clinical trial had demonstrated impressive preliminary efficacy and a strong early safety profile in prostate cancer.\nLicense Extension\nCompletion of the AO-252 License Agreement is conditional on\ninter alia\nthe Company's enlarged ordinary share capital being admitted to trading on the AIM market (\"Admission\") no later than 31 January 2026 (the \"Longstop Date\"). The Company and its advisers are currently progressing key documents relating to the Transaction (defined below), including an AIM Admission Document which will be published in due course.\nDue to the impact of the forthcoming holiday season, it is unlikely that Admission will occur prior to 31 January 2026 and therefore the parties to the AO-252 License Agreement have agreed to extend the Longstop Date to 16 March 2026 in return for an amendment to certain commercial terms (refer below). The extension to the Longstop Date will also provide additional time for data readouts from the clinical trial.\nAmendment to Commercial Terms\nIn return for agreeing to extend the Longstop Date, the parties to the AO-252 License Agreement have agreed to amend the following commercial terms in the agreement:\n1.\nThe upfront consideration amount has been increased to \u00a331,875,000\nto be satisfied by the issue of ordinary shares in the capital of the Company (\"Ordinary Shares\") to the shareholders of Coiled USA (the \"Consideration Shares\") at an effective price of 1.7 pence per share, subject to the satisfaction of certain conditions, including Admission (the \"Transaction\");\n2. The total number of additional Ordinary Shares to be issued to A2A Pharma should certain market capitalisation targets be met for a period of 30 consecutive days (the \"Deferred Consideration Shares\") has been amended to the following:\na. Market capitalisation of the Company being greater than or equal to \u00a360 million: 250 million Deferred Consideration Shares;\nb. Market capitalisation of the Company being greater than or equal to \u00a390 million: a further 250 million Deferred Consideration Shares; and\nc. Market capitalisation of the Company being greater than or equal to \u00a3120 million: a further 250 million Deferred Consideration Shares.\nThe Board believes tha",
          "content_length": 9921
        },
        "ingested_at": "2026-01-16T22:42:51.255939Z"
      },
      {
        "event_id": "RNS-9th Dec 2025-conversi",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.255954Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Conversion of CLNs",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/conversion-of-clns-8l8itdd9wcrarzz.html",
          "rns_number": "RNS Number : 7191K",
          "full_content": "9 Dec 2025 07:00\nRNS Number : 7191K\nRoquefort Therapeutics PLC\n09 December 2025\n9 December 2025\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nConversion of CLNs\nRoquefort Therapeutics (LSE:ROQ),\nthe Main Market listed biotech company\n, announces that\nthe Company has received notices, in two tranches, to convert a total face value of \u00a380,000 convertible loan notes (the \"CLNs\") resulting in the issue of 6,282,264 new ordinary shares in the Company (the \"CLN Shares\").\nIn accordance with the terms of the CLNs, which were issued and announced on 23 May 2024, all accrued interest on the CLNs at a rate of 12.5% per annum is included in the conversion into the Company's ordinary shares of \u00a30.01 each (\"Ordinary Shares\"). The conversion price of the first tranche of the CLNs representing a face value of \u00a330,000 is 1.81p and the conversion price of the second tranche of the CLNs representing a face value of \u00a350,000 is 1.29p. The conversion price is calculated as being 90% of the price equal to the 10-day volume-weighted average price calculated backwards from the date, which is three business days prior to the notice of conversion given to the Company.\nFollowing conversion of these CLNs, the Company has CLNs with a face value of \u00a3257,894 outstanding.\nAdmission and Total Voting Rights\nApplication will be made for the CLN Shares to be admitted to trading on the London Stock Exchange's Main Market for listed securities, which is expected to occur on or around 16 December 2025 (\"Admission\"). The CLN Shares will rank\npari passu\nin all respects with the Company's existing Ordinary Shares.\nFollowing Admission, the Company's issued share capital will comprise 163,726,294 Ordinary Shares in issue, with each share carrying the right to one vote. The Company does not hold any Ordinary Shares in treasury. The figure of 163,726,294 Ordinary Shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or of a change to their interest in the Company under the FCA's Disclosure and Transparency Rules.\nRegulatory Information\nThis Announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\").\nENDS\nEnquiries:\nRoquefort Therapeutics plc\n+44 (0)20 3918 8633\nStephen West (Chairman) / Dr Darrin Disley (Interim MD)\nSP Angel Corporate Finance LLP (Broker to the Company)\nDavid Hignell / Vadim Alexandre / Devik Mehta\n+44 (0)20 3470 0470\nShard Capital Partners LLP (Broker to the Company)\nDamon Heath\n+44 (0)20 4530 6926\nBurson Buchanan (Public Relations)\nBen Romney / Jamie Hooper\n+44 (0)20 7466 5000\nLEI: \u200e254900P4SISIWOR9RH34\nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ) is focused on completing the\nproposed transaction with A2A Pharmaceuticals, Inc. and Coiled Therapeutics, Inc. which will result in the Company acquiring the exclusive licence rights to AO-252, a novel first-in-class, first-in-human new drug alternative targeting the TACC3 protein for the treatment of certain cancers, initially announced by the Company on 8 September 2025.\nFor further information on Roquefort Therapeutics, please\nvisit\nwww.roquefortplc.com\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nCONUPGAPPUPAGMR",
          "content_length": 4127
        },
        "ingested_at": "2026-01-16T22:42:51.255968Z"
      },
      {
        "event_id": "RNS-1st Dec 2025-ex-entit",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.255981Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Ex-Entitlement Date - Unlisted RNV Shares",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/ex-entitlement-date-unlisted-rnv-shares-0ign7kiqd0h0a60.html",
          "rns_number": "RNS Number : 6886J",
          "full_content": "1 Dec 2025 10:35\nRNS Number : 6886J\nRoquefort Therapeutics PLC\n01 December 2025\n1 December 2025\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nEx-Entitlement Date - Unlisted Redeemable Non-Voting Shares\nRoquefort Therapeutics (LSE:ROQ),\nthe Main Market listed biotech company\n, announces that further to the Company's announcement earlier today confirming that the record date for determining entitlement to the Unlisted Redeemable Non-Voting Shares (\"Unlisted RNV Shares\") has now passed, its ordinary shares will be marked ex-entitlement in respect of the Unlisted RNV Shares with effect from the commencement of trading today, 1 December 2025.\nAccordingly, all holders of ordinary shares and convertible loan notes who were on the Company's register as at close of business on 28 November 2025 will be eligible to receive the Unlisted RNV Shares. In addition, anyone who purchased ordinary shares on Friday, 28 November 2025 will also be eligible to receive the Unlisted RNV Shares.\nA detailed timetable for the crediting of the Unlisted RNV Shares to eligible shareholders, together with full details of the entitlement ratio and the exact number of Unlisted RNV Shares to be issued, will be set out in a further announcement to be made in due course.\nRegulatory Information\nThis Announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\").\nENDS\nEnquiries:\nRoquefort Therapeutics plc\n+44 (0)20 3918 8633\nStephen West (Chairman) / Dr Darrin Disley (Interim MD)\nSP Angel Corporate Finance LLP (Broker to the Company)\nDavid Hignell / Vadim Alexandre / Devik Mehta\n+44 (0)20 3470 0470\nShard Capital Partners LLP (Broker to the Company)\nDamon Heath\n+44 (0)20 4530 6926\nBurson Buchanan (Public Relations)\nBen Romney / Jamie Hooper\n+44 (0)20 7466 5000\nLEI: \u200e254900P4SISIWOR9RH34\nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ) is focused on completing the\nproposed transaction with A2A Pharmaceuticals, Inc. and Coiled Therapeutics, Inc. which will result in the Company acquiring the exclusive licence rights to AO-252, a novel first-in-class, first-in-human new drug alternative targeting the TACC3 protein for the treatment of certain cancers, initially announced by the Company on 8 September 2025.\nFor further information on Roquefort Therapeutics, please\nvisit\nwww.roquefortplc.com\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nFURUAORRVOUURAA",
          "content_length": 3280
        },
        "ingested_at": "2026-01-16T22:42:51.255994Z"
      },
      {
        "event_id": "RNS-1st Dec 2025-determin",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.256008Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Determination of Record Date and Entitlement",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/determination-of-record-date-and-entitlement-2fiznj740yo0c37.html",
          "rns_number": "RNS Number : 5583J",
          "full_content": "1 Dec 2025 07:00\nRNS Number : 5583J\nRoquefort Therapeutics PLC\n01 December 2025\n1 December 2025\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nDetermination of Record Date and Entitlement\nRoquefort Therapeutics (LSE:ROQ),\nthe Main Market listed biotech company\n, announces that, following the announcement on 3 November 2025 regarding the proposed issue of new unlisted redeemable non-voting shares (\"Unlisted RNV Shares\"), the Company confirms that the record date for determining entitlement to the Unlisted RNV Shares has now passed.\nHolders of ordinary shares and convertible loan notes who were on the Company's registers as at close of business on 30 November 2025 (the \"Record Date\") will be entitled to receive Unlisted RNV Shares.\nThe Unlisted RNV Shares will carry the right to all future commercial benefits arising from the Company's Midkine Investments portfolio, with the ultimate intention of facilitating an\nin-specie\ndistribution of the Midkine Investments shares to the holders of Unlisted RNV Shares when the Company's balance sheet permits such a distribution in accordance with the Companies Act 2006.\nFull details of the entitlement ratio, the exact number of Unlisted RNV Shares to be issued, the crediting process and the anticipated timetable will be set out in a further announcement to be made in due course.\nRegulatory Information\nThis Announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\").\nENDS\nEnquiries:\nRoquefort Therapeutics plc\n+44 (0)20 3918 8633\nStephen West (Chairman) / Dr Darrin Disley (Interim MD)\nSP Angel Corporate Finance LLP (Broker to the Company)\nDavid Hignell / Vadim Alexandre / Devik Mehta\n+44 (0)20 3470 0470\nShard Capital Partners LLP (Broker to the Company)\nDamon Heath\n+44 (0)20 4530 6926\nBurson Buchanan (Public Relations)\nBen Romney / Jamie Hooper\n+44 (0)20 7466 5000\nLEI: \u200e254900P4SISIWOR9RH34\nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ) is focused on completing the\nproposed transaction with A2A Pharmaceuticals, Inc. and Coiled Therapeutics, Inc. which will result in the Company acquiring the exclusive licence rights to AO-252, a novel first-in-class, first-in-human new drug alternative targeting the TACC3 protein for the treatment of certain cancers, initially announced by the Company on 8 September 2025.\nFor further information on Roquefort Therapeutics, please\nvisit\nwww.roquefortplc.com\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCFLFSRLTLIVIE",
          "content_length": 3360
        },
        "ingested_at": "2026-01-16T22:42:51.256021Z"
      },
      {
        "event_id": "RNS-25th Nov 2025-holding(",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.256034Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Holding(s) in Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/holdings-in-company-xs1jcq47mea80wx.html",
          "rns_number": "RNS Number : 7986I",
          "full_content": "25 Nov 2025 07:00\nRNS Number : 7986I\nRoquefort Therapeutics PLC\n25 November 2025\nTR-1: Standard form for notification of major holdings\n1. Issuer Details\nISIN\nGB00BMDQ2T15\nIssuer Name\nRoquefort Therapeutics PLC\nUK or Non-UK Issuer\nUK\n2. Reason for Notification\nAn acquisition or disposal of voting rights\n3. Details of person subject to the notification obligation\nName\nTrevor Reginald\nCity of registered office (if applicable)\nStratford-Upon-Avon\nCountry of registered office (if applicable)\nUNITED KINGDOM\n4. Details of the shareholder\nFull name of shareholder(s) if different from the person(s) subject to the notification obligation, above\nCity of registered office (if applicable)\nCountry of registered office (if applicable)\n5. Date on which the threshold was crossed or reached\n24-Nov-2025\n6. Date on which Issuer notified\n24-Nov-2025\n7. Total positions of person(s) subject to the notification obligation\n% of voting rights attached to shares (total of 8.A)\n% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)\nTotal of both in % (8.A + 8.B)\nTotal number of voting rights held in issuer\nResulting situation on the date on which threshold was crossed or reached\n2.400000\n0.000000\n2.400000\n3805076\nPosition of previous notification (if applicable)\n8. Notified details of the resulting situation on the date on which the threshold was crossed or reached\n8A. Voting rights attached to shares\nClass/Type of shares ISIN code(if possible)\nNumber of direct voting rights (DTR5.1)\nNumber of indirect voting rights (DTR5.2.1)\n% of direct voting rights (DTR5.1)\n% of indirect voting rights (DTR5.2.1)\nGB00BMDQ2T15\n3805076\n2.400000\nSub Total 8.A\n3805076\n2.400000%\n8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))\nType of financial instrument\nExpiration date\nExercise/conversion period\nNumber of voting rights that may be acquired if the instrument is exercised/converted\n% of voting rights\nSub Total 8.B1\n8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))\nType of financial instrument\nExpiration date\nExercise/conversion period\nPhysical or cash settlement\nNumber of voting rights\n% of voting rights\nSub Total 8.B2\n9. Information in relation to the person subject to the notification obligation\n1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.\nUltimate controlling person\nName of controlled undertaking\n% of voting rights if it equals or is higher than the notifiable threshold\n% of voting rights through financial instruments if it equals or is higher than the notifiable threshold\nTotal of both if it equals or is higher than the notifiable threshold\n10. In case of proxy voting\nName of the proxy holder\nThe number and % of voting rights held\nThe date until which the voting rights will be held\n11. Additional Information\nNotification of change from previous position of 6.5% (10,305,076 shares) to 2.4% (3,805,076 shares)\n12. Date of Completion\n24-Nov-2025\n13. Place Of Completion\nStratford upon Avon\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nHOLUSABRVSUAUAA",
          "content_length": 3921
        },
        "ingested_at": "2026-01-16T22:42:51.256047Z"
      },
      {
        "event_id": "RNS-24th Nov 2025-director",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.256060Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Director/PDMR Shareholding",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/directorpdmr-shareholding-g5vn8ffzwwr6mpq.html",
          "rns_number": "RNS Number : 6299I",
          "full_content": "24 Nov 2025 07:00\nRNS Number : 6299I\nRoquefort Therapeutics PLC\n24 November 2025\n24 November 2025\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nDirector/PDMR Shareholding\nRoquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, advises that Dr Darrin Disley, Interim Managing Director, has purchased ordinary shares of \u00a30.01 each in the Company (\"Ordinary Shares\"), as detailed below:\nNumber of Ordinary Shares Acquired\nAverage Price Paid per Share\nTotal Consideration Paid\nNumber of Ordinary Shares Now Held\n% of Company's Issued Capital\n5,000,000\n1.70 pence\n\u00a385,000.00\n7,024,196\n4.46%\n-ENDS-\nEnquiries:\nRoquefort Therapeutics plc\n+44 (0)20 3918 8633\nStephen West (Chairman) / Dr Darrin Disley (Interim MD)\nSP Angel Corporate Finance LLP (Joint Broker)\nDavid Hignell / Vadim Alexandre / Devik Mehta\n+44 (0) 20 3470 0470\nShard Capital Partners LLP (Joint Broker)\nDamon Heath\n+44 (0)20 4530 6926\nBurson Buchanan (Public Relations)\nBen Romney / Jamie Hooper\n+44 (0)20 7466 5000\nPeak IR (Investor Relations)\nSeb Wykeham\n+33 (0)7 44 44 15 42\nLEI: \u200e254900P4SISIWOR9RH34\nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ) is focused on completing the\nproposed transaction with A2A Pharmaceuticals, Inc. and Coiled Therapeutics, Inc. which will result in the Company acquiring the exclusive licence rights to AO-252, a novel first-in-class, first-in-human new drug alternative targeting the TACC3 protein for the treatment of certain cancers, most recently announced by the Company on 18 November 2025.\nFor further information on Roquefort Therapeutics, please\nvisit\nwww.roquefortplc.com\nThis announcement contains inside information for the purposes of Article 7 of the UK version of Market Regulation (EU) No 596/2014 on Market Abuse as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended (\"UK MAR\").\nThe notification below, made in accordance with the requirements of the UK MAR, provides further detail:\nNOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM\n1\nDetails of the person discharging managerial responsibilities / person closely associated\na)\nName\nDarrin Disley\n2\nReason for the notification\na)\nPosition/status\nInterim Managing Director\nb)\nInitial notification /Amendment\nInitial\n3\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor\na)\nName\nRoquefort Therapeutics plc\nb)\nLEI\n254900P4SISIWOR9RH34\n4\nDetails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\na)\nDescription of the financial instrument, type of instrument\nIdentification code\nOrdinary shares of \u00a30.01 par value\nISIN: GB00BMDQ2T15\nb)\nNature of the transaction\nPurchase of 5,000,000 ordinary shares\nc)\nPrice(s) and volume(s)\nPrice(s)\nVolume(s)\n1.70 pence per share\n5,000,000\nd\nAggregated information\n- Aggregated volume\n- Price\n- 5,000,000\n- 1. 70p\ne)\nDate of the transactions\n21 November 2025\nf)\nPlace of the transactions\nLondon Stock Exchange (XLON); Main Market\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nDSHBRBDBDSDDGUX",
          "content_length": 3996
        },
        "ingested_at": "2026-01-16T22:42:51.256072Z"
      },
      {
        "event_id": "RNS-18th Nov 2025-executed",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.256086Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Executed License Agreement & Transaction Update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/executed-license-agreement-transaction-update-ef2ih3lroxvgffm.html",
          "rns_number": "RNS Number : 8895H",
          "full_content": "18 Nov 2025 07:00\nRNS Number : 8895H\nRoquefort Therapeutics PLC\n18 November 2025\n18 November 2025\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nExecuted License Agreement & Transaction Update\nRoquefort\nTherapeutics\nplc (\nLSE:ROQ\n), the Main Market listed biotech company, is pleased to announce that further to the announcements made on 8 September, 16 October and 3 November 2025, the Company has entered into a binding exclusive license agreement with Coiled Therapeutics, Inc. (\"Coiled USA\") and A2A Pharmaceuticals, Inc. (\"A2A Pharma\") regarding the worldwide exclusive rights to AO-252 (the \"AO-252 License Agreement\").\nAO-252 is a clinical stage, novel first-in-class, first in-human new drug alternative targeting the TACC3 protein for the treatment of multiple cancers. TACC3 is over-expressed in multiple cancers, driving chromosomal instability, metastasis, and cancer cell migration.\nHighlights\n\u00b7\nImmediate access to a clinical asset, first-in-class oncology candidate with encouraging efficacy, responses, and clinical benefit with a very benign safety profile;\n\u00b7\nCurrently undertaking a Phase I trial in the USA (trials ID: NCT06136884) in advanced solid tumours;\n\u00b7\nEarly clinical trial demonstrates tumour shrinkage with minimal side effects;\n\u00b7\nAO-252 has strong monotherapy efficacy in preclinical models of prostate, breast, gastric, ovarian, endometrial and lung cancers and potentially less toxic approach to traditional cancer treatments like chemotherapy and other targeted therapies;\n\u00b7\nStrong market opportunity, based on biomarker population with up to 350,000 patients in the US and Europe;\n\u00b7\nMultiple near term value inflection points based on future data readouts; and\n\u00b7\nUpon completion of the Transaction (as defined below), it is proposed that the name of the Company be changed to Coiled Therapeutics plc.\nTransaction Details\nPursuant to the AO-252 License Agreement, Coiled USA has granted worldwide exclusive rights to AO-252 in return for an upfront consideration amount of \u00a325.5 million\nto be satisfied by the issue of ordinary shares in the capital of the Company (\"Ordinary Shares\") to the shareholders of Coiled USA (the \"Consideration Shares\") subject to the satisfaction of certain conditions, including the Placing and Admission, further details of which are set out below (the \"Transaction\").\nAs part of the proposed\nTransaction, the Company will (i) cancel the listing of its ordinary shares on the Equity Shares (Transition) category of the Official List of the Financial Conduct Authority (previously the Standard listing segment of the Main Market) and trading on the Main Market for listed securities of the London Stock Exchange, (ii) make application for its ordinary share capital to be admitted to trading on the AIM market (\"Admission\") and (iii) carry out an equity placing by the issue of new ordinary shares to raise a minimum of \u00a310.5 million conditional on Admission (\"Placing\").\nThe issue price of the Consideration Shares is 1.7 pence per share, adjusted for the effect of dilution of any additional Ordinary Shares on issue at Admission (excluding the Consideration Shares and Placing shares) over and above an agreed base line number of Ordinary Shares on issue of 208.5 million shares (the Company currently has 157,444,030 Ordinary Shares in issue).\nDue to the number of Consideration Shares being issued relative to the Company's existing Ordinary Shares in issue, the Transaction will constitute a reverse takeover.\nCompletion of the AO-252 License Agreement is conditional on\ninter alia\n(i) the Placing having completed; (ii) certain individuals proposed by Coiled USA being appointed to the Board of the Company; (iii) Coiled USA changing its name to exclude the word \"Coiled\" or any derivatives thereof; and (iv) Admission occurring no later than 31 January 2026 (or such other date as may be agreed between the parties).\nUpon completion of the Transaction it is proposed that the name of the Company be changed to Coiled Therapeutics plc.\nThe Company and its advisers are currently progressing key documents relating to the Transaction, including an AIM Admission Document which will be published in due course.\nShareholders should be aware that there is a possibility that the Transaction will not proceed. The Company looks forward to providing shareholders with further updates on the Transaction in due course.\nDeferred Consideration\nIn addition to the Consideration Shares, there is the potential for additional Ordinary Shares to be issued to A2A Pharma should certain market capitalisation targets be met for a period of 30 consecutive days, as follows (the \"Deferred Consideration Shares\"):\na) Market capitalisation of the Company being greater than or equal to \u00a360 million: 200 million Deferred Consideration Shares;\nb) Market capitalisation of the Company being greater than or equal to \u00a390 million: a further 200 million Deferred Consideration Shares; and\nc) Market capitalisation of the Company be",
          "content_length": 11969
        },
        "ingested_at": "2026-01-16T22:42:51.256116Z"
      },
      {
        "event_id": "RNS-3rd Nov 2025-mkcellou",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.256132Z",
        "source": "LSE_RNS",
        "data": {
          "title": "MK Cell Out-License & Lyramid SPA Update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/mk-cell-out-license-lyramid-spa-update-sdbzfz54z46hhrt.html",
          "rns_number": "RNS Number : 8172F",
          "full_content": "3 Nov 2025 07:00\nRNS Number : 8172F\nRoquefort Therapeutics PLC\n03 November 2025\n3 November 2025\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nMK Cell Out-License & Lyramid SPA Update\nRoquefort Therapeutics (LSE:ROQ),\nthe Main Market listed biotech company\n, announces it has entered into an agreement to out-license its MK Cell patents to Pleiades Pharma Ltd (\"Pleiades\") in return for up to US$25 million in milestone cash payments together and a royalty payment obligation (the \"MK Cell Out-License\").\nBackground\nAs announced on 8 September 2025, the Company is proposing to acquire from A2A Pharmaceuticals, Inc. and Coiled Therapeutics, Inc. the exclusive licence rights to AO-252, a novel first-in-class, first-in-human new drug alternative targeting the TACC3 protein for the treatment of certain cancers (the \"Proposed Transaction\"), retain the STAT-6 program and has ceased discussions around the sale of its wholly owned subsidiary Oncogeni Ltd. Further details on the progress of the Proposed Transaction will be announced in due course.\nFollowing the announcement of the Proposed Transaction, the Company initiated discussions with Pleiades regarding the grant of an exclusive worldwide license for its MK Cell program, which has resulted in the signing of the MK Cell Out-License.\nMK Cell Out-License\nTo accommodate the Group Restructuring (refer below) that was signalled in August 2025, the parties to the MK Cell Out-License are Roquefort Therapeutics' wholly owned subsidiary Midkine Investments Ltd (\"Midkine Investments\") and Pleiades. The consideration payable by Pleiades for the MK Cell Out-License is a combination of milestone cash payments and a royalty payment obligation of 1.5% perpetuity royalty on all global net sales of products derived from the licensed technology.\nThe total milestone cash payments of up to US$25 million is payable by Pleiades as follows:\na) US$500,000 upon Pleiades securing a minimum fundraising amount, with potential to increase to US$650,000 upon Pleiades securing a increased fundraising amount;\nb) US$500,000 upon the filing of a regulatory submission for the first study in humans;\nc) US$1 million upon the first regulatory approval for the initiation of a confirmatory Phase 2 or a Phase 3 clinical study;\nd) US$1 million upon the first regulatory submission for registration;\ne) US$1 million upon the first regulatory approval; and\nf) Up to US$21 million upon reaching various worldwide sales targets (\"WST\"): US$1.5 million on WST of US$10 million, US$5 million on WST of US$100 million, US$5 million on WST of US$150 million and US$9.5 million on WST of US$300 million.\nLyramid SPA Update\nOn 1 February 2025 the Company signed a binding share purchase agreement (\"SPA\") for the sale of its wholly owned subsidiary Lyramid Pty Ltd (\"Lyramid\") to Pleiades for a total consideration amount of up to US$10.8 million. Completion of the SPA is contingent on Pleaides completing a fundraising round by a certain date (the \"Longstop Date\"). The current Longstop Date was 31 October 2025. Pleiades' fundraising with institutional and sovereign wealth fund investors in the GCC (Gulf Cooperation Council) is continuing, however the current Longstop Date did not allow sufficient time for Pleiades to complete its current fundraising round and accordingly the parties have agreed to extend the Longstop Date to 31 January 2026. The total consideration amount for the sale of Lyramid of up to US$10.8 million is unchanged.\nIn addition to extending the Longstop Date, the parties have agreed to amend the following terms in the SPA:\ni) Change the selling party in the agreement from Roquefort Therapeutics plc to Midkine Investments Ltd to account for the Group Restructuring (refer below); and\nii) Recognise that the third party license agreement granting Lyramid rights to the Midkine antibody program will terminate in accordance with its provisions on 4 November 2025.\nGroup Restructuring\nThe Company intends to carve out the value of the Lyramid SPA and the MK Cell Out-License for the benefit of existing shareholders and convertible loan holders. In order to facilitate this, the Company has recently undertaken the following restructuring of the Group (the \"Group Restructuring\"):\na) The entire issued shares of Lyramid have been acquired by Midkine Investments (a 100% owned subsidiary of Roquefort Therapeutics) such that Lyramid is now 100% owned by Midkine Investments; and\nb) The rights to the MK Cell program held by Oncogeni Ltd have been novated to Midkine Investments such that Midkine Investments now holds the underlying exclusive worldwide rights to the MK Cell program.\nIt is the intention of the Company to issue new unlisted redeemable non-voting shares (\"Unlisted RNV Shares\") to the holders of Roquefort Therapeutics ordinary shares and convertible loan notes listed on the Company's registers as at 30 November 2025. The Unlisted RNV Shares will entitle holders to all commercial benefits from Midki",
          "content_length": 8562
        },
        "ingested_at": "2026-01-16T22:42:51.256150Z"
      },
      {
        "event_id": "RNS-16th Oct 2025-fundrais",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.256164Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Fundraise & Transaction Update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/fundraise-transaction-update-0z4hwi26c1m21wo.html",
          "rns_number": "RNS Number : 5247D",
          "full_content": "16 Oct 2025 07:00\nRNS Number : 5247D\nRoquefort Therapeutics PLC\n16 October 2025\n16\nOctober 2025\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nFundraise & Transaction Update\nRoquefort\nTherapeutics\nplc (\nLSE:ROQ\n), the Main Market listed biotech company, is pleased to announce that it has raised funds of \u00a3300,000, with \u00a3200,000 by way of advance subscription agreements (\"Advance Subscriptions\") from certain strategic investors, and \u00a3100,000 by way of a loan from A2A Pharmaceuticals, Inc. (\"A2A Pharma\") (the \"A2A Pharma Loan\").\nThe aggregate net proceeds of the Advance Subscriptions and A2A Pharma Loan will be used to fund the upfront costs of the proposed transaction with A2A Pharma and Coiled Therapeutics, Inc. (\"Coiled USA\") which will result in the Company acquiring the exclusive licence rights to AO-252, a novel first-in-class, first-in-human new drug alternative targeting the TACC3 protein for the treatment of certain cancers (the \"Proposed Transaction\"), initially announced by the Company on 8 September 2025.\nStephen West, the Company's Chairman, participated in the Advance Subscriptions with an investment of \u00a345,000.\nTerms of the Advance Subscriptions\nThe Advance Subscriptions instrument allows investors to subscribe for ordinary shares in the Company at a discount of 20% to the issue price at the next placing (\"Next Placing Price\") undertaken by the Company in conjunction with the Proposed Transaction. The determination of the issue price and the issue of the Advance Subscriptions shares will take place in conjunction with completion of the Proposed Transaction. The Advance Subscriptions instrument includes a right to receive a one for one warrant in the event that the Advance Subscription shares are still held by the investor on 30 June 2026 (\"Loyalty Warrant\"). The Loyalty Warrant has an exercise price equal to the Next Placing Price and a term of two years from the issue date.\nTerms of the A2A Pharma Loan\nThe A2A Pharma Loan accrues interest at a rate of 5% and is repayable on the earlier of (a) the date of completion of the Proposed Transaction; (b) the date falling 12 months after the loan; or (c) the date falling 6 months after the term sheet relating to the Proposed Transaction is terminated.\nA2A Pharma may, at its sole discretion, elect to convert some or all of the A2A Pharma Loan into ordinary shares in Roquefort Therapeutics at a price of 2p per share.\nProposed Transaction Update\nThe Company has appointed all the advisors required to complete the documentation for the Proposed Transaction and drafting of the main transaction documents is now progressing well. The Company will provide further updates on the Proposed Transaction in due course.\nStephen West, Executive Chairman, commented:\n\"We are pleased to have completed this fundraise which provides the funding for the upfront costs associated with our recently announced proposed value accretive transaction. It is particularly pleasing to see the participation of A2A Pharma for a significant amount of the proceeds raised, demonstrating their commitment to move the deal towards completion in an efficient and timely manner. We look forward to providing more updates as appropriate as we hit the critical milestones of this transformative transaction.\n\"\nEnquiries:\nRoquefort Therapeutics plc\n+44 (0)20 3918 8633\nStephen West (Chairman) / Dr Darrin Disley (Interim MD)\nSP Angel Corporate Finance LLP (Broker to the Company)\nDavid Hignell / Vadim Alexandre / Devik Mehta\n+44 (0)20 3470 0470\nCPS Capital (Broker to A2A Pharmaceuticals & Coiled USA)\nJason Peterson / David Valentino\n+61 (0)8 9223 2222\nBurson Buchanan (Public Relations)\nBen Romney / Jamie Hooper\n+44 (0)20 7466 5000\nLEI: \u200e254900P4SISIWOR9RH34\nFor further information on Roquefort Therapeutics, please\nvisit\nwww.roquefortplc.com\nThis announcement contains inside information for the purposes of Article 7 of the UK version of Market Regulation (EU) No 596/2014 on Market Abuse as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended (\"UK MAR\").\nAbout Coiled USA\nCoiled USA is a clinical stage oncology company and is a spin-out of A2A Pharmaceuticals, Inc. (\"A2A Pharma\"). Coiled USA, in conjunction with A2A Pharma, holds the exclusive worldwide rights to AO-252, a novel, brain-penetrant small molecule inhibitor designed to disrupt TACC3 protein-protein interactions.\nCoiled USA has advanced the AO-252 program through pre-clinical development and IND approval and commenced Phase I trials in the USA (trials ID: NCT06136884). Coiled USA is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments.\nAbout A2A Pharma\nA2A Pharma is a private, well-funded company that uses proprietary computational systems, including generative AI with its SCULPT\u2122 platform to accelerate the development of novel drug alternatives for life threatening diseases like cancer. This enables a more effic",
          "content_length": 6409
        },
        "ingested_at": "2026-01-16T22:42:51.256181Z"
      },
      {
        "event_id": "RNS-30th Sep 2025-interimr",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.256194Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Interim Results to 30 June 2025",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/interim-results-to-30-june-2025-60zjhnht6m5vbbx.html",
          "rns_number": "RNS Number : 2608B",
          "full_content": "30 Sep 2025 07:00\nRNS Number : 2608B\nRoquefort Therapeutics PLC\n30 September 2025\n30 September 2025\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nInterim Results to 30 June 2025\nRoquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company announces its interim results for the six-month period ended 30 June 2025 (the \"period\" or \"H1\").\nHighlights\n\u00b7\nThe Company announced its intention to pivot away from its existing focus on pre-clinical assets to more mature clinical stage assets\n\u00b7\nSigned binding share purchase agreement with Pleiades Pharma Limited (\"Pleiades Pharma\") for the proposed sale of Lyramid Pty Ltd (\"Lyramid\") for a consideration of $10.8 million\no\nLong stop date of the transaction to complete is 31 October 2025\n\u00b7\nSigned term sheet with The Nation Trust Holding LLC (\"Nation Trust\") for the sale of Oncogeni Ltd (\"Oncogeni\")\u00a0for a consideration cash amount of up to US$12 million consisting of upfront and milestone payments\n\u00b7\nRaised \u00a3236,000 by way of a private placement with the proceeds being for general working capital purposes as the Company continued to work towards completion of the Lyramid and Oncogeni transactions\n\u00b7\nAjan Reginald resigned as CEO, Prof. Sir Martin Evans resigned as Non-Executive Director and Dr Darrin M Disley OBE, a Non-Executive Director, was appointed Interim Managing Director in March 2025\n\u00b7\nCash at period end of \u00a3182,923 and a net loss of \u00a3467,167 for the 6 months to 30 June 2025\nPost Period End Highlights\n\u00b7\nIn line with the Company's new strategy of focusing on more mature clinical stage assets, the Company announced the proposed acquisition (the \"Transaction\") of Coiled Therapeutics, Inc. (\"Coiled USA\"), a clinical stage oncology company, currently in a Phase I trial for its AO-252 therapy in the USA (trials ID: NCT06136884) in advanced solid tumours and is showing encouraging efficacy, responses, and clinical benefit with a benign safety profile\no\nTerm sheet is binding with exclusivity until 31 January 2026 and may only be cancelled early upon payment of a termination fee of US$1 million\no\nUpon completion of the Transaction it is proposed that the name of the Company be changed to Coiled Therapeutics plc\n\u00b7\nCoiled USA has expressed interest in advancing the STAT-6 program into clinical trials, and accordingly the Company has terminated discussions with Nation Trust for the sale of Oncogeni\n\u00b7\nAs previously announced the Company intends to transfer ownership of its wholly owned subsidiary Lyramid to the Company's underlying shareholders so the Company's existing shareholders benefit from the Pleiades Pharma sale\n\u00b7\nThe Company has the option to carve out the MK Cell therapy prior to completion of the Transaction\nOutlook\n\u00b7\nThe principal focus of the Company is to deliver on the new strategy of targeting clinical stage assets by completing the proposed acquisition of Coiled USA\n\u00b7\nThe primary focus of the enlarged entity (to be renamed Coiled Therapeutics plc) will be on advancing clinical trials for the AO-252 therapy:\no\nEarly Phase I data on AO-252 is very encouraging, and we believe it could be a promising alternative for helping patients with a variety of cancers\no\nPlan to start dose expansion studies in Q4 2025 and enrol a sufficient number of patients in 2026 to plan for Phase III registrational trials\n\u00b7\nIn addition, the Company plans to advance STAT-6 through IND and prepare for clinical trials\nRegulatory Information\nThis Announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\").\nCommenting on the Interim Results, Roquefort Therapeutics Chairman, Stephen West said:\n\"During the period Roquefort Therapeutics announced a new strategic direction to refocus from pre-clinical assets towards clinical stage assets with a clearer path towards value creation and we are pleased to have identified Coiled Therapeutics from A2A Pharmaceuticals as our transformational acquisition. Our focus for the remainder of the year is to complete the proposed acquisition of Coiled Therapeutics, which will potentially set the Company up with two clinical stage assets: AO-252 an STAT-6. We will keep shareholders updated as to its progress and I would like to thank them for their ongoing support.\"\nEnquiries:\nRoquefort Therapeutics plc\n+44 (0)20 3918 8633\nStephen West (Chairman) / Dr Darrin Disley (Interim MD)\nSP Angel Corporate Finance LLP (Broker)\nDavid Hignell / Vadim Alexandre / Devik Mehta\n+44 (0)20 3470 0470\nBurson Buchanan (Public Relations)\nBen Romney / Jamie Hooper\n+44 (0)20 7466 5000\nPeak IR (Investor Relations)\nSeb Wykeham\n+33 (0)7 44 44 15 42\nLEI: \u200e254900P4SISIWOR9RH34\nChairman Statement\nI am pleased to present the interim financial statements to shareholders for the six months ended 30 June 2025.\nThis was a busy period for Roquefort Therapeutics as the Company sought to ext",
          "content_length": 32247
        },
        "ingested_at": "2026-01-16T22:42:51.256212Z"
      },
      {
        "event_id": "RNS-24th Sep 2025-investor",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.256225Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Investor Presentation via Engage Investor",
          "category": "RNS-R",
          "url": "https://www.lse.co.uk/rns/ROQ/investor-presentation-via-engage-investor-j3ssitzf62o6mpj.html",
          "rns_number": "RNS Number : 5229A",
          "full_content": "24 Sep 2025 07:00\nRNS Number : 5229A\nRoquefort Therapeutics PLC\n24 September 2025\n24 September 2025\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nInvestor Presentation via Engage Investor\nRoquefort Therapeutics (LSE:ROQ),\nthe Main Market listed biotech company\n, announces that the Company's Chairman Stephen West alongside Edward Painter and Sridhar Vempati, Chairman and Chief Strategy Officer respectively of A2A Pharmaceuticals, Inc. (\"A2A Pharma\") will host a live interactive presentation on the Engage Investor platform on Monday, 29 September 2025 at 4pm BST.\nThe objective of the presentation is to provide investors with an update relating to the proposed acquisition of Coiled Therapeutics, Inc. and its AO-252 clinical stage program from A2A Pharma.\nAll current shareholders and interested investors are invited to join and investors are encouraged to pre-submit questions via the Engage Investor platform. Investors can also submit questions at any time during the live presentation.\nInvestors can sign up to Engage Investor at no cost and follow Roquefort Therapeutics from their personalised investor hub.\nRegister interest in this event here:\nhttps://engageinvestor.news/ROQ_IP_0925\nENDS\nEnquiries:\nRoquefort Therapeutics plc\n+44 (0)20 3918 8633\nStephen West (Chairman) / Dr Darrin Disley (Interim MD)\nSP Angel Corporate Finance LLP (Broker to the Company)\nDavid Hignell / Vadim Alexandre / Devik Mehta\n+44 (0)20 3470 0470\nCPS Capital (Broker to A2A Pharmaceuticals)\nJason Peterson / David Valentino\n+61 (0)8 9223 2222\nBurson Buchanan (Public Relations)\nBen Romney / Jamie Hooper\n+44 (0)20 7466 5000\nPeak IR (Investor Relations)\nSeb Wykeham\n+33 (0)7 44 44 15 42\nLEI: \u200e254900P4SISIWOR9RH34\nFor further information on Roquefort Therapeutics, please visit\nwww.roquefortplc.com\nand @RoquefortTherap on X (formerly Twitter)\nThis information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNRAUOUBRVSUKUAR",
          "content_length": 2576
        },
        "ingested_at": "2026-01-16T22:42:51.256238Z"
      },
      {
        "event_id": "RNS-8th Sep 2025-proposed",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.256251Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Proposed Acquisition of Clinical Stage Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/proposed-acquisition-of-clinical-stage-company-ivsk3wbvac9krr8.html",
          "rns_number": "RNS Number : 3792Y",
          "full_content": "8 Sep 2025 07:00\nRNS Number : 3792Y\nRoquefort Therapeutics PLC\n08 September 2025\n8 September 2025\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nProposed Acquisition of Clinical Stage Company\nTransformative Acquisition for Roquefort Therapeutics\nRoquefort\nTherapeutics\nplc (\nLSE:ROQ\n), the Main Market listed biotech company, is pleased to announce that it has entered into Head of Terms (\"Term Sheet\") to acquire 100% of the issued capital of Coiled Therapeutics, Inc. (\"Coiled USA\") by way of a reverse takeover (the \"Transaction\").\nHighlights\n\u00b7\nAcquisition of Coiled USA for an upfront amount of \u00a330 million, payable in shares\n\u00b7\nCoiled USA is a spin-out from A2A Pharmaceuticals which holds exclusive worldwide rights to AO-252\n\u00b7\nAO-252 is a novel first-in-class, first-in-human new drug alternative targeting the TACC3 protein for the treatment of cancer\n\u00b7\nPrevious company spun out from A2A Pharmaceuticals, Biomea Fusion, reached a peak market capitalisation of over US$1 billion\n\u00b7\nAO-252 is currently in a Phase I trial in the USA (trials ID: NCT06136884) in advanced solid tumours and is showing encouraging efficacy, responses, and clinical benefit with a very benign safety profile\n\u00b7\nAO-252 has shown strong efficacy in preclinical models of multiple solid tumours as a more precise and potentially less toxic approach to traditional cancer treatments like chemotherapy and other targeted therapies\n\u00b7\nCoiled USA plans to start dose expansion studies in Q4 2025 and enrol a sufficient number of patients in 2026 to plan for Phase 3 registrational trials\n\u00b7\nLooking to progress the Company's existing STAT-6 program through IND into Phase I clinical trials\n\u00b7\nA2A Pharmaceuticals and its investors are committed to providing the majority of the funding requirement over the next two years with an investment of \u00a36 million\n\u00b7\nThe Term Sheet is binding as to exclusivity until 31 January 2026 and may only be cancelled early upon payment of a termination fee of US$1 million\n\u00b7\nPrior to completion of the Transaction, Roquefort Therapeutics intends to carve-out Lyramid Pty Ltd and the MK Cell program for the benefit of existing shareholders\n\u00b7\nUpon completion of the Transaction it is proposed that the name of the Company be changed to Coiled Therapeutics plc\n\u00b7\nThe Transaction was introduced to A2A Pharmaceuticals and managed by Perth based Stockbroker and Corporate Advisory firm, CPS Capital Group Pty Ltd\nAbout Coiled USA\nCoiled USA is a clinical stage oncology company and is a spin-out of A2A Pharmaceuticals, Inc. (\"A2A Pharmaceuticals\"). Coiled USA, through A2A Pharmaceuticals, holds the exclusive worldwide rights to AO-252, a novel, brain-penetrant small molecule inhibitor designed to disrupt TACC3 protein-protein interactions. TACC3, or Transforming Acidic Coiled-Coil Containing Protein 3, is a protein over-expressed in multiple cancer cells and has important roles in DNA damage repair, DNA replication/transcription, immunity and mitosis. AO-252 has shown strong preclinical efficacy with complete tumour regression as monotherapy in ovarian, triple negative breast, endometrial, gastric, and prostate cancers with strong efficacy in\nin-vivo\nbrain metastases as well.\nAO-252 is a more precise and potentially less toxic new drug alternative to traditional cancer treatments like chemotherapy and other targeted therapies because TACC3 is not required in normal cells. Whilst initially focused as a monotherapy, AO-252 could work well in combination with other drugs such as immunotherapies helping to overcome potential resistance.\nA2A Pharmaceuticals and Coiled USA have advanced the AO-252 program through pre-clinical development and IND approval and have commenced Phase I trials in the USA (trials ID: NCT06136884). Coiled USA is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments.\nCoiled USA is enrolling further patients for its Phase I trial for AO-252\nfor TP53 mutated ovarian, endometrial and triple-negative breast cancers. An amendment has been filed to expand the market of AO-252 into all solid tumours. Based on the biomarket population, AO-252 could potentially be used to help as many as 350,000 cancer patients across multiple indications in the USA and European Union.\nInitial results are encouraging with the drug showing very good safety and significant signs of efficacy, responses and clinical benefit in patients on low dosage.\nAbout A2A Pharmaceuticals\nA2A Pharmaceuticals is a private, well-funded company that uses proprietary computational systems, including generative AI with its SCULPT\u2122 platform to accelerate the development of novel drug alternatives for life threatening diseases like cancer. This enables a more efficient process than traditional trial and error approaches to drug discovery.\nA2A Pharmaceuticals aims to develop therapies to early clinical stages and then spin them out into standalone entities to progress them through clinical dev",
          "content_length": 12083
        },
        "ingested_at": "2026-01-16T22:42:51.256268Z"
      },
      {
        "event_id": "RNS-28th Aug 2025-lyramids",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.256282Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Lyramid SPA 2nd Extension & Carve Out",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/lyramid-spa-2nd-extension-carve-out-xcks4a6d7rp0xz7.html",
          "rns_number": "RNS Number : 9207W",
          "full_content": "28 Aug 2025 07:00\nRNS Number : 9207W\nRoquefort Therapeutics PLC\n28 August 2025\n28 August 2025\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nLyramid SPA 2nd Extension & Carve Out\nRoquefort Therapeutics (LSE:ROQ),\nthe Main Market listed biotech company focused on\ndeveloping first in class medicines in the high value and high growth immunology and oncology markets\n, advises that deadline to complete the binding share purchase agreement (the \"SPA\") for the sale of its wholly owned subsidiary Lyramid Pty Ltd (\"Lyramid\") to Pleiades Pharma Limited (\"Pleiades\") (the \"Transaction\") has been extended from 31 August 2025 to 31 October 2025.\nBackground & Reason for Extension\nOn 1 February 2025 the Company signed the SPA for the sale of its wholly owned subsidiary Lyramid to Pleiades for a total consideration amount of up to US$10.8 million. Completion of the SPA is contingent\ninter alia\non Pleaides completing a fundraising round by a certain date (the \"Longstop Date\"). The Longstop Date was originally 30 June 2025; however, the parties agreed in June 2025 to extend this date to 31 August 2025. The parties have now mutually agreed in writing to extend this date further to 31 October 2025.\nPleiades' fundraising with institutional and sovereign wealth fund investors in the GCC (Gulf Cooperation Council) has progressed. The terms for investment have been determined with the due diligence now proceeding. Therefore, the Company and Pleiades have agreed to a two-month extension.\nUpon completion of the Transaction, the Company will receive shares in Pleiades (\"Pleiades Consideration Shares\") and potentially some cash of up to US$2 million. The amount of cash received upfront will be determined at completion via a mechanism in the SPA.\nIncorporation of a New Equity Holding Company\nAs the Transaction is now likely to complete, a new equity holding company has now been incorporated (Midkine Investments Ltd) to hold the Pleiades Consideration Shares. At completion of the Transaction, existing shareholders and convertible loan note holders in\nRoquefort Therapeutics will\nbe issued with shares in Midkine Investments Ltd pro-rata with their interest in Roquefort Therapeutics. This will effectively carve out the Pleiades shares for the benefit of existing Roquefort Therapeutics shareholders.\nThe Company will provide shareholders with further updates regarding the progress of this material Transaction as appropriate.\nDr Darrin Disley, OBE, Roquefort Therapeutics Interim Managing Director commented:\n\"We are encouraged by the progress Pleiades has made with its new investors and pleased to be able to reach an agreement to extend the date by a further two months to enable this material Transaction to complete. We have recently incorporated Midkine Investments Ltd in order to carve-out a significant portion of value from this Transaction for existing Roquefort Therapeutics shareholders ahead of advancing our plans to acquire clinical stage assets and/or revenue generating life science businesses.\"\nRegulatory Information\nThis Announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\").\nENDS\nEnquiries:\nRoquefort Therapeutics plc\n+44 (0)20 3918 8633\nStephen West (Chairman) / Dr Darrin Disley (Interim MD)\nSP Angel Corporate Finance LLP (Broker)\nDavid Hignell / Vadim Alexandre / Devik Mehta\n+44 (0) 20 3470 0470\nBurson Buchanan (Public Relations)\nBen Romney / Jamie Hooper\n+44 (0)20 7466 5000\nPeak IR (Investor Relations)\nSeb Wykeham\n+33 (0)7 44 44 15 42\nLEI: \u200e254900P4SISIWOR9RH34\nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ) is developing first in class drugs in the\nimmunology and oncology markets\nprior to securing a value accretive exit.\nRoquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer and immunology assets.\nFor further information on Roquefort Therapeutics, please\nvisit\nwww.roquefortplc.com\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCGZGZRDNNGKZM",
          "content_length": 4872
        },
        "ingested_at": "2026-01-16T22:42:51.256294Z"
      },
      {
        "event_id": "RNS-7th Jul 2025-director",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.256307Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Director/PDMR Shareholding",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/directorpdmr-shareholding-tvqeglxkletrs40.html",
          "rns_number": "RNS Number : 8938P",
          "full_content": "7 Jul 2025 07:00\nRNS Number : 8938P\nRoquefort Therapeutics PLC\n07 July 2025\n7 July 2025\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nDirector/PDMR Shareholding\nRoquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on\ndeveloping first in class medicines in the high value and high growth immunology and oncology markets\n, advises that Stephen West, Executive Chairman has purchased ordinary shares of \u00a30.01 each in the Company (\"Ordinary Shares\"), as detailed below:\nNumber of Ordinary Shares Acquired\nAverage Price Paid per Share\nTotal Consideration Paid\nNumber of Ordinary Shares Now Held\n% of Company's Issued Capital\n2,400,000\n1.50 pence\n\u00a336,000.00\n9,110,853\n5.79%\n7,028,485 of Mr West's Ordinary Shares are held in the name of Cresthaven Investments Pty Ltd ATF the Bellini Trust.\n-ENDS-\nEnquiries:\nRoquefort Therapeutics plc\n+44 (0)20 3918 8633\nStephen West (Chairman) / Dr Darrin Disley (Interim MD)\nSP Angel Corporate Finance LLP (Broker)\nDavid Hignell / Vadim Alexandre / Devik Mehta\n+44 (0) 20 3470 0470\nBurson Buchanan (Public Relations)\nBen Romney / Jamie Hooper\n+44 (0)20 7466 5000\nPeak IR (Investor Relations)\nSeb Wykeham\n+33 (0)7 44 44 15 42\nLEI: \u200e254900P4SISIWOR9RH34\nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ) is developing first in class drugs in the\nimmunology and oncology markets\nprior to securing a value accretive exit.\nRoquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer and immunology assets.\nFor further information on Roquefort Therapeutics, please\nvisit\nwww.roquefortplc.com\nThis announcement contains inside information for the purposes of Article 7 of the UK version of Market Regulation (EU) No 596/2014 on Market Abuse as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended (\"UK MAR\").\nThe notification below, made in accordance with the requirements of the UK MAR, provides further detail:\nNOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM\n1\nDetails of the person discharging managerial responsibilities / person closely associated\na)\nName\nStephen West\n2\nReason for the notification\na)\nPosition/status\nExecutive Chairman\nb)\nInitial notification /Amendment\nInitial\n3\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor\na)\nName\nRoquefort Therapeutics plc\nb)\nLEI\n254900P4SISIWOR9RH34\n4\nDetails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\na)\nDescription of the financial instrument, type of instrument\nIdentification code\nOrdinary shares of \u00a30.01 par value\nISIN: GB00BMDQ2T15\nb)\nNature of the transaction\nPurchase of 2,400,000 ordinary shares\nc)\nPrice(s) and volume(s)\nPrice(s)\nVolume(s)\n1.50 pence per share\n2,400,000\nd\nAggregated information\n- Aggregated volume\n- Price\n- 2,400,000\n- 1.50p\ne)\nDate of the transactions\n4 July 2025\nf)\nPlace of the transactions\nLondon Stock Exchange (XLON); Main Market\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nDSHBUGDRBGGDGUL",
          "content_length": 3969
        },
        "ingested_at": "2026-01-16T22:42:51.256319Z"
      },
      {
        "event_id": "RNS-30th Jun 2025-director",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.256332Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Director/PDMR Shareholding",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/directorpdmr-shareholding-gmkrp2szkd1tr1c.html",
          "rns_number": "RNS Number : 8517O",
          "full_content": "30 Jun 2025 07:00\nRNS Number : 8517O\nRoquefort Therapeutics PLC\n30 June 2025\n30 June 2025\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nDirector/PDMR Shareholding\nRoquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on\ndeveloping first in class medicines in the high value and high growth immunology and oncology markets\n, advises that Dr Simon Sinclair, Non-Executive Director has purchased ordinary shares of \u00a30.01 each in the Company (\"Ordinary Shares\"), as detailed below:\nNumber of Ordinary Shares Acquired\nAverage Price Paid per Share\nTotal Consideration Paid\nNumber of Ordinary Shares Now Held\n% of Company's Issued Capital\n72,507\n1.37 pence\n\u00a3995.01\n108,428\n0.07%\n-ENDS-\nEnquiries:\nRoquefort Therapeutics plc\n+44 (0)20 3918 8633\nStephen West (Chairman) / Dr Darrin Disley (Interim MD)\nSP Angel Corporate Finance LLP (Broker)\nDavid Hignell / Vadim Alexandre / Devik Mehta\n+44 (0) 20 3470 0470\nBurson Buchanan (Public Relations)\nBen Romney / Jamie Hooper\n+44 (0)20 7466 5000\nPeak IR (Investor Relations)\nSeb Wykeham\n+33 (0)7 44 44 15 42\nLEI: \u200e254900P4SISIWOR9RH34\nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ) is developing first in class drugs in the\nimmunology and oncology markets\nprior to securing a value accretive exit.\nRoquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer and immunology assets.\nFor further information on Roquefort Therapeutics, please\nvisit\nwww.roquefortplc.com\nThis announcement contains inside information for the purposes of Article 7 of the UK version of Market Regulation (EU) No 596/2014 on Market Abuse as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended (\"UK MAR\").\nThe notification below, made in accordance with the requirements of the UK MAR, provides further detail:\nNOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM\n1\nDetails of the person discharging managerial responsibilities / person closely associated\na)\nName\nSimon Sinclair\n2\nReason for the notification\na)\nPosition/status\nNon-Executive Director\nb)\nInitial notification /Amendment\nInitial\n3\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor\na)\nName\nRoquefort Therapeutics plc\nb)\nLEI\n254900P4SISIWOR9RH34\n4\nDetails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\na)\nDescription of the financial instrument, type of instrument\nIdentification code\nOrdinary shares of \u00a30.01 par value\nISIN: GB00BMDQ2T15\nb)\nNature of the transaction\nPurchase of 72,507 ordinary shares\nc)\nPrice(s) and volume(s)\nPrice(s)\nVolume(s)\n1.37 pence per share\n72,507\nd\nAggregated information\n- Aggregated volume\n- Price\n- 72,507\n- 1.37p\ne)\nDate of the transactions\n27 June 2025\nf)\nPlace of the transactions\nLondon Stock Exchange (XLON); Main Market\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nDSHDGGDLSBDDGUR",
          "content_length": 3853
        },
        "ingested_at": "2026-01-16T22:42:51.256345Z"
      },
      {
        "event_id": "RNS-27th Jun 2025-lyramids",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.256358Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Lyramid SPA Extension",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/lyramid-spa-extension-19inmby9dlyd00n.html",
          "rns_number": "RNS Number : 6479O",
          "full_content": "27 Jun 2025 07:00\nRNS Number : 6479O\nRoquefort Therapeutics PLC\n27 June 2025\n27 June 2025\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nLyramid SPA Extension\nRoquefort Therapeutics (LSE:ROQ),\nthe Main Market listed biotech company focused on\ndeveloping first in class medicines in the high value and high growth immunology and oncology markets\n, advises that deadline to complete the binding share purchase agreement (the \"SPA\") for the sale of its wholly owned subsidiary Lyramid Pty Ltd (\"Lyramid\") to Pleiades Pharma Limited (\"Pleiades\") (the \"Transaction\") has been extended from 30 June 2025 to 31 August 2025.\nBackground & Reason for Extension\nOn 1 February 2025 the Company signed the SPA for the sale of its wholly owned subsidiary Lyramid to Pleiades for a total consideration amount of up to US$10.8 million. Completion of the SPA is contingent\ninter alia\non Pleaides completing a fundraising round by a certain date (the \"Longstop Date\"). The Longstop Date was originally 30 June 2025; however, the parties have mutually agreed in writing to extend this date to 31 August 2025.\nPleiades has advised that its fundraising with certain high-profile investors in the United Arab Emirates is advancing; however, due to the recent geopolitical events in the region they are experiencing some delays in closing the funding round and have requested a two month extension to allow additional time to close the funding.\nUpon completion of the Transaction, the Company will receive shares in Pleiades (\"Pleiades Consideration Shares\") and potentially some cash of up to US$2 million. The amount of cash received upfront will be determined at completion via a mechanism in the SPA.\nIntention to Incorporate a New Equity Holding Company\nImmediately prior to completion, it is the intention of the Company to incorporate a new subsidiary company to hold the Pleiades Consideration Shares (\"New Equity Holding Company\"). Existing shareholders and convertible loan note holders in\nRoquefort Therapeutics at completion will then\nbe issued with shares in New Equity Holding Company pro-rata with their interest in Roquefort Therapeutics. This will effectively carve out the Pleiades shares for the benefit of existing shareholders.\nThe Company will provide shareholders with further updates regarding the progress of this material Transaction as appropriate.\nDr Darrin Disley, OBE, Roquefort Therapeutics Interim Managing Director commented:\n\"Although it is frustrating that we were unable to complete the Lyramid SPA by the original Long Stop Date we are pleased that Pleiades have agreed to extend the date by two months to enable this material Transaction to complete. In parallel we are working on plans to carve-out a significant portion of value from this Transaction for existing Roquefort Therapeutics shareholders ahead of advancing our plans to acquire clinical stage assets and/or revenue generating life science businesses.\"\nRegulatory Information\nThis Announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\").\nENDS\nEnquiries:\nRoquefort Therapeutics plc\n+44 (0)20 3918 8633\nStephen West (Chairman) / Dr Darrin Disley (Interim MD)\nSP Angel Corporate Finance LLP (Broker)\nDavid Hignell / Vadim Alexandre / Devik Mehta\n+44 (0) 20 3470 0470\nBurson Buchanan (Public Relations)\nBen Romney / Jamie Hooper\n+44 (0)20 7466 5000\nPeak IR (Investor Relations)\nSeb Wykeham\n+33 (0)7 44 44 15 42\nLEI: \u200e254900P4SISIWOR9RH34\nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ) is developing first in class drugs in the\nimmunology and oncology markets\nprior to securing a value accretive exit.\nRoquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer and immunology assets.\nFor further information on Roquefort Therapeutics, please\nvisit\nwww.roquefortplc.com\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCUNABRVVUNUAR",
          "content_length": 4782
        },
        "ingested_at": "2026-01-16T22:42:51.256370Z"
      },
      {
        "event_id": "RNS-26th Jun 2025-resultso",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.256383Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Results of AGM",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/results-of-agm-qr020zfmd2e47q2.html",
          "rns_number": "RNS Number : 6026O",
          "full_content": "26 Jun 2025 13:00\nRNS Number : 6026O\nRoquefort Therapeutics PLC\n26 June 2025\n26 June 2025\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nResults of AGM\nRoquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on\ndeveloping first in class medicines in the high value and high growth immunology and oncology markets\n, is pleased to announce that at the Company's Annual General Meeting (\"\nAGM\n\") held earlier today, all resolutions proposed were duly passed.\nThe resolutions were put to shareholders via a poll, the results of which were as follows:\nResolution\nPoll Results\nTotal Votes Withheld*\nFor\nAgainst\nTotal Votes Cast\n1\nShares\n15,989,492\n205,120\n16,194,612\n289,738\n%\n98.73%\n1.27%\n2\nShares\n15,758,683\n432,163\n16,190,846\n293,504\n%\n97.33%\n2.67%\n3\nShares\n15,668,163\n522,683\n16,190,846\n293,504\n%\n96.77%\n3.23%\n4\nShares\n15,842,448\n352,163\n16,194,611\n289,739\n%\n97.83%\n2.17%\n5\nShares\n15,842,449\n352,163\n16,194,612\n289,738\n%\n97.83%\n2.17%\n6\nShares\n15,989,492\n205,120\n16,194,612\n289,738\n%\n98.73%\n1.27%\n7\nShares\n15,989,492\n205,120\n16,194,612\n289,738\n%\n98.73%\n1.27%\n8\nShares\n15,671,929\n522,683\n16,194,612\n289,738\n%\n96.77%\n3.23%\n9\nShares\n15,636,863\n557,749\n16,194,612\n289,738\n%\n96.56%\n3.44%\n*\nVotes withheld are not counted in the calculation of the proportion of votes for and against a resolution.\nThe total number of ordinary shares in issue on 24 June 2025, the deadline for casting votes by proxy in advance of the AGM, was 157,444,030 shares. 10.3% of voting capital was instructed in respect of the resolutions put to the AGM.\nEnquiries:\nRoquefort Therapeutics plc\n+44 (0)20 3918 8633\nStephen West (Chairman) / Dr Darrin Disley (Interim MD)\nSP Angel Corporate Finance LLP (Broker)\nDavid Hignell / Vadim Alexandre / Devik Mehta\n+44 (0) 20 3470 0470\nBurson Buchanan (Public Relations)\nBen Romney / Jamie Hooper\n+44 (0)20 7466 5000\nPeak IR (Investor Relations)\nSeb Wykeham\n+33 (0)7 44 44 15 42\nLEI: \u200e254900P4SISIWOR9RH34\nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ) is developing first in class drugs in the\nimmunology and oncology markets\nprior to securing a value accretive exit.\nRoquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer and immunology assets.\nFor further information on Roquefort Therapeutics, please\nvisit\nwww.roquefortplc.com\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nRAGFLFSLREIRFIE",
          "content_length": 3127
        },
        "ingested_at": "2026-01-16T22:42:51.256396Z"
      },
      {
        "event_id": "RNS-13th Jun 2025-issueofe",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.256409Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Issue of Equity",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/issue-of-equity-medpprq9hf27whq.html",
          "rns_number": "RNS Number : 8401M",
          "full_content": "13 Jun 2025 16:00\nRNS Number : 8401M\nRoquefort Therapeutics PLC\n13 June 2025\n13 June 2025\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nIssue of Equity\nRoquefort Therapeutics (LSE:ROQ),\nthe Main Market listed biotech company focused on\ndeveloping first in class medicines in the high value and high growth immunology and oncology markets\n, announces the issue of 2,466,547 new ordinary shares of \u00a30.01 each (\"Ordinary Shares\") in settlement of amounts owed to a former employee of the Company (\"Settlement Shares\").\nAdmission and Total Voting Rights\nApplication will be made for the Settlement Shares to be admitted to trading on the London Stock Exchange's Main Market for listed securities, which is expected to occur on or around 19 June 2025 (\"Admission\"). The Settlement Shares will rank\npari passu\nin all respects with the Company's existing Ordinary Shares.\nFollowing Admission, the Company's issued share capital will comprise 157,444,030 Ordinary Shares in issue, with each share carrying the right to one vote. The Company does not hold any Ordinary Shares in treasury. The figure of 157,444,030 Ordinary Shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or of a change to their interest in the Company under the FCA's Disclosure and Transparency Rules.\nRegulatory Information\nThis Announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\").\nENDS\nEnquiries:\nRoquefort Therapeutics plc\n+44 (0)20 3918 8633\nStephen West (Chairman) / Dr Darrin Disley (Interim MD)\nSP Angel Corporate Finance LLP (Broker)\nDavid Hignell / Vadim Alexandre / Devik Mehta\n+44 (0) 20 3470 0470\nBurson Buchanan (Public Relations)\nBen Romney / Jamie Hooper\n+44 (0)20 7466 5000\nPeak IR (Investor Relations)\nSeb Wykeham\n+33 (0)7 44 44 15 42\nLEI: \u200e254900P4SISIWOR9RH34\nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ) is developing first in class drugs in the\nimmunology and oncology markets\nprior to securing a value accretive exit.\nRoquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer and immunology assets.\nFor further information on Roquefort Therapeutics, please\nvisit\nwww.roquefortplc.com\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nIOEXXLFFEQLFBBV",
          "content_length": 3220
        },
        "ingested_at": "2026-01-16T22:42:51.256421Z"
      },
      {
        "event_id": "RNS-2nd Jun 2025-noticeof",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.256434Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Notice of Annual General Meeting",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/notice-of-annual-general-meeting-0857bff0qh25xjt.html",
          "rns_number": "RNS Number : 8971K",
          "full_content": "2 Jun 2025 07:00\nRNS Number : 8971K\nRoquefort Therapeutics PLC\n02 June 2025\n2 June 2025\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nNotice of Annual General Meeting\nRoquefort Therapeutics (LSE:ROQ),\nthe Main Market listed biotech company focused on\ndeveloping first in class medicines in the high value and high growth immunology and oncology markets\n,\nhas today posted its Notice of Annual General Meeting to Shareholders. The Annual General Meeting is scheduled to take place at the offices of Reynolds Porter Chamberlain LLP, Tower Bridge House, St Katherine's Way, London E1W 1AA at 10.00 am on 26 June 2025.\nThe Notice of Annual General Meeting and Forms of Proxy can be downloaded from the Company's corporate website at:\nhttps://www.roquefortplc.com/shareholder-documents\nENDS\nEnquiries:\nRoquefort Therapeutics plc\n+44 (0)20 3918 8633\nStephen West (Chairman) / Dr Darrin Disley (Interim MD)\nSP Angel Corporate Finance LLP (Broker)\nDavid Hignell / Vadim Alexandre / Devik Mehta\n+44 (0) 20 3470 0470\nBurson Buchanan (Public Relations)\nBen Romney / Jamie Hooper\n+44 (0)20 7466 5000\nPeak IR (Investor Relations)\nSeb Wykeham\n+33 (0)7 44 44 15 42\nLEI: \u200e254900P4SISIWOR9RH34\nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ) is developing first in class drugs in the\nimmunology and oncology markets\nprior to securing a value accretive exit.\nRoquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer and immunology assets.\nFor further information on Roquefort Therapeutics, please\nvisit\nwww.roquefortplc.com\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNOAPKDBNNBKDQAK",
          "content_length": 2366
        },
        "ingested_at": "2026-01-16T22:42:51.256447Z"
      },
      {
        "event_id": "RNS-23rd May 2025-extensio",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.256459Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Extension of Convertible Loan Notes",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/extension-of-convertible-loan-notes-ydi5rxqzlz8m8ie.html",
          "rns_number": "RNS Number : 8808J",
          "full_content": "23 May 2025 07:00\nRNS Number : 8808J\nRoquefort Therapeutics PLC\n23 May 2025\n23 May 2025\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nExtension of Convertible Loan Notes\nRoquefort Therapeutics (LSE:ROQ),\nthe Main Market listed biotech company focused on\ndeveloping first in class medicines in the high value and high growth immunology and oncology markets\n, announces that it has agreed with the holders of its convertible loan notes (\"CLNs\") to extend the maturity date to 31 December 2025\n.\nOn 23 May 2024 the Board resolved to issue CLNs with a total face value of \u00a3655,000. After taking into account previous conversions, there are currently CLNs with a total face value of \u00a3307,894 outstanding (\"Remaining CLNs\"). The Remaining CLNs were due to mature today (\"Maturity Date\"); however, the Company has agreed with the holders of the Remaining CLNs to extend the Maturity Date to 31 December 2025. All other terms and conditions of the CLNs remain unchanged.\nStephen West, Roquefort Therapeutics Chairman commented:\n\"We are pleased that the holders of the Remaining CLNs have agreed to extend the maturity date to the end of the year. This allows us sufficient time to focus on completing the previously announced Lyramid and Oncogeni transactions, whilst assessing other clinical stage assets and/or revenue generating life science businesses for possible M&A activity.\"\nRegulatory Information\nThis Announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\").\nENDS\nEnquiries:\nRoquefort Therapeutics plc\n+44 (0)20 3918 8633\nStephen West (Chairman) / Dr Darrin Disley (Interim MD)\nSP Angel Corporate Finance LLP (Broker)\nDavid Hignell / Vadim Alexandre / Devik Mehta\n+44 (0) 20 3470 0470\nBurson Buchanan (Public Relations)\nBen Romney / Jamie Hooper\n+44 (0)20 7466 5000\nPeak IR (Investor Relations)\nSeb Wykeham\n+33 (0)7 44 44 15 42\nLEI: \u200e254900P4SISIWOR9RH34\nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ) is developing first in class drugs in the\nimmunology and oncology markets\nprior to securing a value accretive exit.\nRoquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer and immunology assets.\nFor further information on Roquefort Therapeutics, please\nvisit\nwww.roquefortplc.com\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCFLLLLEELBBBV",
          "content_length": 3228
        },
        "ingested_at": "2026-01-16T22:42:51.256472Z"
      },
      {
        "event_id": "RNS-13th May 2025-corporat",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.256485Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Corporate Update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/corporate-update-lqqrmn44vr38esz.html",
          "rns_number": "RNS Number : 3380I",
          "full_content": "13 May 2025 07:00\nRNS Number : 3380I\nRoquefort Therapeutics PLC\n13 May 2025\n13 May 2025\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nCorporate Update\nRoquefort Therapeutics (LSE:ROQ),\nthe Main Market listed biotech company focused on\ndeveloping first in class medicines in the high value and high growth immunology and oncology markets\n, provides an update on the two previously announced material corporate transactions and the forward strategy for the Company\n.\nMaterial Corporate Transactions\nSale of Lyramid for US$10.8 Million\nOn 1 February 2025 the Company signed a binding share purchase agreement (the \"SPA\") for the sale of its wholly owned subsidiary Lyramid Pty Ltd (\"Lyramid\") to Pleiades Pharma Limited (\"Pleiades\") for a consideration amount of US$10.8 million. Completion of the SPA is contingent\ninter alia\non Pleaides finalising certain in-licensing transactions (the \"Licensing Condition Precedent\") and completing a current fundraising round no later than 30 June 2025 (the \"Funding Condition Precedent\"). As announced on 4 March 2025, the Licensing Condition Precedent has been satisfied with the Funding Condition Precedent remaining outstanding.\nPleiades has advised that its fundraising has progressed to the level of negotiating term sheets with certain high-profile investors in the United Arab Emirates (\"UAE\") and, whereas there can be no guarantees, Pleiades remains confident of satisfying the Funding Condition Precedent on schedule.\nThe completion of the transaction with Pleiades will give the Company and its shareholders exposure to a well-funded company with a significant portfolio of pre-clinical and clinical assets including a Phase 3 stage cell therapy and Phase 2 stage vaccine. A future trade-sale or stock exchange listing of Pleiades may result in a significant cash windfall to the Company which could be distributed to shareholders as a special dividend.\nSale of Oncogeni Ltd for up to US$12 Million\nAs announced on 10 March 2025, the Company signed a term sheet for the proposed sale of its wholly owned subsidiary Oncogeni Ltd (\"Oncogeni\") to The Nation Trust Holding LLC (\"Nation Trust\") for a consideration cash amount of up to US$12 million (the \"Term Sheet\"). It was the intention of the parties to sign a binding share purchase agreement (the \"Oncogeni SPA\") within 60 days of signing the Term Sheet; however, this has not yet occurred.\nNegotiations with Nation Trust are continuing with fortnightly meetings held in the UAE and it is now expected that the binding Oncogeni SPA will be executed in June 2025, with completion shortly thereafter.\nThe Company will provide shareholders with further updates regarding the progress of the two abovenamed material corporate transactions as appropriate.\nForward Strategy\nRoquefort Therapeutics is seeking to generate significant short-term value by completing the two abovenamed material corporate transactions and to build upon the recent change in leadership to pursue other value accretive opportunities during 2025.\nThe Company is focused on pursuing life science opportunities that are either clinical stage assets (phase 1 or phase 2) or life science businesses that are revenue generating with healthy growth rates, high product gross margins and, with the application of suitable operational gearing, can become profitable within approximately two years. The new leadership team recognises the benefit of pivoting from its existing focus on pre-clinical assets to more mature assets, to capitalise on current market conditions for biotech companies.\nRoquefort Therapeutics is currently assessing several opportunities and shareholders will be provided with further progress updates as appropriate.\nDr Darrin Disley, OBE, Roquefort Therapeutics Interim Managing Director commented:\n\"The Company remains focused on completing the Lyramid and Oncogeni transactions which, on completion, will validate our initial business model of acquiring early-stage pre-clinical assets and then selling them with a solid medium return on investment. The current headwinds facing biotech companies, particularly those whose assets are in the pre-clinical phase, dictates that an adjustment in business model is required. Accordingly, the Company is leveraging off the abovenamed material transactions and change in leadership to pivot its focus towards acquiring clinical stage assets and/or revenue generating life science businesses. This is an exciting transition stage for the Company and we look forward to updating the market as it progresses.\"\nRegulatory Information\nThis Announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\").\nENDS\nEnquiries:\nRoquefort Therapeutics plc\n+44 (0)20 3918 8633\nStephen West (Chairman) / Dr Darrin Disley (Interim MD)\nSP Angel Corporate Finance LLP (Broker)\nDavid Hign",
          "content_length": 6391
        },
        "ingested_at": "2026-01-16T22:42:51.256501Z"
      },
      {
        "event_id": "RNS-30th Apr 2025-annualre",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.256515Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Annual Report & Financial Statements - 31 Dec 2024",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/annual-report-financial-statements-31-dec-2024-xv6p17je1c0bwh0.html",
          "rns_number": "RNS Number : 7162G",
          "full_content": "30 Apr 2025 07:00\nRNS Number : 7162G\nRoquefort Therapeutics PLC\n30 April 2025\n30 April 2025\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nAnnual Report & Financial Statements - 31 Dec 2024\nRoquefort Therapeutics plc (LSE:ROQ),\nthe Main Market listed biotech company focused on\ndeveloping first in class medicines in the high value and high growth immunology and oncology markets\n, announces its audited results for year ended 31 December 2024.\nCopies of the Annual Report and Financial Statements will be made available on the Company's website at:\nhttps://www.roquefortplc.com/results-centre\nHighlights\n\u00b7\nConfidential out-licencing discussions continued with potential partners in 2024 which led to the Company signing a binding sale and purchase agreement in February 2025 for the sale of its wholly owned subsidiary Lyramid Pty Ltd (\"Lyramid SPA\")\n\u00b7\nImplemented significant cost cutting measures and restructured the Board\n\u00b7\nIssued unsecured convertible loan notes (the \"CLNs\") raising net proceeds of \u00a3584,915\n\u00b7\nContinued pre-clinical development with encouraging positive results\n\u00b7\nCash at year end 31 December 2024 of \u00a3337,112\nPre-clinical Highlights\n\u00b7\nFurther progress with Midkine m\nRNA\nby combining with a lipid nanoparticle (\"LNP\") delivery system in a validated\nin vivo\nmodel of liver cancer and demonstrated the safety and efficacy in reducing functional Midkine of the novel mRNA LNP combination\n\u00b7\nContinued the development of the novel STAT-6 medicines in validated\nin vitro\nmodels of colon cancer with the results demonstrating efficacy of the Group's four new siRNA sequences in reducing STAT-6 expression by 40-50%\n\u00b7\nNew set of experiments investigated the use of the siRNA in the STAT-6 inflammation and immunology (\"I&I\") field, which demonstrated efficacy in a validated\nin vitro\nexperimental model of immunological disease\nPost Period End Highlights\n\u00b7\nSale of Lyramid Pty Ltd:\nin February 2025 the Company signed the Lyramid SPA for the sale of its wholly owned subsidiary Lyramid Pty Ltd to Pleiades Pharma Ltd (\"Pleiades\") for a consideration amount of US$10.8 million. Completion is contingent\ninter alia\non Pleaides completing a current fundraising round no later than 30 June 2025\n\u00b7\nSale of Oncogeni Ltd\n: in March 2025 the Company signed a term sheet for the sale of its wholly owned subsidiary Oncogeni Ltd to The Nation Trust Holding LLC for a cash consideration amount of US$12 million, consisting of upfront and milestone payments\n\u00b7\nFundraise\n: On 14 March 2025 the Company raised \u00a3236,000 by way of a private placement with the proceeds being for general working capital purposes as the Company continues to work towards completion of the Lyramid Pty Ltd and Oncogeni Ltd transactions\n\u00b7\nBoard Changes\n: As part of a planned transition, Ajan Reginald resigned as CEO and Prof. Sir Martin Evans resigned as Non-Executive Director, both with effect from close of business on 17 March 2025. Dr Darrin M Disley OBE, a Non-Executive Director, was appointed Interim Managing Director with effect from close of business on 17 March 2025\nOutlook\n\u00b7\nRoquefort Therapeutics is looking to generate significant short-term value by completing the two previously announced material corporate transactions and to build upon the recent change in leadership in order to pursue other value accretive opportunities during 2025\nCommenting on the Annual Results, Executive Chairman, Stephen West said:\n\"During 2024 the Company continued its pre-clinical development, reporting positive progress across all our programs as well as out licensing discussions, a key pillar of our strategy. In order to preserve costs, the Company announced cost cutting measures in May 2024 as well as a fundraise of over \u00a3580,000 by way of CLNs. Roquefort Therapeutics remains in active discussions regarding the sales of Lyramid and Oncogeni for a combined consideration of over $20 million and is working towards finalising both transactions. During March 2025, we raised a further \u00a3236,000 by way of a private placing which provides the Company with sufficient working capital until Q2 2026, excluding any cash inflows that are generated from the proposed asset sales. Our focus for 2025 is to generate short term value by completing the two transactions and pursuing new value accretive opportunities.\n\"\nEnquiries:\nRoquefort Therapeutics plc\n+44 (0)20 3918 8633\nStephen West (Chairman) / Darrin Disley (Interim MD)\nSP Angel Corporate Finance LLP (Broker)\nDavid Hignell / Vadim Alexandre / Devik Mehta\n+44 (0) 20 3470 0470\nBurson Buchanan (Public Relations)\nBen Romney / Jamie Hooper\n+44 (0)20 7466 5000\nPeak IR (Investor Relations)\nSeb Wykeham\n+33 (0)7 44 44 15 42\nLEI: \u200e254900P4SISIWOR9RH34\nCHAIRMAN'S STATEMENT\nI am pleased to report Roquefort Therapeutics' audited financial statements and strategic progress to shareholders for the year ended 31 December 2024. During the period the Company continued to progress its corporate strategy, which is to develop its novel patent pro",
          "content_length": 111564
        },
        "ingested_at": "2026-01-16T22:42:51.256532Z"
      },
      {
        "event_id": "RNS-14th Mar 2025-privatep",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.256545Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Private Placing and Conversion of CLNs",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/private-placing-and-conversion-of-clns-v1ki2pht0kb0yj8.html",
          "rns_number": "RNS Number : 6428A",
          "full_content": "14 Mar 2025 07:00\nRNS Number : 6428A\nRoquefort Therapeutics PLC\n14 March 2025\n14 March 2025\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nPrivate Placing and Conversion of CLNs\nRoquefort Therapeutics (LSE:ROQ),\nthe Main Market listed biotech company focused on\ndeveloping first in class medicines in the high value and high growth immunology and oncology markets\n, announces that it has raised \u00a3236,000 by way of a private placing (the \"Placing\") of 15,733,333 new ordinary shares in the capital of the Company (the \"Placing Shares\") at a price of 1.5p, a discount of 6.25% to the closing price of 1.6p on 13 March 2025. In addition,\nthe Company has received a notice to convert a total face value of \u00a350,000 convertible loan notes (the \"CLNs\") resulting in the issue of 3,507,548 new ordinary shares in the Company (the \"CLN Shares\").\nThe proceeds of the Placing will be used for general working capital purposes as the Company continues to work towards completion of the US$10.8 million Lyramid Pty Ltd and US$12 million Oncogeni Ltd transactions. Any cash proceeds generated from the Oncogeni and Lyramid transactions will go towards progressing other value accretive opportunities.\nIn accordance with the terms of the CLNs, which were issued on 23 May 2024, all accrued interest on the CLNs at a rate of 12.5% per annum is included in the conversion into the Company's ordinary shares of \u00a30.01 each (\"Ordinary Shares\"). The conversion price of the CLNs is 1.57p, being 90% of the price equal to the 10-day volume-weighted average price calculated backwards from the date, which is three business days prior to the notice of conversion given to the Company.\nFollowing conversion of these CLNs, the Company has CLNs with a face value of \u00a3337,894 outstanding.\nAdmission and Total Voting Rights\nApplication will be made for the Placing Shares and CLN Shares to be admitted to trading on the London Stock Exchange's Main Market for listed securities, which is expected to occur on or around 21 March 2025 (\"Admission\"). The Placing Shares and CLN Shares will rank\npari passu\nin all respects with the Company's existing Ordinary Shares.\nFollowing Admission, the Company's issued share capital will comprise 154,977,483 Ordinary Shares in issue, with each share carrying the right to one vote. The Company does not hold any Ordinary Shares in treasury. The figure of 154,977,483 Ordinary Shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or of a change to their interest in the Company under the FCA's Disclosure and Transparency Rules.\nStephen West, Roquefort Therapeutics Chairman commented:\n\"Roquefort Therapeutics continues to operate at a reduced cost base (as announced in May 2024) and today's Placing, along with existing cash, will provide the Company with sufficient headroom for at least the next 12 months, excluding any cash inflows that are generated from the proposed asset sales that we have recently announced. We remain focused on completing the sales of Oncogeni and Lyramid and this fundraise ensures we have sufficient capacity to help execute our strategy.\"\nRegulatory Information\nThis Announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\").\nENDS\nEnquiries:\nRoquefort Therapeutics plc\n+44 (0)20 3918 8633\nStephen West (Chairman) / Ajan Reginald (CEO)\nSP Angel Corporate Finance LLP (Broker)\nDavid Hignell / Vadim Alexandre / Devik Mehta\n+44 (0) 20 3470 0470\nBurson Buchanan (Public Relations)\nBen Romney / Jamie Hooper\n+44 (0)20 7466 5000\nPeak IR (Investor Relations)\nSeb Wykeham\n+33 (0)7 44 44 15 42\nLEI: \u200e254900P4SISIWOR9RH34\nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ) is developing first in class drugs in the\nimmunology and oncology markets\nprior to securing a value accretive exit.\nRoquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer and immunology assets.\nFor further information on Roquefort Therapeutics, please\nvisit\nwww.roquefortplc.com\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Polic",
          "content_length": 5023
        },
        "ingested_at": "2026-01-16T22:42:51.256560Z"
      },
      {
        "event_id": "RNS-10th Mar 2025-boardcha",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.256573Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Board Changes",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/board-changes-j1tvggoky1lq85c.html",
          "rns_number": "RNS Number : 9097Z",
          "full_content": "10 Mar 2025 07:30\nRNS Number : 9097Z\nRoquefort Therapeutics PLC\n10 March 2025\n10 March 2025\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nBoard Changes\nRoquefort Therapeutics (LSE:ROQ),\nthe Main Market listed biotech company focused on\ndeveloping first in class medicines in the high value and high growth immunology and oncology markets\n, announces that as part of a planned transition, Ajan Reginald has advised his intention to resign as CEO and Director of the Company and Prof. Sir Martin Evans has also tendered his resignation as Non-Executive Director, both of which are with effect from close of business on 17 March 2025. Dr Darrin M Disley OBE, currently a Non-Executive Director, will be appointed Interim Managing Director with effect from close of business on 17 March 2025.\nDarrin Disley is a seasoned life sciences entrepreneur with a history of value creation in the UK market. His most notable achievement is leading gene editing company Horizon Discovery from start-up phase in 2007 to a \u00a368 million AIM IPO in 2014 and growing the business to generate significant revenues with a global presence before stepping down to pursue other interests in 2018. Horizon was eventually acquired by PerkinElmer in 2021 for a total Enterprise value of \u00a3296 million. Roquefort Therapeutics is pleased to have Dr Disley leading the business and his significant expertise will be of benefit to the Company going forward.\nMr Reginald's resignation is part of a planned transition as the Company completes the execution of the first phase of its business strategy via completion of the trade sales of its wholly-owned subsidiaries Lyramid Pty Ltd (\"Lyramid\") and Oncogeni Limited (\"Oncogeni\"). Ajan will remain a consultant to the Company and Chairman of the Company's wholly owned subsidiary Oncogeni in order to oversee the proposed sale of Oncogeni to The Nations Trust Holding, as announced earlier today, and to oversee the sale of Lyramid to Pleiades Pharma Ltd. Ajan has agreed to waive the notice period under his service agreement.\nStephen West, Roquefort Therapeutics Chairman commented:\n\"I would like to thank Ajan for his contribution during his time as CEO of Roquefort Therapeutics and am pleased that he is remaining as a consultant to the business to oversee the Lyramid and Oncogeni transactions. I would like to wish Ajan and Sir Martin well with their future endeavours. At the same time I would like to welcome Darrin as Interim Managing Director and look forward to working with him on communicating the forward strategy of the Company, which will build upon the change in leadership and the successful completion of the Lyramid and Oncogeni transactions.\"\nRegulatory Information\nThis Announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\").\nENDS\nEnquiries:\nRoquefort Therapeutics plc\n+44 (0)20 3918 8633\nStephen West (Chairman)\nSP Angel Corporate Finance LLP (Broker)\nDavid Hignell / Vadim Alexandre / Devik Mehta\n+44 (0) 20 3470 0470\nBurson Buchanan (Public Relations)\nBen Romney / Jamie Hooper\n+44 (0)20 7466 5000\nPeak IR (Investor Relations)\nSeb Wykeham\n+33 (0)7 44 44 15 42\nLEI: \u200e254900P4SISIWOR9RH34\nAbout Dr Darrin M Disley, OBE\nDarrin is a renowned scientist, entrepreneur, angel investor and enterprise champion who has started, grown, or invested in over 40 start-up life science, technology and social enterprises, raising US$600 million in business financing and closing US$700 million in commercial deals. He was CEO of Horizon Discovery Group plc for 11 years, during which he led the company from start-up through a \u00a368 million AIM IPO, and rapid scale-up powered by multiple acquisitions of US peer companies to become a global market leader in gene editing and gene modulation technologies. He was awarded a lifetime Queen's Award for Enterprise Promotion in 2016 for his work in promoting enterprise across the UK and appointed OBE in 2018 for his services to business and enterprise in the healthcare sector.\nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ) is developing first in class drugs in the\nimmunology and oncology markets\nprior to securing a value accretive exit.\nRoquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer and immunology assets.\nFor further information on Roquefort Therapeutics, please\nvisit\nwww.roquefortplc.com\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse ho",
          "content_length": 5322
        },
        "ingested_at": "2026-01-16T22:42:51.256589Z"
      },
      {
        "event_id": "RNS-10th Mar 2025-proposed",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.256603Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Proposed Sale of Oncogeni Ltd",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/proposed-sale-of-oncogeni-ltd-2cz7cm63mlwnz9o.html",
          "rns_number": "RNS Number : 9096Z",
          "full_content": "10 Mar 2025 07:00\nRNS Number : 9096Z\nRoquefort Therapeutics PLC\n10 March 2025\n10 March 2025\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nProposed Sale of Oncogeni Ltd\nRoquefort Therapeutics (LSE:ROQ),\nthe Main Market listed biotech company focused on\ndeveloping first in class medicines in the high value and high growth immunology and oncology markets\n, is pleased to announce the signing of a term sheet for the proposed sale of its wholly owned subsidiary Oncogeni Ltd (\"Oncogeni\") to The Nations Trust Holding LLC (\"Nations Trust\") for a consideration cash amount of up to US$12 million (the \"Term Sheet\"). Roquefort Therapeutics and Nations Trust Holding intend to sign a binding share purchase agreement (the \"SPA\") within 60 days, at which time further details of the transaction will be announced.\nPrincipal Transaction Terms\nThe Term Sheet includes the following principal terms:\n\u00b7\nSale of 100% of the issued share capital of Oncogeni to Nations Trust; and\n\u00b7\nCash consideration of US$12 million consisting of upfront and milestone payments.\nOncogeni Portfolio\nOncogeni holds the Company's exclusive licences to the Mesodermal Killer cell (MK) and STAT-6 siRNA (siRNA) patents. Since acquiring Oncogeni in 2022\nfor \u00a35 million in consideration (100% shares)\n, Roquefort Therapeutics has completed the in-house development of the MK and siRNA programs in oncology and immunology indications and expanded the siRNA patent portfolio.\nAbout Nations Trust Holding LLC\nNations Trust Holding LLC, based in the UAE, is\none of the largest and most diversified conglomerates based in the UAE\nwith dedicated Investment and R&D subsidiaries and services.\nThe Company will provide shareholders with further updates regarding the progress of the SPA as appropriate.\nAjan Reginald, Roquefort Therapeutics CEO commented:\n\"The proposed sale of Oncogeni is an important step towards completing the initial phase of the Company's strategy to acquire and develop pre-clinical assets and to then realise value through completing trade-sale transactions. We are pleased to be working with such a well-funded and highly resourced partner to take the Oncogeni portfolio into clinical trials, which if successful, will create long term value for the Company.\"\nRegulatory Information\nThis Announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\").\nENDS\nEnquiries:\nRoquefort Therapeutics plc\n+44 (0)20 3918 8633\nStephen West (Chairman) / Ajan Reginald (CEO)\nSP Angel Corporate Finance LLP (Broker)\nDavid Hignell / Vadim Alexandre / Devik Mehta\n+44 (0) 20 3470 0470\nBurson Buchanan (Public Relations)\nBen Romney / Jamie Hooper\n+44 (0)20 7466 5000\nPeak IR (Investor Relations)\nSeb Wykeham\n+33 (0)7 44 44 15 42\nLEI: \u200e254900P4SISIWOR9RH34\nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ) is developing first in class drugs in the\nimmunology and oncology markets\nprior to securing a value accretive exit.\nRoquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer and immunology assets.\nFor further information on Roquefort Therapeutics, please\nvisit\nwww.roquefortplc.com\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nDISUKOVRVNUORAR",
          "content_length": 4085
        },
        "ingested_at": "2026-01-16T22:42:51.256615Z"
      },
      {
        "event_id": "RNS-4th Mar 2025-updateon",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.256628Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Update on Sale of Lyramid",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/update-on-sale-of-lyramid-58z5ksh1u4k6ka6.html",
          "rns_number": "RNS Number : 1850Z",
          "full_content": "4 Mar 2025 07:00\nRNS Number : 1850Z\nRoquefort Therapeutics PLC\n04 March 2025\n4 March 2025\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nUpdate on Sale of Lyramid\nRoquefort Therapeutics (LSE:ROQ),\nthe Main Market listed biotech company focused on\ndeveloping first in class medicines in the high value and high growth immunology and oncology markets\n, is pleased to provide an update on the binding share purchase agreement (the \"SPA\") signed on 1 February 2025 for the sale of its wholly owned subsidiary Lyramid Pty Ltd (\"Lyramid\") to Pleiades Pharma Limited (\"Pleiades\") for a consideration amount of US$10.8 million (the \"Transaction\").\nAs announced on 3 February 2025, completion of the SPA is contingent\ninter alia\non Pleaides finalising certain in-licensing transactions and completing a current fundraising round no later than 30 June 2025 (each a \"Condition Precedent\").\nPleiades has now completed the in-licencing of the clinical stage PapMV cancer and infectious disease vaccine platform and the S100A9 immunotherapy from Innate BioSynergy (the \"Pleiades Licenses\"), to satisfy this Condition Precedent. The Pleiades Licenses are exclusive worldwide licenses for all the registered and unregistered intellectual property rights for the PapMV and S100A9 programs, including granted US patents for PapMV.\nPleiades has advised that its fundraising is progressing as expected and whereas there can be no guarantees, based on certain indications made by prospective investors it is confident of satisfying this Condition Precedent on schedule.\nThe Company will provide shareholders with further updates regarding the Transaction as appropriate.\nAjan Reginald, Roquefort Therapeutics CEO commented:\n\"We are pleased that the in-licenses have been signed, which is a key condition precedent for the sale of Lyramid, and that fundraising is progressing as expected. We look forward to progressing the Transaction to completion and remain focused on executing further transactions for our other programs in the future.\"\nRegulatory Information\nThis Announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\").\nENDS\nEnquiries:\nRoquefort Therapeutics plc\n+44 (0)20 3918 8633\nStephen West (Chairman) / Ajan Reginald (CEO)\nSP Angel Corporate Finance LLP (Broker)\nDavid Hignell / Vadim Alexandre / Devik Mehta\n+44 (0) 20 3470 0470\nBurson Buchanan (Public Relations)\nBen Romney / Jamie Hooper\n+44 (0)20 7466 5000\nPeak IR (Investor Relations)\nSeb Wykeham\n+33 (0)7 44 44 15 42\nLEI: \u200e254900P4SISIWOR9RH34\nAbout Pleiades\nPleiades is a private company developing a portfolio of novel clinical and pre-clinical medicines and is led by Caroline Fortier, an experienced Pharma CEO with a track-record of completing more than US$750 million in trade sale exits to Big Pharma. Pleiades is progressing its funding discussions with multiple institutional investors.\nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company developing first in class drugs in the high value and high growth\nimmunology and oncology markets\nprior to partnering with big pharma.\nRoquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of:\n\u00b7\nMidkine antibodies with significant\nin vivo\nefficacy and toxicology studies;\n\u00b7\nMidkine RNA therapeutics with novel anti-cancer gene editing action;\n\u00b7\nMidkine mRNA therapeutics with novel anti-cancer approach;\n\u00b7\nSTAT-6 siRNA therapeutics targeting solid tumours with significant\nin vivo\nefficacy; and\n\u00b7\nMK cell therapy with direct and NK cell-mediated anti-cancer action\nFor further information on Roquefort Therapeutics, please\nvisit\nwww.roquefortplc.com\nand\n@RoquefortTherap\non X (formerly Twitter).\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nUPDUPUMPWUPAPGW",
          "content_length": 4756
        },
        "ingested_at": "2026-01-16T22:42:51.256640Z"
      },
      {
        "event_id": "RNS-4th Feb 2025-director",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.256653Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Director/PDMR Shareholding",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/directorpdmr-shareholding-kpoyug66ads94lq.html",
          "rns_number": "RNS Number : 8629V",
          "full_content": "4 Feb 2025 10:58\nRNS Number : 8629V\nRoquefort Therapeutics PLC\n04 February 2025\n4 February 2025\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nDirector/PDMR Shareholding\nRoquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on\ndeveloping first in class medicines in the high value and high growth immunology and oncology markets\n, advises that Stephen West, Executive Chairman and Ajan Reginald, CEO have purchased ordinary shares of \u00a30.01 each in the Company (\"Ordinary Shares\"), as detailed below:\nDirector\nNumber of Ordinary Shares Acquired\nAverage Price Paid per Share\nTotal Consideration Paid\nNumber of Ordinary Shares Now Held\n% of Company's Issued Capital\nStephen West*\n400,000\n2.57 pence\n\u00a310,338.85\n6,710,853\n4.9%\nAjan Reginald\n191,059\n2.60 pence\n\u00a35,000.00\n12,537,472\n9.2%\n*4,628,485 of Mr West's Ordinary Shares are held in the name of Cresthaven Investments Pty Ltd ATF the Bellini Trust.\n-ENDS-\nEnquiries:\nRoquefort Therapeutics plc\n+44 (0)20 3918 8633\nStephen West (Chairman) / Ajan Reginald (CEO)\nSP Angel Corporate Finance LLP (Broker)\nDavid Hignell / Vadim Alexandre / Devik Mehta\n+44 (0) 20 3470 0470\nBurson Buchanan (Public Relations)\nBen Romney / Jamie Hooper / George Beale\n+44 (0)20 7466 5000\nPeak IR (Investor Relations)\nSeb Wykeham\n+33 (0)7 44 44 15 42\nLEI: \u200e254900P4SISIWOR9RH34\nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company developing first in class drugs in the high value and high growth\nimmunology and oncology markets\nprior to partnering with big pharma.\nRoquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of:\n\u00b7\nMidkine antibodies with significant\nin vivo\nefficacy and toxicology studies;\n\u00b7\nMidkine RNA therapeutics with novel anti-cancer gene editing action;\n\u00b7\nMidkine mRNA therapeutics with novel anti-cancer approach;\n\u00b7\nSTAT-6 siRNA therapeutics targeting solid tumours with significant\nin vivo\nefficacy; and\n\u00b7\nMK cell therapy with direct and NK cell-mediated anti-cancer action\nFor further information on Roquefort Therapeutics, please\nvisit\nwww.roquefortplc.com\nand\n@RoquefortTherap\non Twitter.\nThis announcement contains inside information for the purposes of Article 7 of the UK version of Market Regulation (EU) No 596/2014 on Market Abuse as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended (\"UK MAR\").\nThe notification below, made in accordance with the requirements of the UK MAR, provides further detail:\nNOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM\n1\nDetails of the person discharging managerial responsibilities / person closely associated\na)\nName\nStephen West\n2\nReason for the notification\na)\nPosition/status\nExecutive Chairman\nb)\nInitial notification /Amendment\nInitial\n3\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor\na)\nName\nRoquefort Therapeutics plc\nb)\nLEI\n254900P4SISIWOR9RH34\n4\nDetails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\na)\nDescription of the financial instrument, type of instrument\nIdentification code\nOrdinary shares of \u00a30.01 par value\nISIN: GB00BMDQ2T15\nb)\nNature of the transaction\nPurchase of 400,000 ordinary shares\nc)\nPrice(s) and volume(s)\nPrice(s)\nVolume(s)\n2.57 pence per share\n400,000\nd\nAggregated information\n- Aggregated volume\n- Price\n- 400,000\n- 2.57p\ne)\nDate of the transactions\n4 February 2025\nf)\nPlace of the transactions\nLondon Stock Exchange (XLON); Main Market\nThe notification below, made in accordance with the requirements of the UK MAR, provides further detail:\nNOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM\n1\nDetails of the person discharging managerial responsibilities / person closely associated\na)\nName\nAjan Reginald\n2\nReason for the notification\na)\nPosition/status\nChief Executive Officer\nb)\nInitial notification /Amendment\nInitial\n3\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor\na)\nName\nRoquefort Therapeutics plc\nb)\nLEI\n254900P4SISIWOR9RH34\n4\nDetails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\na)\nDescription of the financial instrument, type of instrument\nIdentification code\nOrdinary shares of \u00a30.01 par value\nISIN: GB00BMDQ2T15\nb)\nNature of the transaction\nTrust distribution of 34,432 ordinary shares\nc)\nPrice(s) and volume(s)\nPrice(s)\nVolume(s)\n2.6 pence per share\n191,059\nd\nAggregated information\n- Aggre",
          "content_length": 5932
        },
        "ingested_at": "2026-01-16T22:42:51.256667Z"
      },
      {
        "event_id": "RNS-3rd Feb 2025-sharepur",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.256681Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Share Purchase Agreement Signed - Sale of Lyramid",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/share-purchase-agreement-signed-sale-of-lyramid-6hmspso6augwuq8.html",
          "rns_number": "RNS Number : 6233V",
          "full_content": "3 Feb 2025 07:00\nRNS Number : 6233V\nRoquefort Therapeutics PLC\n03 February 2025\n3 February 2025\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nShare Purchase Agreement Signed - Sale of Lyramid\nRoquefort Therapeutics (LSE:ROQ),\nthe Main Market listed biotech company focused on\ndeveloping first in class medicines in the high value and high growth immunology and oncology markets\n, is pleased to announce the signing of a binding share purchase agreement (the \"SPA\") for the sale of its wholly owned subsidiary Lyramid Pty Ltd (\"Lyramid\") to Pleiades Pharma Limited (\"Pleiades\") for a consideration amount of US$10.8 million (the \"Transaction\"). This announcement follows the signing of a term sheet with Pleiades, as announced on 2 January 2025.\nPrincipal Transaction Terms\nThe SPA includes the following principal terms:\n\u00b7\nSale of 100% of the issued share capital of Lyramid to Pleiades;\n\u00b7\nConsideration amount of US$10.8 million consisting of equity in Pleiades, together with the potential for upfront cash (to be finalised at Transaction completion); and\n\u00b7\nCompletion is contingent\ninter alia\non Pleaides completing a current fundraising round and finalising certain in-licensing transactions no later than 30 June 2025.\nFollowing completion of the Transaction, Roquefort Therapeutics will hold a material equity position in Pleiades, a well-funded private company with a portfolio of clinical assets and pre-clinical programs.\nMidkine Portfolio\nLyramid holds the Company's Midkine patents for the mRNA and oligonucleotide programs and the exclusive licence for the antibody programs. Since acquiring Lyramid in 2021\nfor \u00a31 million in consideration (50% in cash and 50% in shares)\n, Roquefort Therapeutics has expanded the portfolio with the in-house development of the mRNA and oligonucleotide programs and completed pre-clinical development of the three modalities.\nPleiades' Portfolio\nPleiades holds exclusive commercial rights to two innovative programs PapMV and S100A9.\nPapMV Program\nThe Papaya Mosaic Virus (PapMV) is a clinical stage nanoparticle-based immune-therapy that enhances the immune defences by stimulating two receptors TLR7 and TLR8, which enhance the body's immune response against cancer and infectious diseases. PapMV successfully completed a Phase 1 clinical trial in Canada of 48 patients as an adjuvant to a (GSK) trivalent influenza vaccine.\nBy stimulating TLR 7/8, PapMV may offer several benefits including preventing viral infections and tumour metastases and enhancing cancer immunotherapy. When administered by inhalation, PapMV Nano could also be one of the first immune boosters used to prevent respiratory infections in the elderly and immunocompromised population.\nPapMV has also demonstrated statistically significant (Pin vivo\nmodels of cancer and infectious disease including:\n\u00b7\nCOVID-19: protection against infection, reduction in lung inflammation and in virus titre\n\u00b7\nInfluenza A (H3N2):\nprotection against\ninfection\n\u00b7\nInfluenza A (H1N1):\nprotection against\ninfection\n\u00b7\nMelanoma:\ndecreases progression and improved survival\n\u00b7\nLung cancer: prevention of implantation of lung metastasis\nThe results of the Phase 1 clinical trial and multiple pre-clinical studies support the safety and efficacy of the PapMV platform and its readiness to enter Phase 1b/2 clinical trials in cancer and infectious disease indications.\nS100A9 Program\nThe S100A9 protein immunotherapy platform is based on S100A9, a novel secreted protein which is released by immune cells in response to infections, the presence of cancer cells or other immune aggressions. The S100A9 binds to TLR2 and TLR4 to amplify the response to these pathogens. S100A9 has been shown to reduce cancer resistance by blocking the activity of myeloid-derived suppressor cells (MDSCs) which is also purported to\nenhance the clinical responses to immunotherapy in cancer.\nIn validated\nin vivo\nefficacy models of cancer, S100A9 demonstrated a statistically significant (P\nacute myeloid leukemia\n(AML).\nAbout Pleiades\nPleiades is a private company developing a portfolio of novel clinical and pre-clinical medicines and is led by Caroline Fortier, an experienced Pharma CEO with a track-record of completing more than US$750 million in trade sale exits to Big Pharma. Pleiades is progressing its funding discussions with multiple institutional investors.\nThe Company will provide shareholders with further updates regarding the Transaction as appropriate.\nAjan Reginald, Roquefort Therapeutics CEO commented:\n\"Through the sale of Lyramid we gain a material share in an exciting clinical portfolio being developed by a highly experienced team. This Transaction validates our strategy to develop novel programs and realise value through licensing and trade sales. Roquefort Therapeutics acquired Lyramid in 2021 for \u00a31 million and has progressed the asset to a value of US$10.8 million in just over three years. We are delighted to partner with Caroline and the Pleiades team and believe",
          "content_length": 8200
        },
        "ingested_at": "2026-01-16T22:42:51.256697Z"
      },
      {
        "event_id": "RNS-2nd Jan 2025-proposed",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.256711Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Proposed Sale of Midkine Portfolio",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/proposed-sale-of-midkine-portfolio-uejhx1p7qbzj6i2.html",
          "rns_number": "RNS Number : 8858R",
          "full_content": "2 Jan 2025 07:00\nRNS Number : 8858R\nRoquefort Therapeutics PLC\n02 January 2025\n2 January 2025\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nProposed Sale of Midkine Portfolio\nRoquefort Therapeutics (LSE:ROQ),\nthe Main Market listed biotech company focused on\ndeveloping first in class medicines in the high value and high growth immunology and oncology markets\n, is pleased to announce the signing of a term sheet for the proposed sale of its wholly owned subsidiary Lyramid Pty Ltd (\"Lyramid\") to Pleiades Pharma Limited (\"Pleiades\") for a minimum consideration amount of US$10 million (the \"Term Sheet\"). Roquefort Therapeutics and Pleiades intend to sign a binding share purchase agreement (the \"SPA\") within 30 days, at which time further details of the transaction will be announced.\nPrincipal Transaction Terms\nThe Term Sheet includes the following principal terms:\n\u00b7\nSale of 100% of the issued share capital of Lyramid to Pleiades;\n\u00b7\nMinimum consideration amount of US$10 million consisting of equity in Pleiades, together with the potential for upfront cash;\n\u00b7\nCompletion is contingent\ninter alia\non Pleaides completing a current fundraising round and finalising certain in-licensing transactions; and\n\u00b7\nA 30-day exclusivity period to enable the signing of the SPA, which is currently at an advanced stage.\nPost completion of the proposed transaction Roquefort Therapeutics will hold a material equity position in Pleiades, a private well-funded company with a portfolio of clinical assets and pre-clinical programs.\nMidkine Portfolio\nLyramid holds the Company's Midkine patents for the mRNA and oligonucleotide programs and the exclusive licence for the antibody programs. Since acquiring Lyramid in 2021\nfor \u00a31 million in consideration (50% in cash and 50% in shares)\n, Roquefort Therapeutics has expanded the portfolio with the in-house development of the mRNA and oligonucleotide programs and completed pre-clinical development of the three modalities.\nAbout Pleiades\nPleiades is a private company developing a portfolio of novel clinical and pre-clinical medicines and is led by Caroline Fontier, an experienced Pharma CEO with a track-record of completing more than US$750 million in trade sale exits to Big Pharma.\nThe signing of the Term Sheet replaces and supersedes the proposed antibody licensing partnership with PDC-CRO which was announced on 23 May 2024. PDC-CRO will remain a key strategic partner to Pleiades and Roquefort Therapeutics, and the preferred clinical research partner for the Middle East region.\nThe Company will provide shareholders with further updates regarding the progress of the SPA as appropriate.\nAjan Reginald, Roquefort Therapeutics CEO commented:\n\"The sale of Lyramid validates our strategy to acquire, develop and then to realise value through licensing and trade-sale transactions. This strategy is particularly important in the UK, where private company valuations typically exceed those of UK public biotech entities. Through this transaction we will capitalise on this valuation arbitrage and retain upside potential in the Midkine portfolio. Most importantly we gain a share of an exciting clinical portfolio being developed by a highly experienced team.\"\nENDS\nEnquiries:\nRoquefort Therapeutics plc\n+44 (0)20 3918 8633\nStephen West (Chairman) / Ajan Reginald (CEO)\nSP Angel Corporate Finance LLP (Broker)\nDavid Hignell / Vadim Alexandre / Devik Mehta\n+44 (0) 20 3470 0470\nBurson Buchanan (Public Relations)\nBen Romney / Jamie Hooper\n+44 (0)20 7466 5000\nPeak IR (Investor Relations)\nSeb Wykeham\n+33 (0)7 44 44 15 42\nLEI: \u200e254900P4SISIWOR9RH34\nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company developing first in class drugs in the high value and high growth\nimmunology and oncology markets\nprior to partnering with big pharma.\nRoquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of:\n\u00b7\nMidkine antibodies with significant\nin vivo\nefficacy and toxicology studies;\n\u00b7\nMidkine RNA therapeutics with novel anti-cancer gene editing action;\n\u00b7\nMidkine mRNA therapeutics with novel anti-cancer approach;\n\u00b7\nSTAT-6 siRNA therapeutics targeting solid tumours with significant\nin vivo\nefficacy; and\n\u00b7\nMK cell therapy with direct and NK cell-mediated anti-cancer action\nFor further information on Roquefort Therapeutics, please\nvisit\nwww.roquefortplc.com\nand\n@RoquefortTherap\non X (formerly Twitter).\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to anal",
          "content_length": 5328
        },
        "ingested_at": "2026-01-16T22:42:51.256727Z"
      },
      {
        "event_id": "RNS-4th Dec 2024-director",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.256740Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Director Share Distribution",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/director-share-distribution-vpkjjb4d1l46miq.html",
          "rns_number": "RNS Number : 8386O",
          "full_content": "4 Dec 2024 16:00\nRNS Number : 8386O\nRoquefort Therapeutics PLC\n04 December 2024\n4 December 2024\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nDirector Share Distribution\nRoquefort Therapeutics (LSE:ROQ),\nthe Main Market listed biotech company focused on\ndeveloping first in class medicines in the high value and high growth immunology and oncology markets\n,\nhas been advised by VG Corporate Trustee Limited that an employee benefit trust (unrelated to the Company), has been terminated and the trust assets have been distributed to the beneficiaries. As a result of the trust distribution, three Directors of the Company (Ajan Reginald, Dr Darrin Disley and Sir Marin Evans) have received ordinary shares of \u00a30.01 each in the Company (\"Ordinary Shares\"), as detailed below:\nDirector\nNumber of Ordinary Shares Received for Nil Consideration\nNumber of Ordinary Shares Now Held\n% of Company's Issued Capital\nAjan Reginald\n34,432\n12,346,413\n9.1%\nDr Darrin Disley\n9,146\n2,024,196\n1.5%\nSir Martin Evans\n2,690\n2,690\n0.0%\n-ENDS-\nEnquiries:\nRoquefort Therapeutics plc\n+44 (0)20 3918 8633\nStephen West (Chairman) / Ajan Reginald (CEO)\nSP Angel Corporate Finance LLP (Broker)\nDavid Hignell / Vadim Alexandre / Devik Mehta\n+44 (0) 20 3470 0470\nBurson Buchanan (Public Relations)\nBen Romney / Jamie Hooper / George Beale\n+44 (0)20 7466 5000\nPeak IR (Investor Relations)\nSeb Wykeham\n+33 (0)7 44 44 15 42\nLEI: \u200e254900P4SISIWOR9RH34\nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company developing first in class drugs in the high value and high growth\nimmunology and oncology markets\nprior to partnering with big pharma.\nRoquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of:\n\u00b7\nMidkine antibodies with significant\nin vivo\nefficacy and toxicology studies;\n\u00b7\nMidkine RNA therapeutics with novel anti-cancer gene editing action;\n\u00b7\nMidkine mRNA therapeutics with novel anti-cancer approach;\n\u00b7\nSTAT-6 siRNA therapeutics targeting solid tumours with significant\nin vivo\nefficacy; and\n\u00b7\nMK cell therapy with direct and NK cell-mediated anti-cancer action\nFor further information on Roquefort Therapeutics, please\nvisit\nwww.roquefortplc.com\nand\n@RoquefortTherap\non X (formerly Twitter).\nThis announcement contains inside information for the purposes of Article 7 of the UK version of Market Regulation (EU) No 596/2014 on Market Abuse as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended (\"UK MAR\").\nThe notification below, made in accordance with the requirements of the UK MAR, provides further detail:\nNOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM\n1\nDetails of the person discharging managerial responsibilities / person closely associated\na)\nName\nAjan Reginald\n2\nReason for the notification\na)\nPosition/status\nChief Executive Officer\nb)\nInitial notification /Amendment\nInitial\n3\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor\na)\nName\nRoquefort Therapeutics plc\nb)\nLEI\n254900P4SISIWOR9RH34\n4\nDetails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\na)\nDescription of the financial instrument, type of instrument\nIdentification code\nOrdinary shares of \u00a30.01 par value\nISIN: GB00BMDQ2T15\nb)\nNature of the transaction\nTrust distribution of 34,432 ordinary shares\nc)\nPrice(s) and volume(s)\nPrice(s)\nVolume(s)\n0 pence per share\n34,432\nd\nAggregated information\n- Aggregated volume\n- Price\n- 34,432\n- 0p\ne)\nDate of the transactions\n3 December 2024\nf)\nPlace of the transactions\nLondon Stock Exchange (XLON); Main Market\nThe notification below, made in accordance with the requirements of the UK MAR, provides further detail:\nNOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM\n1\nDetails of the person discharging managerial responsibilities / person closely associated\na)\nName\nDr Darrin Disley\n2\nReason for the notification\na)\nPosition/status\nNon-Executive Director\nb)\nInitial notification /Amendment\nInitial\n3\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor\na)\nName\nRoquefort Therapeutics plc\nb)\nLEI\n254900P4SISIWOR9RH34\n4\nDetails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\na)\nDescription of the financial instrument, type of instrument\nIdentification code\nOrdinary shares of \u00a30.01 par value\nISIN: GB00BMDQ2T15\nb)\nNature of the transaction\nTrust distribution of 9,146 ordinary sh",
          "content_length": 7345
        },
        "ingested_at": "2026-01-16T22:42:51.256755Z"
      },
      {
        "event_id": "RNS-7th Nov 2024-conversi",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.256769Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Conversion of Convertible Loan Notes",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/conversion-of-convertible-loan-notes-mw7p6wpxr3h9jun.html",
          "rns_number": "RNS Number : 2613L",
          "full_content": "7 Nov 2024 07:00\nRNS Number : 2613L\nRoquefort Therapeutics PLC\n07 November 2024\n7 November 2024\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nConversion of Convertible Loan Notes\nRoquefort Therapeutics (LSE:ROQ),\nthe Main Market listed biotech company focused on\ndeveloping first in class medicines in the high value and high growth immunology and oncology markets\n, announces it has received notices to convert a total face value of \u00a3267,106 convertible loan notes (the \"CLNs\") resulting in the issue of 6,586,604 new ordinary shares in the Company (the \"CLN Shares\").\nIn accordance with the terms of the CLNs, which were issued on 23 May 2024, all accrued interest on the CLNs at a rate of 12.5% per annum is included in the conversion into the Company's ordinary shares of \u00a30.01 each (\"Ordinary Shares\"). The conversion price of the CLNs is 4.29p, being 90% of the price equal to the 10-day volume-weighted average price calculated backwards from the date, which is three business days prior to the notice of conversion given to the Company.\nFollowing conversion of these CLNs, the Company has CLNs with a face value of \u00a3387,894 outstanding.\nDirector/PDMR Shareholding\nThe abovementioned notices to convert included notices from directors Stephen West, Ajan Reginald and Darrin Disley, as follows:\nDirector\nCLN Face Value\nCLN Shares\nTotal Ordinary Shares Held After CLN Shares Issued\nStephen West\n\u00a328,158\n694,352\n6,310,853\nAjan Reginald\n\u00a326,316\n648,930\n12,311,981\nDarrin Disley\n\u00a321,053\n519,149\n2,015,050\nAdmission and Total Voting Rights\nApplication will be made for the CLN Shares to be admitted to trading on the London Stock Exchange's Main Market for listed securities, which is expected to occur on or around 12 November 2024 (\"Admission\"). The CLN Shares will rank\npari passu\nin all respects with the Company's existing Ordinary Shares.\nFollowing Admission, the Company's issued share capital will comprise 135,736,602 Ordinary Shares in issue, with each share carrying the right to one vote. The Company does not hold any Ordinary Shares in treasury. The figure of 135,736,602 Ordinary Shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or of a change to their interest in the Company under the FCA's Disclosure and Transparency Rules.\nRegulatory Information\nThis Announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\").\nENDS\nEnquiries:\nRoquefort Therapeutics plc\n+44 (0)20 3918 8633\nStephen West (Chairman) / Ajan Reginald (CEO)\nSP Angel Corporate Finance LLP (Broker)\nDavid Hignell / Vadim Alexandre / Devik Mehta\n+44 (0) 20 3470 0470\nBuchanan (Public Relations)\nBen Romney / Jamie Hooper / George Beale\n+44 (0)20 7466 5000\nPeak IR (Investor Relations)\nSeb Wykeham\n+33 (0)7 44 44 15 42\nLEI: \u200e254900P4SISIWOR9RH34\nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company developing first in class drugs in the high value and high growth\nimmunology and oncology markets\nprior to partnering with big pharma.\nRoquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of:\n\u00b7\nMidkine antibodies with significant\nin vivo\nefficacy and toxicology studies;\n\u00b7\nMidkine RNA therapeutics with novel anti-cancer gene editing action;\n\u00b7\nMidkine mRNA therapeutics with novel anti-cancer approach;\n\u00b7\nSTAT-6 siRNA therapeutics targeting solid tumours with significant\nin vivo\nefficacy; and\n\u00b7\nMK cell therapy with direct and NK cell-mediated anti-cancer action\nFor further information on Roquefort Therapeutics, please\nvisit\nwww.roquefortplc.com\nand\n@RoquefortTherap\non X (formerly Twitter).\nThe notification below, made in accordance with the requirements of the UK MAR, provides further detail:\nNOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM\n1\nDetails of the person discharging managerial responsibilities / person closely associated\na)\nName\nStephen West\n2\nReason for the notification\na)\nPosition/status\nExecutive Chairman\nb)\nInitial notification /Amendment\nInitial\n3\nDetails of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor\na)\nName\nRoquefort Therapeutics plc\nb)\nLEI\n254900P4SISIWOR9RH34\n4\nDetails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\na)\nDescription of the financial instrument, type of instrument\nIdentification code\nOrdinary shares of \u00a30.01 par value\nISIN: GB00BMDQ2T15\nb)\nNature of the transaction\nConversion of loan notes int",
          "content_length": 8725
        },
        "ingested_at": "2026-01-16T22:42:51.256784Z"
      },
      {
        "event_id": "RNS-27th Sep 2024-interimr",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.256797Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Interim Results to 30 June 2024",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/interim-results-to-30-june-2024-5fx248pxya5pzx2.html",
          "rns_number": "RNS Number : 8697F",
          "full_content": "27 Sep 2024 07:00\nRNS Number : 8697F\nRoquefort Therapeutics PLC\n27 September 2024\n27 September 2024\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nInterim Results to 30 June 2024\nRoquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on\ndeveloping first in class drugs in the high value and high growth immunology and oncology markets\n, is pleased to announce its interim results for the six-month period ended 30 June 2024 (the \"period\" or \"H1\").\nHighlights\n\u00b7\nSigned a term sheet in May 2024 for the Company's first therapeutic out-licensing deal for its Midkine antibody program with PDC FZ-LLC (\"PDC\") for an initial consideration of US$10 million\n\u00b7\nSignificant progress made across pre-clinical portfolio with positive results announced in MK cells, Midkine mRNA and STAT-6 siRNA programs\n\u00b7\nConvertible loan notes (the \"Convertible Loan Notes\") raising net proceeds of \u00a3584,915 announced in May 2024 providing funds for at least 12 months, in conjunction with Company's existing cash reserves\n\u00b7\nSignificant cost cutting measures announced in May 2024 to further support cashflow, while working on completing cash generative out-licensing deals\n\u00b7\nSir Martin Evans moved from his executive position as Chief Scientific Officer to Non-Executive Director and Dr Michael Stein stepped down as Non-Executive Director in May 2024\n\u00b7\nCash at period end of \u00a3\n595,662\nand a net loss of \u00a3\n596,547\nfor the 6 months to 30 June 2024\nPost Period End Highlights\n\u00b7\nAdditional experiments completed for potential out licensing partners for the STAT-6 siRNA program\n\u00b7\nEuropean Patent Office and Japan Patent Office granted patents for the Company's MK cell therapy, across 40 countries including the UK, EU and Japan\n\u00b7\nThe Company received a UK R&D refund of \u00a3123,593 in September 2024\nOutlook\n\u00b7\nThe Company continues to work with PDC towards finalising a binding out-licensing agreement for its Midkine antibody portfolio, with updates to be provided to the market in due course\n\u00b7\nThe Company remains committed to securing other therapeutic licensing deals and is in active discussions in this regard\nCommenting on the Interim Results, Roquefort Therapeutics CEO, Ajan Reginald said:\n\"During the first half of the year we continued with our strategy to select novel medicines in high value pharmaceutical markets and developed them to deliver the results required to attract Big Pharma partners. This culminated in Roquefort Therapeutics announcing the signing of a term sheet for our first therapeutic licensing deal with PDC, whilst also engaging with multiple Big Pharma partners regarding our siRNA programs in Immunology and Inflammation.\nThe Board is mindful of operational costs, and in May 2024 we raised the necessary funds for an additional 12 months, which enables us to complete the development of our pre-clinical programs and to retain the flexibility needed in negotiating the ongoing out-licensing transactions. I would like to thank my colleagues at Roquefort Therapeutics in completing the necessary pre-clinical milestones which have allowed the Company to engage in out-licensing discussions with large pharma companies and other partners. With excellent pre-clinical data, and the necessary funding in place, I am confident in our ability to complete additional licensing deals and look forward to providing our shareholders with further updates as appropriate.\"\nChairman Statement\nI am pleased to present the interim financial statements to shareholders for the six months ending 30 June 2024.\nThe highlight of the period was signing a term sheet for the out-licensing of our Midkine antibody portfolio to PDC, a leading MEA pharmaceutical organisation. Under the non-binding strategic out-licensing term sheet, Roquefort Therapeutics receives US$10 million total initial consideration value including a guaranteed share of the trade sale proceeds on successful completion of Phase 1 clinical trials. PDC will develop one or more of the Midkine antibodies within a new Special Purpose Vehicle (\"SPV\") to complete the Phase 1 clinical trial and then seek a trade sale of the SPV. We are now working with PDC to complete the definitive licence agreement, and further updates will be made as this progresses.\nA summary of the agreed commercial terms in the term sheet are listed below:\n\u00b7\nInitial consideration value of US$10 million, which includes non-dilutive equity in the SPV;\n\u00b7\nExclusive worldwide licence granted to the SPV for 20 years;\n\u00b7\nWithin three years, PDC to develop at least one of the Midkine antibodies within the SPV to the completion of a Phase 1 trial and then, upon success, to complete a trade sale of the SPV; and\n\u00b7\nRoquefort Therapeutics will receive circa 24% from any successful trade sale proceeds, which if the Phase 1 trial is successful, this 24% is projected to be worth up to US$50M (gross) based on similar phase 1 trade sales.\nAdditionally, we made progress with further out-licensing discussions, notably for ou",
          "content_length": 28443
        },
        "ingested_at": "2026-01-16T22:42:51.256815Z"
      },
      {
        "event_id": "RNS-23rd Sep 2024-grantofj",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.256829Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Grant of Japan MK Cell Patent",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/grant-of-japan-mk-cell-patent-jhsbv048q0rh6y6.html",
          "rns_number": "RNS Number : 1376F",
          "full_content": "23 Sep 2024 07:00\nRNS Number : 1376F\nRoquefort Therapeutics PLC\n23 September 2024\n23 September 2024\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nGrant of Japan MK Cell Patent\nRoquefort Therapeutics (LSE:ROQ),\nthe Main Market listed biotech company focused on\ndeveloping first in class medicines in the high value and high growth immunology and oncology markets\n, is pleased to announce that the Japan Patent Office has granted the patent for its Mesodermal Killer (\"MK\") cell therapy.\nThe granting of the MK cell patent by the Japan Patent Office follows the granting of the European patent announced on 2 September 2024, thereby expanding patent protection to the UK, EU and Japan.\nNovel Cellular Immunology / Oncology Medicine\nMesodermal Killer cells are a novel therapeutic cell type developed from the pioneering work of Roquefort Therapeutics' non-executive director, Nobel Laureate, Professor Sir Martin Evans.\nMK cells display a novel immunophenotype\n[i]\nand thus\nrepresent a new class of cell, which is confirmed by the granting of patents by the European Patent Office and the Japan Patent Office. The MK cells form an off-the-shelf (allogenic) cellular immunotherapy, with both a direct effect and the ability to recruit and activate Natural Killer (\"NK\") cells\n[ii]\nto modulate an immune response in immunology and oncology indications.\nCommercial Opportunity in Japan\nThere is a two-fold commercial significance to the granting of the MK cell patent in Japan. Firstly, the Japan patent enables the opportunity to licence the MK cells to Japan Big Pharma companies for the Japan market alone, where the Roquefort Therapeutics' Board has extensive experience of working and partnering (including with Big Pharma companies such as Daiichi Sankyo, Astellas and Chughai).\nSecondly, the granted Japan patent allows the Company to access\nan accelerated route-to-market for promising cellular medicines in Japan. The accelerated designation not only speeds up drug development, but also the market approval (MAA) assessment. The attractive benefit package that this designation confers includes market approval granted based on Phase 1 and 2 clinical trials if safety is confirmed\n[iii]\n. This may significantly increase the value of cellular medicines as this enables a cheaper and faster route to market.\nPre-Clinical Development\nSince Roquefort Therapeutics acquired the MK cell program as part of the Oncogeni acquisition in 2022, the Company has tested the MK cells in combination with NK cells. MK cells were shown to activate Natural Killer cells and this activation produced up to a two-fold increase in NK efficacy, indicating the potential for MK + NK combination medicines in the high value difficult to treat immunology and oncology disease areas. The Company now plans to complete\nin vivo\nstudies in preparation for a key value inflection point of initiating a clinical study. This clinical trial may utilise the favourable clinical trial and tax regimes in Japan and Australia to enable faster and cheaper routes to market.\nRoquefort Therapeutics CEO Ajan Reginald commented:\n\"The granting of this Japan patent for MK cell therapy highlights both the quality of our intellectual property and the novelty of the MK cells together with the enhanced commercial opportunity in Japan. The granted patent creates the opportunity for the Company to out-license the MK cell rights for the territory of Japan to a Japanese Big Pharma company. Japan is the most sophisticated cell therapy market, with a high number of potential partners and an appealing accelerated pathway to market. The Roquefort Therapeutics Board has the personal experience and a strong network from completing deals with Japan Big Pharma. We have initiated these discussions and will update the market in due course\"\nENDS\nEnquiries:\nRoquefort Therapeutics plc\n+44 (0)20 3918 8633\nStephen West (Chairman) / Ajan Reginald (CEO)\nSP Angel Corporate Finance LLP (Broker)\nDavid Hignell / Vadim Alexandre / Devik Mehta\n+44 (0) 20 3470 0470\nBuchanan (Public Relations)\nBen Romney / Jamie Hooper / George Beale\n+44 (0)20 7466 5000\nPeak IR (Investor Relations)\nSeb Wykeham\n+33 (0)7 44 44 15 42\nLEI: \u200e254900P4SISIWOR9RH34\nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company developing first in class drugs in the high value and high growth\nimmunology and\noncology markets prior to partnering or selling to big pharma.\nRoquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of:\n\u00b7\nMidkine antibodies with significant\nin vivo\nefficacy and toxicology studies;\n\u00b7\nMidkine RNA therapeutics with novel anti-cancer gene editing action;\n\u00b7\nMidkine mRNA therapeutics with novel anti-cancer approach;\n\u00b7\nSTAT-6 siRNA therapeutics targeting solid tumours with significant\nin vivo\nefficacy; and\n\u00b7\nMK cell therapy with direct and NK cell-med",
          "content_length": 6491
        },
        "ingested_at": "2026-01-16T22:42:51.256845Z"
      },
      {
        "event_id": "RNS-19th Sep 2024-stat-6si",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.256859Z",
        "source": "LSE_RNS",
        "data": {
          "title": "STAT-6 siRNA Demonstrates Efficacy in Immunology",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/stat-6-sirna-demonstrates-efficacy-in-immunology-k8j6266z5vyzhzr.html",
          "rns_number": "RNS Number : 7436E",
          "full_content": "19 Sep 2024 07:00\nRNS Number : 7436E\nRoquefort Therapeutics PLC\n19 September 2024\n19 September 2024\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nSTAT-6 siRNA Demonstrates Efficacy in Immunology\nRoquefort Therapeutics (LSE:ROQ),\nthe Main Market listed biotech company focused on\ndeveloping first in class medicines in the high value and high growth immunology and oncology markets\n, is pleased to announce that its STAT-6 siRNA has demonstrated efficacy in a validated\nin vitro\nexperimental model of immunological disease.\nSTAT-6 siRNA Immunology / Oncology Medicine\nsiRNA therapeutics are an innovative new class of medicines based on RNA interference (RNAi), whereby a gene is downregulated by disrupting its messaging machinery, which was recognized with the 2006 Nobel Prize in Physiology or Medicine. Roquefort Therapeutics' siRNA programs target STAT-6. Signal Transducer and Activator of Transcription (STAT) proteins are both signalling proteins and transcription factors that play a role in cell growth, differentiation and function. STAT-6 is a key nodal transcription factor that selectively mediates downstream signalling of IL-4 and IL-13, dominant and central cytokines in the pathophysiology of Type 2 inflammatory diseases\n[1]\n.\nAs previously announced, Roquefort Therapeutics' siRNA programs have demonstrated\nin vivo\nefficacy in oncology. This new set of experiments investigated the use of the siRNA in the STAT-6 inflammation and immunology (\"I&I\") field validated by Sanofi and Recludix Pharma in 20231. In these preliminary experiments, the Company's siRNA demonstrated a significant reduction in the levels of STAT-6 produced compared to multiple controls at multiple time points. On completion of this experimental protocol, more of the methodology and results will be disclosed in a scientific publication at a recognised international conference and / or peer reviewed journal.\nPre-Clinical Development\nFollowing the Company's acquisition of Oncogeni Ltd in September 2022 in which Roquefort Therapeutics acquired a portfolio of pre-clinical STAT-6 siRNA anti-cancer medicines, the Company developed four additional siRNA sequences to complement this portfolio. The portfolio of siRNA medicines all target STAT-6 and its SH2 (Src-homology-2) domain.\nThe Company is developing the siRNA in both the oncology and I&I fields in which STAT-6 is a relevant target. Today's announcement reports the Company's first results from the ongoing program of development in the I&I field following discussions and advice from potential Big Pharma partners.\nRoquefort Therapeutics is actively pursuing an out-licensing deal with Big Pharma for its STAT-6 siRNA program. The Company believes that these positive I&I results, combined with the Company's existing positive oncology results, strengthen the attractiveness of the siRNA programs to potential Big Pharma partners. The Company will update the market as the out-licensing process progresses.\nRoquefort Therapeutics CEO Ajan Reginald commented:\n\"Today's siRNA results are the Company's first in I&I and complement the strong in vivo efficacy results already demonstrated in oncology. The STAT-6 siRNA and MK cell therapy programs have both demonstrated significant potential in the attractive inflammation and immunology (I&I) field. The development of these programs in the I&I field is based on the direct feedback from potential Big Pharma partners. The STAT-6 field is particularly attractive because of the recent validation by Sanofi and Recludix and our relatively strong competitive position with completed in vivo efficacy experiments.\nOur strategy remains to complete meaningful partnerships with one or more Big Pharma companies to validate the business model and to reset the market's perception of the attractiveness of the Company. The ongoing transaction with PDC and these siRNA results are key steps in this process, on which we expect to update the market with further milestones in 2024.\"\nENDS\nEnquiries:\nRoquefort Therapeutics plc\n+44 (0)20 3918 8633\nStephen West (Chairman) / Ajan Reginald (CEO)\nSP Angel Corporate Finance LLP (Broker)\nDavid Hignell / Vadim Alexandre / Devik Mehta\n+44 (0) 20 3470 0470\nBuchanan (Public Relations)\nBen Romney / Jamie Hooper / George Beale\n+44 (0)20 7466 5000\nPeak IR (Investor Relations)\nSeb Wykeham\n+33 (0)7 44 44 15 42\nLEI: \u200e254900P4SISIWOR9RH34\nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company developing first in class drugs in the high value and high growth immuno-oncology segment prior to partnering or selling to big pharma.\nRoquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of:\n\u00b7\nMidkine antibodies with significant\nin vivo\nefficacy and toxicology studies;\n\u00b7\nMidkine RNA therapeutics with novel anti-cancer gene editing action;\n\u00b7\nMidkine mRNA therapeutics w",
          "content_length": 6294
        },
        "ingested_at": "2026-01-16T22:42:51.256876Z"
      },
      {
        "event_id": "RNS-2nd Sep 2024-grantofm",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.256889Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Grant of MK Cell Patent & Licencing Update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/grant-of-mk-cell-patent-licencing-update-4gj9hp2971oqhzp.html",
          "rns_number": "RNS Number : 4162C",
          "full_content": "2 Sep 2024 07:00\nRNS Number : 4162C\nRoquefort Therapeutics PLC\n02 September 2024\n2 September 2024\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nGrant of MK Cell Patent & Licencing Update\nRoquefort Therapeutics (LSE:ROQ),\nthe Main Market listed biotech company focused on\ndeveloping first in class medicines in the high value and high growth immunology and oncology markets\n, confirms that the European Patent Office has granted the patent for its Mesodermal Killer (\"MK\") cell therapy, across 39 counties including the UK and EU\n[i]\n.\nNovel Cellular Immunology / Oncology Medicine\nMesodermal Killer cells are a novel therapeutic cell type developed from the pioneering work of Roquefort Therapeutics' non-executive director, Nobel Laureate, Professor Sir Martin Evans.\nMK cells display a novel immunophenotype\n[ii]\nand thus\nrepresent a new class of cell, which is confirmed by the granting of this patent.\nThe Company's MK cells form an off-the-shelf (allogenic) cellular medicine, which underpins a promising new form of immunotherapy. MK cells have been shown to have both a direct effect and to recruit and activate Natural Killer (\"NK\") cells\n[iii]\nimmune response in immunology and oncology indications. Cell based immunotherapy is an attractive new niche highlighted by the recent successful US$167 million NASDAQ IPO of Artiva Biotherapeutics\n[iv]\nand the licensing deals of Dragonfly Therapeutics and Fate Therapeutics (NASDAQ: FATE), with both immunology and oncology indications.\nThe granted\nEuropean Patent Organization\npatent is valid in 39 countries across Europe and provides protection for both the composition of matter of the MK cell type and for a population of NK cells primed (activated) by the MK cells. This affords Roquefort Therapeutics protection for a portfolio of multiple novel medicines comprising of the MK cells alone, MK + NK cells or primed NK cells.\nPre-Clinical Development\nSince Roquefort Therapeutics acquired the MK cell programme as part of the Oncogeni acquisition in 2021, the Company has tested the MK cells in combination with NK cells. MK cells were shown to activate Natural Killer cells and this activation produced up to a two-fold increase in cytotoxicity compared to treatment with NK cells alone. The data, whilst early stage, indicates how the MK cell programme can be used to activate Natural Killer cells in the high value difficult to treat immunology and oncology disease areas.\nThe Company plans to complete\nin vivo\nstudies to demonstrate MK activation of NK cells in high value immunology and / or cancer indications in preparation for a key value inflection point of initiating a clinical study.\nOut-Licencing Update\nAs announced on 23 May 2024, Roquefort Therapeutics signed a term sheet for the out-licensing of its Midkine antibody portfolio to PDC FZ-LLC (\"PDC\"), a leading MEA pharmaceutical research and development organisation. The Company continues to work with PDC to progress this transaction to completion.\nIn addition, Roquefort Therapeutics is actively pursuing an out-licensing deal with Big Pharma for its STAT-6 siRNA programme. As part of this initiative the Company is carrying out additional\nin vitro\nexperiments in an immunology setting - with the results expected shortly. The Company believes that positive immunology results will enhance the Company's existing positive oncology results and therefore strengthen the programme's attractiveness to potential licensees. The Company will update the market as this process progresses.\nRoquefort Therapeutics CEO Ajan Reginald commented:\n\"The granting of this European patent for MK cell therapy highlights both the security of our foundational IP in confirming the novelty of the MK cells and the commercial potential of MK cells in immunology and oncology markets. These markets are highly attractive to both Big Pharma and to sophisticated Biotech investors, recently highlighted by Artiva's oversubscribed IPO in July 2024.\nRoquefort Therapeutics has the potential to build a similar immunotherapy franchise having already established the ability to manufacture the allogenic (off-the-shelf) MK cells and to incorporate and prime NK cells in a scalable manufacturing process. The MK cells generate a significant activation of NK cells which may augment the efficacy of NK cells, which is the critical attribute in immunology and oncology indications. The strategic implication of the granting of the MK cell patent is that this creates a significant franchise opportunity in immunology for the Company.\nWe have had a busy summer meeting with PDC to work on progressing our licensing deal, as well as advancing the STAT-6 siRNA programme in immunology for Big Pharma partners interested in a potential licence or sale.\nWith both the MK cell therapy and the STAT-6 siRNA being in the attractive immunology market, and the out- licensing deals we are working on closing in Q4, we believe the next few months have the potential to be transformationa",
          "content_length": 8335
        },
        "ingested_at": "2026-01-16T22:42:51.256906Z"
      },
      {
        "event_id": "RNS-27th Jun 2024-resultso",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.256919Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Results of AGM",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/results-of-agm-ntegyin2i8n0fht.html",
          "rns_number": "RNS Number : 1942U",
          "full_content": "27 Jun 2024 12:46\nRNS Number : 1942U\nRoquefort Therapeutics PLC\n27 June 2024\n27 June 2024\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nResults of AGM\nRoquefort Therapeutics (LSE:ROQ, OTCQB: ROQAF), the Main Market listed biotech company focused on\ndeveloping first in class medicines in the high value and high growth immuno-oncology market\n, is pleased to announce that at the Company's Annual General Meeting (\"\nAGM\n\") held earlier today, all resolutions proposed were duly passed.\nThe resolutions were put to shareholders via a poll, the results of which were as follows:\nResolution\nPoll Results\nTotal Votes Withheld*\nFor\nAgainst\nTotal Votes Cast\n1\nShares\n24,948,663\n-\n24,948,663\n-\n%\n100.00%\n-\n2\nShares\n24,943,456\n-\n24,943,456\n5,191\n%\n100.00%\n-\n3\nShares\n24,943,472\n-\n24,943,472\n5,191\n%\n100.00%\n-\n4\nShares\n20,529,178\n-\n20,529,178\n4,419,485\n%\n100.00%\n-\n5\nShares\n24,948,663\n-\n24,948,663\n-\n%\n100.00%\n-\n6\nShares\n24,948,663\n-\n24,948,663\n-\n%\n100.00%\n-\n7\nShares\n24,938,750\n9,913\n24,948,663\n-\n%\n99.96%\n0.04%\n8\nShares\n24,938,730\n9,933\n24,948,663\n-\n%\n99.96%\n0.04%\n*\nVotes withheld are not counted in the calculation of the proportion of votes for and against a resolution.\nThe total number of ordinary shares in issue on 25 June 2024, the deadline for casting votes by proxy in advance of the AGM, was 129,149,998 shares. 19.3% of voting capital was instructed in respect of the resolutions put to the AGM.\nEnquiries:\nRoquefort Therapeutics plc\n+44 (0)20 3918 8633\nStephen West (Chairman) / Ajan Reginald (CEO)\nSP Angel Corporate Finance LLP (Broker)\nJeff Keating / David Hignell / Vadim Alexandre\n+44 (0) 20 3470 0470\nBuchanan (Public Relations)\nBen Romney / Jamie Hooper / George Beale\n+44 (0)20 7466 5000\nPeak IR (Investor Relations)\nSeb Wykeham\n+33 (0)7 44 44 15 42\nLEI: \u200e254900P4SISIWOR9RH34\nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth immuno-oncology segment prior to partnering or selling to big pharma.\nRoquefort Therapeutics' portfolio consists of five novel, patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of:\n\u00b7\nMidkine antibodies with significant\nin vivo\nefficacy and toxicology studies;\n\u00b7\nMidkine RNA therapeutics with novel anti-cancer gene editing action;\n\u00b7\nMidkine mRNA therapeutics with novel anti-cancer approach;\n\u00b7\nSTAT-6 siRNA therapeutics targeting solid tumours with significant\nin vivo\nefficacy; and\n\u00b7\nMK cell therapy with direct and NK-mediated anti-cancer action\nFor further information on Roquefort Therapeutics, please\nvisit\nwww.roquefortplc.com\nand\n@RoquefortTherap\non X (formerly Twitter).\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nRAGFLFSLREIDFIS",
          "content_length": 3532
        },
        "ingested_at": "2026-01-16T22:42:51.256931Z"
      },
      {
        "event_id": "RNS-20th Jun 2024-appointm",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.256944Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Appointment of Broker",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/appointment-of-broker-nnnbvad47sp6ft5.html",
          "rns_number": "RNS Number : 1220T",
          "full_content": "20 Jun 2024 07:00\nRNS Number : 1220T\nRoquefort Therapeutics PLC\n20 June 2024\n20 June 2024\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\")\nAppointment of Broker\nRoquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF),\u00a0the Main Market listed biotech company focused on\u00a0developing first in class medicines in the high value and high growth immuno-oncology market, is pleased to announce the appointment of SP Angel Corporate Finance LLP as its broker with immediate effect.\n-ENDS-\nEnquiries:\nRoquefort Therapeutics plc\n+44 (0)20 3918 8633\nStephen West (Chairman) / Ajan Reginald (CEO)\nSP Angel Corporate Finance LLP (Broker)\nJeff Keating / David Hignell / Vadim Alexandre\n+44 (0) 20 3470 0470\nBuchanan (Public Relations)\nBen Romney / Jamie Hooper / George Beale\n+44 (0)20 7466 5000\nPeak IR (Investor Relations)\nSeb Wykeham\n+33 (0)7 44 44 15 42\nLEI: \u200e254900P4SISIWOR9RH34\nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth immuno-oncology segment prior to partnering or selling to big pharma.\nRoquefort Therapeutics' portfolio consists of five novel, patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of:\n\u00b7\nMidkine antibodies with significant\nin vivo\nefficacy and toxicology studies;\n\u00b7\nMidkine RNA therapeutics with novel anti-cancer gene editing action;\n\u00b7\nMidkine mRNA therapeutics with novel anti-cancer approach;\n\u00b7\nSTAT-6 siRNA therapeutics targeting solid tumours with significant\nin vivo\nefficacy; and\n\u00b7\nMK cell therapy with direct and NK-mediated anti-cancer action\nFor further information on Roquefort Therapeutics, please\u00a0visit\nwww.roquefortplc.com\nand\u00a0@RoquefortTherap\u00a0on X (formerly Twitter).\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nAPPUKUNRSWUNAAR",
          "content_length": 2581
        },
        "ingested_at": "2026-01-16T22:42:51.256957Z"
      },
      {
        "event_id": "RNS-4th Jun 2024-noticeof",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.256969Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Notice of Annual General Meeting",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/notice-of-annual-general-meeting-q4dqtrynjnhhmr7.html",
          "rns_number": "RNS Number : 9048Q",
          "full_content": "4 Jun 2024 07:00\nRNS Number : 9048Q\nRoquefort Therapeutics PLC\n04 June 2024\n4 June 2024\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nNotice of Annual General Meeting\nRoquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF),\nthe Main Market listed biotech company focused on\ndeveloping first in class medicines in the high value and high growth immuno-oncology market\n, has today posted its Notice of Annual General Meeting to Shareholders. The Annual General Meeting is scheduled to take place at the offices of Reynolds Porter Chamberlain LLP, Tower Bridge House, St Katherine's Way, London E1W 1AA at 10.00 am on 27 June 2024.\nThe Notice of Annual General Meeting and Forms of Proxy can be downloaded from the Company's corporate website at:\nhttps://www.roquefortplc.com/shareholder-documents\n-ENDS-\nEnquiries:\nRoquefort Therapeutics plc\nStephen West (Chairman) / Ajan Reginald (CEO)\n+44 (0)20 3918 8633\nHybridan LLP (Joint Broker)\nClaire Louise Noyce\nOptiva Securities Limited (Joint Broker)\n+44 (0)203 764 2341\nVishal Balasingham / Daniel Ingram\nBuchanan (Public Relations)\nBen Romney / Jamie Hooper / George Beale\n+44 (0)20 3411 1881\n+44 (0)20 7466 5000\nLEI: \u200e254900P4SISIWOR9RH34\nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma.\nRoquefort Therapeutics' portfolio consists of five fully funded, novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of:\n\u00b7\nMidkine antibodies with significant\nin vivo\nefficacy and toxicology studies;\n\u00b7\nMidkine RNA therapeutics with novel anti-cancer gene editing action;\n\u00b7\nMidkine mRNA therapeutics with novel anti-cancer approach;\n\u00b7\nSTAT-6 siRNA therapeutics targeting solid tumours with significant\nin vivo\nefficacy; and\n\u00b7\nMK cell therapy with direct and NK-mediated anti-cancer action\nFor further information on Roquefort Therapeutics, please\nvisit\nwww.roquefortplc.com\nand\n@RoquefortTherap\non X (formerly Twitter).\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNOAQKNBDNBKDDAK",
          "content_length": 2924
        },
        "ingested_at": "2026-01-16T22:42:51.256982Z"
      },
      {
        "event_id": "RNS-23rd May 2024-issueofc",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.256995Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Issue of Convertible Loan Notes & Board Changes",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/issue-of-convertible-loan-notes-board-changes-dokrom0p2ude3hi.html",
          "rns_number": "RNS Number : 6257P",
          "full_content": "23 May 2024 07:05\nRNS Number : 6257P\nRoquefort Therapeutics PLC\n23 May 2024\n23 May 2024\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nIssue of Convertible Loan Notes & Board Changes\nRoquefort Therapeutics plc (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on\ndeveloping first in class medicines in the high value and high growth immuno-oncology market\nannounces the issuance of unsecured Convertible Loan Notes to raise net proceeds of \u00a3584,915 (after issue discount and fees), the implementation of significant cost cutting and the restructure of the Board.\nConvertible Loan Notes\nRoquefort Therapeutics has received commitments for \u00a3655,000 of convertible loan notes to existing and new investors to raise net proceeds of \u00a3584,915 (after issue discount and fees) (\"CLN Offer\"), to bolster the Company's cash reserves and provide sufficient funding, in conjunction with existing cash reserves, for the Company for at least 12 months, during which time it expects to sign a further licencing agreement and further commercialise its pre-clinical portfolio.\nChairman Stephen West, CEO Ajan Reginald and Non-Executive Director Dr Darrin Disley all participated in the CLN Offer with Mr West investing \u00a326,750, Mr Reginald investing \u00a325,000 and Dr Disley investing \u00a320,000.\nThe Convertible Loan Notes are unsecured with a 12 month maturity, have a total face value of \u00a3655,000 and have been issued to noteholders at 95% of the face value. The interest rate is 12.5% accrued daily and paid upon conversion (in shares) or repayment (in cash). The conversion price of the Convertible Loan Notes is calculated as the lower of a) 6 pence per share; and b) 90% of the price equal to the 10-day volume-weighted average price calculated backwards from the date which is three business days prior to the notice of conversion given to the Company. Other than with the written consent of the Company, the noteholder is only permitted to convert the Convertible Loan Notes into equity after three months from the date of issue. Noteholders will be issued with a total of 6,222,500 unlisted warrants with an exercise price of 7.5 pence and expiry date of five years from date of issue, being 10 unlisted warrants for every \u00a31.00 invested. In addition, 497,800 broker warrants with the same terms will be issued.\nCost Cutting\nIn conjunction with the CLN Offer, the Company has implemented significant cost cutting including a 50% reduction in salaries and Directors fees effective from 1 March 2024. It is intended that salaries and directors' fees will be re-instated to 100% when a cash generative licencing deal is completed.\nBoard Restructure\nWith the successful completion of the pre-clinical development programs, Professor Sir Martin Evans will serve as a Non-Executive Director going forward and relinquish the role of Chief Scientific Officer. In addition, Dr Michael Stein has completed his tenure as a Non-Executive Director and leaves the Board effective immediately. In due course, as programs progress into clinical trials, the Company will augment the Board and the Scientific Advisory Board with the requisite clinical development expertise.\nAjan Reginald, Roquefort Therapeutics CEO commented:\n\"We are pleased to announce this convertible loan note offering. This funding, together with our existing cash and cost reduction plan, provides the Company with sufficient funds for at least the next 12 months independent of any funds we expect to receive from licensing deals. We have also announced deal terms with PDC for our Midkine antibody portfolio earlier today and expect to complete additional and potentially larger transactions in the second half of this year. This funding provides the Company with the time and flexibility required to complete the PDC transaction and other transactions we are negotiating. I'd like to take this opportunity to congratulate our R&D team on completing the product development which helps to drive these deals and to thank the shareholders, both old and new, who support our mission to create life-saving medicines.\"\nStephen West, Roquefort Therapeutics Chairman commented:\n\"I would like to thank Professor Sir Martin Evans for his time as Chief Scientific Officer, in which time we have made significant pre-clinical progress, and we are pleased to retain his industry leading experience on our Board going forward. Michael Stein has stepped down as a Non-Executive Director and I would like to thank him for his contribution to the Company since its founding and wish him well for the future. Finally, I would like to thank shareholders for their continued support in the Company.\"\nENDS\nEnquiries:\nRoquefort Therapeutics plc\nStephen West (Chairman) / Ajan Reginald (CEO)\n+44 (0)20 3918 8633\nHybridan LLP (Joint Broker)\nClaire Louise Noyce\nOptiva Securities Limited (Joint Broker)\n+44 (0)203 764 2341\nVishal Balasingham / Daniel Ingram\nBuchanan (Public Relations)\nBen Romney / Jamie Hooper / George Beale\n+44 (0",
          "content_length": 6775
        },
        "ingested_at": "2026-01-16T22:42:51.257011Z"
      },
      {
        "event_id": "RNS-23rd May 2024-midkinea",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.257025Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Midkine Antibody Licencing Deal",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/midkine-antibody-licencing-deal-dzmui2y93rm5rzn.html",
          "rns_number": "RNS Number : 6255P",
          "full_content": "23 May 2024 07:00\nRNS Number : 6255P\nRoquefort Therapeutics PLC\n23 May 2024\n23 May 2024\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nMidkine Antibody Licencing Deal\nRoquefort Therapeutics plc (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on\ndeveloping first in class medicines in the high value and high growth immuno-oncology market\nis pleased to\nannounce the signing of a term sheet for the out-licensing of its Midkine antibody portfolio to PDC FZ-LLC (\"PDC\"), a leading MEA pharmaceutical research and development organisation. PDC has a track record of successfully conducting over 150 clinical trials.\nMidkine Out-Licensing Transaction\nRoquefort Therapeutics has signed a term sheet to grant an exclusive worldwide license for its Midkine antibody portfolio to PDC FZ-LLC, part of the PDC group. This is a strategic out-licencing deal in which Roquefort Therapeutics receives $10M total initial consideration value and a guaranteed share of the trade sale proceeds on successful completion of Phase 1 clinical trials. PDC will develop one or more of the Midkine antibodies within a new Special Purpose Vehicle (\"SPV\") to complete the Phase 1 clinical trial and then seek a trade sale of the SPV. The term sheet is non-binding, except for certain provisions including exclusivity to 31 December 2024. Completion of the transaction is subject to due diligence and the negotiation of a definitive licence agreement.\nA summary of the agreed commercial terms in the term sheet are listed below:\n\u00b7\nInitial consideration value of US$10 million, which includes non-dilutive equity in the SPV;\n\u00b7\nExclusive worldwide licence granted to the SPV for 20 years;\n\u00b7\nWithin 3 years, PDC to develop at least one of the Midkine antibodies within the SPV to the completion of a Phase 1 trial and then, upon success, to complete a trade sale of the SPV; and\n\u00b7\nRoquefort Therapeutics will receive circa 24% from any successful trade sale proceeds, which if the Phase 1 trial is successful, this 24% is projected to be worth up to US$50M (gross) based on similar phase 1 trade sales.\nRoquefort Therapeutics is now working with PDC to complete due diligence and has commenced the drafting of the definitive licence agreement. Further updates will be provided by the Company as this progresses and becomes binding.\nAjan Reginald, Roquefort Therapeutics CEO commented:\n\"We are pleased to announce this therapeutic licencing deal with an initial payment which is likely to include $1.25-2.5M upfront and a 24% share of what is substantial potential upside. PDC is a great partner with a strong track record of completing clinical trials and we are confident they will accelerate development of the Midkine antibodies into the clinic. Upon a successful Phase 1 exit, this would create significant returns to the SPV shareholders. We believe this is a good deal for all parties and it validates our business model and highlights our deal making capabilities. We expect to conclude this licensing agreement as soon as possible.\nIn the meantime, we remain focused on completing the other licencing deals that we are negotiating and look forward to updating the market in due course.\"\nMohamed Mostafa, CEO of PDC commented:\n\"PDC is the leading clinical trial organisation in the MEA region with an excellent track record of completing clinical trials. To date we have successfully completed more than 150 clinical trials with leading Big Pharma and Biotech companies. We are encouraged by the Midkine preclinical data from Roquefort Therapeutics and are delighted to license these Midkine antibodies and are confident in our ability to successfully complete the Phase 1 trials which should lead to a trade sale with significant value upside.\"\nENDS\nEnquiries:\nRoquefort Therapeutics plc\nStephen West (Chairman) / Ajan Reginald (CEO)\n+44 (0)20 3918 8633\nHybridan LLP (Joint Broker)\nClaire Louise Noyce\nOptiva Securities Limited (Joint Broker)\n+44 (0)203 764 2341\nVishal Balasingham / Daniel Ingram\nBuchanan (Public Relations)\nBen Romney / Jamie Hooper / George Beale\n+44 (0)20 3411 1881\n+44 (0)20 7466 5000\nLEI: \u200e254900P4SISIWOR9RH34\nAbout PDC\nPDC\nwas founded in 2011 and provides a full-service end-to-end innovative solution for Phase I to IV clinical trials and RWE studies in the Middle East and Africa region. PDC offers direct access to 30+ MEA countries, in line with global standards and local cultures and regulations. PDC's international experience, as well as proven track record of more than 150 successful clinical trials since 2011 provides the assurance that PDC is a reliable partner for clinical development.\nhttps://pdc-cro.com/\nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma.\nRoquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical",
          "content_length": 6384
        },
        "ingested_at": "2026-01-16T22:42:51.257041Z"
      },
      {
        "event_id": "RNS-26th Apr 2024-annualre",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.257055Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Annual Report & Financial Statements - 31 Dec 2023",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/annual-report-financial-statements-31-dec-2023-frp9y662iyp0bjc.html",
          "rns_number": "RNS Number : 1217M",
          "full_content": "26 Apr 2024 07:00\nRNS Number : 1217M\nRoquefort Therapeutics PLC\n26 April 2024\n26 April 2024\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nAnnual Report & Financial Statements - 31 Dec 2023\nRoquefort Therapeutics plc (LSE:ROQ\n, OTCQB:ROQAF\n),\nthe Main Market listed biotech company focused on\ndeveloping first in class medicines in the high value and high growth oncology market\n, announces its audited results for year ended 31 December 2023.\nCopies of the Annual Report and Financial Statements will be made available on the Company's website at:\nhttps://www.roquefortplc.com/results-centre\nHighlights\n\u00b7\nSigned exclusive worldwide license agreement (excluding Japan) with Randox Laboratories for 10 years to utilise Midkine antibodies in medical diagnostics\no\nHighly synergetic - deal will accelerate ability to diagnose patients and therefore reduce time and costs when it reaches clinical trials\n\u00b7\nFormed a Scientific Advisory Board to help drive drug development programs forward, comprised of experienced Professors Jo Martin, Trevor Jones and Armand Keating\n\u00b7\nContinued pre-clinical development with encouraging positive results for all five novel patent protected pre-clinical anti-cancer medicines\n\u00b7\nCash at year end 31 December 2023 of \u00a3537,322\nPre-clinical highlights\n\u00b7\nCreated a new novel family of mRNA therapeutics consisting of four mRNA therapeutics targeting Midkine.\nAchieved positive\nin vivo\nresults in anti-cancer mRNA therapeutic in breast and liver cancer where the studies demonstrated a statistically significant reduction in both cancer growth and migration\n\u00b7\nMidkine antibody programs, targeting metastatic breast cancer and metastatic lung cancer, successfully demonstrated\nin vivo\nsafety. In addition, the Company released its first\nin vivo\nresults for an osteosarcoma orphan drug indication, which has an accelerated development pathway and the potential for market exclusivity\n\u00b7\nAnti-cancer Midkine RNA oligonucleotide program targeting Midkine expressing cancers showed further pre-clinical progress having produced >90%\nin vitro\nefficacy in human liver and neuroblastoma cancer cells\n\u00b7\nStrengthened IP position in siRNA therapeutics with a new patent filing. Developed four siRNA sequences to strengthen portfolio. Sequences developed in combination with a Nano particle delivery system to target high mortality cancers including colon and breast\n\u00b7\nMK Cell program reached a significant milestone when tested in combination with Natural Killer (\"NK\") cells -\nactivation of NK cells produced up to a two-fold increase in cytotoxicity over NK cells alone in three difficult to treat cancers: ovarian cancer, acute myeloid leukaemia and multiple myeloma\nPost Period End Highlights\n\u00b7\nContinued the development of novel STAT-6 medicines in validated\nin vitro\nmodels of colon cancer with the results demonstrating efficacy of the four new siRNA sequences in reducing STAT-6 expression by 40-50%\n\u00b7\nFurther progress in mRNA by combining with a LNP delivery system in a validated\nin vivo\nmodel of liver cancer and demonstrated the safety and efficacy in reducing functional Midkine of the novel mRNA LNP combination\n\u00b7\nContinued studies in validated models of NK cell activation and cytotoxicity and demonstrated an anti-cancer effect in leukaemia. This efficacy was superior to NK cells alone confirming that the MK Cells activate NK cells\nOutlook\n\u00b7\nThe significant pre-clinical development achievements have put the Company in a position to open various out licencing discussions with big pharma as well as a private equity fund across the US, EU and Japan, where talks are ongoing\n\u00b7\nFavourable market conditions remain with big pharma set for a large revenue shortfall owing to patent expirations and a need for new blockbuster medicines\n\u00b7\nFocus is to secure at least one out licencing therapeutics deal and the potential to prepare at least one program for a phase 1 clinical study\nCommenting on the Annual Results, Chief Executive Officer, Ajan Reginald said:\n\"In 2023 we delivered on our strategy by meeting our pre-clinical milestones and significantly advancing our entire portfolio. We also strengthened the portfolio with additional patents by creating a new novel family of mRNA therapeutics, which is a highly attractive new field of medicine.\n\"We demonstrated the Company's deal making ability by signing our first licence agreement with Randox Laboratories in the medical diagnostics field and are pleased with its continued progress. We remain highly focused on, and are progressing, the key commercial goal to secure one or more therapeutic out-licencing transactions\n.\"\nEnquiries:\nRoquefort Therapeutics plc\nStephen West (Chairman) / Ajan Reginald (CEO)\n+44 (0)20 3290 9339\nHybridan LLP (Joint Broker)\nClaire Louise Noyce\nOptiva Securities Limited (Joint Broker)\n+44 (0)203 764 2341\nChristian Dennis\nBuchanan (Public Relations)\nJamie Hooper / Ben Romney / George Beale\n+44 (0)20 3411 1881\n+44 (0)20 7466 5000\nLEI: \u200e254900P4SISIWOR9RH34\nC",
          "content_length": 121324
        },
        "ingested_at": "2026-01-16T22:42:51.257072Z"
      },
      {
        "event_id": "RNS-5th Apr 2024-response",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.257085Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Response to Share Price Movement",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/response-to-share-price-movement-4wwdzuic8wg5wgl.html",
          "rns_number": "RNS Number : 4141J",
          "full_content": "5 Apr 2024 07:00\nRNS Number : 4141J\nRoquefort Therapeutics PLC\n05 April 2024\n5 April 2024\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nResponse to Share Price Movement\nRoquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF),\nthe Main Market listed biotech company focused on\ndeveloping first in class medicines in the high value and high growth oncology market,\nnotes recent bulletin board speculation about a placing that the Company may be undertaking.\nThe Company recently engaged its advisers to commence a process of market soundings in relation to a potential fundraise. However, in response to incorrect bulletin board comments regarding a speculative placing price and resulting unusual share price movements, the Board has decided to not proceed with any potential placing at this time.\nAs previously announced, Roquefort Therapeutics remains focused on completing an out-licensing agreement during the course of 2024 with potential Big Pharma partners and will update the market when a binding agreement is entered into.\nENDS\nEnquiries:\nRoquefort Therapeutics plc\nStephen West (Chairman) / Ajan Reginald (CEO)\n+44 (0)20 3918 8633\nHybridan LLP (Joint Broker)\nClaire Louise Noyce\nOptiva Securities Limited (Joint Broker)\n+44 (0)203 764 2341\nChristian Dennis\nBuchanan (Public Relations)\nBen Romney / Jamie Hooper / George Beale\n+44 (0)20 3411 1881\n+44 (0)20 7466 5000\nLEI: \u200e254900P4SISIWOR9RH34\nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma.\nRoquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of:\n\u00b7\nMidkine antibodies with significant\nin vivo\nefficacy and toxicology studies;\n\u00b7\nMidkine RNA therapeutics with novel anti-cancer gene editing action;\n\u00b7\nMidkine mRNA therapeutics with novel anti-cancer approach;\n\u00b7\nSTAT-6 siRNA therapeutics targeting solid tumours with significant\nin vivo\nefficacy; and\n\u00b7\nMK cell therapy with direct and NK cell-mediated anti-cancer action\nFor further information on Roquefort Therapeutics, please\nvisit\nwww.roquefortplc.com\nand\n@RoquefortTherap\non X (formerly Twitter).\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nSPMQKQBDDBKBNQK",
          "content_length": 3132
        },
        "ingested_at": "2026-01-16T22:42:51.257109Z"
      },
      {
        "event_id": "RNS-11th Mar 2024-positive",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.257129Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Positive Results: Midkine mRNA and STAT-6 siRNA",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/positive-results-midkine-mrna-and-stat-6-sirna-ceyd3hvr8csx1ji.html",
          "rns_number": "RNS Number : 2450G",
          "full_content": "11 Mar 2024 07:00\nRNS Number : 2450G\nRoquefort Therapeutics PLC\n11 March 2024\n11 March 2024\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nPositive Results: Midkine mRNA and STAT-6 siRNA Programs\nPre-clinical development milestones\nRoquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF),\nthe Main Market listed biotech company focused on\ndeveloping first in class medicines in the high value and high growth oncology market\n, provides an update on the development of the Midkine mRNA and STAT-6 siRNA programs.\nMidkine mRNA Program Milestone\nFurther to the announcement on 6 February 2024, where Roquefort Therapeutics announced that its mRNA therapeutics were undergoing studies in combination with proprietary lipid nanoparticle (LNP) delivery systems, the Company has continued development in validated\nin vivo\nmodels. These latest experiments combined the mRNA with a LNP delivery system in a validated\nin vivo\nmodel of liver cancer and demonstrated the safety and efficacy in reducing functional Midkine of the novel mRNA LNP combination.\nThis represents a significant milestone in both the discovery of a novel mRNA therapeutic and in the safe combination with an LNP to allow for the delivery of the mRNA as an anti-cancer medicine. Liver cancer is a leading cause of cancer deaths worldwide, accounting for more than 700,000 deaths each year\n[1]\n. Midkine is associated with liver cancer progression, resistance and prognosis\n[2]\n. A novel therapeutic that targets Midkine expressing liver cancers with the cutting-edge mRNA technology offers the potential for a first-in-class medicine in the $3B liver cancer market.\nSTAT-6 siRNA Program Milestone\nOn 7 August 2023 the Company announced that it had\ndeveloped four additional siRNA sequences that attack the target STAT-6 (Signal Transducer and Activator of Transcription)\nand its SH2 (Src-homology-2) domain.\nThe Company has continued the development of these novel STAT-6 medicines in validated\nin vitro\nmodels of colon cancer with the results demonstrating efficacy of the four new siRNA sequences in reducing STAT-6 expression by 40-50%.\nColorectal cancer (CRC) is the\nthird most\ndiagnosed malignancy and a major leading cause of cancer-related deaths worldwide\nwith\n~1.9 million new cases per year and accounted for over 900,000 deaths in 2020\n[3]\n. Despite advances in therapeutic regimens, the number of patients presenting with metastatic CRC (mCRC) is increasing due to resistance to therapy\n[4]\n. STAT-6 has been implicated in colorectal cancer development, progression, metastasis, poor survival, and resistance to treatment\n[5]\n. Therefore, a\nnovel therapeutic that targets STAT-6 expressing colon cancers offers the potential for a first-in-class medicine in the $12B colon cancer market\n[6]\n.\nRoquefort Therapeutics CEO Ajan Reginald commented:\n\"We have made significant progress across our pre-clinical drug development programs in Q4 2023 and in Q1 2024. First with the MK cell program announced in February 2024 and today, with the results with our Midkine mRNA and STAT-6 siRNA programs. Both programs highlight Roquefort Therapeutics' ability to select and develop valuable new medicines for the most difficult to treat cancers. Successfully combining our Midkine mRNA with LNP delivery creates potential for a highly promising new medicine for liver cancer and the novel STAT-6 siRNAs have shown great promise in colon cancer.\nBy focusing on oncology patients with the worst prognosis, who are not well treated with existing medicines, we hope to develop new first-in-class medicines that dramatically improve survival and as a consequence, are the most valuable to potential Pharma acquirers.\nBig Pharma is set to face a $200 billion\n[7]\nfall in revenue from 2024-2030 due to patent expirations while also earning record profits over the last five years. Therefore Big Pharma will have to fill this gap by acquiring new blockbuster medicines to fill this shortfall, and so it is a great time to have our portfolio of potential blockbuster medicines. We remain in active out licencing discussions with Big Pharma companies and a specialist private equity fund across the US, EU and Japan and will update the market should a binding agreement be entered into with one or more partners.\"\nENDS\nEnquiries:\nRoquefort Therapeutics plc\nStephen West (Chairman) / Ajan Reginald (CEO)\n+44 (0)20 3918 8633\nHybridan LLP (Joint Broker)\nClaire Louise Noyce\nOptiva Securities Limited (Joint Broker)\n+44 (0)203 764 2341\nChristian Dennis\nBuchanan (Public Relations)\nBen Romney / Jamie Hooper / George Beale\n+44 (0)20 3411 1881\n+44 (0)20 7466 5000\nLEI: ?254900P4SISIWOR9RH34\nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma.\nRoquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer medici",
          "content_length": 7475
        },
        "ingested_at": "2026-01-16T22:42:51.257145Z"
      },
      {
        "event_id": "RNS-6th Feb 2024-operatio",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.257157Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Operations Update",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/operations-update-4pqpvm5ib7q0wtd.html",
          "rns_number": "RNS Number : 0796C",
          "full_content": "6 Feb 2024 07:00\nRNS Number : 0796C\nRoquefort Therapeutics PLC\n06 February 2024\n6 February 2024\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nOperations Update\nRoquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF),\nthe Main Market listed biotech company focused on\ndeveloping first in class medicines in the high value and high growth oncology market\n, provides an update on its pre-clinical drug development programs, Randox licencing agreement and out-licencing discussions.\nPre-Clinical Drug Development Programs\nFurther to the Company's announcement on 6 November 2023, where Roquefort Therapeutics' announced that new test results for its MK cells combined with natural killer (NK) cells demonstrated a profound cancer killing effect across solid, lymphoma and leukaemia in validated\nin vivo\nmodels, the Company has continued studies in validated models of NK cell activation and cytotoxicity and demonstrated an anti-cancer effect in leukaemia. This efficacy was superior to NK cells alone confirming that the MK cells activate NK cells. NK cell activation is a new field with high commercial potential in which large pharmaceutical partners completed significant deals in 2022 and 2023.\nDuring Q1 2024 the Company's Midkine RNA oligonucleotide and STAT-6 siRNA programs have been undergoing studies in combination with proprietary lipid nanoparticle (LNP) delivery systems. The initial studies have shown successful encapsulation with the LNPs and biological activity of the combination in liver cancer. Further results are expected to be reported by the end of Q1 2024.\nRandox Licencing Agreement (Diagnostics)\nAs announced in February 2023, the Company signed a Licence and Royalty Agreement with leading diagnostics group, Randox Laboratories (\"Randox\") in relation to its Midkine antibody portfolio. Randox is developing and manufacturing human\nin vitro\ndiagnostic (IVD) tests to detect the high Midkine levels associated with cancer and other diseases. These IVD tests will accelerate Roquefort Therapeutics' portfolio of Midkine medicines in clinical trials and, subject to approval, in diagnosing patients with Midkine expressing cancers. As Randox's development progresses the Company expects to receive further milestone payments during 2024 and, upon success, this is expected to generate royalties for the Company from 2025.\nOut-Licencing Discussions (Therapeutics)\nIn line with its strategy, the Company is currently engaged in confidential out-licencing discussions with potential partners, including large pharmaceuticals companies and a specialist private equity fund. A further announcement will be made should a binding agreement be entered into with one or more partners. The programs and jurisdictions being negotiated include the Midkine antibodies and STAT-6 isRNA programs, and relate to licences for the US, Europe and Japan markets.\nRoquefort Therapeutics CEO Ajan Reginald commented:\n\"We have been making great progress across our pre-clinical drug development programs and are particularly excited with the recent results from our MK cell program which is a very attractive novel therapeutic approach. The MK cell program has demonstrated both direct killing and natural killer cell activation in a commercially attractive field which has significant interest from large pharmaceutical companies. MK cells are a new class of cellular medicine and add to the Midkine programs and the siRNA program to create a portfolio of five first-in-class medicines.\nWe are pleased with the progress our Midkine diagnostics licencing agreement with Randox is making and the IVD tests not only validate Midkine as a target, but it will also help accelerate our Midkine portfolio in the clinic, further adding to its commercial appeal.\nWe are delivering on our strategy to select and acquire novel science and to precisely develop this into commercially valuable medicines. We are developing first in class medicines, which given the patent cliff faced by big pharma, are some of the most valuable assets in the Biopharmaceutical space. The Company remains in discussions with multiple potential partners and looks forward to updating shareholders as to our progress in due course.\"\nENDS\nEnquiries:\nRoquefort Therapeutics plc\nStephen West (Chairman) / Ajan Reginald (CEO)\n+44 (0)20 3918 8633\nHybridan LLP (Joint Broker)\nClaire Louise Noyce\nOptiva Securities Limited (Joint Broker)\n+44 (0)203 764 2341\nChristian Dennis\nBuchanan (Public Relations)\nBen Romney / Jamie Hooper / George Beale\n+44 (0)20 3411 1881\n+44 (0)20 7466 5000\nLEI: ?254900P4SISIWOR9RH34\nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma.\nSince listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target",
          "content_length": 6715
        },
        "ingested_at": "2026-01-16T22:42:51.257172Z"
      },
      {
        "event_id": "RNS-24th Nov 2023-changeof",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.257184Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Change of Auditor",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/change-of-auditor-oqjoibwpshf7fv2.html",
          "rns_number": "RNS Number : 5173U",
          "full_content": "24 Nov 2023 07:00\nRNS Number : 5173U\nRoquefort Therapeutics PLC\n24 November 2023\n24 November 2023\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nChange of Auditor\nRoquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF),\nthe Main Market listed biotech company focused on\ndeveloping first in class medicines in the high value and high growth oncology market\n, announces that RPG Crouch Chapman LLP has been appointed as its new independent auditor with immediate effect.\nThe Board has approved the appointment of RPG Crouch Chapman LLP as the Company's auditor for the financial year ending 31 December 2023. The re-appointment of RPG Crouch Chapman LLP for the financial year ending 31 December 2024 will be subject to approval by shareholders at the next Annual General Meeting of the Company to be held in 2024.\nIn accordance with Section 519 of the Companies Act 2006, the Company's previous auditor, BDO LLP, has confirmed that there are no circumstances connected with their resignation which they considered should be brought to the attention of the Company's members or creditors in accordance with Section 519 of the Companies Act 2006.\nENDS\nEnquiries:\nRoquefort Therapeutics plc\nStephen West (Chairman) / Ajan Reginald (CEO)\n+44 (0)20 3918 8633\nHybridan LLP (Joint Broker)\nClaire Louise Noyce\nOptiva Securities Limited (Joint Broker)\n+44 (0)203 764 2341\nChristian Dennis\nBuchanan (Public Relations)\nBen Romney / Jamie Hooper / George Beale\n+44 (0)20 3411 1881\n+44 (0)20 7466 5000\nLEI: ?254900P4SISIWOR9RH34\nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma.\nSince listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.\nRoquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of:\n\u00b7\nMidkine antibodies with significant\nin vivo\nefficacy and toxicology studies;\n\u00b7\nMidkine RNA therapeutics with novel anti-cancer gene editing action;\n\u00b7\nMidkine mRNA therapeutics with novel anti-cancer approach;\n\u00b7\nSTAT-6 siRNA therapeutics targeting solid tumours with significant\nin vivo\nefficacy; and\n\u00b7\nMK cell therapy with direct and NK cell-mediated anti-cancer action\nFor further information on Roquefort Therapeutics, please\nvisit\nwww.roquefortplc.com\nand\n@RoquefortTherap\non X (formerly Twitter).\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nAPPDZMZMVFKGFZM",
          "content_length": 3656
        },
        "ingested_at": "2026-01-16T22:42:51.257197Z"
      },
      {
        "event_id": "RNS-6th Nov 2023-signific",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.257210Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Significant Mesodermal Killer Cell Milestone",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/significant-mesodermal-killer-cell-milestone-n3zvzhr61wevlu1.html",
          "rns_number": "RNS Number : 4114S",
          "full_content": "6 Nov 2023 07:00\nRNS Number : 4114S\nRoquefort Therapeutics PLC\n06 November 2023\n6 November 2023\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nSignificant Mesodermal Killer Cell Milestone\nRoquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF),\nthe Main Market listed biotech company focused on\ndeveloping first in class medicines in the high value and high growth oncology market\n, announces that the Mesodermal killer (\"MK\") cell program has reached a significant milestone.\nAs announced in September 2022, the Company's MK cells are a proprietary and novel class of cellular medicine. While MK cells kill cancer cells directly, their more profound effect is the activation of natural killer (\"NK\") cells. As previously announced, this direct killing of cancer cells and activation of NK cells to increase cytotoxicity have each been demonstrated in validated\nin vivo\nmodels of lymphoma and myeloma.\nIn the new results announced today, MK cells were tested in combination with NK cells and showed: (1) the activation of NK cells; and (2) that this activation produced up to a two-fold increase in cytotoxicity over NK cells alone in three different difficult to treat cancers, which was statistically significant*:\n\u00b7\nOvarian cancer (P\n\u00b7\nAcute myeloid leukemia (P\n\u00b7\nMultiple myeloma\n?\n(P\nThis demonstration of the activation of NK cells in multiple cancer types including solid tumours, lymphomas and leukaemia is a significant commercial milestone because the NK cell activation is a highly attractive modality for large pharmaceutical companies. The recent transactions in this niche market include the $1.4B partnership between Sanofi and Innate Pharma\n[1]\nand >$300M Gilead and Dragonfly Therapeutics transaction\n[2]\nfor Innate and Dragonfly's proprietary activators of NK cells.\nThe Company's MK cells will now progress into further\nin vivo\nstudies in validated models of NK cell activation and cancer cytotoxicity.\nRoquefort Therapeutics CEO Ajan Reginald said:\n\"This is an excellent set of results which demonstrates the Company's strategy to select and acquire novel medicines and to rapidly develop them to reach significant commercial milestones.\n\"Our MK cells combined with natural killer cells show a profound cancer killing effect across solid tumours, lymphoma and leukaemia. The NK cell activator is a highly attractive market niche with a number of recent high value transactions. Today's results build on the excellent results we have reported for our siRNA and Midkine programs.\n\"Our portfolio is attracting interest from Big Pharma and private equity, and in line with our strategy, we are engaged in discussions with these potential partners. In the meantime, we will continue to deliver these value enhancing milestones across our programs on time and within budget.\"\nENDS\nEnquiries:\nRoquefort Therapeutics plc\nStephen West (Chairman) / Ajan Reginald (CEO)\n+44 (0)20 3918 8633\nHybridan LLP (Joint Broker)\nClaire Louise Noyce\nOptiva Securities Limited (Joint Broker)\n+44 (0)203 764 2341\nChristian Dennis\nBuchanan (Public Relations)\nBen Romney / Jamie Hooper / George Beale\n+44 (0)20 3411 1881\n+44 (0)20 7466 5000\nLEI: ?254900P4SISIWOR9RH34\nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma.\nSince listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.\nRoquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of:\n\u00b7\nMidkine antibodies with significant\nin vivo\nefficacy and toxicology studies;\n\u00b7\nMidkine RNA therapeutics with novel anti-cancer gene editing action;\n\u00b7\nMidkine mRNA therapeutics with novel anti-cancer approach;\n\u00b7\nSTAT-6 siRNA therapeutics targeting solid tumours with significant\nin vivo\nefficacy; and\n\u00b7\nMK cell therapy with direct and NK cell-mediated anti-cancer action\nFor further information on Roquefort Therapeutics, please\nvisit\nwww.roquefortplc.com\nand\n@RoquefortTherap\non X (formerly Twitter).\n*P\nhttps://www.fiercebiotech.com/biotech/gilead-follows-big-pharma-peers-dragonflys-pond-300m-deal-nk-cell-engagers\n[1]\nhttps://www.biospace.com/article/sanofi-deepens-nk-cell-therapy-partnership-with-innate-pharma/\n[2]\nhttps://www.fiercebiotech.com/biotech/gilead-follows-big-pharma-peers-dragonflys-pond-300m-deal-nk-cell-engagers\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as",
          "content_length": 5635
        },
        "ingested_at": "2026-01-16T22:42:51.257223Z"
      },
      {
        "event_id": "RNS-27th Sep 2023-interimr",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.257236Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Interim Results to 30 June 2023",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/interim-results-to-30-june-2023-hrqrwdgtswrzd84.html",
          "rns_number": "RNS Number : 7420N",
          "full_content": "27 Sep 2023 07:00\nRNS Number : 7420N\nRoquefort Therapeutics PLC\n27 September 2023\n27 September 2023\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nInterim Results to 30 June 2023\nRoquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on\ndeveloping first-in-class medicines in the high value and high growth oncology market\n, is pleased to present its interim results for the six-month period ended 30 June 2023 (the \"period\" or \"H1\").\nHighlights\n\u00b7\nSigned exclusive worldwide license agreement (excluding Japan) with Randox Laboratories for 10 years to utilise Midkine antibodies in the non-core medical diagnostics field:\no\nhighly synergistic - allows the Company to remain focused on the higher value therapeutic market while accelerating the diagnosis of patients with Midkine cancers to establish the Midkine cancer market\no\nreduces the time and cost of clinical trials, and diagnostics have been shown to increase trial success rates\n[1]\no\nhighlights the Company's leadership position in Midkine and the Company's in-house deal making capabilities and is expected to strengthen the balance sheet\n\u00b7\nFormation of an expert Scientific Advisory Board of\nProfessors Jo Martin, Trevor Jones and Armand Keating\nto review and advise on the development of the portfolio\n\u00b7\nKey milestone achieved with ROQ-A1 and ROQ-A2 Midkine antibody programs, targeting metastatic breast cancer, and lung and liver metastasis, successfully demonstrated\nin vivo\nsafety in pre-clinical development programs and progressed into\nin vivo\nefficacy studies\n\u00b7\nThe Company's first Orphan drug indication targets osteosarcoma in which, ROQ-A1 and ROQ-A2 demonstrated\nin vivo\nefficacy. This creates significant commercial potential for an Orphan drug designation which, if successful, would confer market exclusivity in multiple jurisdictions including seven years in the USA and 10 years in the EU and UK\n[2]\n\u00b7\nPortfolio further enhanced to a total of five programmes with the in-house development of a family of novel mRNA cancer medicines, which have demonstrated\nin vitro\nefficacy in validated models of breast and liver cancer\n\u00b7\nsiRNA, MK cell therapy and Midkine oligonucleotide programs progressing into pre-clinical development\n\u00b7\nCash at period end of \u00a31,379,021 and for the 6 months to 30 June 2023, net loss of \u00a3742,833\nPost Period End Highlights\n\u00b7\nPatent portfolio significantly expanded with\nfiling of the international phase PCT (Patent Treaty Cooperation) patent for proprietary anti-cancer\nmRNA and RNA oligonucleotide\ntherapeutics, and\nnew patent filing for its family of novel anti-cancer siRNA therapeutics\nOutlook\n\u00b7\nOn course with targets for clinical readiness for one of the Company's development programs during H2 2023\n\u00b7\nNear-term IND and licensing opportunities from advanced stage of development of Midkine portfolio products, MK cell and siRNA products\n\u00b7\nStrategic goal to take advantage of the paradigm shift that 90% of successful biotech programs are acquired by big pharma\n\u00b7\nCreate value by identifying early innovation, developing it either in-house or with a research partner towards clinical trials and utilise experience to licence or sell to big pharma\nCommenting on the Interim Results, Roquefort Therapeutics CEO Ajan Reginald said:\n\"\nIn H1 2023, we have met the Company's strategic R&D targets, expanded our product portfolio to five programs with the addition of an innovative mRNA program, enhanced our IP leadership position in Midkine and STAT-6 siRNA and completed the partnership with Randox, one of the UK's leading medical diagnostics providers.\n\"To provide an industry context, our product portfolio now includes three programs (antibodies, siRNA and MK cell) with robust in vivo efficacy results, and so, our portfolio is more advanced in development than some leading UK biotech companies recently valued at US$100M. The STAT-6 siRNA is a good example of our strategy to discover and acquire unvalidated targets before big pharma realises the value. In July, Sanofi completed a US$1.2B deal with Recludix for their pre-clinical STAT-6 program, which is in the same pre-clinical stage of development as our STAT-6 siRNA program. Even though STAT-6 had been worked by pharma for circa 20 years, before this deal it was still an unvalidated target. After Sanofi's $Billion valuation and validation, many of the big pharma companies are seeking STAT-6 programs.\n\"Similarly, the Randox deal for diagnostics demonstrates the significant (under) valuation of the Midkine market, in which we have an IP leadership position. Randox, a sophisticated diagnostics company, acquired the rights for diagnostics only, and while diagnostics are highly synergistic and very important, this is a far less commercially valuable market than the Midkine therapeutics market.\n\"This industry context underpins our strategy to acquire and develop medicines in novel targets such as STAT-6 and Midkine before they are highly valued to create th",
          "content_length": 34892
        },
        "ingested_at": "2026-01-16T22:42:51.257252Z"
      },
      {
        "event_id": "RNS-22nd Sep 2023-investor",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.257265Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Investor Presentation via Investor Meet Company",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/investor-presentation-via-investor-meet-company-5wfar730bf53eev.html",
          "rns_number": "RNS Number : 3947N",
          "full_content": "22 Sep 2023 11:42\nRNS Number : 3947N\nRoquefort Therapeutics PLC\n22 September 2023\n22 September 2023\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nInvestor Presentation via Investor Meet Company\nRoquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF),\nthe Main Market listed biotech company focused on\ndeveloping first in class medicines in the high value and high growth oncology market\n, announces that CEO Ajan Reginald and Chairman Stephen West will give a live presentation via the Investor Meet Company platform at\n10am\nBST on\nWednesday, 27 September 2023.\nThe objective of the presentation will be to provide investors with an update relating to the Company's Interim Results.\nThe presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.\nInvestors can sign up to Investor Meet Company for free and can arrange to meet ROQUEFORT THERAPEUTICS via:\nhttps://www.investormeetcompany.com/roquefort-therapeutics-plc/register-investor\nInvestors who already follow\nROQUEFORT THERAPEUTICS\nPLC\non the Investor Meet Company platform will automatically be invited.\nENDS\nEnquiries:\nRoquefort Therapeutics plc\nStephen West (Chairman) / Ajan Reginald (CEO)\n+44 (0)20 3918 8633\nHybridan LLP (Joint Broker)\nClaire Louise Noyce\nOptiva Securities Limited (Joint Broker)\n+44 (0)203 764 2341\nChristian Dennis\nBuchanan (Public Relations)\nBen Romney / Jamie Hooper / George Beale\n+44 (0)20 3411 1881\n+44 (0)20 7466 5000\nLEI: \u200e254900P4SISIWOR9RH34\nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma.\nSince listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.\nRoquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of:\n\u00b7\nMidkine antibodies with significant\nin vivo\nefficacy and toxicology studies;\n\u00b7\nMidkine RNA therapeutics with novel anti-cancer gene editing action;\n\u00b7\nMidkine mRNA therapeutics with novel anti-cancer approach;\n\u00b7\nSTAT-6 siRNA therapeutics targeting solid tumours with significant\nin vivo\nefficacy; and\n\u00b7\nMK cell therapy with direct and NK-mediated anti-cancer action\nFor further information on Roquefort Therapeutics, please\nvisit\nwww.roquefortplc.com\nand\n@RoquefortTherap\non Twitter.\nThis information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nNRAFZGZLGZNGFZM",
          "content_length": 3661
        },
        "ingested_at": "2026-01-16T22:42:51.257278Z"
      },
      {
        "event_id": "RNS-14th Aug 2023-expansio",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.257290Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Expansion of Patent Portfolio",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/expansion-of-patent-portfolio-dfhgx1yj2okim26.html",
          "rns_number": "RNS Number : 1451J",
          "full_content": "14 Aug 2023 07:00\nRNS Number : 1451J\nRoquefort Therapeutics PLC\n14 August 2023\n14 August 2023\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nExpansion of Patent Portfolio\nSuccessful filing of the international (PCT) patent enhances Midkine IP leadership position\nRoquefort Therapeutics (LSE:ROQ),\nthe Main Market listed biotech company focused on\ndeveloping first in class medicines in the high value and high growth oncology market\nis pleased to announce the successful filing of the international phase PCT (Patent Treaty Cooperation) patent for its proprietary anti-cancer\nmRNA and RNA oligonucleotide\ntherapeutics\n.\nToday's announcement follows the development of the Company's novel anti-cancer RNA oligonucleotide and mRNA therapeutics targeting Midkine (\"MDK\") announced on 13 and 22 June 2023, which are undergoing\nin vitro\nand\nin vivo\nstudies at the University of Sydney and University of New South Wales. The studies demonstrated efficacy with the Company's MDK RNA Oligonucleotides and mRNA in validated\nin vitro\nmodels of breast and liver cancer.\nThe PCT patent, governed by the World Intellectual Property Organisation (WIPO), once approved, provides patent protection for the invention in more than 155 countries\n[1]\n. The filing consolidates and enhances the Company's intellectual property portfolio and leadership position in Midkine with composition of matter and methods for the protection for both mRNA and RNA oligonucleotide modalities. While the mRNA and RNA oligonucleotides target different regions of the Midkine, both have demonstrated anti-cancer efficacy\nin vitro.\n[2]\nThe MDK RNA oligonucleotide and mRNA programs have now progressed into combinations studies with a proprietary targeted nano-particle delivery technology and are scheduled to progress into\nin vivo\nstudies in Q4 2023.\nAjan Reginald, Chief Executive Officer of Roquefort Therapeutics, said:\n\"mRNA technology promises to revolutionize future treatments for cancer (AAMC\n[3]\n) and as such we are delighted that we are part of this cutting-edge field to treat the hardest-to-treat cancers. Both the mRNA and RNA oligonucleotides attack the novel Midkine target, in which the Company are pioneers. Midkine expression is highly associated with cancer progression and poor survival.\nAs we've recently seen with the validation of STAT-6 (through a $Billion licensing deal), we believe Midkine will become a highly attractive, validated target and we will be uniquely positioned with a portfolio of patented antibody, mRNA and RNA oligonucleotide medicines. Therefore our focus is continue to deliver on R&D and commercial milestones that highlight the significant potential of Midkine as a novel cancer target.\"\n-Ends-\nEnquiries:\nRoquefort Therapeutics plc\nStephen West (Chairman) / Ajan Reginald (CEO)\n+44 (0)20 3918 8633\nHybridan LLP (Joint Broker)\nClaire Louise Noyce\nOptiva Securities Limited (Joint Broker)\n+44 (0)203 764 2341\nChristian Dennis\nBuchanan (Public Relations)\nBen Romney / Jamie Hooper / George Beale\n+44 (0)20 3411 1881\n+44 (0)20 7466 5000\nLEI: \u200e254900P4SISIWOR9RH34\nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma.\nSince listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.\nRoquefort Therapeutics' portfolio consists of five fully funded, novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of four best-in-class medicines consists of:\n\u00b7\nMidkine antibodies with significant\nin vivo\nefficacy and toxicology studies;\n\u00b7\nMidkine RNA oligonucleotide therapeutics with novel anti-cancer gene editing action;\n\u00b7\nMidkine mRNA therapeutics with novel anti-cancer approach\n\u00b7\nSTAT-6 siRNA therapeutics targeting solid tumours with significant\nin vivo\nefficacy; and\n\u00b7\nMK cell therapy with direct and NK-mediated anti-cancer action.\nFor further information on Roquefort Therapeutics, please\nvisit\nwww.roquefortplc.com\nand\n@RoquefortTherap\non Twitter.\n[1]\nwww.wipo.int/pct\n[2]\nhttps://www.roquefortplc.com/regulatory-news/39390\nand\nhttps://www.roquefortplc.com/regulatory-news/39288\n[3]\nhttps://www.aamc.org/news/mrna-technology-promises-revolutionize-future-vaccines-and-treatments-cancer-infectious-diseases\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For furth",
          "content_length": 5482
        },
        "ingested_at": "2026-01-16T22:42:51.257306Z"
      },
      {
        "event_id": "RNS-7th Aug 2023-developm",
        "event_type": "rns_announcement",
        "date": "2026-01-16T22:42:51.257319Z",
        "source": "LSE_RNS",
        "data": {
          "title": "Development of New Novel siRNA Therapeutics",
          "category": "RNS",
          "url": "https://www.lse.co.uk/rns/ROQ/development-of-new-novel-sirna-therapeutics-syt9cvquudm0nkv.html",
          "rns_number": "RNS Number : 4842I",
          "full_content": "7 Aug 2023 07:00\nRNS Number : 4842I\nRoquefort Therapeutics PLC\n07 August 2023\n7 August 2023\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nDevelopment of New Novel siRNA Therapeutics\nPortfolio and IP position enhanced with expansion of novel siRNA medicines\nRoquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF),\nthe Main Market listed biotech company focused on\ndeveloping first in class medicines in the high value and high growth oncology market\nis pleased to announce the successful development of new siRNA sequences and new patent filing for its family of novel anti-cancer siRNA therapeutics.\nFollowing the Company's acquisition of Oncogeni Ltd in September 2022, where Roquefort Therapeutics acquired a portfolio of pioneering pre-clinical siRNA anti-cancer medicines\nwith significant\nin vivo\nefficacy\n, the Company's drug discovery team, led by Vice President of Drug Discovery, Professor Graham Robertson, has recently developed four additional siRNA sequences to complement the existing siRNA portfolio. The new siRNA sequences expand the Company's portfolio of siRNA medicines that attack the targets STAT-6 (Signal Transducer and Activator of Transcription)\n[1]\nand its SH2 (Src-homology-2) domain\n[2]\n.\nThe Company has recently completed a new patent filing to strengthen its siRNA patent position to protect both the composition of matter and methods of use.\nsiRNA therapeutics are an innovative new class of medicines based on RNA interference (RNAi), which was recognized with the 2006 Nobel Prize in Medicine or Physiology and pioneered by a leading biotech company Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) which recently completed a $2.8 billion partnership with Roche (SWX: ROG)\n[3]\n.\nThe siRNA targets STAT-6 and SH2 were recently validated by Sanofi (NASDAQ: SNY) in a licensing transaction with Recludix that included a US$125 million upfront payment and represented a total deal value of up to US$1.2 billion\n[4]\nfor a program in the pre-clinical stage of development that targets the SH2 domain of STAT6. Roquefort Therapeutic's siRNA programs are also in pre-clinical development and target STAT-6 and the SH2 domain and have shown significant\nin vivo\nanti-cancer activity (*p\n[5]\n.\nThe Company's siRNA sequences are being developed in combination with nano-particle delivery systems to target the hard-to-treat, high mortality solid cancers including colon and breast cancer with results expected in Q4 2023.\nAjan Reginald, Chief Executive Officer of Roquefort Therapeutics, said:\n\"We are encouraged by the recent commercial validations of both siRNA as a therapeutic modality and STAT-6 and SH2 as highly attractive medicinal targets. The recent multi-billion dollar licensing deals indicate a high level of interest in this niche in which we were early innovators and were able to acquire strong patent positions before the market valued these asset classes. Our siRNA programs target the very attractive SH2 domain and have demonstrated highly specific efficacy in validated STAT-6 models. The patents that we have recently filed consolidate our leadership position in targeting STAT-6 and SH2 with siRNA.\nIn parallel to our R&D activities, our business development remains active in what is becoming an attractive market with current deal volumes 150% higher than in Q2 2022\n[6]\nand M&A transactions forecast to exceed the levels seen in 2022\n[7]\n. This market is reportedly driven by Big Pharma's requirement for new products to replace the lost revenues expected as a result of the \"$200B patent cliff\": $200 billion in annual pharma revenue at risk through 2030 due to patent expirations\n[8]\n.\nIn this market, newly validated targets like STAT-6 and novel modalities like siRNA are garnering high deal values because they offer the potential to create first-in-class medicines which have a greater likelihood of generating blockbuster (multi-billion dollar) revenues\n[9]\n. Our strategy fits this paradigm, whereby we create significant value by discovering these first-in-class medicines\nbefore the market recognises them and enhancing their value with targeted R&D to optimise the appeal to Big Pharma.\nOur portfolio of five potential first-in-class medicines includes newly validated targets (STAT-6 and Midkine) and novel modalities (siRNA, mRNA and cell therapy) and so, we are well positioned to create significant shareholder value in this market and will continue delivering the R&D results that Big Pharma are looking for.\"\n-Ends-\nEnquiries:\nRoquefort Therapeutics plc\nStephen West (Chairman) / Ajan Reginald (CEO)\n+44 (0)20 3918 8633\nHybridan LLP (Joint Broker)\nClaire Louise Noyce\nOptiva Securities Limited (Joint Broker)\n+44 (0)203 764 2341\nChristian Dennis\nBuchanan (Public Relations)\nBen Romney / Jamie Hooper / George Beale\n+44 (0)20 3411 1881\n+44 (0)20 7466 5000\nLEI: \u200e254900P4SISIWOR9RH34\nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class ",
          "content_length": 8295
        },
        "ingested_at": "2026-01-16T22:42:51.257335Z"
      },
      {
        "event_id": "SOCIAL-18Dec20251248-Bottmzup--8946544",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:10.784120",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bottmzup",
          "content": "Been buying the dips into the low 0.2ps for 2 years! All profit from here going in to '26, lovely jubbly..gold at an all time high too. Have a look yourself, you might be able to offset your extra long wait for a return here (with no gaurantees) :-) ps. so you checked that I did say I sold at the time then? Maybe you're the one not to be trusted for posting blatant lies?",
          "sentiment": 0.0,
          "engagement": "6,741",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-22T21:15:10.794516+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251332-hamilton--6179100",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:10.783683",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "You\u2019ve been buying around here for two years and then saying we will have to wait for ROQ : ) Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,508",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-22T21:15:10.794498+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251456-pumpky-26368910",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:10.783134",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Next month will be 1 year since the deal was announced",
          "sentiment": 0.0,
          "engagement": "17,615",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-22T21:15:10.794480+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251556-billy101--4568281",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:10.782712",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "What you going to do about it  then Pumpky surely your not going to hang a round with all your knowledge",
          "sentiment": 0.0,
          "engagement": "31,677",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-22T21:15:10.794462+00:00"
      },
      {
        "event_id": "SOCIAL-19Dec20250709-Bottmzup--3791948",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:10.782295",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bottmzup",
          "content": "Wrong again liar. I bought in earlier in '25 so held for maybe 9 months. Bought in for the two deals to be completed before I began to learn what bs this company was capable of....extending completion dates and stringing shareholders along with vague promises, whilst hoping and praying that they would fall for the jam tomorrow bull**it and wouldn't sell. I smelled a rat as soon as they extended the long stop date for the second time early on. Then they decided to completely change the plan with a complicated set up of a reverse takeover including relisting on AIM! I knew the gullible would then hold out for these lucky dip free shares, and there could be a last minute spike for me to get out of this absolute circus. I've been taken for a mug before on AIM during my long learning curve, not any more. Back in my tradesman days, we used to send apprentices to the stores to get a long wait, playing them for mugs. Now this crowd are doing the same to the gullible shareholders with 'intentions' to make good on their promises!!! Eeeek! They even moved the goal posts again with the long stop for this new deal just last week! Dear oh dear, how many clues do you need?",
          "sentiment": 0.0,
          "engagement": "6,741",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-22T21:15:10.794444+00:00"
      },
      {
        "event_id": "SOCIAL-19Dec20250729-Downagai--1076378",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:10.781826",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Surprised you sold so low given you could get nearly 3p the end of that week if your plan was to get out all along. Bit of a missed opportunity, hindsight a bummer \ud83e\udd14",
          "sentiment": 0.0,
          "engagement": "782",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-22T21:15:10.794426+00:00"
      },
      {
        "event_id": "SOCIAL-19Dec20251315-hamilton-54875921",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:10.781415",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "I was referring to you saying you\u2019d been in ECR for two years but nice try ! Yep, he could have got nearer 3p for his shares and he\u2019s lost out on the Midkine ones now also. Gambling in ECR now, what a disaster that has been. Turn the chart upside down and it might make you feel better : ) Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,508",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-22T21:15:10.794409+00:00"
      },
      {
        "event_id": "SOCIAL-20Dec20251024-Bottmzup-68526948",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:10.780978",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bottmzup",
          "content": "Downagain, I'm surprised, I had you down as being someone with a modicum of understanding on how the stock market works. Both the day before and the day of the cutoff to get the lucky dip shares, the share price had a high of 3p, an intraday high of 3p! So that is the highest price paid on both days. I was watching like a shytehouse spider with live real time trades, as an LSE subscriber, and the morning looked to be struggling to challenge 3p again, and as the afternoon started it looked even less likely. I did some dummy sell quotes in the morning and the highest offer was 2.6p! I sensed the negativity and watched as the sells came through....so to get out at 2.3p was quite satisfying on the day, and very satisfying in the subsequent falling sessions. Ham, watch ECR in the new year once they announce that gold production has started. I wont be on here rubbing your nose in it, but I might send you just a friendly wink ;-) ps. there's a disclaimer included on all investment instruments, which goes something like...\"Past performance is not indicative of future results\" This works both ways!",
          "sentiment": 0.0,
          "engagement": "6,741",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-22T21:15:10.794391+00:00"
      },
      {
        "event_id": "SOCIAL-20Dec20251638-Downagai--2826722",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:10.780518",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Thanks for explaining what an intraday high is I had forgotten \ud83d\ude00. I was quoted 2.8 to sell on the Friday hence my comment. As long as you're happy with your transaction  all good \ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "782",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-22T21:15:10.794373+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20250738-Downagai-40627721",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:10.780104",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Blimey, quiet here. Let's hope the company's being a but more active \ud83d\ude00",
          "sentiment": 0.0,
          "engagement": "782",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-22T21:15:10.794355+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251222-billy101-41057096",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:10.779678",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Nope just waiting buying down down to the BOD's now and market \\merry Xmas & Happy New Year",
          "sentiment": 0.0,
          "engagement": "31,677",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-22T21:15:10.794337+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20250828-hamilton--3731531",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:10.779257",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "Looks like it is 1:1000 ratio for the carve out shares: https://find-and-update.company-information.service.gov.uk/company/16674669/filing-history Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,508",
          "price_at_post": "1.30",
          "thread_title": "MIDKINE shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=F548BD7E-2DF0-4F40-A04F-ABE79EA22B1A"
        },
        "ingested_at": "2026-01-22T21:15:10.794319+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20251003-billy101--7930718",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:10.778821",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Ham well done didn't look at CH for info. Well looks like somethings moving ahead",
          "sentiment": 0.0,
          "engagement": "31,677",
          "price_at_post": "1.30",
          "thread_title": "RE: MIDKINE shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=F548BD7E-2DF0-4F40-A04F-ABE79EA22B1A"
        },
        "ingested_at": "2026-01-22T21:15:10.794301+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20251010-billy101-87830303",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:10.778295",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "That may well value the company higher and easier to administrate share dealings if any. I get 6400 shares",
          "sentiment": 0.0,
          "engagement": "31,677",
          "price_at_post": "1.30",
          "thread_title": "RE: MIDKINE shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=F548BD7E-2DF0-4F40-A04F-ABE79EA22B1A"
        },
        "ingested_at": "2026-01-22T21:15:10.794283+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20251046-Merciama-36837020",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:10.777849",
        "source": "LSE_CHAT",
        "data": {
          "author": "Merciaman",
          "content": "Good spot Hamilton - but does it not now suggest, with 15.7 million shares, that it's 1 Midkine share for every 10 Roquefort share held as per the record date ? It was 1,000 for 1 with the initial Midkine set-up of 157,445 shares, but the number of Midkine shares has now been increased 100 fold ?",
          "sentiment": 0.0,
          "engagement": "283",
          "price_at_post": "1.30",
          "thread_title": "RE: MIDKINE shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=F548BD7E-2DF0-4F40-A04F-ABE79EA22B1A"
        },
        "ingested_at": "2026-01-22T21:15:10.794265+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20261216-Dicko80--3186048",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:10.777406",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dicko80",
          "content": "Need to factor in 163m shares in issue Hopefully gets sorted this month",
          "sentiment": 0.0,
          "engagement": "2,425",
          "price_at_post": "1.25",
          "thread_title": "RE: MIDKINE shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=F548BD7E-2DF0-4F40-A04F-ABE79EA22B1A"
        },
        "ingested_at": "2026-01-22T21:15:10.794248+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20261340-hamilton-57270446",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:10.776974",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "Flurry of buys out of the blue ? Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,508",
          "price_at_post": "1.30",
          "thread_title": "RE: MIDKINE shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=F548BD7E-2DF0-4F40-A04F-ABE79EA22B1A"
        },
        "ingested_at": "2026-01-22T21:15:10.794230+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20261412-Bobat123-61362666",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:10.776556",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bobat123",
          "content": "Looks like someone loading up",
          "sentiment": 0.0,
          "engagement": "6,785",
          "price_at_post": "1.30",
          "thread_title": "RE: MIDKINE shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=F548BD7E-2DF0-4F40-A04F-ABE79EA22B1A"
        },
        "ingested_at": "2026-01-22T21:15:10.794212+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20261419-Bobat123-91373668",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:10.776135",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bobat123",
          "content": "MK Cell Out-License & Lyramid SPA Update anyday soon",
          "sentiment": 0.0,
          "engagement": "6,785",
          "price_at_post": "1.30",
          "thread_title": "RE: MIDKINE shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=F548BD7E-2DF0-4F40-A04F-ABE79EA22B1A"
        },
        "ingested_at": "2026-01-22T21:15:10.794194+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261111-bunsenbu-87049068",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:10.775708",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "\u2022\tROQ is down ~50% in two months \u2022\tNo asset failure, no trial failure, no cancellation \u2022\tFall driven by one large seller and ex-entitlement adjustment \u2022\tDirector bought ~\u00a385k not long ago \u2022\tBig seller now out of the register \u2022\tCurrent price already reflects delays \u2022\tAny positive update (deal progress / clarity) forces a re-rating from a very low base Conclusion: At ~1.4p, ROQ is priced for outcomes that haven\u2019t happened \u2014 making upside colossal \ud83d\ude80",
          "sentiment": 0.0,
          "engagement": "7,070",
          "price_at_post": "1.30",
          "thread_title": "Poised for a Huge Potential Move \ud83d\ude80",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=B4DB7DB8-4FE4-4116-B458-031274C4D528"
        },
        "ingested_at": "2026-01-22T21:15:10.794176+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261119-Bobat123--9033242",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:10.775248",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bobat123",
          "content": "Added more today .  Gla",
          "sentiment": 0.5,
          "engagement": "6,785",
          "price_at_post": "1.30",
          "thread_title": "RE: Poised for a Huge Potential Move \ud83d\ude80",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=B4DB7DB8-4FE4-4116-B458-031274C4D528"
        },
        "ingested_at": "2026-01-22T21:15:10.794158+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261129-Bobat123-35952219",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:10.774814",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bobat123",
          "content": "Buys getting printed.",
          "sentiment": 0.0,
          "engagement": "6,785",
          "price_at_post": "1.30",
          "thread_title": "RE: Poised for a Huge Potential Move \ud83d\ude80",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=B4DB7DB8-4FE4-4116-B458-031274C4D528"
        },
        "ingested_at": "2026-01-22T21:15:10.794140+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261249-Bobat123-23650189",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:10.774391",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bobat123",
          "content": "Roquefort Therapeutics PLC (LSE:ROQ) said it has amended its exclusive licensing agreement with Coiled Therapeutics, Inc. and A2A Pharmaceuticals, Inc. relating to its AO-252 programme, extending the long stop date to 16 March 2026. The revision follows continued progress in the ongoing Phase I clinical study. The trial has been broadened to cover patients with all solid tumours, while placing particular emphasis on prostate cancer. Management said this prioritisation is underpinned by encouraging pre-clinical results and constructive engagement with potential commercial partners, reflecting growing interest in new oral treatment options for prostate cancer. The amended agreement provides additional time for upcoming clinical data readouts and includes revised commercial terms, notably an increase in the number of consideration shares, highlighting the perceived value of the AO-252 asset.",
          "sentiment": 0.5,
          "engagement": "6,785",
          "price_at_post": "1.40",
          "thread_title": "RE: Poised for a Huge Potential Move \ud83d\ude80",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=B4DB7DB8-4FE4-4116-B458-031274C4D528"
        },
        "ingested_at": "2026-01-22T21:15:10.794122+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261548-Downagai--1412903",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:10.773944",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "It's down because MK Cell Out-License & Lyramid SPA are not not in the price as carved out.",
          "sentiment": 0.0,
          "engagement": "782",
          "price_at_post": "1.35",
          "thread_title": "RE: Poised for a Huge Potential Move \ud83d\ude80",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=B4DB7DB8-4FE4-4116-B458-031274C4D528"
        },
        "ingested_at": "2026-01-22T21:15:10.794094+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261615-pumpky-80447342",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:10.773499",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "31Jan not far away \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,615",
          "price_at_post": "1.35",
          "thread_title": "RE: Poised for a Huge Potential Move \ud83d\ude80",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=B4DB7DB8-4FE4-4116-B458-031274C4D528"
        },
        "ingested_at": "2026-01-22T21:15:10.794076+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261803-cassdav5-71127171",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:05.676372",
        "source": "LSE_CHAT",
        "data": {
          "author": "cassdav57",
          "content": "Hoping for an update in the next couple of weeks. In the meantime searching all articles Claude AI came up with the following. The AO-252 trial appears to be progressing well with: Positive safety data - No dose-limiting toxicities reported so far Encouraging efficacy signals - Two-thirds of patients showing tumor reduction Dose escalation continuing - From 160mg to 240mg, suggesting room for further optimization Expansion planned - Adding more cancer types including prostate cancer This is very early-stage data (Phase I), so while promising, it's important to remember these trials are primarily designed to assess safety and find the optimal dose. Efficacy data at this stage is preliminary, and the drug will need to progress through Phase II and III trials to demonstrate its true effectiveness. The data does support the rationale for the Roquefort RTO transaction, showing that AO-252 is an active clinical asset with apparently good tolerability and early signs of anti-tumour activity. The AO-252 trial appears to be progressing well with: Positive safety data - No dose-limiting toxicities reported so far Encouraging efficacy signals - Two-thirds of patients showing tumour reduction Dose escalation continuing - From 160mg to 240mg, suggesting room for further optimization Expansion planned - Adding more cancer types including prostate cancer This is very early-stage data (Phase I), so while promising, it's important to remember these trials are primarily designed to assess safety and find the optimal dose. Efficacy data at this stage is preliminary, and the drug will need to progress through Phase II and III trials to demonstrate its true effectiveness. The data does support the rationale for the Roquefort RTO transaction, showing that AO-252 is an active clinical asset with apparently good tolerability and early signs of anti-tumour activity. Nothing new but on the reassuring side for a good outcome for patients and investors.",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "1.35",
          "thread_title": "Update soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3C606899-BC3E-4A48-A326-42E1649178FD"
        },
        "ingested_at": "2026-01-22T21:15:10.794056+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261806-cassdav5--1438885",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:05.675892",
        "source": "LSE_CHAT",
        "data": {
          "author": "cassdav57",
          "content": "Sorry about pasting twice!!!!",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "1.35",
          "thread_title": "RE: Update soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3C606899-BC3E-4A48-A326-42E1649178FD"
        },
        "ingested_at": "2026-01-22T21:15:10.794039+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261357-leew--1178526",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:05.675485",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Yes next news should be fun and hopefully find out a little more on the split out shares and the RTO this month.",
          "sentiment": 0.0,
          "engagement": "2,605",
          "price_at_post": "1.35",
          "thread_title": "RE: Update soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3C606899-BC3E-4A48-A326-42E1649178FD"
        },
        "ingested_at": "2026-01-22T21:15:10.794021+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261508-pumpky-43419849",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:05.675066",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Or another extension \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,615",
          "price_at_post": "1.35",
          "thread_title": "RE: Update soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3C606899-BC3E-4A48-A326-42E1649178FD"
        },
        "ingested_at": "2026-01-22T21:15:10.794003+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261634-Downagai-91266474",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:05.674653",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "The radio silence is a concern, if they extend again its not going to br favourable given the last one",
          "sentiment": 0.0,
          "engagement": "782",
          "price_at_post": "1.35",
          "thread_title": "RE: Update soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3C606899-BC3E-4A48-A326-42E1649178FD"
        },
        "ingested_at": "2026-01-22T21:15:10.793985+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261702-billy101-66407102",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:05.674243",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Pumpky you maybe right.......................just a waiting game",
          "sentiment": 0.0,
          "engagement": "31,677",
          "price_at_post": "1.35",
          "thread_title": "RE: Update soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3C606899-BC3E-4A48-A326-42E1649178FD"
        },
        "ingested_at": "2026-01-22T21:15:10.793967+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260842-bbr391--3453983",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:05.673817",
        "source": "LSE_CHAT",
        "data": {
          "author": "bbr391",
          "content": "A passing of 1.5p should be good news . The Latter is also very , very , very possible . Good luck All Shareholders Outstanding ( Maybe )",
          "sentiment": 0.0,
          "engagement": "8,990",
          "price_at_post": "1.35",
          "thread_title": "Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-01-22T21:15:10.793949+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20260745-Downagai-69192157",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:05.673394",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Tbh the lack of news and clarity here is starting to be s concern. The rto delay has already seen a significant impact to the terms for ROQ. Really need to understand progress here now IMHO",
          "sentiment": 0.0,
          "engagement": "782",
          "price_at_post": "1.20",
          "thread_title": "RE: Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-01-22T21:15:10.793931+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261649-Downagai-80874841",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:05.672967",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Quiet here \ud83d\ude34",
          "sentiment": 0.0,
          "engagement": "782",
          "price_at_post": "1.20",
          "thread_title": "RE: Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-01-22T21:15:10.793913+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261714-pumpky--7901046",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:05.672555",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "What is there to say? Just waiting for news",
          "sentiment": 0.0,
          "engagement": "17,615",
          "price_at_post": "1.20",
          "thread_title": "RE: Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-01-22T21:15:10.793895+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261743-Downagai-73345349",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:05.672143",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "True enough",
          "sentiment": 0.0,
          "engagement": "782",
          "price_at_post": "1.20",
          "thread_title": "RE: Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-01-22T21:15:10.793877+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260918-cassdav5--6589299",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:05.671721",
        "source": "LSE_CHAT",
        "data": {
          "author": "cassdav57",
          "content": "The exclusivity period should be ending soon (January 2026), so we might hear updates about whether the deal proceeds in the coming weeks. The  main hope for good news  for me was the director buy in November of 5 million shares (\u00a385k) and the calibre of the trails technology plus funding through A2A Pharmaceuticals.  So yes, definitely a waiting game, currently I am down about 50% and will be holding and making some small additions at these low or lower prices until things become clearer as upside could be considerable.",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "1.20",
          "thread_title": "News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-01-22T21:15:10.793859+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260924-cassdav5-11757433",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:05.671312",
        "source": "LSE_CHAT",
        "data": {
          "author": "cassdav57",
          "content": "Sorry guys, Realise, The exclusivity period extended to March 16th but would still expect news by end of Jan.",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-01-22T21:15:10.793841+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260941-pumpky--3791796",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:05.670892",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Isnt the Pileades deal January?",
          "sentiment": 0.0,
          "engagement": "17,615",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-01-22T21:15:10.793823+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261027-Merciama--8403362",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:05.670488",
        "source": "LSE_CHAT",
        "data": {
          "author": "Merciaman",
          "content": "It is Pumpky, 31/1 deadline for Pleiades to buy Lyramid from Midkine Investments. The reverse takeover of Roquefort to form Coiled Therapeutics has the 16th March deadline.",
          "sentiment": 0.0,
          "engagement": "283",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-01-22T21:15:10.793805+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261116-cassdav5-26908334",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:05.670061",
        "source": "LSE_CHAT",
        "data": {
          "author": "cassdav57",
          "content": "Yes pumpky your correct.  My bad, brain fog on different aspects of deal and moving targets. The deal requires ROQ's enlarged share capital to be admitted to trading on AIM by this new March 16, 2026 deadline to complete the transaction. So they have about 2 more months to finalize everything and get the AIM listing done.",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-01-22T21:15:10.793788+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260739-Downagai--6133419",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:05.669650",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "That'd an easy read. Nothing new really though that I can see",
          "sentiment": 0.0,
          "engagement": "782",
          "price_at_post": "1.20",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-22T21:15:10.793770+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260751-billy101-33272837",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:05.669241",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "There is alot in there, so they have starteed the PR now. The Key milestone dates for 2025-2027 and Financial valuation on page 4 will keep investors happy. Its a long read",
          "sentiment": 0.0,
          "engagement": "31,677",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-22T21:15:10.793752+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260756-bbr391-15958977",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:05.668810",
        "source": "LSE_CHAT",
        "data": {
          "author": "bbr391",
          "content": "Progress to date Roquefort has demonstrated significant anti-cancer activity with its STAT-6 siRNA therapeutics, as validated in in vivo models of breast and colon cancer. These results further reinforce the potential of STAT-6 targeting approaches in multiple tumour types and provide a strong foundation for advancing this programme towards clinical evaluation. STAT-6 targeting siRNA constructs have shown significant in vivo anti-cancer activity in validated models of colon cancer. STAT-6 siRNAs demonstrated a significant reduction in the proliferation of colorectal cancer with a ca.50% reduction in cell growth at seven days. This anti-cancer effect was replicated in a validated in vivo model of colorectal cancer with a significant reduction in cancer weight and volume over 28 days As usual . One feels the Americans are getting good research at a very very very low cost . Outstanding",
          "sentiment": 0.5,
          "engagement": "8,990",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-22T21:15:10.793734+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260804-leew-18245104",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:05.668348",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Well digesting the financial pages was my first port of call and to be honest the purchase price we are paying is very reasonable and if the shares are issued at 1.7 as adv used then on the RTO I see some potential for immediate upside with no real news other than we have done the RTO and its purchase value. Add that to then normal news on progression in phase 1 and beyond we could see some very good gains. Will need to digest the technical aspect later but form investment strategy I am happy",
          "sentiment": 0.0,
          "engagement": "2,605",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-22T21:15:10.793716+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260805-davey50--7889063",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:05.667919",
        "source": "LSE_CHAT",
        "data": {
          "author": "davey50",
          "content": "Just play the game, buy them when totally unloved and sell them when the shares are spiking and the herd arrives rinse and repeat. I took 500k more at the bell 1.23p ish...what a price...they were chasing this up to 2.5p not long ago",
          "sentiment": 0.0,
          "engagement": "7,034",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-22T21:15:10.793699+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260806-billy101-26107339",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:05.667504",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Keeping this short and brief for us investors page 7 matters. And if they tick all the boxes with TACC3 Inhibitor thats mentioned on page 14 then were off to the moon. The rest of the read research note is for my daughters and son in law to translate to me!",
          "sentiment": 0.0,
          "engagement": "31,677",
          "price_at_post": "1.20",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-22T21:15:10.793681+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260826-billy101-76694001",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:05.667064",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Only issue I have with todays RNS(RESEARCH NOTE) . It should have been released in November.",
          "sentiment": 0.0,
          "engagement": "31,677",
          "price_at_post": "1.30",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-22T21:15:10.793663+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261212-Downagai-28141462",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:05.666640",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Wow how to lose \u00a3730 in 3 hours. Unlucky trader Sam \ud83e\udd26\u200d\u2642\ufe0f",
          "sentiment": 0.0,
          "engagement": "782",
          "price_at_post": "1.30",
          "thread_title": "Loss",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=A17EF4D3-D0D3-4793-A674-53112286A2B2"
        },
        "ingested_at": "2026-01-22T21:15:10.793645+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261029-Aklee-42241304",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:05.666196",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aklee",
          "content": "I see Davey is here peddling his usual nonsense. Be careful on any share he is in. Always sells into the smallest rise whilst claiming it's someone else",
          "sentiment": 0.0,
          "engagement": "3,570",
          "price_at_post": "1.25",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-22T21:15:10.793627+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261147-Downagai-59335382",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:02.688814",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Well with all the fanfare around this never thought I'd be able to buy under 1.2p. If the deal happens near 50% upside straight away. What not to like \ud83d\ude03\ud83d\ude80",
          "sentiment": 0.5,
          "engagement": "782",
          "price_at_post": "1.20",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-22T21:15:10.793608+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261253-pumpky--1067191",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:02.688404",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "IF being the operative word \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,615",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-22T21:15:10.793591+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261256-Escapeto--5307546",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:02.687988",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Disappointed \ud83d\ude1e. DOWN.",
          "sentiment": 0.0,
          "engagement": "1,297",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-22T21:15:10.793572+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261257-pumpky-24255773",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:02.687574",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "3rd November RNS Caroline Fortier  We anticipate the round of funding to be completed before the Long stop date of 31Januaey 2026",
          "sentiment": 0.0,
          "engagement": "17,615",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-22T21:15:10.793554+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261315-billy101--3804304",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:02.687164",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Could go in until 16th March",
          "sentiment": 0.0,
          "engagement": "31,677",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-22T21:15:10.793536+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261326-pumpky--7186562",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:02.686734",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Pileades deal 16  March ?",
          "sentiment": 0.0,
          "engagement": "17,615",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-22T21:15:10.793517+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261350-Escapeto-22814668",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:02.686323",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "They'll miss it.",
          "sentiment": 0.0,
          "engagement": "1,297",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-22T21:15:10.793499+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261447-billy101-48403787",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:02.685909",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Read pages 28 and 29",
          "sentiment": 0.0,
          "engagement": "31,677",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-22T21:15:10.793481+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261742-pumpky--3046276",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:02.685494",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Read them and what? SP Angel are the Brokers  for Roquefort \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,615",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-22T21:15:10.793463+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20262322-Escapeto--4477184",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:02.685077",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Huge bull market for biotech , roq at all time low.",
          "sentiment": 0.0,
          "engagement": "1,297",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-22T21:15:10.793445+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20262335-Downagai-57004527",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:02.684667",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "It's because they keep promising the earth and delivering nothing with no updates and just delays",
          "sentiment": 0.0,
          "engagement": "782",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-22T21:15:10.793428+00:00"
      },
      {
        "event_id": "SOCIAL-17Jan20260249-Escapeto-46283060",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:02.684263",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "I'm hopeful, but not convinced this team can build value. I'm not sure what it is but just look at the history for starters. Continual missed deadlines. At the very least don't make a rod for your back with deadlines you never keep.",
          "sentiment": 0.0,
          "engagement": "1,297",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-22T21:15:10.793411+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260730-Downagai--7683499",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:02.683839",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "They need to provide an update, this radio silence is very poor",
          "sentiment": 0.0,
          "engagement": "782",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-22T21:15:10.793393+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260810-billy101--6101162",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:02.683430",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "We had news last wek in R/note.",
          "sentiment": 0.0,
          "engagement": "31,677",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-22T21:15:10.793376+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260834-Downagai-29061463",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:02.682999",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "About progess on the deals? What page please I missed that thanks",
          "sentiment": 0.0,
          "engagement": "782",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-22T21:15:10.793358+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260840-billy101--6756841",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:02.682585",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "We will get updates on deals when and if  they are complete. They can't keep doing a running commentary on progress of deals. We have been told the aims in the R/Note. We have split Mk(nearly) upon condition of Coil happening. We are in different phases in trials. Anything else is conjecture. Whilst this is happening its stalemate on all pathways.",
          "sentiment": 0.0,
          "engagement": "31,677",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-22T21:15:10.793341+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20260756-Downagai-47704032",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:02.682160",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Interesting pre market spread today. I wish",
          "sentiment": 0.0,
          "engagement": "782",
          "price_at_post": "1.60",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-22T21:15:10.793323+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260813-SharePic--2201073",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:02.681739",
        "source": "LSE_CHAT",
        "data": {
          "author": "SharePicks",
          "content": "Good start so far today.",
          "sentiment": 0.0,
          "engagement": "1,180",
          "price_at_post": "1.15",
          "thread_title": "ROQ",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=34D50F4B-4B38-438B-BCC4-912454A889E9"
        },
        "ingested_at": "2026-01-22T21:15:10.793304+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260903-davey50-84352526",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:02.681333",
        "source": "LSE_CHAT",
        "data": {
          "author": "davey50",
          "content": "Just need to clear the slack below 1.4p and then the herd will arrive, if trls can do 300% then roq is always good for a spike a few times a year",
          "sentiment": 0.0,
          "engagement": "7,034",
          "price_at_post": "1.30",
          "thread_title": "RE: ROQ",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=34D50F4B-4B38-438B-BCC4-912454A889E9"
        },
        "ingested_at": "2026-01-22T21:15:10.793287+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260911-SharePic-65150077",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:02.680912",
        "source": "LSE_CHAT",
        "data": {
          "author": "SharePicks",
          "content": "I've added this to portfolio. Lets see where it goes.",
          "sentiment": 0.0,
          "engagement": "1,180",
          "price_at_post": "1.30",
          "thread_title": "1.5p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=EC7A8D0C-531B-4D1D-A5F0-14D0049CD3D9"
        },
        "ingested_at": "2026-01-22T21:15:10.793269+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261337-bbr391--4403859",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:02.680503",
        "source": "LSE_CHAT",
        "data": {
          "author": "bbr391",
          "content": "Come to Papa . We will all soon be very very pleased (possibly). Outstanding",
          "sentiment": 0.5,
          "engagement": "8,990",
          "price_at_post": "1.35",
          "thread_title": "Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-22T21:15:10.793251+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261338-Downagai--3590569",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:02.680073",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "IYHO I take it \ud83d\ude03",
          "sentiment": 0.0,
          "engagement": "782",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-22T21:15:10.793232+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261653-Kikudi--5652143",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:02.679660",
        "source": "LSE_CHAT",
        "data": {
          "author": "Kikudi",
          "content": "Some please give me highlights of ROQ that will save me go through  RNS I want to invest. Thanks in advance",
          "sentiment": 0.0,
          "engagement": "15",
          "price_at_post": "1.35",
          "thread_title": "Can",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=28165808-701F-48DA-95C7-867899DCB7C6"
        },
        "ingested_at": "2026-01-22T21:15:10.793213+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20262130-leew--8434845",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:02.679238",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Honestly if you want to invest best check yourself. I don\u2019t think reading a few RNA\u2019s and googling a few things is that bad.",
          "sentiment": 0.0,
          "engagement": "2,605",
          "price_at_post": "1.35",
          "thread_title": "RE: Can",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=28165808-701F-48DA-95C7-867899DCB7C6"
        },
        "ingested_at": "2026-01-22T21:15:10.793190+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20262142-leew--6783818",
        "event_type": "social_post",
        "date": "2026-01-22T21:15:02.678785",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Well there is a lot of news due bbr, would be great to get the RTO confirmed and initially just get the SP back to 1.7p and then see where the RTO then takes it as there is some potential for increasing in market cap after so fingers crossed. Would also be good on the back of that to then here about the spin off and the deals associated to that to see when some cash might come in from the free shares.",
          "sentiment": 0.0,
          "engagement": "2,605",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-22T21:15:10.793168+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20250714-leew--5859738",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:06.625255",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "If you are in an early stage pharma, and you think a 6 week delay is an issue you need to rethink your understanding. No issue with the amended timing and I like the detail on the phase 1 update provided and highlights what can happen in an early stage pharma in clinical results start to show promise. It should not be underestimated the effort required to reach phase 1 testing and we are about to RTO in a company doing it, which means we are doing it.",
          "sentiment": 0.0,
          "engagement": "2,601",
          "price_at_post": "1.40",
          "thread_title": "RE: Morning all",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=CEA5BAB3-1369-4620-A383-C9A2EB10C0AF"
        },
        "ingested_at": "2026-01-21T21:24:06.639491+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20250715-Downagai-25334454",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:06.624833",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Wow modest increase 25% and \u00a36m. How is that justified for 6 weeks \ud83d\ude33",
          "sentiment": 0.0,
          "engagement": "777",
          "price_at_post": "1.40",
          "thread_title": "RE: Morning all",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=CEA5BAB3-1369-4620-A383-C9A2EB10C0AF"
        },
        "ingested_at": "2026-01-21T21:24:06.639473+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20250716-Downagai-69233799",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:06.624428",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "No issue with the delay but at what cost, taking the micky",
          "sentiment": 0.0,
          "engagement": "777",
          "price_at_post": "1.40",
          "thread_title": "RE: Morning all",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=CEA5BAB3-1369-4620-A383-C9A2EB10C0AF"
        },
        "ingested_at": "2026-01-21T21:24:06.639456+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20250718-hamilton-54550160",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:06.624012",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "They have referred to that company being sold for $3 billion a few times in that rns. Is similar happened here it\u2019s a 100 bagger. If that were to happen then it\u2019s life changing even if you only have a small investment. Let\u2019s see how the market reacts. Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,501",
          "price_at_post": "1.40",
          "thread_title": "RE: Morning all",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=CEA5BAB3-1369-4620-A383-C9A2EB10C0AF"
        },
        "ingested_at": "2026-01-21T21:24:06.639438+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20250722-pumpky--1346437",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:06.623587",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "DUE TO THE festive holiday season deal has been extended \ud83d\ude02 Obviously Xmas is more important \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,607",
          "price_at_post": "1.40",
          "thread_title": "RE: Morning all",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=CEA5BAB3-1369-4620-A383-C9A2EB10C0AF"
        },
        "ingested_at": "2026-01-21T21:24:06.639420+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20250724-leew--8426079",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:06.623184",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "They get an extra circa 1.8m upfront and then extra shares when everyone is likely to be in profit at various stages. It\u2019s a pharma, if they move they really move and seems like the additional progress made in the new year to the drug is decent hence the adjustments.",
          "sentiment": 0.0,
          "engagement": "2,601",
          "price_at_post": "1.40",
          "thread_title": "RE: Morning all",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=CEA5BAB3-1369-4620-A383-C9A2EB10C0AF"
        },
        "ingested_at": "2026-01-21T21:24:06.639403+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20250725-Downagai--5732287",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:06.622763",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "It will react badly, 1.1 today I fear",
          "sentiment": 0.0,
          "engagement": "777",
          "price_at_post": "1.40",
          "thread_title": "RE: Morning all",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=CEA5BAB3-1369-4620-A383-C9A2EB10C0AF"
        },
        "ingested_at": "2026-01-21T21:24:06.639385+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20250727-pumpky--4885261",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:06.622361",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "And another \u00a36 million as per 18th November RNS",
          "sentiment": 0.0,
          "engagement": "17,607",
          "price_at_post": "1.40",
          "thread_title": "RE: Morning all",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=CEA5BAB3-1369-4620-A383-C9A2EB10C0AF"
        },
        "ingested_at": "2026-01-21T21:24:06.639367+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20250730-billy101--4745404",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:06.621940",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "I\u2019m see the RNS\u2019s are just starting!!!! Did say they start to update with XYZ trials, phase 1 -2 etc etc You want news you\u2019re going to get it.",
          "sentiment": 0.0,
          "engagement": "31,674",
          "price_at_post": "1.40",
          "thread_title": "RE: Morning all",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=CEA5BAB3-1369-4620-A383-C9A2EB10C0AF"
        },
        "ingested_at": "2026-01-21T21:24:06.639350+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20250739-billy101-26612029",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:06.621517",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "RNSs like today will be the money and value builders. What does the Coil Portfolio hold?",
          "sentiment": 0.0,
          "engagement": "31,674",
          "price_at_post": "1.65",
          "thread_title": "RE: Morning all",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=CEA5BAB3-1369-4620-A383-C9A2EB10C0AF"
        },
        "ingested_at": "2026-01-21T21:24:06.639332+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20250740-leew--3953987",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:06.621090",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Phase  1-2 can be very news heavy. All people need to do is check the market caps of companies in phase 1 trials and phase 2 trials to see the worth here. It\u2019s a flippant comment but the up front is kind of irrelevant when the strike price remains the same as you are buying value not keeping lights on, which is a concept a few miss as all they see is \u201cit\u2019s costing more\u201d",
          "sentiment": 0.0,
          "engagement": "2,601",
          "price_at_post": "1.40",
          "thread_title": "RE: Morning all",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=CEA5BAB3-1369-4620-A383-C9A2EB10C0AF"
        },
        "ingested_at": "2026-01-21T21:24:06.639314+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20250741-pumpky-77457736",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:06.620680",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Initiation of Phase 1 in 1st product \u00a31 million milestone payment Won't do much to a company with a Market capital of Circa \u00a333 million",
          "sentiment": 0.0,
          "engagement": "17,607",
          "price_at_post": "1.40",
          "thread_title": "RE: Morning all",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=CEA5BAB3-1369-4620-A383-C9A2EB10C0AF"
        },
        "ingested_at": "2026-01-21T21:24:06.639296+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20250745-billy101-83298230",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:06.620271",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "What you going to do Pumpky, who you going to call. Looks your with all of us through all the phases and trails, raises, spending and. Yes your favourite line who\u2019s paying the wages. Can\u2019t wait to share the start of 2026 with you as a partner in Coil!!!!",
          "sentiment": 0.0,
          "engagement": "31,674",
          "price_at_post": "1.65",
          "thread_title": "RE: Morning all",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=CEA5BAB3-1369-4620-A383-C9A2EB10C0AF"
        },
        "ingested_at": "2026-01-21T21:24:06.639278+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20250746-bbr391-71481115",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:06.619837",
        "source": "LSE_CHAT",
        "data": {
          "author": "bbr391",
          "content": "Mechanism: importantly, efficacy was observed to be independent of androgen signalling, suggesting broad potential utility in resistant disease. Outstanding Well done All @ Colied / Roq . Great research begins with cash input",
          "sentiment": 0.5,
          "engagement": "8,990",
          "price_at_post": "1.40",
          "thread_title": "BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.639260+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20250751-Downagai-32010752",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:06.619411",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "I understand the positives but you cant avoid the fact that they have just shafted us for an additional 25%  on the deal to their benefit for a 6 week extension. How can anyone be happy with that",
          "sentiment": 0.0,
          "engagement": "777",
          "price_at_post": "1.65",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.639243+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20250755-hamilton-54940328",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:06.618991",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "Pumpkin Do you work r have worked in the past ? Do you or did you work for free ? Can you tell me which other companies that are listed who don\u2019t pay their managers or directors anything ? Await your response ! Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,501",
          "price_at_post": "1.65",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.639225+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20250755-Escapeto--1468583",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:06.618496",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "A least get the dates right and deliver to them. That is a basic. Continually missing dates, time and again, that is a poor show. In my industry they used to say .. Get it right FIRST time. Getting it wrong costs.",
          "sentiment": 0.0,
          "engagement": "1,296",
          "price_at_post": "1.65",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.639207+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20250757-leew--1758827",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:06.618074",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Think of it this way, you are making an assumption that the progression currently in the business we are taking over is exactly the same as it was in Sept and November and ignoring the rest of the update. If the progress in the company in the last 3-4 months warrants it\u2019s worth more it\u2019s worth more.",
          "sentiment": 0.0,
          "engagement": "2,601",
          "price_at_post": "1.65",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.639189+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20250758-billy101--8252191",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:06.617663",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "The commercial interest in oral targeted therapies for multiple types of solid tumours, including prostate cancer, was recently demonstrated by the announcement on 17 November 2025 by Johnson & Johnson that it was acquiring Halda Therapeutics OpCo, Inc (\"Halda\") for US$3.05 billion in cash. Prior to the acquisition, Halda's Phase I/II clinical trial had demonstrated impressive preliminary efficacy and a strong early safety profile in prostate cancer. Come on whats not to like sum big pharma going to come knocking at some point!",
          "sentiment": 0.0,
          "engagement": "31,674",
          "price_at_post": "1.55",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.639172+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20250800-leew--3984138",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:06.617246",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Escape, sorry but I have been involved with fundraising for companies and the DD involved, very rarely is it smooth and very rarely are initial expectations met given the complexity involved and the DD with a lot of parties and data rooms etc. 6 weeks is a very modest increase so they are well advanced in the raise.",
          "sentiment": 0.0,
          "engagement": "2,601",
          "price_at_post": "1.65",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.639151+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20250800-billy101-81311936",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:06.616816",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Pre market is showing up again like yesterday. Let see if it like that at open",
          "sentiment": 0.0,
          "engagement": "31,674",
          "price_at_post": "1.55",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.639133+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20250801-billy101--3141733",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:06.616277",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Now showing 17.8% up",
          "sentiment": 0.0,
          "engagement": "31,674",
          "price_at_post": "1.55",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.639108+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20250810-pumpky-10269610",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:06.615847",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "1.48 to buy",
          "sentiment": 0.0,
          "engagement": "17,607",
          "price_at_post": "1.55",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.639080+00:00"
      },
      {
        "event_id": "SOCIAL-12Dec20250923-hamilton--1752339",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:06.615432",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "Nice \u00a3350 loss in an hour for the 175592 trader - loser. Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,501",
          "price_at_post": "1.40",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.639062+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20250714-hamilton-51569972",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:06.614983",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "Pumpky Did you find any other listed companies where directors or management don\u2019t get paid ? Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,501",
          "price_at_post": "1.40",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.639045+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20250825-pumpky--3602124",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:02.125797",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "No \ud83d\ude02 Neither have I had a reply to Confirm that they are still on 25% of their wages Until a Cash Generating deal has been completed \ud83d\ude02 Let's hope they don't earn a Million pound each \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,607",
          "price_at_post": "1.40",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.639027+00:00"
      },
      {
        "event_id": "SOCIAL-16Dec20250828-hamilton--3327339",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:02.125388",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "I hope they do as we will do alright also if that\u2019s the case. Next spike soon probably as it went as highly as 3p offer a few weeks ago. Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,501",
          "price_at_post": "1.40",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.639009+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251416-Escapeto--2035044",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:02.124969",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Definitely not a 'BOOM'. Disappointing.",
          "sentiment": 0.0,
          "engagement": "1,296",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.638991+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251649-Bottmzup--2333728",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:02.124557",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bottmzup",
          "content": "It was obvious that there was going to be a sell off after the hype about the free shares. Glad I sold at 2.3p....I can now buy back at almost half the price...which I wouldn't touch with a bargepole until some encouraging news is announced. This mob loves to muddy the waters with complicated jam tomorrow 'intentions' to make everyone rich, without actually announcing detailed actions to prove it! They announced that these two deals worth millions were going to happen this year back when I bought in many months ago, and now its all a mish mash of potential deals with add ons and distractions under an unsure timeframe with uncertain outcomes...just 'intentions'! Hamiltonbro, in his infinate wisdom, posted on Dec 1st... 'I\u2019d be fuming if I sold my shares last week which would have meant me losing out on the free Midkine shares.' It's taken me a couple of decades of involvement in trading and investing. particularly on AIM, to learn and realise that these companies are not interested in shareholders...they are interested in themselves. And their cute teams of educated and well paid manipulators of PR can fool the public in to thinking that they are on to a good thing, whilst shafting them out of their financial capital...gradually. Be aware...be very aware!",
          "sentiment": 0.0,
          "engagement": "6,738",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.638973+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251718-pumpky-62903441",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:02.124107",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Roll on the Pileades extension and the 1.7 pence placing and how many Free shares we are going to get \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,607",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.638956+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251751-Escapeto-10581584",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:02.123695",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "I rate this a hold / weak sell. Is this becoming an entity which exists to pay wages as a primary function? Close to all time low. Triple bottom maybe? This team fails to realize over multiple years that meeting deadlines in any business adds confidence",
          "sentiment": 0.0,
          "engagement": "1,296",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.638938+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251835-Gigontbs-83004253",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:02.123272",
        "source": "LSE_CHAT",
        "data": {
          "author": "Gigontbsaaa",
          "content": "Bottmzup well done you :) Wonder where flightman went lols",
          "sentiment": 0.0,
          "engagement": "403",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.638920+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251838-pumpky-70362208",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:02.122850",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Flight man is on the ENET BOARD With 240 million shares \ud83d\ude19shares \ud83d\ude02 and has  contacted the Director \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,607",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.638902+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251843-Downagai-29492235",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:02.122441",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Bottmzup you didn't get free shares then",
          "sentiment": 0.0,
          "engagement": "777",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.638884+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251844-Downagai--7935533",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:02.122023",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "And everyone who buys in will do very well \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "777",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.638866+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251846-Downagai--5074251",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:02.121616",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "It's still risk reward for me. If rto goes ahead on new terms this will level at 1.7 so fair increase but risk it won't, who knows, may even get new commercials lowering placing price \ud83e\udd37\u200d\u2642\ufe0f",
          "sentiment": 0.0,
          "engagement": "777",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.638849+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20251847-Gigontbs--8870361",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:02.121204",
        "source": "LSE_CHAT",
        "data": {
          "author": "Gigontbsaaa",
          "content": "240m of course he does lol. What a loon",
          "sentiment": 0.0,
          "engagement": "403",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.638831+00:00"
      },
      {
        "event_id": "SOCIAL-17Dec20252032-billy101-55160930",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:02.120791",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Wait for the spikes theres got a be a few lined up to raise a few pounds unless II buy the lot.",
          "sentiment": 0.0,
          "engagement": "31,674",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.638813+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250719-hamilton-63129806",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:02.120375",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "If you sold at 2.3p and buy back now you are 1p better off bottom. If you didn't get the shares in Midkine which are worth a minimum of 5p per share then unlucky. They could be worth multiples of 5p considering the links to Ely. Risk it won\u2019t happen but happy to risk it. Know which route I would have taken. Well done on selling at 2.3p. Strange you have chosen now to come on the board and try and highlight that you are a great investor. Why didn\u2019t you say at the time that you sold ? Another one not to be trusted. Each to their own. Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,501",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.638795+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250802-pumpky--3501949",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:02.119934",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Midkine only worth 5 pence if you can sell them \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,607",
          "price_at_post": "1.70",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.638777+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250811-hamilton-61620205",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:02.119529",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "Sell them ? What about dividends ? Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,501",
          "price_at_post": "1.40",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.638758+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250812-pumpky-31715112",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:02.119112",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Dividends When? \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,607",
          "price_at_post": "1.35",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.638740+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250832-hamilton--7782498",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:02.118699",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "Why are you bothered when you don\u2019t hold ? Sad life you must lead posting negative thoughts on here all the time. Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,501",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.638723+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250833-hamilton--5966784",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:02.118285",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "HEMO done about as badly as ROQ since you told us to buy that as well pumpkin ! Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,501",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.638705+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250837-Bottmzup-39305076",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:02.117858",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bottmzup",
          "content": "Hamilton, I did say I'd sold on that Friday, read my posts. I also explained why, because this company have been failing to do what they said they would, ie sell those assets. All hope and hype, you yourself said 'could' be worth \u00a3xxm. I also said that I put my sell funds in to ECR...have a look at what they announced today...currently up 26% on double the average daily volume in the first half hour. I participate in the stock market to make money, and I don't care what company name is on my profits. I don't chase 'maybe' dreams and uncertain promises, and ROQ have proved this year that they are capable of uncertain promises....so I ditched them when I got the chance to take a profit.",
          "sentiment": 0.0,
          "engagement": "6,738",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.638687+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250841-pumpky-41417680",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:02.117349",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Hemo went to \u00a316 I told you to buy @ \u00a31.80 \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,607",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.638669+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250842-pumpky--6149219",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:02.116933",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "I'm awaiting my Free shares Guess the company still trying to work them out \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,607",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.638651+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250846-billy101-73078922",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:02.116511",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Pumpky you'll get your shares when everything is done/completed its in black and white. Parked up. In the meantime you investments gone down shock horror. You could just sell up start the year of a fresh",
          "sentiment": 0.0,
          "engagement": "31,674",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.638633+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250906-pumpky--3811060",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:02.115940",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Billy How many Free shares we getting? Flightman says Pro rata",
          "sentiment": 0.0,
          "engagement": "17,607",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.638615+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250914-billy101--2976558",
        "event_type": "social_post",
        "date": "2026-01-21T21:24:02.115507",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Pumpky for me its going to be eqivalent to 7.4m shares (in my isa and wifes isa) How the ratio gets split will be upto final valuation minus comonay expenses and CGT for us investors as they will be treated as div stock maybe. However you being a super investor and all that you would have known this answer as you seem to know what we don't!!!!",
          "sentiment": 0.0,
          "engagement": "31,674",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.638598+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250919-billy101-15826491",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:57.163926",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Pumpky just for you as I know your Crystal b ullx isn't working today From RNS 01/12/25 A detailed timetable for the crediting of the Unlisted RNV Shares to eligible shareholders, together with full details of the entitlement ratio and the exact number of Unlisted RNV Shares to be issued, will be set out in a further announcement to be made in due course.",
          "sentiment": 0.0,
          "engagement": "31,674",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.638580+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20250925-hamilton--6821562",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:57.163507",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "ECR lol You might get your money back at this rate then. Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,501",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.638562+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251248-Bottmzup--3441134",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:57.163082",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bottmzup",
          "content": "Been buying the dips into the low 0.2ps for 2 years! All profit from here going in to '26, lovely jubbly..gold at an all time high too. Have a look yourself, you might be able to offset your extra long wait for a return here (with no gaurantees) :-) ps. so you checked that I did say I sold at the time then? Maybe you're the one not to be trusted for posting blatant lies?",
          "sentiment": 0.0,
          "engagement": "6,738",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.638544+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251332-hamilton-37902577",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:57.162658",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "You\u2019ve been buying around here for two years and then saying we will have to wait for ROQ : ) Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,501",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.638526+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251456-pumpky--5010269",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:57.162241",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Next month will be 1 year since the deal was announced",
          "sentiment": 0.0,
          "engagement": "17,607",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.638508+00:00"
      },
      {
        "event_id": "SOCIAL-18Dec20251556-billy101--3632071",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:57.161818",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "What you going to do about it  then Pumpky surely your not going to hang a round with all your knowledge",
          "sentiment": 0.0,
          "engagement": "31,674",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.638490+00:00"
      },
      {
        "event_id": "SOCIAL-19Dec20250709-Bottmzup--2046621",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:57.161403",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bottmzup",
          "content": "Wrong again liar. I bought in earlier in '25 so held for maybe 9 months. Bought in for the two deals to be completed before I began to learn what bs this company was capable of....extending completion dates and stringing shareholders along with vague promises, whilst hoping and praying that they would fall for the jam tomorrow bull**it and wouldn't sell. I smelled a rat as soon as they extended the long stop date for the second time early on. Then they decided to completely change the plan with a complicated set up of a reverse takeover including relisting on AIM! I knew the gullible would then hold out for these lucky dip free shares, and there could be a last minute spike for me to get out of this absolute circus. I've been taken for a mug before on AIM during my long learning curve, not any more. Back in my tradesman days, we used to send apprentices to the stores to get a long wait, playing them for mugs. Now this crowd are doing the same to the gullible shareholders with 'intentions' to make good on their promises!!! Eeeek! They even moved the goal posts again with the long stop for this new deal just last week! Dear oh dear, how many clues do you need?",
          "sentiment": 0.0,
          "engagement": "6,738",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.638472+00:00"
      },
      {
        "event_id": "SOCIAL-19Dec20250729-Downagai-24570596",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:57.160913",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Surprised you sold so low given you could get nearly 3p the end of that week if your plan was to get out all along. Bit of a missed opportunity, hindsight a bummer \ud83e\udd14",
          "sentiment": 0.0,
          "engagement": "777",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.638454+00:00"
      },
      {
        "event_id": "SOCIAL-19Dec20251315-hamilton--4491779",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:57.160503",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "I was referring to you saying you\u2019d been in ECR for two years but nice try ! Yep, he could have got nearer 3p for his shares and he\u2019s lost out on the Midkine ones now also. Gambling in ECR now, what a disaster that has been. Turn the chart upside down and it might make you feel better : ) Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,501",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.638436+00:00"
      },
      {
        "event_id": "SOCIAL-20Dec20251024-Bottmzup--2582487",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:57.160072",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bottmzup",
          "content": "Downagain, I'm surprised, I had you down as being someone with a modicum of understanding on how the stock market works. Both the day before and the day of the cutoff to get the lucky dip shares, the share price had a high of 3p, an intraday high of 3p! So that is the highest price paid on both days. I was watching like a shytehouse spider with live real time trades, as an LSE subscriber, and the morning looked to be struggling to challenge 3p again, and as the afternoon started it looked even less likely. I did some dummy sell quotes in the morning and the highest offer was 2.6p! I sensed the negativity and watched as the sells came through....so to get out at 2.3p was quite satisfying on the day, and very satisfying in the subsequent falling sessions. Ham, watch ECR in the new year once they announce that gold production has started. I wont be on here rubbing your nose in it, but I might send you just a friendly wink ;-) ps. there's a disclaimer included on all investment instruments, which goes something like...\"Past performance is not indicative of future results\" This works both ways!",
          "sentiment": 0.0,
          "engagement": "6,738",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.638418+00:00"
      },
      {
        "event_id": "SOCIAL-20Dec20251638-Downagai-85514852",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:57.159621",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Thanks for explaining what an intraday high is I had forgotten \ud83d\ude00. I was quoted 2.8 to sell on the Friday hence my comment. As long as you're happy with your transaction  all good \ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "777",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.638400+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20250738-Downagai--2149658",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:57.159211",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Blimey, quiet here. Let's hope the company's being a but more active \ud83d\ude00",
          "sentiment": 0.0,
          "engagement": "777",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.638382+00:00"
      },
      {
        "event_id": "SOCIAL-23Dec20251222-billy101-85368925",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:57.158797",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Nope just waiting buying down down to the BOD's now and market \\merry Xmas & Happy New Year",
          "sentiment": 0.0,
          "engagement": "31,674",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T21:24:06.638364+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20250828-hamilton--8047843",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:57.158379",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "Looks like it is 1:1000 ratio for the carve out shares: https://find-and-update.company-information.service.gov.uk/company/16674669/filing-history Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,501",
          "price_at_post": "1.30",
          "thread_title": "MIDKINE shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=F548BD7E-2DF0-4F40-A04F-ABE79EA22B1A"
        },
        "ingested_at": "2026-01-21T21:24:06.638346+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20251003-billy101--5972941",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:57.157947",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Ham well done didn't look at CH for info. Well looks like somethings moving ahead",
          "sentiment": 0.0,
          "engagement": "31,674",
          "price_at_post": "1.30",
          "thread_title": "RE: MIDKINE shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=F548BD7E-2DF0-4F40-A04F-ABE79EA22B1A"
        },
        "ingested_at": "2026-01-21T21:24:06.638329+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20251010-billy101--6513236",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:57.157525",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "That may well value the company higher and easier to administrate share dealings if any. I get 6400 shares",
          "sentiment": 0.0,
          "engagement": "31,674",
          "price_at_post": "1.30",
          "thread_title": "RE: MIDKINE shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=F548BD7E-2DF0-4F40-A04F-ABE79EA22B1A"
        },
        "ingested_at": "2026-01-21T21:24:06.638310+00:00"
      },
      {
        "event_id": "SOCIAL-31Dec20251046-Merciama-22396793",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:57.157094",
        "source": "LSE_CHAT",
        "data": {
          "author": "Merciaman",
          "content": "Good spot Hamilton - but does it not now suggest, with 15.7 million shares, that it's 1 Midkine share for every 10 Roquefort share held as per the record date ? It was 1,000 for 1 with the initial Midkine set-up of 157,445 shares, but the number of Midkine shares has now been increased 100 fold ?",
          "sentiment": 0.0,
          "engagement": "283",
          "price_at_post": "1.30",
          "thread_title": "RE: MIDKINE shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=F548BD7E-2DF0-4F40-A04F-ABE79EA22B1A"
        },
        "ingested_at": "2026-01-21T21:24:06.638292+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20261216-Dicko80-60780720",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:57.156678",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dicko80",
          "content": "Need to factor in 163m shares in issue Hopefully gets sorted this month",
          "sentiment": 0.0,
          "engagement": "2,425",
          "price_at_post": "1.25",
          "thread_title": "RE: MIDKINE shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=F548BD7E-2DF0-4F40-A04F-ABE79EA22B1A"
        },
        "ingested_at": "2026-01-21T21:24:06.638274+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20261340-hamilton-85320394",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:57.156265",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "Flurry of buys out of the blue ? Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,501",
          "price_at_post": "1.30",
          "thread_title": "RE: MIDKINE shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=F548BD7E-2DF0-4F40-A04F-ABE79EA22B1A"
        },
        "ingested_at": "2026-01-21T21:24:06.638257+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20261412-Bobat123-47451114",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:57.155835",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bobat123",
          "content": "Looks like someone loading up",
          "sentiment": 0.0,
          "engagement": "6,784",
          "price_at_post": "1.30",
          "thread_title": "RE: MIDKINE shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=F548BD7E-2DF0-4F40-A04F-ABE79EA22B1A"
        },
        "ingested_at": "2026-01-21T21:24:06.638239+00:00"
      },
      {
        "event_id": "SOCIAL-2Jan20261419-Bobat123--7507493",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:57.155419",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bobat123",
          "content": "MK Cell Out-License & Lyramid SPA Update anyday soon",
          "sentiment": 0.0,
          "engagement": "6,784",
          "price_at_post": "1.30",
          "thread_title": "RE: MIDKINE shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=F548BD7E-2DF0-4F40-A04F-ABE79EA22B1A"
        },
        "ingested_at": "2026-01-21T21:24:06.638221+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261111-bunsenbu--7898544",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:57.154991",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "\u2022\tROQ is down ~50% in two months \u2022\tNo asset failure, no trial failure, no cancellation \u2022\tFall driven by one large seller and ex-entitlement adjustment \u2022\tDirector bought ~\u00a385k not long ago \u2022\tBig seller now out of the register \u2022\tCurrent price already reflects delays \u2022\tAny positive update (deal progress / clarity) forces a re-rating from a very low base Conclusion: At ~1.4p, ROQ is priced for outcomes that haven\u2019t happened \u2014 making upside colossal \ud83d\ude80",
          "sentiment": 0.0,
          "engagement": "7,064",
          "price_at_post": "1.30",
          "thread_title": "Poised for a Huge Potential Move \ud83d\ude80",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=B4DB7DB8-4FE4-4116-B458-031274C4D528"
        },
        "ingested_at": "2026-01-21T21:24:06.638203+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261119-Bobat123-54225744",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:57.154533",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bobat123",
          "content": "Added more today .  Gla",
          "sentiment": 0.5,
          "engagement": "6,784",
          "price_at_post": "1.30",
          "thread_title": "RE: Poised for a Huge Potential Move \ud83d\ude80",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=B4DB7DB8-4FE4-4116-B458-031274C4D528"
        },
        "ingested_at": "2026-01-21T21:24:06.638184+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261129-Bobat123--1578572",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:57.153980",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bobat123",
          "content": "Buys getting printed.",
          "sentiment": 0.0,
          "engagement": "6,784",
          "price_at_post": "1.30",
          "thread_title": "RE: Poised for a Huge Potential Move \ud83d\ude80",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=B4DB7DB8-4FE4-4116-B458-031274C4D528"
        },
        "ingested_at": "2026-01-21T21:24:06.638167+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261249-Bobat123--6040028",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:57.153546",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bobat123",
          "content": "Roquefort Therapeutics PLC (LSE:ROQ) said it has amended its exclusive licensing agreement with Coiled Therapeutics, Inc. and A2A Pharmaceuticals, Inc. relating to its AO-252 programme, extending the long stop date to 16 March 2026. The revision follows continued progress in the ongoing Phase I clinical study. The trial has been broadened to cover patients with all solid tumours, while placing particular emphasis on prostate cancer. Management said this prioritisation is underpinned by encouraging pre-clinical results and constructive engagement with potential commercial partners, reflecting growing interest in new oral treatment options for prostate cancer. The amended agreement provides additional time for upcoming clinical data readouts and includes revised commercial terms, notably an increase in the number of consideration shares, highlighting the perceived value of the AO-252 asset.",
          "sentiment": 0.5,
          "engagement": "6,784",
          "price_at_post": "1.40",
          "thread_title": "RE: Poised for a Huge Potential Move \ud83d\ude80",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=B4DB7DB8-4FE4-4116-B458-031274C4D528"
        },
        "ingested_at": "2026-01-21T21:24:06.638148+00:00"
      },
      {
        "event_id": "SOCIAL-5Jan20261548-Downagai-82900587",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:54.382504",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "It's down because MK Cell Out-License & Lyramid SPA are not not in the price as carved out.",
          "sentiment": 0.0,
          "engagement": "777",
          "price_at_post": "1.35",
          "thread_title": "RE: Poised for a Huge Potential Move \ud83d\ude80",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=B4DB7DB8-4FE4-4116-B458-031274C4D528"
        },
        "ingested_at": "2026-01-21T21:24:06.638126+00:00"
      },
      {
        "event_id": "SOCIAL-7Jan20261615-pumpky-82195725",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:54.382079",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "31Jan not far away \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,607",
          "price_at_post": "1.35",
          "thread_title": "RE: Poised for a Huge Potential Move \ud83d\ude80",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=B4DB7DB8-4FE4-4116-B458-031274C4D528"
        },
        "ingested_at": "2026-01-21T21:24:06.638069+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261803-cassdav5--7548555",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:54.381666",
        "source": "LSE_CHAT",
        "data": {
          "author": "cassdav57",
          "content": "Hoping for an update in the next couple of weeks. In the meantime searching all articles Claude AI came up with the following. The AO-252 trial appears to be progressing well with: Positive safety data - No dose-limiting toxicities reported so far Encouraging efficacy signals - Two-thirds of patients showing tumor reduction Dose escalation continuing - From 160mg to 240mg, suggesting room for further optimization Expansion planned - Adding more cancer types including prostate cancer This is very early-stage data (Phase I), so while promising, it's important to remember these trials are primarily designed to assess safety and find the optimal dose. Efficacy data at this stage is preliminary, and the drug will need to progress through Phase II and III trials to demonstrate its true effectiveness. The data does support the rationale for the Roquefort RTO transaction, showing that AO-252 is an active clinical asset with apparently good tolerability and early signs of anti-tumour activity. The AO-252 trial appears to be progressing well with: Positive safety data - No dose-limiting toxicities reported so far Encouraging efficacy signals - Two-thirds of patients showing tumour reduction Dose escalation continuing - From 160mg to 240mg, suggesting room for further optimization Expansion planned - Adding more cancer types including prostate cancer This is very early-stage data (Phase I), so while promising, it's important to remember these trials are primarily designed to assess safety and find the optimal dose. Efficacy data at this stage is preliminary, and the drug will need to progress through Phase II and III trials to demonstrate its true effectiveness. The data does support the rationale for the Roquefort RTO transaction, showing that AO-252 is an active clinical asset with apparently good tolerability and early signs of anti-tumour activity. Nothing new but on the reassuring side for a good outcome for patients and investors.",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "1.35",
          "thread_title": "Update soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3C606899-BC3E-4A48-A326-42E1649178FD"
        },
        "ingested_at": "2026-01-21T21:24:06.638049+00:00"
      },
      {
        "event_id": "SOCIAL-8Jan20261806-cassdav5-89612845",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:54.381198",
        "source": "LSE_CHAT",
        "data": {
          "author": "cassdav57",
          "content": "Sorry about pasting twice!!!!",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "1.35",
          "thread_title": "RE: Update soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3C606899-BC3E-4A48-A326-42E1649178FD"
        },
        "ingested_at": "2026-01-21T21:24:06.638031+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261357-leew--6839434",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:54.380780",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Yes next news should be fun and hopefully find out a little more on the split out shares and the RTO this month.",
          "sentiment": 0.0,
          "engagement": "2,601",
          "price_at_post": "1.35",
          "thread_title": "RE: Update soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3C606899-BC3E-4A48-A326-42E1649178FD"
        },
        "ingested_at": "2026-01-21T21:24:06.638012+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261508-pumpky--8907072",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:54.380371",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Or another extension \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,607",
          "price_at_post": "1.35",
          "thread_title": "RE: Update soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3C606899-BC3E-4A48-A326-42E1649178FD"
        },
        "ingested_at": "2026-01-21T21:24:06.637994+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261634-Downagai--8308649",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:54.379954",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "The radio silence is a concern, if they extend again its not going to br favourable given the last one",
          "sentiment": 0.0,
          "engagement": "777",
          "price_at_post": "1.35",
          "thread_title": "RE: Update soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3C606899-BC3E-4A48-A326-42E1649178FD"
        },
        "ingested_at": "2026-01-21T21:24:06.637964+00:00"
      },
      {
        "event_id": "SOCIAL-9Jan20261702-billy101-51498808",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:54.379544",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Pumpky you maybe right.......................just a waiting game",
          "sentiment": 0.0,
          "engagement": "31,674",
          "price_at_post": "1.35",
          "thread_title": "RE: Update soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3C606899-BC3E-4A48-A326-42E1649178FD"
        },
        "ingested_at": "2026-01-21T21:24:06.637927+00:00"
      },
      {
        "event_id": "SOCIAL-12Jan20260842-bbr391--3569632",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:54.379126",
        "source": "LSE_CHAT",
        "data": {
          "author": "bbr391",
          "content": "A passing of 1.5p should be good news . The Latter is also very , very , very possible . Good luck All Shareholders Outstanding ( Maybe )",
          "sentiment": 0.0,
          "engagement": "8,990",
          "price_at_post": "1.35",
          "thread_title": "Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-01-21T21:24:06.637906+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20260745-Downagai--7066322",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:54.378692",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Tbh the lack of news and clarity here is starting to be s concern. The rto delay has already seen a significant impact to the terms for ROQ. Really need to understand progress here now IMHO",
          "sentiment": 0.0,
          "engagement": "777",
          "price_at_post": "1.20",
          "thread_title": "RE: Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-01-21T21:24:06.637888+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261649-Downagai-46101177",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:54.378282",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Quiet here \ud83d\ude34",
          "sentiment": 0.0,
          "engagement": "777",
          "price_at_post": "1.20",
          "thread_title": "RE: Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-01-21T21:24:06.637870+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261714-pumpky-23686103",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:54.377858",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "What is there to say? Just waiting for news",
          "sentiment": 0.0,
          "engagement": "17,607",
          "price_at_post": "1.20",
          "thread_title": "RE: Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-01-21T21:24:06.637851+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261743-Downagai--1495718",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:54.377449",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "True enough",
          "sentiment": 0.0,
          "engagement": "777",
          "price_at_post": "1.20",
          "thread_title": "RE: Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-01-21T21:24:06.637834+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260918-cassdav5--7929848",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:54.377029",
        "source": "LSE_CHAT",
        "data": {
          "author": "cassdav57",
          "content": "The exclusivity period should be ending soon (January 2026), so we might hear updates about whether the deal proceeds in the coming weeks. The  main hope for good news  for me was the director buy in November of 5 million shares (\u00a385k) and the calibre of the trails technology plus funding through A2A Pharmaceuticals.  So yes, definitely a waiting game, currently I am down about 50% and will be holding and making some small additions at these low or lower prices until things become clearer as upside could be considerable.",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "1.20",
          "thread_title": "News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-01-21T21:24:06.637816+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260924-cassdav5--7996912",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:54.376619",
        "source": "LSE_CHAT",
        "data": {
          "author": "cassdav57",
          "content": "Sorry guys, Realise, The exclusivity period extended to March 16th but would still expect news by end of Jan.",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-01-21T21:24:06.637798+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260941-pumpky--1474533",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:54.376207",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Isnt the Pileades deal January?",
          "sentiment": 0.0,
          "engagement": "17,607",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-01-21T21:24:06.637780+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261027-Merciama-13250776",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:54.375784",
        "source": "LSE_CHAT",
        "data": {
          "author": "Merciaman",
          "content": "It is Pumpky, 31/1 deadline for Pleiades to buy Lyramid from Midkine Investments. The reverse takeover of Roquefort to form Coiled Therapeutics has the 16th March deadline.",
          "sentiment": 0.0,
          "engagement": "283",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-01-21T21:24:06.637762+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261116-cassdav5--2420571",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:54.375370",
        "source": "LSE_CHAT",
        "data": {
          "author": "cassdav57",
          "content": "Yes pumpky your correct.  My bad, brain fog on different aspects of deal and moving targets. The deal requires ROQ's enlarged share capital to be admitted to trading on AIM by this new March 16, 2026 deadline to complete the transaction. So they have about 2 more months to finalize everything and get the AIM listing done.",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-01-21T21:24:06.637744+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260739-Downagai--7568533",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:54.374937",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "That'd an easy read. Nothing new really though that I can see",
          "sentiment": 0.0,
          "engagement": "777",
          "price_at_post": "1.20",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T21:24:06.637725+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260751-billy101-18207747",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:54.374527",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "There is alot in there, so they have starteed the PR now. The Key milestone dates for 2025-2027 and Financial valuation on page 4 will keep investors happy. Its a long read",
          "sentiment": 0.0,
          "engagement": "31,674",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T21:24:06.637707+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260756-bbr391-77628927",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:54.374087",
        "source": "LSE_CHAT",
        "data": {
          "author": "bbr391",
          "content": "Progress to date Roquefort has demonstrated significant anti-cancer activity with its STAT-6 siRNA therapeutics, as validated in in vivo models of breast and colon cancer. These results further reinforce the potential of STAT-6 targeting approaches in multiple tumour types and provide a strong foundation for advancing this programme towards clinical evaluation. STAT-6 targeting siRNA constructs have shown significant in vivo anti-cancer activity in validated models of colon cancer. STAT-6 siRNAs demonstrated a significant reduction in the proliferation of colorectal cancer with a ca.50% reduction in cell growth at seven days. This anti-cancer effect was replicated in a validated in vivo model of colorectal cancer with a significant reduction in cancer weight and volume over 28 days As usual . One feels the Americans are getting good research at a very very very low cost . Outstanding",
          "sentiment": 0.5,
          "engagement": "8,990",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T21:24:06.637689+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260804-leew--6919484",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:54.373618",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Well digesting the financial pages was my first port of call and to be honest the purchase price we are paying is very reasonable and if the shares are issued at 1.7 as adv used then on the RTO I see some potential for immediate upside with no real news other than we have done the RTO and its purchase value. Add that to then normal news on progression in phase 1 and beyond we could see some very good gains. Will need to digest the technical aspect later but form investment strategy I am happy",
          "sentiment": 0.0,
          "engagement": "2,601",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T21:24:06.637671+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260805-davey50-60532069",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:54.373178",
        "source": "LSE_CHAT",
        "data": {
          "author": "davey50",
          "content": "Just play the game, buy them when totally unloved and sell them when the shares are spiking and the herd arrives rinse and repeat. I took 500k more at the bell 1.23p ish...what a price...they were chasing this up to 2.5p not long ago",
          "sentiment": 0.0,
          "engagement": "7,031",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T21:24:06.637653+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260806-billy101-90252686",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:54.372678",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Keeping this short and brief for us investors page 7 matters. And if they tick all the boxes with TACC3 Inhibitor thats mentioned on page 14 then were off to the moon. The rest of the read research note is for my daughters and son in law to translate to me!",
          "sentiment": 0.0,
          "engagement": "31,674",
          "price_at_post": "1.20",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T21:24:06.637635+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260826-billy101-64165176",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:54.372228",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Only issue I have with todays RNS(RESEARCH NOTE) . It should have been released in November.",
          "sentiment": 0.0,
          "engagement": "31,674",
          "price_at_post": "1.30",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T21:24:06.637616+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261212-Downagai--6052364",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:51.085271",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Wow how to lose \u00a3730 in 3 hours. Unlucky trader Sam \ud83e\udd26\u200d\u2642\ufe0f",
          "sentiment": 0.0,
          "engagement": "777",
          "price_at_post": "1.30",
          "thread_title": "Loss",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=A17EF4D3-D0D3-4793-A674-53112286A2B2"
        },
        "ingested_at": "2026-01-21T21:24:06.637598+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261029-Aklee-28581114",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:51.084857",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aklee",
          "content": "I see Davey is here peddling his usual nonsense. Be careful on any share he is in. Always sells into the smallest rise whilst claiming it's someone else",
          "sentiment": 0.0,
          "engagement": "3,565",
          "price_at_post": "1.25",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T21:24:06.637580+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261147-Downagai--5273162",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:51.084446",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Well with all the fanfare around this never thought I'd be able to buy under 1.2p. If the deal happens near 50% upside straight away. What not to like \ud83d\ude03\ud83d\ude80",
          "sentiment": 0.5,
          "engagement": "777",
          "price_at_post": "1.20",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T21:24:06.637561+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261253-pumpky--8481045",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:51.084032",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "IF being the operative word \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,607",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T21:24:06.637543+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261256-Escapeto-39969279",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:51.083625",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Disappointed \ud83d\ude1e. DOWN.",
          "sentiment": 0.0,
          "engagement": "1,296",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T21:24:06.637525+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261257-pumpky--7872602",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:51.083215",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "3rd November RNS Caroline Fortier  We anticipate the round of funding to be completed before the Long stop date of 31Januaey 2026",
          "sentiment": 0.0,
          "engagement": "17,607",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T21:24:06.637507+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261315-billy101-50343307",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:51.082780",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Could go in until 16th March",
          "sentiment": 0.0,
          "engagement": "31,674",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T21:24:06.637489+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261326-pumpky-90804993",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:51.082371",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Pileades deal 16  March ?",
          "sentiment": 0.0,
          "engagement": "17,607",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T21:24:06.637470+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261350-Escapeto--3378572",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:51.081952",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "They'll miss it.",
          "sentiment": 0.0,
          "engagement": "1,296",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T21:24:06.637452+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261447-billy101-24388190",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:51.081549",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Read pages 28 and 29",
          "sentiment": 0.0,
          "engagement": "31,674",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T21:24:06.637434+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261742-pumpky-70439314",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:51.081136",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Read them and what? SP Angel are the Brokers  for Roquefort \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,607",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T21:24:06.637416+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20262322-Escapeto-84511734",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:51.080717",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Huge bull market for biotech , roq at all time low.",
          "sentiment": 0.0,
          "engagement": "1,296",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T21:24:06.637398+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20262335-Downagai--7063026",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:51.080305",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "It's because they keep promising the earth and delivering nothing with no updates and just delays",
          "sentiment": 0.0,
          "engagement": "777",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T21:24:06.637381+00:00"
      },
      {
        "event_id": "SOCIAL-17Jan20260249-Escapeto--4824907",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:51.079892",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "I'm hopeful, but not convinced this team can build value. I'm not sure what it is but just look at the history for starters. Continual missed deadlines. At the very least don't make a rod for your back with deadlines you never keep.",
          "sentiment": 0.0,
          "engagement": "1,296",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T21:24:06.637363+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260730-Downagai-39229061",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:51.079480",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "They need to provide an update, this radio silence is very poor",
          "sentiment": 0.0,
          "engagement": "777",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T21:24:06.637345+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260810-billy101-90099046",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:51.079063",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "We had news last wek in R/note.",
          "sentiment": 0.0,
          "engagement": "31,674",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T21:24:06.637328+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260834-Downagai--7444037",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:51.078647",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "About progess on the deals? What page please I missed that thanks",
          "sentiment": 0.0,
          "engagement": "777",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T21:24:06.637310+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260840-billy101--2564932",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:51.078237",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "We will get updates on deals when and if  they are complete. They can't keep doing a running commentary on progress of deals. We have been told the aims in the R/Note. We have split Mk(nearly) upon condition of Coil happening. We are in different phases in trials. Anything else is conjecture. Whilst this is happening its stalemate on all pathways.",
          "sentiment": 0.0,
          "engagement": "31,674",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T21:24:06.637292+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20260756-Downagai-47924175",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:51.077803",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Interesting pre market spread today. I wish",
          "sentiment": 0.0,
          "engagement": "777",
          "price_at_post": "1.60",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T21:24:06.637274+00:00"
      },
      {
        "event_id": "SOCIAL-Today0813-SharePic-20149984",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:51.077396",
        "source": "LSE_CHAT",
        "data": {
          "author": "SharePicks",
          "content": "Good start so far today.",
          "sentiment": 0.0,
          "engagement": "1,170",
          "price_at_post": "1.15",
          "thread_title": "ROQ",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=34D50F4B-4B38-438B-BCC4-912454A889E9"
        },
        "ingested_at": "2026-01-21T21:24:06.637255+00:00"
      },
      {
        "event_id": "SOCIAL-Today0903-davey50-62051300",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:51.076977",
        "source": "LSE_CHAT",
        "data": {
          "author": "davey50",
          "content": "Just need to clear the slack below 1.4p and then the herd will arrive, if trls can do 300% then roq is always good for a spike a few times a year",
          "sentiment": 0.0,
          "engagement": "7,031",
          "price_at_post": "1.30",
          "thread_title": "RE: ROQ",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=34D50F4B-4B38-438B-BCC4-912454A889E9"
        },
        "ingested_at": "2026-01-21T21:24:06.637237+00:00"
      },
      {
        "event_id": "SOCIAL-Today0911-SharePic-20942978",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:51.076575",
        "source": "LSE_CHAT",
        "data": {
          "author": "SharePicks",
          "content": "I've added this to portfolio. Lets see where it goes.",
          "sentiment": 0.0,
          "engagement": "1,170",
          "price_at_post": "1.30",
          "thread_title": "1.5p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=EC7A8D0C-531B-4D1D-A5F0-14D0049CD3D9"
        },
        "ingested_at": "2026-01-21T21:24:06.637220+00:00"
      },
      {
        "event_id": "SOCIAL-Today1337-bbr391--7200475",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:51.076164",
        "source": "LSE_CHAT",
        "data": {
          "author": "bbr391",
          "content": "Come to Papa . We will all soon be very very pleased (possibly). Outstanding",
          "sentiment": 0.5,
          "engagement": "8,990",
          "price_at_post": "1.35",
          "thread_title": "Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-21T21:24:06.637201+00:00"
      },
      {
        "event_id": "SOCIAL-Today1338-Downagai--6853963",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:51.075729",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "IYHO I take it \ud83d\ude03",
          "sentiment": 0.0,
          "engagement": "777",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-21T21:24:06.637177+00:00"
      },
      {
        "event_id": "SOCIAL-Today1653-Kikudi--7082237",
        "event_type": "social_post",
        "date": "2026-01-21T21:23:51.075296",
        "source": "LSE_CHAT",
        "data": {
          "author": "Kikudi",
          "content": "Some please give me highlights of ROQ that will save me go through  RNS I want to invest. Thanks in advance",
          "sentiment": 0.0,
          "engagement": "15",
          "price_at_post": "1.35",
          "thread_title": "Can",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=28165808-701F-48DA-95C7-867899DCB7C6"
        },
        "ingested_at": "2026-01-21T21:24:06.637153+00:00"
      },
      {
        "event_id": "SOCIAL-19Dec20251315-hamilton--1517427",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:17.462896",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "I was referring to you saying you\u2019d been in ECR for two years but nice try ! Yep, he could have got nearer 3p for his shares and he\u2019s lost out on the Midkine ones now also. Gambling in ECR now, what a disaster that has been. Turn the chart upside down and it might make you feel better : ) Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,490",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T01:07:25.332900Z"
      },
      {
        "event_id": "SOCIAL-20Dec20251024-Bottmzup--2655389",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:17.462462",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bottmzup",
          "content": "Downagain, I'm surprised, I had you down as being someone with a modicum of understanding on how the stock market works. Both the day before and the day of the cutoff to get the lucky dip shares, the share price had a high of 3p, an intraday high of 3p! So that is the highest price paid on both days. I was watching like a shytehouse spider with live real time trades, as an LSE subscriber, and the morning looked to be struggling to challenge 3p again, and as the afternoon started it looked even less likely. I did some dummy sell quotes in the morning and the highest offer was 2.6p! I sensed the negativity and watched as the sells came through....so to get out at 2.3p was quite satisfying on the day, and very satisfying in the subsequent falling sessions. Ham, watch ECR in the new year once they announce that gold production has started. I wont be on here rubbing your nose in it, but I might send you just a friendly wink ;-) ps. there's a disclaimer included on all investment instruments, which goes something like...\"Past performance is not indicative of future results\" This works both ways!",
          "sentiment": 0.0,
          "engagement": "6,734",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T01:07:25.332873Z"
      },
      {
        "event_id": "SOCIAL-20Dec20251638-Downagai--1216536",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:17.461989",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Thanks for explaining what an intraday high is I had forgotten \ud83d\ude00. I was quoted 2.8 to sell on the Friday hence my comment. As long as you're happy with your transaction  all good \ud83d\udc4d",
          "sentiment": 0.0,
          "engagement": "775",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T01:07:25.332846Z"
      },
      {
        "event_id": "SOCIAL-23Dec20250738-Downagai--3930603",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:17.461525",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Blimey, quiet here. Let's hope the company's being a but more active \ud83d\ude00",
          "sentiment": 0.0,
          "engagement": "775",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T01:07:25.332819Z"
      },
      {
        "event_id": "SOCIAL-23Dec20251222-billy101--7212106",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:17.461108",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Nope just waiting buying down down to the BOD's now and market \\merry Xmas & Happy New Year",
          "sentiment": 0.0,
          "engagement": "31,656",
          "price_at_post": "1.30",
          "thread_title": "RE: BOOM",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=51DDB17F-0C17-42DC-AF11-3CEC2E46DC5D"
        },
        "ingested_at": "2026-01-21T01:07:25.332793Z"
      },
      {
        "event_id": "SOCIAL-31Dec20250828-hamilton-81871553",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:17.460677",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "Looks like it is 1:1000 ratio for the carve out shares: https://find-and-update.company-information.service.gov.uk/company/16674669/filing-history Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,490",
          "price_at_post": "1.30",
          "thread_title": "MIDKINE shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=F548BD7E-2DF0-4F40-A04F-ABE79EA22B1A"
        },
        "ingested_at": "2026-01-21T01:07:25.332766Z"
      },
      {
        "event_id": "SOCIAL-31Dec20251003-billy101-52789150",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:17.460250",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Ham well done didn't look at CH for info. Well looks like somethings moving ahead",
          "sentiment": 0.0,
          "engagement": "31,656",
          "price_at_post": "1.30",
          "thread_title": "RE: MIDKINE shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=F548BD7E-2DF0-4F40-A04F-ABE79EA22B1A"
        },
        "ingested_at": "2026-01-21T01:07:25.332739Z"
      },
      {
        "event_id": "SOCIAL-31Dec20251010-billy101--6931230",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:17.459812",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "That may well value the company higher and easier to administrate share dealings if any. I get 6400 shares",
          "sentiment": 0.0,
          "engagement": "31,656",
          "price_at_post": "1.30",
          "thread_title": "RE: MIDKINE shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=F548BD7E-2DF0-4F40-A04F-ABE79EA22B1A"
        },
        "ingested_at": "2026-01-21T01:07:25.332713Z"
      },
      {
        "event_id": "SOCIAL-31Dec20251046-Merciama--4159235",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:17.459387",
        "source": "LSE_CHAT",
        "data": {
          "author": "Merciaman",
          "content": "Good spot Hamilton - but does it not now suggest, with 15.7 million shares, that it's 1 Midkine share for every 10 Roquefort share held as per the record date ? It was 1,000 for 1 with the initial Midkine set-up of 157,445 shares, but the number of Midkine shares has now been increased 100 fold ?",
          "sentiment": 0.0,
          "engagement": "283",
          "price_at_post": "1.30",
          "thread_title": "RE: MIDKINE shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=F548BD7E-2DF0-4F40-A04F-ABE79EA22B1A"
        },
        "ingested_at": "2026-01-21T01:07:25.332686Z"
      },
      {
        "event_id": "SOCIAL-2Jan20261216-Dicko80-73941694",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:17.458934",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dicko80",
          "content": "Need to factor in 163m shares in issue Hopefully gets sorted this month",
          "sentiment": 0.0,
          "engagement": "2,425",
          "price_at_post": "1.25",
          "thread_title": "RE: MIDKINE shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=F548BD7E-2DF0-4F40-A04F-ABE79EA22B1A"
        },
        "ingested_at": "2026-01-21T01:07:25.332660Z"
      },
      {
        "event_id": "SOCIAL-2Jan20261340-hamilton--2367974",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:17.458496",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "Flurry of buys out of the blue ? Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,490",
          "price_at_post": "1.30",
          "thread_title": "RE: MIDKINE shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=F548BD7E-2DF0-4F40-A04F-ABE79EA22B1A"
        },
        "ingested_at": "2026-01-21T01:07:25.332633Z"
      },
      {
        "event_id": "SOCIAL-2Jan20261412-Bobat123-19886755",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:13.915910",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bobat123",
          "content": "Looks like someone loading up",
          "sentiment": 0.0,
          "engagement": "6,779",
          "price_at_post": "1.30",
          "thread_title": "RE: MIDKINE shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=F548BD7E-2DF0-4F40-A04F-ABE79EA22B1A"
        },
        "ingested_at": "2026-01-21T01:07:25.332607Z"
      },
      {
        "event_id": "SOCIAL-2Jan20261419-Bobat123--3081546",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:13.915500",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bobat123",
          "content": "MK Cell Out-License & Lyramid SPA Update anyday soon",
          "sentiment": 0.0,
          "engagement": "6,779",
          "price_at_post": "1.30",
          "thread_title": "RE: MIDKINE shares",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=F548BD7E-2DF0-4F40-A04F-ABE79EA22B1A"
        },
        "ingested_at": "2026-01-21T01:07:25.332580Z"
      },
      {
        "event_id": "SOCIAL-5Jan20261111-bunsenbu--3466791",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:13.915084",
        "source": "LSE_CHAT",
        "data": {
          "author": "bunsenburner123",
          "content": "\u2022\tROQ is down ~50% in two months \u2022\tNo asset failure, no trial failure, no cancellation \u2022\tFall driven by one large seller and ex-entitlement adjustment \u2022\tDirector bought ~\u00a385k not long ago \u2022\tBig seller now out of the register \u2022\tCurrent price already reflects delays \u2022\tAny positive update (deal progress / clarity) forces a re-rating from a very low base Conclusion: At ~1.4p, ROQ is priced for outcomes that haven\u2019t happened \u2014 making upside colossal \ud83d\ude80",
          "sentiment": 0.0,
          "engagement": "7,060",
          "price_at_post": "1.30",
          "thread_title": "Poised for a Huge Potential Move \ud83d\ude80",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=B4DB7DB8-4FE4-4116-B458-031274C4D528"
        },
        "ingested_at": "2026-01-21T01:07:25.332554Z"
      },
      {
        "event_id": "SOCIAL-5Jan20261119-Bobat123-44623304",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:13.914629",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bobat123",
          "content": "Added more today .  Gla",
          "sentiment": 0.5,
          "engagement": "6,779",
          "price_at_post": "1.30",
          "thread_title": "RE: Poised for a Huge Potential Move \ud83d\ude80",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=B4DB7DB8-4FE4-4116-B458-031274C4D528"
        },
        "ingested_at": "2026-01-21T01:07:25.332527Z"
      },
      {
        "event_id": "SOCIAL-5Jan20261129-Bobat123--7111666",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:13.914215",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bobat123",
          "content": "Buys getting printed.",
          "sentiment": 0.0,
          "engagement": "6,779",
          "price_at_post": "1.30",
          "thread_title": "RE: Poised for a Huge Potential Move \ud83d\ude80",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=B4DB7DB8-4FE4-4116-B458-031274C4D528"
        },
        "ingested_at": "2026-01-21T01:07:25.332501Z"
      },
      {
        "event_id": "SOCIAL-5Jan20261249-Bobat123--5583098",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:13.913792",
        "source": "LSE_CHAT",
        "data": {
          "author": "Bobat123",
          "content": "Roquefort Therapeutics PLC (LSE:ROQ) said it has amended its exclusive licensing agreement with Coiled Therapeutics, Inc. and A2A Pharmaceuticals, Inc. relating to its AO-252 programme, extending the long stop date to 16 March 2026. The revision follows continued progress in the ongoing Phase I clinical study. The trial has been broadened to cover patients with all solid tumours, while placing particular emphasis on prostate cancer. Management said this prioritisation is underpinned by encouraging pre-clinical results and constructive engagement with potential commercial partners, reflecting growing interest in new oral treatment options for prostate cancer. The amended agreement provides additional time for upcoming clinical data readouts and includes revised commercial terms, notably an increase in the number of consideration shares, highlighting the perceived value of the AO-252 asset.",
          "sentiment": 0.5,
          "engagement": "6,779",
          "price_at_post": "1.40",
          "thread_title": "RE: Poised for a Huge Potential Move \ud83d\ude80",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=B4DB7DB8-4FE4-4116-B458-031274C4D528"
        },
        "ingested_at": "2026-01-21T01:07:25.332473Z"
      },
      {
        "event_id": "SOCIAL-5Jan20261548-Downagai-26010970",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:13.913375",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "It's down because MK Cell Out-License & Lyramid SPA are not not in the price as carved out.",
          "sentiment": 0.0,
          "engagement": "775",
          "price_at_post": "1.35",
          "thread_title": "RE: Poised for a Huge Potential Move \ud83d\ude80",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=B4DB7DB8-4FE4-4116-B458-031274C4D528"
        },
        "ingested_at": "2026-01-21T01:07:25.332447Z"
      },
      {
        "event_id": "SOCIAL-7Jan20261615-pumpky--2625480",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:13.912957",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "31Jan not far away \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,600",
          "price_at_post": "1.35",
          "thread_title": "RE: Poised for a Huge Potential Move \ud83d\ude80",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=B4DB7DB8-4FE4-4116-B458-031274C4D528"
        },
        "ingested_at": "2026-01-21T01:07:25.332420Z"
      },
      {
        "event_id": "SOCIAL-8Jan20261803-cassdav5-38328372",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:13.912544",
        "source": "LSE_CHAT",
        "data": {
          "author": "cassdav57",
          "content": "Hoping for an update in the next couple of weeks. In the meantime searching all articles Claude AI came up with the following. The AO-252 trial appears to be progressing well with: Positive safety data - No dose-limiting toxicities reported so far Encouraging efficacy signals - Two-thirds of patients showing tumor reduction Dose escalation continuing - From 160mg to 240mg, suggesting room for further optimization Expansion planned - Adding more cancer types including prostate cancer This is very early-stage data (Phase I), so while promising, it's important to remember these trials are primarily designed to assess safety and find the optimal dose. Efficacy data at this stage is preliminary, and the drug will need to progress through Phase II and III trials to demonstrate its true effectiveness. The data does support the rationale for the Roquefort RTO transaction, showing that AO-252 is an active clinical asset with apparently good tolerability and early signs of anti-tumour activity. The AO-252 trial appears to be progressing well with: Positive safety data - No dose-limiting toxicities reported so far Encouraging efficacy signals - Two-thirds of patients showing tumour reduction Dose escalation continuing - From 160mg to 240mg, suggesting room for further optimization Expansion planned - Adding more cancer types including prostate cancer This is very early-stage data (Phase I), so while promising, it's important to remember these trials are primarily designed to assess safety and find the optimal dose. Efficacy data at this stage is preliminary, and the drug will need to progress through Phase II and III trials to demonstrate its true effectiveness. The data does support the rationale for the Roquefort RTO transaction, showing that AO-252 is an active clinical asset with apparently good tolerability and early signs of anti-tumour activity. Nothing new but on the reassuring side for a good outcome for patients and investors.",
          "sentiment": 0.0,
          "engagement": "34",
          "price_at_post": "1.35",
          "thread_title": "Update soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3C606899-BC3E-4A48-A326-42E1649178FD"
        },
        "ingested_at": "2026-01-21T01:07:25.332394Z"
      },
      {
        "event_id": "SOCIAL-8Jan20261806-cassdav5--8869710",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:13.912069",
        "source": "LSE_CHAT",
        "data": {
          "author": "cassdav57",
          "content": "Sorry about pasting twice!!!!",
          "sentiment": 0.0,
          "engagement": "34",
          "price_at_post": "1.35",
          "thread_title": "RE: Update soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3C606899-BC3E-4A48-A326-42E1649178FD"
        },
        "ingested_at": "2026-01-21T01:07:25.332367Z"
      },
      {
        "event_id": "SOCIAL-9Jan20261357-leew-65607048",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:13.911661",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Yes next news should be fun and hopefully find out a little more on the split out shares and the RTO this month.",
          "sentiment": 0.0,
          "engagement": "2,599",
          "price_at_post": "1.35",
          "thread_title": "RE: Update soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3C606899-BC3E-4A48-A326-42E1649178FD"
        },
        "ingested_at": "2026-01-21T01:07:25.332341Z"
      },
      {
        "event_id": "SOCIAL-9Jan20261508-pumpky--7893260",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:13.911254",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Or another extension \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,600",
          "price_at_post": "1.35",
          "thread_title": "RE: Update soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3C606899-BC3E-4A48-A326-42E1649178FD"
        },
        "ingested_at": "2026-01-21T01:07:25.332314Z"
      },
      {
        "event_id": "SOCIAL-9Jan20261634-Downagai--5972014",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:13.910835",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "The radio silence is a concern, if they extend again its not going to br favourable given the last one",
          "sentiment": 0.0,
          "engagement": "775",
          "price_at_post": "1.35",
          "thread_title": "RE: Update soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3C606899-BC3E-4A48-A326-42E1649178FD"
        },
        "ingested_at": "2026-01-21T01:07:25.332288Z"
      },
      {
        "event_id": "SOCIAL-9Jan20261702-billy101--1575793",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:13.910428",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Pumpky you maybe right.......................just a waiting game",
          "sentiment": 0.0,
          "engagement": "31,656",
          "price_at_post": "1.35",
          "thread_title": "RE: Update soon",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3C606899-BC3E-4A48-A326-42E1649178FD"
        },
        "ingested_at": "2026-01-21T01:07:25.332261Z"
      },
      {
        "event_id": "SOCIAL-12Jan20260842-bbr391--1327306",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:13.910001",
        "source": "LSE_CHAT",
        "data": {
          "author": "bbr391",
          "content": "A passing of 1.5p should be good news . The Latter is also very , very , very possible . Good luck All Shareholders Outstanding ( Maybe )",
          "sentiment": 0.0,
          "engagement": "8,989",
          "price_at_post": "1.35",
          "thread_title": "Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-01-21T01:07:25.332234Z"
      },
      {
        "event_id": "SOCIAL-13Jan20260745-Downagai--2357915",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:13.909577",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Tbh the lack of news and clarity here is starting to be s concern. The rto delay has already seen a significant impact to the terms for ROQ. Really need to understand progress here now IMHO",
          "sentiment": 0.0,
          "engagement": "775",
          "price_at_post": "1.20",
          "thread_title": "RE: Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-01-21T01:07:25.332208Z"
      },
      {
        "event_id": "SOCIAL-13Jan20261649-Downagai-45304481",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:13.909168",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Quiet here \ud83d\ude34",
          "sentiment": 0.0,
          "engagement": "775",
          "price_at_post": "1.20",
          "thread_title": "RE: Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-01-21T01:07:25.332182Z"
      },
      {
        "event_id": "SOCIAL-13Jan20261714-pumpky--7564317",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:13.908748",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "What is there to say? Just waiting for news",
          "sentiment": 0.0,
          "engagement": "17,600",
          "price_at_post": "1.20",
          "thread_title": "RE: Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-01-21T01:07:25.332155Z"
      },
      {
        "event_id": "SOCIAL-13Jan20261743-Downagai-13697828",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:13.908334",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "True enough",
          "sentiment": 0.0,
          "engagement": "775",
          "price_at_post": "1.20",
          "thread_title": "RE: Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-01-21T01:07:25.332128Z"
      },
      {
        "event_id": "SOCIAL-14Jan20260918-cassdav5-67494911",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:13.907912",
        "source": "LSE_CHAT",
        "data": {
          "author": "cassdav57",
          "content": "The exclusivity period should be ending soon (January 2026), so we might hear updates about whether the deal proceeds in the coming weeks. The  main hope for good news  for me was the director buy in November of 5 million shares (\u00a385k) and the calibre of the trails technology plus funding through A2A Pharmaceuticals.  So yes, definitely a waiting game, currently I am down about 50% and will be holding and making some small additions at these low or lower prices until things become clearer as upside could be considerable.",
          "sentiment": 0.0,
          "engagement": "34",
          "price_at_post": "1.20",
          "thread_title": "News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-01-21T01:07:25.332085Z"
      },
      {
        "event_id": "SOCIAL-14Jan20260924-cassdav5-21954340",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:13.907501",
        "source": "LSE_CHAT",
        "data": {
          "author": "cassdav57",
          "content": "Sorry guys, Realise, The exclusivity period extended to March 16th but would still expect news by end of Jan.",
          "sentiment": 0.0,
          "engagement": "34",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-01-21T01:07:25.332058Z"
      },
      {
        "event_id": "SOCIAL-14Jan20260941-pumpky-28906218",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:13.907074",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Isnt the Pileades deal January?",
          "sentiment": 0.0,
          "engagement": "17,600",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-01-21T01:07:25.332029Z"
      },
      {
        "event_id": "SOCIAL-14Jan20261027-Merciama-60334892",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:13.906660",
        "source": "LSE_CHAT",
        "data": {
          "author": "Merciaman",
          "content": "It is Pumpky, 31/1 deadline for Pleiades to buy Lyramid from Midkine Investments. The reverse takeover of Roquefort to form Coiled Therapeutics has the 16th March deadline.",
          "sentiment": 0.0,
          "engagement": "283",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-01-21T01:07:25.332003Z"
      },
      {
        "event_id": "SOCIAL-14Jan20261116-cassdav5-28557741",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:13.906233",
        "source": "LSE_CHAT",
        "data": {
          "author": "cassdav57",
          "content": "Yes pumpky your correct.  My bad, brain fog on different aspects of deal and moving targets. The deal requires ROQ's enlarged share capital to be admitted to trading on AIM by this new March 16, 2026 deadline to complete the transaction. So they have about 2 more months to finalize everything and get the AIM listing done.",
          "sentiment": 0.0,
          "engagement": "34",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-01-21T01:07:25.331976Z"
      },
      {
        "event_id": "SOCIAL-15Jan20260739-Downagai-45673739",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:13.905783",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "That'd an easy read. Nothing new really though that I can see",
          "sentiment": 0.0,
          "engagement": "775",
          "price_at_post": "1.20",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T01:07:25.331949Z"
      },
      {
        "event_id": "SOCIAL-15Jan20260751-billy101--6479642",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:08.909565",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "There is alot in there, so they have starteed the PR now. The Key milestone dates for 2025-2027 and Financial valuation on page 4 will keep investors happy. Its a long read",
          "sentiment": 0.0,
          "engagement": "31,656",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T01:07:25.331923Z"
      },
      {
        "event_id": "SOCIAL-15Jan20260756-bbr391--8240837",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:08.909145",
        "source": "LSE_CHAT",
        "data": {
          "author": "bbr391",
          "content": "Progress to date Roquefort has demonstrated significant anti-cancer activity with its STAT-6 siRNA therapeutics, as validated in in vivo models of breast and colon cancer. These results further reinforce the potential of STAT-6 targeting approaches in multiple tumour types and provide a strong foundation for advancing this programme towards clinical evaluation. STAT-6 targeting siRNA constructs have shown significant in vivo anti-cancer activity in validated models of colon cancer. STAT-6 siRNAs demonstrated a significant reduction in the proliferation of colorectal cancer with a ca.50% reduction in cell growth at seven days. This anti-cancer effect was replicated in a validated in vivo model of colorectal cancer with a significant reduction in cancer weight and volume over 28 days As usual . One feels the Americans are getting good research at a very very very low cost . Outstanding",
          "sentiment": 0.5,
          "engagement": "8,989",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T01:07:25.331896Z"
      },
      {
        "event_id": "SOCIAL-15Jan20260804-leew-80449184",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:08.908675",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Well digesting the financial pages was my first port of call and to be honest the purchase price we are paying is very reasonable and if the shares are issued at 1.7 as adv used then on the RTO I see some potential for immediate upside with no real news other than we have done the RTO and its purchase value. Add that to then normal news on progression in phase 1 and beyond we could see some very good gains. Will need to digest the technical aspect later but form investment strategy I am happy",
          "sentiment": 0.0,
          "engagement": "2,599",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T01:07:25.331869Z"
      },
      {
        "event_id": "SOCIAL-15Jan20260805-davey50--1144391",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:08.908264",
        "source": "LSE_CHAT",
        "data": {
          "author": "davey50",
          "content": "Just play the game, buy them when totally unloved and sell them when the shares are spiking and the herd arrives rinse and repeat. I took 500k more at the bell 1.23p ish...what a price...they were chasing this up to 2.5p not long ago",
          "sentiment": 0.0,
          "engagement": "7,022",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T01:07:25.331843Z"
      },
      {
        "event_id": "SOCIAL-15Jan20260806-billy101--1210083",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:08.907839",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Keeping this short and brief for us investors page 7 matters. And if they tick all the boxes with TACC3 Inhibitor thats mentioned on page 14 then were off to the moon. The rest of the read research note is for my daughters and son in law to translate to me!",
          "sentiment": 0.0,
          "engagement": "31,656",
          "price_at_post": "1.20",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T01:07:25.331816Z"
      },
      {
        "event_id": "SOCIAL-15Jan20260826-billy101-41843801",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:08.907412",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Only issue I have with todays RNS(RESEARCH NOTE) . It should have been released in November.",
          "sentiment": 0.0,
          "engagement": "31,656",
          "price_at_post": "1.30",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T01:07:25.331789Z"
      },
      {
        "event_id": "SOCIAL-15Jan20261212-Downagai--4784430",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:08.906988",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Wow how to lose \u00a3730 in 3 hours. Unlucky trader Sam \ud83e\udd26\u200d\u2642\ufe0f",
          "sentiment": 0.0,
          "engagement": "775",
          "price_at_post": "1.30",
          "thread_title": "Loss",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=A17EF4D3-D0D3-4793-A674-53112286A2B2"
        },
        "ingested_at": "2026-01-21T01:07:25.331763Z"
      },
      {
        "event_id": "SOCIAL-16Jan20261029-Aklee--5265097",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:08.906576",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aklee",
          "content": "I see Davey is here peddling his usual nonsense. Be careful on any share he is in. Always sells into the smallest rise whilst claiming it's someone else",
          "sentiment": 0.0,
          "engagement": "3,559",
          "price_at_post": "1.25",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T01:07:25.331737Z"
      },
      {
        "event_id": "SOCIAL-16Jan20261147-Downagai-43012455",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:08.906160",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Well with all the fanfare around this never thought I'd be able to buy under 1.2p. If the deal happens near 50% upside straight away. What not to like \ud83d\ude03\ud83d\ude80",
          "sentiment": 0.5,
          "engagement": "775",
          "price_at_post": "1.20",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T01:07:25.331709Z"
      },
      {
        "event_id": "SOCIAL-16Jan20261253-pumpky-91938449",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:08.905741",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "IF being the operative word \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,600",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T01:07:25.331683Z"
      },
      {
        "event_id": "SOCIAL-16Jan20261256-Escapeto-54659555",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:08.905332",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Disappointed \ud83d\ude1e. DOWN.",
          "sentiment": 0.0,
          "engagement": "1,293",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T01:07:25.331656Z"
      },
      {
        "event_id": "SOCIAL-16Jan20261257-pumpky-42826164",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:08.904908",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "3rd November RNS Caroline Fortier  We anticipate the round of funding to be completed before the Long stop date of 31Januaey 2026",
          "sentiment": 0.0,
          "engagement": "17,600",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T01:07:25.331629Z"
      },
      {
        "event_id": "SOCIAL-16Jan20261315-billy101--2543934",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:08.904496",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Could go in until 16th March",
          "sentiment": 0.0,
          "engagement": "31,656",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T01:07:25.331602Z"
      },
      {
        "event_id": "SOCIAL-16Jan20261326-pumpky--2935154",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:08.904017",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Pileades deal 16  March ?",
          "sentiment": 0.0,
          "engagement": "17,600",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T01:07:25.331576Z"
      },
      {
        "event_id": "SOCIAL-16Jan20261350-Escapeto--2063181",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:08.903610",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "They'll miss it.",
          "sentiment": 0.0,
          "engagement": "1,293",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T01:07:25.331549Z"
      },
      {
        "event_id": "SOCIAL-16Jan20261447-billy101--6175436",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:08.903204",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Read pages 28 and 29",
          "sentiment": 0.0,
          "engagement": "31,656",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T01:07:25.331522Z"
      },
      {
        "event_id": "SOCIAL-16Jan20261742-pumpky--9472380",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:08.902776",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Read them and what? SP Angel are the Brokers  for Roquefort \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,600",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T01:07:25.331496Z"
      },
      {
        "event_id": "SOCIAL-16Jan20262322-Escapeto-80191362",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:08.902363",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Huge bull market for biotech , roq at all time low.",
          "sentiment": 0.0,
          "engagement": "1,293",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T01:07:25.331468Z"
      },
      {
        "event_id": "SOCIAL-16Jan20262335-Downagai--1081502",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:08.901947",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "It's because they keep promising the earth and delivering nothing with no updates and just delays",
          "sentiment": 0.0,
          "engagement": "775",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T01:07:25.331441Z"
      },
      {
        "event_id": "SOCIAL-17Jan20260249-Escapeto--7745455",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:08.901538",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "I'm hopeful, but not convinced this team can build value. I'm not sure what it is but just look at the history for starters. Continual missed deadlines. At the very least don't make a rod for your back with deadlines you never keep.",
          "sentiment": 0.0,
          "engagement": "1,293",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T01:07:25.331414Z"
      },
      {
        "event_id": "SOCIAL-19Jan20260730-Downagai-59209727",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:08.901119",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "They need to provide an update, this radio silence is very poor",
          "sentiment": 0.0,
          "engagement": "775",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T01:07:25.331387Z"
      },
      {
        "event_id": "SOCIAL-19Jan20260810-billy101-14019043",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:08.900702",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "We had news last wek in R/note.",
          "sentiment": 0.0,
          "engagement": "31,656",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T01:07:25.331359Z"
      },
      {
        "event_id": "SOCIAL-19Jan20260834-Downagai-80661975",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:08.900280",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "About progess on the deals? What page please I missed that thanks",
          "sentiment": 0.0,
          "engagement": "775",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T01:07:25.331332Z"
      },
      {
        "event_id": "SOCIAL-19Jan20260840-billy101--2475117",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:08.899855",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "We will get updates on deals when and if  they are complete. They can't keep doing a running commentary on progress of deals. We have been told the aims in the R/Note. We have split Mk(nearly) upon condition of Coil happening. We are in different phases in trials. Anything else is conjecture. Whilst this is happening its stalemate on all pathways.",
          "sentiment": 0.0,
          "engagement": "31,656",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T01:07:25.331304Z"
      },
      {
        "event_id": "SOCIAL-20Jan20260756-Downagai--5490323",
        "event_type": "social_post",
        "date": "2026-01-21T01:07:08.899411",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Interesting pre market spread today. I wish",
          "sentiment": 0.0,
          "engagement": "775",
          "price_at_post": "1.60",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-21T01:07:25.331271Z"
      },
      {
        "event_id": "SOCIAL-12Jan20260842-bbr391-15263298",
        "event_type": "social_post",
        "date": "2026-01-16T22:42:58.587520",
        "source": "LSE_CHAT",
        "data": {
          "author": "bbr391",
          "content": "A passing of 1.5p should be good news . The Latter is also very , very , very possible . Good luck All Shareholders Outstanding ( Maybe )",
          "sentiment": 0.0,
          "engagement": "8,987",
          "price_at_post": "1.35",
          "thread_title": "Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-01-16T22:43:07.386433Z"
      },
      {
        "event_id": "SOCIAL-13Jan20260745-Downagai--2467037",
        "event_type": "social_post",
        "date": "2026-01-16T22:42:58.587075",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Tbh the lack of news and clarity here is starting to be s concern. The rto delay has already seen a significant impact to the terms for ROQ. Really need to understand progress here now IMHO",
          "sentiment": 0.0,
          "engagement": "764",
          "price_at_post": "1.20",
          "thread_title": "RE: Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-01-16T22:43:07.386407Z"
      },
      {
        "event_id": "SOCIAL-13Jan20261649-Downagai--1535808",
        "event_type": "social_post",
        "date": "2026-01-16T22:42:58.586641",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Quiet here \ud83d\ude34",
          "sentiment": 0.0,
          "engagement": "764",
          "price_at_post": "1.20",
          "thread_title": "RE: Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-01-16T22:43:07.386380Z"
      },
      {
        "event_id": "SOCIAL-13Jan20261714-pumpky-31764889",
        "event_type": "social_post",
        "date": "2026-01-16T22:42:55.145893",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "What is there to say? Just waiting for news",
          "sentiment": 0.0,
          "engagement": "17,586",
          "price_at_post": "1.20",
          "thread_title": "RE: Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-01-16T22:43:07.386354Z"
      },
      {
        "event_id": "SOCIAL-13Jan20261743-Downagai-66811944",
        "event_type": "social_post",
        "date": "2026-01-16T22:42:55.145488",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "True enough",
          "sentiment": 0.0,
          "engagement": "764",
          "price_at_post": "1.20",
          "thread_title": "RE: Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-01-16T22:43:07.386328Z"
      },
      {
        "event_id": "SOCIAL-14Jan20260918-cassdav5--5890809",
        "event_type": "social_post",
        "date": "2026-01-16T22:42:55.145074",
        "source": "LSE_CHAT",
        "data": {
          "author": "cassdav57",
          "content": "The exclusivity period should be ending soon (January 2026), so we might hear updates about whether the deal proceeds in the coming weeks. The  main hope for good news  for me was the director buy in November of 5 million shares (\u00a385k) and the calibre of the trails technology plus funding through A2A Pharmaceuticals.  So yes, definitely a waiting game, currently I am down about 50% and will be holding and making some small additions at these low or lower prices until things become clearer as upside could be considerable.",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "1.20",
          "thread_title": "News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-01-16T22:43:07.386301Z"
      },
      {
        "event_id": "SOCIAL-14Jan20260924-cassdav5-48433303",
        "event_type": "social_post",
        "date": "2026-01-16T22:42:55.144675",
        "source": "LSE_CHAT",
        "data": {
          "author": "cassdav57",
          "content": "Sorry guys, Realise, The exclusivity period extended to March 16th but would still expect news by end of Jan.",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-01-16T22:43:07.386275Z"
      },
      {
        "event_id": "SOCIAL-14Jan20260941-pumpky--1587723",
        "event_type": "social_post",
        "date": "2026-01-16T22:42:55.144272",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Isnt the Pileades deal January?",
          "sentiment": 0.0,
          "engagement": "17,586",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-01-16T22:43:07.386249Z"
      },
      {
        "event_id": "SOCIAL-14Jan20261027-Merciama-56110121",
        "event_type": "social_post",
        "date": "2026-01-16T22:42:55.143859",
        "source": "LSE_CHAT",
        "data": {
          "author": "Merciaman",
          "content": "It is Pumpky, 31/1 deadline for Pleiades to buy Lyramid from Midkine Investments. The reverse takeover of Roquefort to form Coiled Therapeutics has the 16th March deadline.",
          "sentiment": 0.0,
          "engagement": "283",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-01-16T22:43:07.386223Z"
      },
      {
        "event_id": "SOCIAL-14Jan20261116-cassdav5--7797580",
        "event_type": "social_post",
        "date": "2026-01-16T22:42:55.143455",
        "source": "LSE_CHAT",
        "data": {
          "author": "cassdav57",
          "content": "Yes pumpky your correct.  My bad, brain fog on different aspects of deal and moving targets. The deal requires ROQ's enlarged share capital to be admitted to trading on AIM by this new March 16, 2026 deadline to complete the transaction. So they have about 2 more months to finalize everything and get the AIM listing done.",
          "sentiment": 0.0,
          "engagement": "28",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-01-16T22:43:07.386197Z"
      },
      {
        "event_id": "SOCIAL-15Jan20260739-Downagai-13213546",
        "event_type": "social_post",
        "date": "2026-01-16T22:42:55.143031",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "That'd an easy read. Nothing new really though that I can see",
          "sentiment": 0.0,
          "engagement": "764",
          "price_at_post": "1.20",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-16T22:43:07.386170Z"
      },
      {
        "event_id": "SOCIAL-15Jan20260751-billy101--4997794",
        "event_type": "social_post",
        "date": "2026-01-16T22:42:55.142632",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "There is alot in there, so they have starteed the PR now. The Key milestone dates for 2025-2027 and Financial valuation on page 4 will keep investors happy. Its a long read",
          "sentiment": 0.0,
          "engagement": "31,614",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-16T22:43:07.386143Z"
      },
      {
        "event_id": "SOCIAL-15Jan20260756-bbr391-28504437",
        "event_type": "social_post",
        "date": "2026-01-16T22:42:55.142211",
        "source": "LSE_CHAT",
        "data": {
          "author": "bbr391",
          "content": "Progress to date Roquefort has demonstrated significant anti-cancer activity with its STAT-6 siRNA therapeutics, as validated in in vivo models of breast and colon cancer. These results further reinforce the potential of STAT-6 targeting approaches in multiple tumour types and provide a strong foundation for advancing this programme towards clinical evaluation. STAT-6 targeting siRNA constructs have shown significant in vivo anti-cancer activity in validated models of colon cancer. STAT-6 siRNAs demonstrated a significant reduction in the proliferation of colorectal cancer with a ca.50% reduction in cell growth at seven days. This anti-cancer effect was replicated in a validated in vivo model of colorectal cancer with a significant reduction in cancer weight and volume over 28 days As usual . One feels the Americans are getting good research at a very very very low cost . Outstanding",
          "sentiment": 0.5,
          "engagement": "8,987",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-16T22:43:07.386111Z"
      },
      {
        "event_id": "SOCIAL-15Jan20260804-leew--8234053",
        "event_type": "social_post",
        "date": "2026-01-16T22:42:55.141748",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Well digesting the financial pages was my first port of call and to be honest the purchase price we are paying is very reasonable and if the shares are issued at 1.7 as adv used then on the RTO I see some potential for immediate upside with no real news other than we have done the RTO and its purchase value. Add that to then normal news on progression in phase 1 and beyond we could see some very good gains. Will need to digest the technical aspect later but form investment strategy I am happy",
          "sentiment": 0.0,
          "engagement": "2,589",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-16T22:43:07.386072Z"
      },
      {
        "event_id": "SOCIAL-15Jan20260805-davey50-27423897",
        "event_type": "social_post",
        "date": "2026-01-16T22:42:55.141341",
        "source": "LSE_CHAT",
        "data": {
          "author": "davey50",
          "content": "Just play the game, buy them when totally unloved and sell them when the shares are spiking and the herd arrives rinse and repeat. I took 500k more at the bell 1.23p ish...what a price...they were chasing this up to 2.5p not long ago",
          "sentiment": 0.0,
          "engagement": "7,011",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-16T22:43:07.386045Z"
      },
      {
        "event_id": "SOCIAL-15Jan20260806-billy101--4313470",
        "event_type": "social_post",
        "date": "2026-01-16T22:42:55.140923",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Keeping this short and brief for us investors page 7 matters. And if they tick all the boxes with TACC3 Inhibitor thats mentioned on page 14 then were off to the moon. The rest of the read research note is for my daughters and son in law to translate to me!",
          "sentiment": 0.0,
          "engagement": "31,614",
          "price_at_post": "1.20",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-16T22:43:07.386019Z"
      },
      {
        "event_id": "SOCIAL-15Jan20260826-billy101-45885403",
        "event_type": "social_post",
        "date": "2026-01-16T22:42:55.140502",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Only issue I have with todays RNS(RESEARCH NOTE) . It should have been released in November.",
          "sentiment": 0.0,
          "engagement": "31,614",
          "price_at_post": "1.30",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-16T22:43:07.385992Z"
      },
      {
        "event_id": "SOCIAL-15Jan20261212-Downagai-80561938",
        "event_type": "social_post",
        "date": "2026-01-16T22:42:55.140084",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Wow how to lose \u00a3730 in 3 hours. Unlucky trader Sam \ud83e\udd26\u200d\u2642\ufe0f",
          "sentiment": 0.0,
          "engagement": "764",
          "price_at_post": "1.30",
          "thread_title": "Loss",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=A17EF4D3-D0D3-4793-A674-53112286A2B2"
        },
        "ingested_at": "2026-01-16T22:43:07.385966Z"
      },
      {
        "event_id": "SOCIAL-Today1029-Aklee-25164749",
        "event_type": "social_post",
        "date": "2026-01-16T22:42:55.139681",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aklee",
          "content": "I see Davey is here peddling his usual nonsense. Be careful on any share he is in. Always sells into the smallest rise whilst claiming it's someone else",
          "sentiment": 0.0,
          "engagement": "3,520",
          "price_at_post": "1.25",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-16T22:43:07.385939Z"
      },
      {
        "event_id": "SOCIAL-Today1147-Downagai-75111611",
        "event_type": "social_post",
        "date": "2026-01-16T22:42:55.139281",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Well with all the fanfare around this never thought I'd be able to buy under 1.2p. If the deal happens near 50% upside straight away. What not to like \ud83d\ude03\ud83d\ude80",
          "sentiment": 0.5,
          "engagement": "764",
          "price_at_post": "1.20",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-16T22:43:07.385912Z"
      },
      {
        "event_id": "SOCIAL-Today1253-pumpky-87391224",
        "event_type": "social_post",
        "date": "2026-01-16T22:42:55.138864",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "IF being the operative word \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,586",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-16T22:43:07.385886Z"
      },
      {
        "event_id": "SOCIAL-Today1256-Escapeto--9019781",
        "event_type": "social_post",
        "date": "2026-01-16T22:42:55.138458",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Disappointed \ud83d\ude1e. DOWN.",
          "sentiment": 0.0,
          "engagement": "1,286",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-16T22:43:07.385860Z"
      },
      {
        "event_id": "SOCIAL-Today1257-pumpky--3947827",
        "event_type": "social_post",
        "date": "2026-01-16T22:42:55.138038",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "3rd November RNS Caroline Fortier  We anticipate the round of funding to be completed before the Long stop date of 31Januaey 2026",
          "sentiment": 0.0,
          "engagement": "17,586",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-16T22:43:07.385833Z"
      },
      {
        "event_id": "SOCIAL-Today1315-billy101--2950724",
        "event_type": "social_post",
        "date": "2026-01-16T22:42:55.137635",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Could go in until 16th March",
          "sentiment": 0.0,
          "engagement": "31,614",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-16T22:43:07.385807Z"
      },
      {
        "event_id": "SOCIAL-Today1326-pumpky--6322565",
        "event_type": "social_post",
        "date": "2026-01-16T22:42:55.137222",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Pileades deal 16  March ?",
          "sentiment": 0.0,
          "engagement": "17,586",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-16T22:43:07.385780Z"
      },
      {
        "event_id": "SOCIAL-Today1350-Escapeto--6718702",
        "event_type": "social_post",
        "date": "2026-01-16T22:42:55.136807",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "They'll miss it.",
          "sentiment": 0.0,
          "engagement": "1,286",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-16T22:43:07.385753Z"
      },
      {
        "event_id": "SOCIAL-Today1447-billy101--6413065",
        "event_type": "social_post",
        "date": "2026-01-16T22:42:55.136393",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Read pages 28 and 29",
          "sentiment": 0.0,
          "engagement": "31,614",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-16T22:43:07.385724Z"
      },
      {
        "event_id": "SOCIAL-Today1742-pumpky-62853428",
        "event_type": "social_post",
        "date": "2026-01-16T22:42:55.135950",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Read them and what? SP Angel are the Brokers  for Roquefort \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,586",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-16T22:43:07.385681Z"
      },
      {
        "event_id": "SOCIAL-2Dec20251622-Downagai-52692174",
        "event_type": "social_post",
        "date": "2026-01-10T00:45:06.239069",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "But that is the carved off shares which won't affect roq share price at all now",
          "sentiment": 0.0,
          "engagement": "706",
          "price_at_post": "1.45",
          "thread_title": "RE: I can",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=BBBEFF90-1A11-4040-BE53-CED0B0A0E37D"
        },
        "ingested_at": "2026-01-16T22:43:07.389773Z"
      },
      {
        "event_id": "SOCIAL-2Dec20251622-Downagai-14198163",
        "event_type": "social_post",
        "date": "2026-01-10T00:45:06.239069",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "But that is the carved off shares which won't affect roq share price at all now",
          "sentiment": 0.0,
          "engagement": "706",
          "price_at_post": "1.45",
          "thread_title": "RE: I can",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=BBBEFF90-1A11-4040-BE53-CED0B0A0E37D"
        },
        "ingested_at": "2026-01-21T01:07:25.335753Z"
      },
      {
        "event_id": "SOCIAL-2Dec20251637-pumpky-32209007",
        "event_type": "social_post",
        "date": "2026-01-10T00:45:06.238667",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "TOM 1 DEC  SP 1.71 \ud83d\ude02 BET this bounces Hard yep \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,549",
          "price_at_post": "1.45",
          "thread_title": "RE: I can",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=BBBEFF90-1A11-4040-BE53-CED0B0A0E37D"
        },
        "ingested_at": "2026-01-16T22:43:07.389746Z"
      },
      {
        "event_id": "SOCIAL-2Dec20251637-pumpky--9182150",
        "event_type": "social_post",
        "date": "2026-01-10T00:45:06.238667",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "TOM 1 DEC  SP 1.71 \ud83d\ude02 BET this bounces Hard yep \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,549",
          "price_at_post": "1.45",
          "thread_title": "RE: I can",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=BBBEFF90-1A11-4040-BE53-CED0B0A0E37D"
        },
        "ingested_at": "2026-01-21T01:07:25.335726Z"
      },
      {
        "event_id": "SOCIAL-3Dec20250732-Escapeto-19975130",
        "event_type": "social_post",
        "date": "2026-01-10T00:45:06.238261",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "The funny farm have left. Core stalwarts remain. Let's see how far it drops today. Maybe Even Stevens.",
          "sentiment": 0.0,
          "engagement": "1,278",
          "price_at_post": "1.50",
          "thread_title": "RE: I can",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=BBBEFF90-1A11-4040-BE53-CED0B0A0E37D"
        },
        "ingested_at": "2026-01-16T22:43:07.389720Z"
      },
      {
        "event_id": "SOCIAL-3Dec20250732-Escapeto--6138391",
        "event_type": "social_post",
        "date": "2026-01-10T00:45:06.238261",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "The funny farm have left. Core stalwarts remain. Let's see how far it drops today. Maybe Even Stevens.",
          "sentiment": 0.0,
          "engagement": "1,278",
          "price_at_post": "1.50",
          "thread_title": "RE: I can",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=BBBEFF90-1A11-4040-BE53-CED0B0A0E37D"
        },
        "ingested_at": "2026-01-21T01:07:25.335700Z"
      },
      {
        "event_id": "SOCIAL-3Dec20250755-pumpky-85573488",
        "event_type": "social_post",
        "date": "2026-01-10T00:45:06.237837",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Core Stalwarts or those heavily at a paper loss \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,549",
          "price_at_post": "1.50",
          "thread_title": "RE: I can",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=BBBEFF90-1A11-4040-BE53-CED0B0A0E37D"
        },
        "ingested_at": "2026-01-16T22:43:07.389692Z"
      },
      {
        "event_id": "SOCIAL-3Dec20250755-pumpky-26954441",
        "event_type": "social_post",
        "date": "2026-01-10T00:45:06.237837",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Core Stalwarts or those heavily at a paper loss \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,549",
          "price_at_post": "1.50",
          "thread_title": "RE: I can",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=BBBEFF90-1A11-4040-BE53-CED0B0A0E37D"
        },
        "ingested_at": "2026-01-21T01:07:25.335673Z"
      },
      {
        "event_id": "SOCIAL-3Dec20250822-hamilton--6284674",
        "event_type": "social_post",
        "date": "2026-01-10T00:45:06.237425",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "I\u2019m in profit and have the free shares : ) Easiest 20% you\u2019ll find in the market currently just to get back to the director buy. 4 x current interest rate not to be sniffed at. Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,464",
          "price_at_post": "1.45",
          "thread_title": "RE: I can",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=BBBEFF90-1A11-4040-BE53-CED0B0A0E37D"
        },
        "ingested_at": "2026-01-16T22:43:07.389666Z"
      },
      {
        "event_id": "SOCIAL-3Dec20250822-hamilton--1939737",
        "event_type": "social_post",
        "date": "2026-01-10T00:45:06.237425",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "I\u2019m in profit and have the free shares : ) Easiest 20% you\u2019ll find in the market currently just to get back to the director buy. 4 x current interest rate not to be sniffed at. Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,464",
          "price_at_post": "1.45",
          "thread_title": "RE: I can",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=BBBEFF90-1A11-4040-BE53-CED0B0A0E37D"
        },
        "ingested_at": "2026-01-21T01:07:25.335647Z"
      },
      {
        "event_id": "SOCIAL-3Dec20250826-billy101--3549925",
        "event_type": "social_post",
        "date": "2026-01-10T00:45:06.236999",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "I'm about in profit still. May drop another 20% yet but it may go up 20%/40% who's. Need the final Mcap figure to derive SP coupled with news etc. We know the placing price.",
          "sentiment": 0.0,
          "engagement": "31,560",
          "price_at_post": "1.45",
          "thread_title": "Morning all",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3C6D63E4-BEE4-4F3A-ADB2-2ED803C84BDB"
        },
        "ingested_at": "2026-01-16T22:43:07.389640Z"
      },
      {
        "event_id": "SOCIAL-23Jan20261617-Downagai-57314860",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.113544",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Big sell 3 big buys?",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-24T01:40:09.130727+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261505-billy101-47434054",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.113993",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "What\u2019s another few months. Have you been in since Jan 25?",
          "sentiment": 0.0,
          "engagement": "31,698",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-24T01:40:09.130764+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261504-pumpky-91190298",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.114430",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Deal  has been going on since January 2025",
          "sentiment": 0.0,
          "engagement": "17,626",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-24T01:40:09.130803+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261425-leew--7746988",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.114946",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Could be a delay or could happen on time, funding is never a simple process having been involved myself. The access to the data room and the DD questions from all parties is always significant. Just wait for the confirmation, because all that is needed is patience with ROQ in my view.",
          "sentiment": 0.0,
          "engagement": "2,618",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-24T01:40:09.130832+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260859-davey50-87243843",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.115405",
        "source": "LSE_CHAT",
        "data": {
          "author": "davey50",
          "content": "1.23-1.35p online so mid price to buy, not a bad price for a gamble given it's history of spikes",
          "sentiment": 0.0,
          "engagement": "7,037",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-24T01:40:09.130851+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260806-pumpky--7169642",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.115821",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Anticipate not expect \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,626",
          "price_at_post": "1.45",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-24T01:40:09.130869+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260726-Downagai--5252343",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.116249",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Apparently a couple of days is aay ahead \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-24T01:40:09.130887+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260725-pumpky-89535868",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.116661",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Caroline Fortier We expect to finalise before the 31 January date\" Expect\" Get out card ( maybe delayed due to Trump wanting Greenland \ud83d\ude02)",
          "sentiment": 0.0,
          "engagement": "17,626",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-24T01:40:09.130905+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260725-Downagai-58049649",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.117079",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "No Dicko after all \"Caroline Fortier, Pleiades CEO commented: \"Following the previously announced acquisition of Lyramid, we are delighted to build on our relationship with Roquefort Therapeutics and take an exclusive license of the MK Cell therapy asset which we plan to take into clinical studies targeting high value oncology indications of unmet need. The addition of these assets to our immunotherapy, late-stage pan-specific vaccine and cell therapy portfolio is an important part of our strategy to position ourselves as a material biotechnology company to institutional investors with whom we are currently working to close on a significant equity funding round. In alignment with the extension of the Lyramid SPA we anticipate our funding round to complete ahead of the new 31 January 2026 long stop date.\"",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-24T01:40:09.130923+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260720-Dicko80-29142236",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.117508",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dicko80",
          "content": "What\u2019s the betting they\u2019ll be another extension to us getting our shares ? 1 week deadline",
          "sentiment": 0.0,
          "engagement": "2,427",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-24T01:40:09.130941+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20262142-leew-29852761",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.117916",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Well there is a lot of news due bbr, would be great to get the RTO confirmed and initially just get the SP back to 1.7p and then see where the RTO then takes it as there is some potential for increasing in market cap after so fingers crossed. Would also be good on the back of that to then here about the spin off and the deals associated to that to see when some cash might come in from the free shares.",
          "sentiment": 0.0,
          "engagement": "2,618",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-24T01:40:09.130958+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20262130-leew-56840107",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.118340",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Honestly if you want to invest best check yourself. I don\u2019t think reading a few RNA\u2019s and googling a few things is that bad.",
          "sentiment": 0.0,
          "engagement": "2,618",
          "price_at_post": "1.35",
          "thread_title": "RE: Can",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=28165808-701F-48DA-95C7-867899DCB7C6"
        },
        "ingested_at": "2026-01-24T01:40:09.130976+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261653-Kikudi--1219693",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.118754",
        "source": "LSE_CHAT",
        "data": {
          "author": "Kikudi",
          "content": "Some please give me highlights of ROQ that will save me go through  RNS I want to invest. Thanks in advance",
          "sentiment": 0.0,
          "engagement": "15",
          "price_at_post": "1.35",
          "thread_title": "Can",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=28165808-701F-48DA-95C7-867899DCB7C6"
        },
        "ingested_at": "2026-01-24T01:40:09.130994+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261338-Downagai-29902584",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.119177",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "IYHO I take it \ud83d\ude03",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-24T01:40:09.131012+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261337-bbr391--8324055",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.119594",
        "source": "LSE_CHAT",
        "data": {
          "author": "bbr391",
          "content": "Come to Papa . We will all soon be very very pleased (possibly). Outstanding",
          "sentiment": 0.5,
          "engagement": "8,990",
          "price_at_post": "1.35",
          "thread_title": "Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-24T01:40:09.131030+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260911-SharePic-79603208",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.120004",
        "source": "LSE_CHAT",
        "data": {
          "author": "SharePicks",
          "content": "I've added this to portfolio. Lets see where it goes.",
          "sentiment": 0.0,
          "engagement": "1,198",
          "price_at_post": "1.30",
          "thread_title": "1.5p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=EC7A8D0C-531B-4D1D-A5F0-14D0049CD3D9"
        },
        "ingested_at": "2026-01-24T01:40:09.131049+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260903-davey50-85173924",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.120420",
        "source": "LSE_CHAT",
        "data": {
          "author": "davey50",
          "content": "Just need to clear the slack below 1.4p and then the herd will arrive, if trls can do 300% then roq is always good for a spike a few times a year",
          "sentiment": 0.0,
          "engagement": "7,037",
          "price_at_post": "1.30",
          "thread_title": "RE: ROQ",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=34D50F4B-4B38-438B-BCC4-912454A889E9"
        },
        "ingested_at": "2026-01-24T01:40:09.131068+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260813-SharePic-89822287",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.120830",
        "source": "LSE_CHAT",
        "data": {
          "author": "SharePicks",
          "content": "Good start so far today.",
          "sentiment": 0.0,
          "engagement": "1,198",
          "price_at_post": "1.15",
          "thread_title": "ROQ",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=34D50F4B-4B38-438B-BCC4-912454A889E9"
        },
        "ingested_at": "2026-01-24T01:40:09.131086+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20260756-Downagai--6530709",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.121244",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Interesting pre market spread today. I wish",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.60",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-24T01:40:09.131117+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260840-billy101--8749207",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.121680",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "We will get updates on deals when and if  they are complete. They can't keep doing a running commentary on progress of deals. We have been told the aims in the R/Note. We have split Mk(nearly) upon condition of Coil happening. We are in different phases in trials. Anything else is conjecture. Whilst this is happening its stalemate on all pathways.",
          "sentiment": 0.0,
          "engagement": "31,698",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-24T01:40:09.131137+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260834-Downagai-24779784",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.122092",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "About progess on the deals? What page please I missed that thanks",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-24T01:40:09.131156+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260810-billy101--5811078",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.122513",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "We had news last wek in R/note.",
          "sentiment": 0.0,
          "engagement": "31,698",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-24T01:40:09.131174+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260730-Downagai--6915939",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.122926",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "They need to provide an update, this radio silence is very poor",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-24T01:40:09.131192+00:00"
      },
      {
        "event_id": "SOCIAL-17Jan20260249-Escapeto--3546989",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.123352",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "I'm hopeful, but not convinced this team can build value. I'm not sure what it is but just look at the history for starters. Continual missed deadlines. At the very least don't make a rod for your back with deadlines you never keep.",
          "sentiment": 0.0,
          "engagement": "1,297",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-24T01:40:09.131210+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20262335-Downagai--4298558",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.123758",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "It's because they keep promising the earth and delivering nothing with no updates and just delays",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-24T01:40:09.131229+00:00"
      },
      {
        "event_id": "SOCIAL-Today0849-bbr391--4603609",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.705516",
        "source": "LSE_CHAT",
        "data": {
          "author": "bbr391",
          "content": "Will this old dog ever have It`s day You Decide Outstanding  ( perhaps )",
          "sentiment": 0.0,
          "engagement": "8,993",
          "price_at_post": "1.30",
          "thread_title": "Old Dogs & Englishmen",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=CFBF3BDA-6A27-4675-B082-EFC47765863B"
        },
        "ingested_at": "2026-01-29T09:59:32.031057+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261815-Downagai--2822764",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.706052",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Says 8 trades but only 2 showing??",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-01-29T09:59:32.031118+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261357-billy101-50848644",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.706616",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Will either find out Friday or Monday",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-01-29T09:59:32.031162+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261350-Downagai--4887713",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.707168",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "I don't think the research note it right, the dates are nonsense tbh it's really poor.",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-01-29T09:59:32.031202+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261338-Merciama-93043876",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.707689",
        "source": "LSE_CHAT",
        "data": {
          "author": "Merciaman",
          "content": "Agreed downagain - I saw the section from the research note that Billy points out, and expected an official confirmation from the company regarding date for the deal. In the absence of that there is clearly some uncertainty - does the 31/1 date still apply, or is it indeed a case of both deals now having a longstop date of 16/3 ?",
          "sentiment": 0.0,
          "engagement": "286",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-01-29T09:59:32.031241+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261234-Downagai--4022456",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.708207",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Think they just need to update clearly and transparently",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-01-29T09:59:32.031273+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261206-billy101--8931332",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.708763",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Separately, the Company updated the status of the sale of its subsidiary Lyramid to Pleiades, a transaction worth up to $10.8m. Because Pleiades has not yet completed its fundraising with institutional and sovereign wealth fund investors in the GCC (Gulf Cooperation Council), the longstop date has been extended to 16 March 2026. The SPA has also been amended so that Midkine Investments, rather than Roquefort Therapeutics, is now the selling entity, and to acknowledge the scheduled termination of Lyramid\u2019s third-party licence to the Midkine antibody programme in November 2025.",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-01-29T09:59:32.031305+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261142-billy101--4914999",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.709296",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Didn\u2019t he take on a NED role. Maybe wrong due to information overload.",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-01-29T09:59:32.031339+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261139-hamilton-19586281",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.709808",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "The RTO and the carve out are not related at all apart from being ROQ assets. The thing worrying me is why did AR sell all his shares before the Carve out entitlement date when he was the one that introduced ROQ to Pleiades, apparently ? Another extension coming no doubt. Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,547",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-01-29T09:59:32.031378+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261056-Downagai-41934114",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.710353",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Oops Group Restructuring The Company intends to carve out the value of the Lyramid SPA and the MK Cell Out-License for the benefit of existing shareholders and convertible loan holders. In order to facilitate this, the Company has recently undertaken the following restructuring of the Group (the \"Group Restructuring\"): a) The entire issued shares of Lyramid have been acquired by Midkine Investments (a 100% owned subsidiary of Roquefort Therapeutics) such that Lyramid is now 100% owned by Midkine Investments; and b) The rights to the MK Cell program held by Oncogeni Ltd have been novated to Midkine Investments such that Midkine Investments now holds the underlying exclusive worldwide rights to the MK Cell program. It is the intention of the Company to issue new unlisted redeemable non-voting shares (\"Unlisted RNV Shares\") to the holders of Roquefort Therapeutics ordinary shares and convertible loan notes listed on the Company's registers as at 30 November 2025. The Unlisted RNV Shares will entitle holders to all commercial benefits from Midkine Investments with the ultimate aim of undertaking an in-specie distribution of the Midkine Investments shares once the balance sheet of the Company permits such an action under the Companies Act.",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-01-29T09:59:32.031417+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261054-Downagai--5148784",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.711148",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "London South East Check out our new Alternative Investment section.Click here Share PricesRoquefort Thera Share PriceRoquefort Thera Share Regulatory NewsMK Cell Out-License & Lyramid SPA Update Pin to quick picksRoquefort Thera Regulatory News (ROQ) ROQ Share Price ROQ Share Price ROQ Share News ROQ Share News ROQ Share Chat ROQ Share Chat 10 ROQ Share Trades ROQ Share Trades ROQ Live RNS ROQ Live RNS Sponsored Content Roquefort Thera Information Add ROQ to Timeline Add ROQ to Timeline Add ROQ to Watchlist Add ROQ to Watchlist Add ROQ to Alert Add ROQ to Alert Buy ROQ Shares Buy ROQ Shares Share Price Information for Roquefort Thera (ROQ) Share Price is delayed by 15 minutes Get Live Data 1.30 0.00 (0.00%) Bid: 1.20 Ask: 1.40 Spread: 0.20 (16.667%)Market Cap: \u00a32.13m ROQ Live PriceLast checked at 10:53:52London Stock Exchange Sponsored Content MK Cell Out-License & Lyramid SPA Update 3 Nov 2025 07:00 RNS Number : 8172F Roquefort Therapeutics PLC 03 November 2025 3 November 2025 Roquefort Therapeutics plc (\"Roquefort Therapeutics\" or the \"Company\") MK Cell Out-License & Lyramid SPA Update Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces it has entered into an agreement to out-license its MK Cell patents to Pleiades Pharma Ltd (\"Pleiades\") in return for up to US$25 million in milestone cash payments together and a royalty payment obligation (the \"MK Cell Out-License\"). Background As announced on 8 September 2025, the Company is proposing to acquire from A2A Pharmaceuticals, Inc. and Coiled Therapeutics, Inc. the exclusive licence rights to AO-252, a novel first-in-class, first-in-human new drug alternative targeting the TACC3 protein for the treatment of certain cancers (the \"Proposed Transaction\"), retain the STAT-6 program and has ceased discussions around the sale of its wholly owned subsidiary Oncogeni Ltd. Further details on the progress of the Proposed Transaction will be announced in due course. Following the announcement of the Proposed Transaction, the Company initiated discussions with Pleiades regarding the grant of an exclusive worldwide license for its MK Cell program, which has resulted in the signing of the MK Cell Out-License. MK Cell Out-License To accommodate the Group Restructuring (refer below) that was signalled in August 2025, the parties to the MK Cell Out-License are Roquefort Therapeutics' wholly owned subsidiary Midkine Investments Ltd (\"Midkine Investments\") and Pleiades. The consideration payable by Pleiades for the MK Cell Out-License is a combination of milestone cash payments and a royalty payment obligation of 1.5% perpetuity royalty on all global net sales of products derived from the licensed technology. The total milestone cash payments of up to US$25 million is payable by Pleiades as follows: a) US$500,000 upon Pleiades securing a minimum fundraising",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-01-29T09:59:32.031455+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261043-billy101--1974614",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.711670",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Sorry not RTO shares should have put  Unlisted RNV Shares",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-01-29T09:59:32.031493+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261026-billy101-62894725",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.712198",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Lets hope so. However MK will only happen up on condition of Coil happening otherwise there is no point. ROQ doesn't benefit only the RTO holders. Personally I want the RTO regardless of Coil. Compnaies House registers have all been updated we are just waiting for a completion of something (deal) otherwise we would have had our allocation of RTO shares of 10:1 by now.",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-01-29T09:59:32.031532+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261003-Downagai--2258293",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.712701",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "No that's not right, the deals are not linked, funding due this week",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-01-29T09:59:32.031570+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260947-billy101-61389057",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.713218",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Otherwsie no split required. ROQ will remain one entity with just Pleiades deal.",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-01-29T09:59:32.031609+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260943-billy101-59198241",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.713754",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "The research note has implied the deal(s) have been extended to 16th March. Surely MK will only happen if Coil completes.",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-01-29T09:59:32.031648+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260915-Escapeto-43443953",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.714286",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Delay... They never fail on that one.",
          "sentiment": 0.0,
          "engagement": "1,307",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-01-29T09:59:32.031726+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260810-Downagai--7241565",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.714786",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Tbh given this is carved off it shouldn't technically affect the Roq price anyway hut would be nice to conclude the free shares and understand what is actually going on",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-01-29T09:59:32.031763+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260753-Downagai--7162901",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.715339",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "No way I see this sorted this week. If funding was coming after a year they would not be this close to the wire injo",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.45",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-01-29T09:59:32.031825+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260751-mnsa--3988562",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.715754",
        "source": "LSE_CHAT",
        "data": {
          "author": "mnsa",
          "content": "Let\u2019s hope for once the deliver on the deadline given! If they do this should recover very well! Hoping for some +ve!",
          "sentiment": 0.0,
          "engagement": "311",
          "price_at_post": "1.60",
          "thread_title": "Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-01-29T09:59:32.031861+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260721-hamilton-70381038",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.716197",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "Anyone heard from the company or seen anything ? Literally can\u2019t be bothered with another extension. Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,547",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-29T09:59:32.031880+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261158-Downagai--7872914",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.716610",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "4 more days \ud83d\ude2c",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-29T09:59:32.031898+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20260858-pumpky--4414633",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.717023",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Billy Yes invested in January due to their RNS",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-29T09:59:32.031916+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20262322-Escapeto-70194621",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:27.301413",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Huge bull market for biotech , roq at all time low.",
          "sentiment": 0.0,
          "engagement": "1,307",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-29T09:59:32.031938+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261742-pumpky--3965708",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:27.301822",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Read them and what? SP Angel are the Brokers  for Roquefort \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-29T09:59:32.031975+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261447-billy101--5820944",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.001123",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Read pages 28 and 29",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-29T09:59:32.032014+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261350-Escapeto-81474231",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.001936",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "They'll miss it.",
          "sentiment": 0.0,
          "engagement": "1,307",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-29T09:59:32.032034+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261326-pumpky--8337829",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.002732",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Pileades deal 16  March ?",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-29T09:59:32.032063+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261315-billy101--3950768",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.003543",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Could go in until 16th March",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-29T09:59:32.032114+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261257-pumpky--6356641",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.004326",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "3rd November RNS Caroline Fortier  We anticipate the round of funding to be completed before the Long stop date of 31Januaey 2026",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-29T09:59:32.032138+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261256-Escapeto-67782550",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.005138",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Disappointed \ud83d\ude1e. DOWN.",
          "sentiment": 0.0,
          "engagement": "1,307",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-29T09:59:32.032157+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261253-pumpky-92100637",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.005910",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "IF being the operative word \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-29T09:59:32.032176+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261147-Downagai--3433230",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.006712",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Well with all the fanfare around this never thought I'd be able to buy under 1.2p. If the deal happens near 50% upside straight away. What not to like \ud83d\ude03\ud83d\ude80",
          "sentiment": 0.5,
          "engagement": "864",
          "price_at_post": "1.20",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-29T09:59:32.032206+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261029-Aklee--8653730",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.007517",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aklee",
          "content": "I see Davey is here peddling his usual nonsense. Be careful on any share he is in. Always sells into the smallest rise whilst claiming it's someone else",
          "sentiment": 0.0,
          "engagement": "3,597",
          "price_at_post": "1.25",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-29T09:59:32.032241+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261212-Downagai--3142321",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.008304",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Wow how to lose \u00a3730 in 3 hours. Unlucky trader Sam \ud83e\udd26\u200d\u2642\ufe0f",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "Loss",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=A17EF4D3-D0D3-4793-A674-53112286A2B2"
        },
        "ingested_at": "2026-01-29T09:59:32.032261+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260826-billy101-48236694",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.009089",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Only issue I have with todays RNS(RESEARCH NOTE) . It should have been released in November.",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-29T09:59:32.032281+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260806-billy101--5725833",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.009911",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Keeping this short and brief for us investors page 7 matters. And if they tick all the boxes with TACC3 Inhibitor thats mentioned on page 14 then were off to the moon. The rest of the read research note is for my daughters and son in law to translate to me!",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.20",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-29T09:59:32.032301+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260805-davey50--5394922",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.010700",
        "source": "LSE_CHAT",
        "data": {
          "author": "davey50",
          "content": "Just play the game, buy them when totally unloved and sell them when the shares are spiking and the herd arrives rinse and repeat. I took 500k more at the bell 1.23p ish...what a price...they were chasing this up to 2.5p not long ago",
          "sentiment": 0.0,
          "engagement": "7,050",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-29T09:59:32.032338+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260804-leew--5146804",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.011498",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Well digesting the financial pages was my first port of call and to be honest the purchase price we are paying is very reasonable and if the shares are issued at 1.7 as adv used then on the RTO I see some potential for immediate upside with no real news other than we have done the RTO and its purchase value. Add that to then normal news on progression in phase 1 and beyond we could see some very good gains. Will need to digest the technical aspect later but form investment strategy I am happy",
          "sentiment": 0.0,
          "engagement": "2,632",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-29T09:59:32.032366+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260756-bbr391--5104589",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.012391",
        "source": "LSE_CHAT",
        "data": {
          "author": "bbr391",
          "content": "Progress to date Roquefort has demonstrated significant anti-cancer activity with its STAT-6 siRNA therapeutics, as validated in in vivo models of breast and colon cancer. These results further reinforce the potential of STAT-6 targeting approaches in multiple tumour types and provide a strong foundation for advancing this programme towards clinical evaluation. STAT-6 targeting siRNA constructs have shown significant in vivo anti-cancer activity in validated models of colon cancer. STAT-6 siRNAs demonstrated a significant reduction in the proliferation of colorectal cancer with a ca.50% reduction in cell growth at seven days. This anti-cancer effect was replicated in a validated in vivo model of colorectal cancer with a significant reduction in cancer weight and volume over 28 days As usual . One feels the Americans are getting good research at a very very very low cost . Outstanding",
          "sentiment": 0.5,
          "engagement": "8,993",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-29T09:59:32.032385+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260751-billy101--1325644",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.013194",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "There is alot in there, so they have starteed the PR now. The Key milestone dates for 2025-2027 and Financial valuation on page 4 will keep investors happy. Its a long read",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-29T09:59:32.032403+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260739-Downagai--7505624",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.013953",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "That'd an easy read. Nothing new really though that I can see",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.20",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-29T09:59:32.032426+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261116-cassdav5-28703723",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.014729",
        "source": "LSE_CHAT",
        "data": {
          "author": "cassdav57",
          "content": "Yes pumpky your correct.  My bad, brain fog on different aspects of deal and moving targets. The deal requires ROQ's enlarged share capital to be admitted to trading on AIM by this new March 16, 2026 deadline to complete the transaction. So they have about 2 more months to finalize everything and get the AIM listing done.",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-01-29T09:59:32.032464+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261027-Merciama-81477439",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.015502",
        "source": "LSE_CHAT",
        "data": {
          "author": "Merciaman",
          "content": "It is Pumpky, 31/1 deadline for Pleiades to buy Lyramid from Midkine Investments. The reverse takeover of Roquefort to form Coiled Therapeutics has the 16th March deadline.",
          "sentiment": 0.0,
          "engagement": "286",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-01-29T09:59:32.032487+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260941-pumpky--4039662",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.016237",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Isnt the Pileades deal January?",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-01-29T09:59:32.032505+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260924-cassdav5-30076699",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.016655",
        "source": "LSE_CHAT",
        "data": {
          "author": "cassdav57",
          "content": "Sorry guys, Realise, The exclusivity period extended to March 16th but would still expect news by end of Jan.",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-01-29T09:59:32.032526+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260918-cassdav5-37679968",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.017066",
        "source": "LSE_CHAT",
        "data": {
          "author": "cassdav57",
          "content": "The exclusivity period should be ending soon (January 2026), so we might hear updates about whether the deal proceeds in the coming weeks. The  main hope for good news  for me was the director buy in November of 5 million shares (\u00a385k) and the calibre of the trails technology plus funding through A2A Pharmaceuticals.  So yes, definitely a waiting game, currently I am down about 50% and will be holding and making some small additions at these low or lower prices until things become clearer as upside could be considerable.",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "1.20",
          "thread_title": "News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-01-29T09:59:32.032562+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261743-Downagai--2049626",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.017500",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "True enough",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.20",
          "thread_title": "RE: Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-01-29T09:59:32.032593+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261714-pumpky-85600478",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.017906",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "What is there to say? Just waiting for news",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.20",
          "thread_title": "RE: Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-01-29T09:59:32.032612+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261649-Downagai-40540906",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.018342",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Quiet here \ud83d\ude34",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.20",
          "thread_title": "RE: Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-01-29T09:59:32.032631+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261617-Downagai--8215709",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.113544",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Big sell 3 big buys?",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-29T09:59:32.032661+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261505-billy101-88929205",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.113993",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "What\u2019s another few months. Have you been in since Jan 25?",
          "sentiment": 0.0,
          "engagement": "31,698",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-29T09:59:32.032697+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261504-pumpky--8715894",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.114430",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Deal  has been going on since January 2025",
          "sentiment": 0.0,
          "engagement": "17,626",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-29T09:59:32.032717+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261425-leew-49646083",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.114946",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Could be a delay or could happen on time, funding is never a simple process having been involved myself. The access to the data room and the DD questions from all parties is always significant. Just wait for the confirmation, because all that is needed is patience with ROQ in my view.",
          "sentiment": 0.0,
          "engagement": "2,618",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-29T09:59:32.032736+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260859-davey50-17456280",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.115405",
        "source": "LSE_CHAT",
        "data": {
          "author": "davey50",
          "content": "1.23-1.35p online so mid price to buy, not a bad price for a gamble given it's history of spikes",
          "sentiment": 0.0,
          "engagement": "7,037",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-29T09:59:32.032761+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260806-pumpky-44105741",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.115821",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Anticipate not expect \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,626",
          "price_at_post": "1.45",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-29T09:59:32.032800+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260726-Downagai-50534104",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.116249",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Apparently a couple of days is aay ahead \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-29T09:59:32.032824+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260725-pumpky--3776959",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.116661",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Caroline Fortier We expect to finalise before the 31 January date\" Expect\" Get out card ( maybe delayed due to Trump wanting Greenland \ud83d\ude02)",
          "sentiment": 0.0,
          "engagement": "17,626",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-29T09:59:32.032843+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260725-Downagai-19195106",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.117079",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "No Dicko after all \"Caroline Fortier, Pleiades CEO commented: \"Following the previously announced acquisition of Lyramid, we are delighted to build on our relationship with Roquefort Therapeutics and take an exclusive license of the MK Cell therapy asset which we plan to take into clinical studies targeting high value oncology indications of unmet need. The addition of these assets to our immunotherapy, late-stage pan-specific vaccine and cell therapy portfolio is an important part of our strategy to position ourselves as a material biotechnology company to institutional investors with whom we are currently working to close on a significant equity funding round. In alignment with the extension of the Lyramid SPA we anticipate our funding round to complete ahead of the new 31 January 2026 long stop date.\"",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-29T09:59:32.032862+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260720-Dicko80-42863829",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.117508",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dicko80",
          "content": "What\u2019s the betting they\u2019ll be another extension to us getting our shares ? 1 week deadline",
          "sentiment": 0.0,
          "engagement": "2,427",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-29T09:59:32.032894+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20262142-leew-52425638",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.117916",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Well there is a lot of news due bbr, would be great to get the RTO confirmed and initially just get the SP back to 1.7p and then see where the RTO then takes it as there is some potential for increasing in market cap after so fingers crossed. Would also be good on the back of that to then here about the spin off and the deals associated to that to see when some cash might come in from the free shares.",
          "sentiment": 0.0,
          "engagement": "2,618",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-29T09:59:32.032926+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20262130-leew--8360507",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.118340",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Honestly if you want to invest best check yourself. I don\u2019t think reading a few RNA\u2019s and googling a few things is that bad.",
          "sentiment": 0.0,
          "engagement": "2,618",
          "price_at_post": "1.35",
          "thread_title": "RE: Can",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=28165808-701F-48DA-95C7-867899DCB7C6"
        },
        "ingested_at": "2026-01-29T09:59:32.032945+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261653-Kikudi--8398996",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.118754",
        "source": "LSE_CHAT",
        "data": {
          "author": "Kikudi",
          "content": "Some please give me highlights of ROQ that will save me go through  RNS I want to invest. Thanks in advance",
          "sentiment": 0.0,
          "engagement": "15",
          "price_at_post": "1.35",
          "thread_title": "Can",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=28165808-701F-48DA-95C7-867899DCB7C6"
        },
        "ingested_at": "2026-01-29T09:59:32.032964+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261338-Downagai-25596855",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.119177",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "IYHO I take it \ud83d\ude03",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-29T09:59:32.032991+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261337-bbr391-47569949",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.119594",
        "source": "LSE_CHAT",
        "data": {
          "author": "bbr391",
          "content": "Come to Papa . We will all soon be very very pleased (possibly). Outstanding",
          "sentiment": 0.5,
          "engagement": "8,990",
          "price_at_post": "1.35",
          "thread_title": "Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-29T09:59:32.033030+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260911-SharePic--3086321",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.120004",
        "source": "LSE_CHAT",
        "data": {
          "author": "SharePicks",
          "content": "I've added this to portfolio. Lets see where it goes.",
          "sentiment": 0.0,
          "engagement": "1,198",
          "price_at_post": "1.30",
          "thread_title": "1.5p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=EC7A8D0C-531B-4D1D-A5F0-14D0049CD3D9"
        },
        "ingested_at": "2026-01-29T09:59:32.033051+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260903-davey50--7363949",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.120420",
        "source": "LSE_CHAT",
        "data": {
          "author": "davey50",
          "content": "Just need to clear the slack below 1.4p and then the herd will arrive, if trls can do 300% then roq is always good for a spike a few times a year",
          "sentiment": 0.0,
          "engagement": "7,037",
          "price_at_post": "1.30",
          "thread_title": "RE: ROQ",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=34D50F4B-4B38-438B-BCC4-912454A889E9"
        },
        "ingested_at": "2026-01-29T09:59:32.033070+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260813-SharePic-29964894",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.120830",
        "source": "LSE_CHAT",
        "data": {
          "author": "SharePicks",
          "content": "Good start so far today.",
          "sentiment": 0.0,
          "engagement": "1,198",
          "price_at_post": "1.15",
          "thread_title": "ROQ",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=34D50F4B-4B38-438B-BCC4-912454A889E9"
        },
        "ingested_at": "2026-01-29T09:59:32.033089+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20260756-Downagai--8585817",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.121244",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Interesting pre market spread today. I wish",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.60",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-29T09:59:32.033138+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260840-billy101--4648328",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.121680",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "We will get updates on deals when and if  they are complete. They can't keep doing a running commentary on progress of deals. We have been told the aims in the R/Note. We have split Mk(nearly) upon condition of Coil happening. We are in different phases in trials. Anything else is conjecture. Whilst this is happening its stalemate on all pathways.",
          "sentiment": 0.0,
          "engagement": "31,698",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-29T09:59:32.033167+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260834-Downagai--6171648",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.122092",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "About progess on the deals? What page please I missed that thanks",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-29T09:59:32.033186+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260810-billy101-86592356",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.122513",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "We had news last wek in R/note.",
          "sentiment": 0.0,
          "engagement": "31,698",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-29T09:59:32.033205+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260730-Downagai--8381186",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.122926",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "They need to provide an update, this radio silence is very poor",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-29T09:59:32.033230+00:00"
      },
      {
        "event_id": "SOCIAL-17Jan20260249-Escapeto-54367164",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.123352",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "I'm hopeful, but not convinced this team can build value. I'm not sure what it is but just look at the history for starters. Continual missed deadlines. At the very least don't make a rod for your back with deadlines you never keep.",
          "sentiment": 0.0,
          "engagement": "1,297",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-29T09:59:32.033269+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20262335-Downagai--5316628",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.123758",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "It's because they keep promising the earth and delivering nothing with no updates and just delays",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-29T09:59:32.033290+00:00"
      },
      {
        "event_id": "SOCIAL-Today0823-Downagai--8212153",
        "event_type": "social_post",
        "date": "2026-01-30T23:00:14.646540",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "I started worrying when emails started being ignored tbh this os farcical now",
          "sentiment": 0.0,
          "engagement": "920",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-01-30T23:00:24.732390+00:00"
      },
      {
        "event_id": "SOCIAL-Today0742-pumpky-36216885",
        "event_type": "social_post",
        "date": "2026-01-30T23:00:14.647111",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Monday then \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,680",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-01-30T23:00:24.732412+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260849-bbr391--3276572",
        "event_type": "social_post",
        "date": "2026-01-30T23:00:14.647545",
        "source": "LSE_CHAT",
        "data": {
          "author": "bbr391",
          "content": "Will this old dog ever have It`s day You Decide Outstanding  ( perhaps )",
          "sentiment": 0.0,
          "engagement": "8,994",
          "price_at_post": "1.30",
          "thread_title": "Old Dogs & Englishmen",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=CFBF3BDA-6A27-4675-B082-EFC47765863B"
        },
        "ingested_at": "2026-01-30T23:00:24.732432+00:00"
      },
      {
        "event_id": "SOCIAL-Today0849-bbr391--3276572",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.705516",
        "source": "LSE_CHAT",
        "data": {
          "author": "bbr391",
          "content": "Will this old dog ever have It`s day You Decide Outstanding  ( perhaps )",
          "sentiment": 0.0,
          "engagement": "8,993",
          "price_at_post": "1.30",
          "thread_title": "Old Dogs & Englishmen",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=CFBF3BDA-6A27-4675-B082-EFC47765863B"
        },
        "ingested_at": "2026-01-30T23:00:24.732450+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261815-Downagai--4685999",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.706052",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Says 8 trades but only 2 showing??",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-01-30T23:00:24.732470+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261357-billy101--7855695",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.706616",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Will either find out Friday or Monday",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-01-30T23:00:24.732488+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261350-Downagai--4207327",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.707168",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "I don't think the research note it right, the dates are nonsense tbh it's really poor.",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-01-30T23:00:24.732510+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261338-Merciama-20493419",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.707689",
        "source": "LSE_CHAT",
        "data": {
          "author": "Merciaman",
          "content": "Agreed downagain - I saw the section from the research note that Billy points out, and expected an official confirmation from the company regarding date for the deal. In the absence of that there is clearly some uncertainty - does the 31/1 date still apply, or is it indeed a case of both deals now having a longstop date of 16/3 ?",
          "sentiment": 0.0,
          "engagement": "286",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-01-30T23:00:24.732528+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261234-Downagai-66859097",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.708207",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Think they just need to update clearly and transparently",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-01-30T23:00:24.732546+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261206-billy101-13442172",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.708763",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Separately, the Company updated the status of the sale of its subsidiary Lyramid to Pleiades, a transaction worth up to $10.8m. Because Pleiades has not yet completed its fundraising with institutional and sovereign wealth fund investors in the GCC (Gulf Cooperation Council), the longstop date has been extended to 16 March 2026. The SPA has also been amended so that Midkine Investments, rather than Roquefort Therapeutics, is now the selling entity, and to acknowledge the scheduled termination of Lyramid\u2019s third-party licence to the Midkine antibody programme in November 2025.",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-01-30T23:00:24.732564+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261142-billy101--6289065",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.709296",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Didn\u2019t he take on a NED role. Maybe wrong due to information overload.",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-01-30T23:00:24.732582+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261139-hamilton-74414462",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.709808",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "The RTO and the carve out are not related at all apart from being ROQ assets. The thing worrying me is why did AR sell all his shares before the Carve out entitlement date when he was the one that introduced ROQ to Pleiades, apparently ? Another extension coming no doubt. Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,547",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-01-30T23:00:24.732600+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261056-Downagai--7659608",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.710353",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Oops Group Restructuring The Company intends to carve out the value of the Lyramid SPA and the MK Cell Out-License for the benefit of existing shareholders and convertible loan holders. In order to facilitate this, the Company has recently undertaken the following restructuring of the Group (the \"Group Restructuring\"): a) The entire issued shares of Lyramid have been acquired by Midkine Investments (a 100% owned subsidiary of Roquefort Therapeutics) such that Lyramid is now 100% owned by Midkine Investments; and b) The rights to the MK Cell program held by Oncogeni Ltd have been novated to Midkine Investments such that Midkine Investments now holds the underlying exclusive worldwide rights to the MK Cell program. It is the intention of the Company to issue new unlisted redeemable non-voting shares (\"Unlisted RNV Shares\") to the holders of Roquefort Therapeutics ordinary shares and convertible loan notes listed on the Company's registers as at 30 November 2025. The Unlisted RNV Shares will entitle holders to all commercial benefits from Midkine Investments with the ultimate aim of undertaking an in-specie distribution of the Midkine Investments shares once the balance sheet of the Company permits such an action under the Companies Act.",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-01-30T23:00:24.732618+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261054-Downagai-48852727",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.711148",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "London South East Check out our new Alternative Investment section.Click here Share PricesRoquefort Thera Share PriceRoquefort Thera Share Regulatory NewsMK Cell Out-License & Lyramid SPA Update Pin to quick picksRoquefort Thera Regulatory News (ROQ) ROQ Share Price ROQ Share Price ROQ Share News ROQ Share News ROQ Share Chat ROQ Share Chat 10 ROQ Share Trades ROQ Share Trades ROQ Live RNS ROQ Live RNS Sponsored Content Roquefort Thera Information Add ROQ to Timeline Add ROQ to Timeline Add ROQ to Watchlist Add ROQ to Watchlist Add ROQ to Alert Add ROQ to Alert Buy ROQ Shares Buy ROQ Shares Share Price Information for Roquefort Thera (ROQ) Share Price is delayed by 15 minutes Get Live Data 1.30 0.00 (0.00%) Bid: 1.20 Ask: 1.40 Spread: 0.20 (16.667%)Market Cap: \u00a32.13m ROQ Live PriceLast checked at 10:53:52London Stock Exchange Sponsored Content MK Cell Out-License & Lyramid SPA Update 3 Nov 2025 07:00 RNS Number : 8172F Roquefort Therapeutics PLC 03 November 2025 3 November 2025 Roquefort Therapeutics plc (\"Roquefort Therapeutics\" or the \"Company\") MK Cell Out-License & Lyramid SPA Update Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces it has entered into an agreement to out-license its MK Cell patents to Pleiades Pharma Ltd (\"Pleiades\") in return for up to US$25 million in milestone cash payments together and a royalty payment obligation (the \"MK Cell Out-License\"). Background As announced on 8 September 2025, the Company is proposing to acquire from A2A Pharmaceuticals, Inc. and Coiled Therapeutics, Inc. the exclusive licence rights to AO-252, a novel first-in-class, first-in-human new drug alternative targeting the TACC3 protein for the treatment of certain cancers (the \"Proposed Transaction\"), retain the STAT-6 program and has ceased discussions around the sale of its wholly owned subsidiary Oncogeni Ltd. Further details on the progress of the Proposed Transaction will be announced in due course. Following the announcement of the Proposed Transaction, the Company initiated discussions with Pleiades regarding the grant of an exclusive worldwide license for its MK Cell program, which has resulted in the signing of the MK Cell Out-License. MK Cell Out-License To accommodate the Group Restructuring (refer below) that was signalled in August 2025, the parties to the MK Cell Out-License are Roquefort Therapeutics' wholly owned subsidiary Midkine Investments Ltd (\"Midkine Investments\") and Pleiades. The consideration payable by Pleiades for the MK Cell Out-License is a combination of milestone cash payments and a royalty payment obligation of 1.5% perpetuity royalty on all global net sales of products derived from the licensed technology. The total milestone cash payments of up to US$25 million is payable by Pleiades as follows: a) US$500,000 upon Pleiades securing a minimum fundraising",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-01-30T23:00:24.732636+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261043-billy101--3611147",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.711670",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Sorry not RTO shares should have put  Unlisted RNV Shares",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-01-30T23:00:24.732654+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261026-billy101-52084100",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.712198",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Lets hope so. However MK will only happen up on condition of Coil happening otherwise there is no point. ROQ doesn't benefit only the RTO holders. Personally I want the RTO regardless of Coil. Compnaies House registers have all been updated we are just waiting for a completion of something (deal) otherwise we would have had our allocation of RTO shares of 10:1 by now.",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-01-30T23:00:24.732672+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261003-Downagai-62633993",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.712701",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "No that's not right, the deals are not linked, funding due this week",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-01-30T23:00:24.732690+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260947-billy101-78849124",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.713218",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Otherwsie no split required. ROQ will remain one entity with just Pleiades deal.",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-01-30T23:00:24.732708+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260943-billy101--7040975",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.713754",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "The research note has implied the deal(s) have been extended to 16th March. Surely MK will only happen if Coil completes.",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-01-30T23:00:24.732726+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260915-Escapeto--2626772",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.714286",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Delay... They never fail on that one.",
          "sentiment": 0.0,
          "engagement": "1,307",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-01-30T23:00:24.732744+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260810-Downagai-55109728",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.714786",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Tbh given this is carved off it shouldn't technically affect the Roq price anyway hut would be nice to conclude the free shares and understand what is actually going on",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-01-30T23:00:24.732762+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260753-Downagai--4775138",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.715339",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "No way I see this sorted this week. If funding was coming after a year they would not be this close to the wire injo",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.45",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-01-30T23:00:24.732780+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260751-mnsa-39276309",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.715754",
        "source": "LSE_CHAT",
        "data": {
          "author": "mnsa",
          "content": "Let\u2019s hope for once the deliver on the deadline given! If they do this should recover very well! Hoping for some +ve!",
          "sentiment": 0.0,
          "engagement": "311",
          "price_at_post": "1.60",
          "thread_title": "Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-01-30T23:00:24.732798+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260721-hamilton-41620114",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.716197",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "Anyone heard from the company or seen anything ? Literally can\u2019t be bothered with another extension. Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,547",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-30T23:00:24.732815+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261158-Downagai--7755709",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.716610",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "4 more days \ud83d\ude2c",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-30T23:00:24.732833+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20260858-pumpky-29057556",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.717023",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Billy Yes invested in January due to their RNS",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-30T23:00:24.732851+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20262322-Escapeto-76655953",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:27.301413",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Huge bull market for biotech , roq at all time low.",
          "sentiment": 0.0,
          "engagement": "1,307",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-30T23:00:24.732869+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261742-pumpky--2966074",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:27.301822",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Read them and what? SP Angel are the Brokers  for Roquefort \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-30T23:00:24.732886+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261447-billy101--8993093",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.001123",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Read pages 28 and 29",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-30T23:00:24.732904+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261350-Escapeto-59561067",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.001936",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "They'll miss it.",
          "sentiment": 0.0,
          "engagement": "1,307",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-30T23:00:24.732922+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261326-pumpky--4151208",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.002732",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Pileades deal 16  March ?",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-30T23:00:24.732940+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261315-billy101-77426709",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.003543",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Could go in until 16th March",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-30T23:00:24.732958+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261257-pumpky-14812699",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.004326",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "3rd November RNS Caroline Fortier  We anticipate the round of funding to be completed before the Long stop date of 31Januaey 2026",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-30T23:00:24.732977+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261256-Escapeto-71842825",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.005138",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Disappointed \ud83d\ude1e. DOWN.",
          "sentiment": 0.0,
          "engagement": "1,307",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-30T23:00:24.732995+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261253-pumpky-76212686",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.005910",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "IF being the operative word \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-30T23:00:24.733012+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261147-Downagai-26346204",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.006712",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Well with all the fanfare around this never thought I'd be able to buy under 1.2p. If the deal happens near 50% upside straight away. What not to like \ud83d\ude03\ud83d\ude80",
          "sentiment": 0.5,
          "engagement": "864",
          "price_at_post": "1.20",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-30T23:00:24.733030+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261029-Aklee-93185740",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.007517",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aklee",
          "content": "I see Davey is here peddling his usual nonsense. Be careful on any share he is in. Always sells into the smallest rise whilst claiming it's someone else",
          "sentiment": 0.0,
          "engagement": "3,597",
          "price_at_post": "1.25",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-30T23:00:24.733048+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261212-Downagai--7779639",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.008304",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Wow how to lose \u00a3730 in 3 hours. Unlucky trader Sam \ud83e\udd26\u200d\u2642\ufe0f",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "Loss",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=A17EF4D3-D0D3-4793-A674-53112286A2B2"
        },
        "ingested_at": "2026-01-30T23:00:24.733066+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260826-billy101-21960242",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.009089",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Only issue I have with todays RNS(RESEARCH NOTE) . It should have been released in November.",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-30T23:00:24.733084+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260806-billy101--2412756",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.009911",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Keeping this short and brief for us investors page 7 matters. And if they tick all the boxes with TACC3 Inhibitor thats mentioned on page 14 then were off to the moon. The rest of the read research note is for my daughters and son in law to translate to me!",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.20",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-30T23:00:24.733120+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260805-davey50-67529036",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.010700",
        "source": "LSE_CHAT",
        "data": {
          "author": "davey50",
          "content": "Just play the game, buy them when totally unloved and sell them when the shares are spiking and the herd arrives rinse and repeat. I took 500k more at the bell 1.23p ish...what a price...they were chasing this up to 2.5p not long ago",
          "sentiment": 0.0,
          "engagement": "7,050",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-30T23:00:24.733140+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260804-leew-85642757",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.011498",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Well digesting the financial pages was my first port of call and to be honest the purchase price we are paying is very reasonable and if the shares are issued at 1.7 as adv used then on the RTO I see some potential for immediate upside with no real news other than we have done the RTO and its purchase value. Add that to then normal news on progression in phase 1 and beyond we could see some very good gains. Will need to digest the technical aspect later but form investment strategy I am happy",
          "sentiment": 0.0,
          "engagement": "2,632",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-30T23:00:24.733159+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260756-bbr391-28392186",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.012391",
        "source": "LSE_CHAT",
        "data": {
          "author": "bbr391",
          "content": "Progress to date Roquefort has demonstrated significant anti-cancer activity with its STAT-6 siRNA therapeutics, as validated in in vivo models of breast and colon cancer. These results further reinforce the potential of STAT-6 targeting approaches in multiple tumour types and provide a strong foundation for advancing this programme towards clinical evaluation. STAT-6 targeting siRNA constructs have shown significant in vivo anti-cancer activity in validated models of colon cancer. STAT-6 siRNAs demonstrated a significant reduction in the proliferation of colorectal cancer with a ca.50% reduction in cell growth at seven days. This anti-cancer effect was replicated in a validated in vivo model of colorectal cancer with a significant reduction in cancer weight and volume over 28 days As usual . One feels the Americans are getting good research at a very very very low cost . Outstanding",
          "sentiment": 0.5,
          "engagement": "8,993",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-30T23:00:24.733177+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260751-billy101--2660406",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.013194",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "There is alot in there, so they have starteed the PR now. The Key milestone dates for 2025-2027 and Financial valuation on page 4 will keep investors happy. Its a long read",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-30T23:00:24.733195+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260739-Downagai-90476181",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.013953",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "That'd an easy read. Nothing new really though that I can see",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.20",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-30T23:00:24.733214+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261116-cassdav5--6078341",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.014729",
        "source": "LSE_CHAT",
        "data": {
          "author": "cassdav57",
          "content": "Yes pumpky your correct.  My bad, brain fog on different aspects of deal and moving targets. The deal requires ROQ's enlarged share capital to be admitted to trading on AIM by this new March 16, 2026 deadline to complete the transaction. So they have about 2 more months to finalize everything and get the AIM listing done.",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-01-30T23:00:24.733232+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261027-Merciama--5096652",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.015502",
        "source": "LSE_CHAT",
        "data": {
          "author": "Merciaman",
          "content": "It is Pumpky, 31/1 deadline for Pleiades to buy Lyramid from Midkine Investments. The reverse takeover of Roquefort to form Coiled Therapeutics has the 16th March deadline.",
          "sentiment": 0.0,
          "engagement": "286",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-01-30T23:00:24.733250+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260941-pumpky-28382107",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.016237",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Isnt the Pileades deal January?",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-01-30T23:00:24.733268+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260924-cassdav5-32214469",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.016655",
        "source": "LSE_CHAT",
        "data": {
          "author": "cassdav57",
          "content": "Sorry guys, Realise, The exclusivity period extended to March 16th but would still expect news by end of Jan.",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-01-30T23:00:24.733287+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260918-cassdav5-28626134",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.017066",
        "source": "LSE_CHAT",
        "data": {
          "author": "cassdav57",
          "content": "The exclusivity period should be ending soon (January 2026), so we might hear updates about whether the deal proceeds in the coming weeks. The  main hope for good news  for me was the director buy in November of 5 million shares (\u00a385k) and the calibre of the trails technology plus funding through A2A Pharmaceuticals.  So yes, definitely a waiting game, currently I am down about 50% and will be holding and making some small additions at these low or lower prices until things become clearer as upside could be considerable.",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "1.20",
          "thread_title": "News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-01-30T23:00:24.733305+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261743-Downagai-78263207",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.017500",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "True enough",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.20",
          "thread_title": "RE: Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-01-30T23:00:24.733323+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261714-pumpky-14393072",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.017906",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "What is there to say? Just waiting for news",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.20",
          "thread_title": "RE: Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-01-30T23:00:24.733341+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261649-Downagai-68011934",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.018342",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Quiet here \ud83d\ude34",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.20",
          "thread_title": "RE: Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-01-30T23:00:24.733359+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261617-Downagai-52299359",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.113544",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Big sell 3 big buys?",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-30T23:00:24.733377+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261505-billy101--5392141",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.113993",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "What\u2019s another few months. Have you been in since Jan 25?",
          "sentiment": 0.0,
          "engagement": "31,698",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-30T23:00:24.733396+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261504-pumpky--5989372",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.114430",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Deal  has been going on since January 2025",
          "sentiment": 0.0,
          "engagement": "17,626",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-30T23:00:24.733414+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261425-leew-52451053",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.114946",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Could be a delay or could happen on time, funding is never a simple process having been involved myself. The access to the data room and the DD questions from all parties is always significant. Just wait for the confirmation, because all that is needed is patience with ROQ in my view.",
          "sentiment": 0.0,
          "engagement": "2,618",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-30T23:00:24.733432+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260859-davey50-69299634",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.115405",
        "source": "LSE_CHAT",
        "data": {
          "author": "davey50",
          "content": "1.23-1.35p online so mid price to buy, not a bad price for a gamble given it's history of spikes",
          "sentiment": 0.0,
          "engagement": "7,037",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-30T23:00:24.733450+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260806-pumpky--2439938",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.115821",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Anticipate not expect \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,626",
          "price_at_post": "1.45",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-30T23:00:24.733468+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260726-Downagai-33566454",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.116249",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Apparently a couple of days is aay ahead \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-30T23:00:24.733487+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260725-pumpky-11748155",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.116661",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Caroline Fortier We expect to finalise before the 31 January date\" Expect\" Get out card ( maybe delayed due to Trump wanting Greenland \ud83d\ude02)",
          "sentiment": 0.0,
          "engagement": "17,626",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-30T23:00:24.733505+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260725-Downagai-76010981",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.117079",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "No Dicko after all \"Caroline Fortier, Pleiades CEO commented: \"Following the previously announced acquisition of Lyramid, we are delighted to build on our relationship with Roquefort Therapeutics and take an exclusive license of the MK Cell therapy asset which we plan to take into clinical studies targeting high value oncology indications of unmet need. The addition of these assets to our immunotherapy, late-stage pan-specific vaccine and cell therapy portfolio is an important part of our strategy to position ourselves as a material biotechnology company to institutional investors with whom we are currently working to close on a significant equity funding round. In alignment with the extension of the Lyramid SPA we anticipate our funding round to complete ahead of the new 31 January 2026 long stop date.\"",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-30T23:00:24.733523+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260720-Dicko80--4206882",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.117508",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dicko80",
          "content": "What\u2019s the betting they\u2019ll be another extension to us getting our shares ? 1 week deadline",
          "sentiment": 0.0,
          "engagement": "2,427",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-30T23:00:24.733542+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20262142-leew--6630026",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.117916",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Well there is a lot of news due bbr, would be great to get the RTO confirmed and initially just get the SP back to 1.7p and then see where the RTO then takes it as there is some potential for increasing in market cap after so fingers crossed. Would also be good on the back of that to then here about the spin off and the deals associated to that to see when some cash might come in from the free shares.",
          "sentiment": 0.0,
          "engagement": "2,618",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-30T23:00:24.733560+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20262130-leew-39108893",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.118340",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Honestly if you want to invest best check yourself. I don\u2019t think reading a few RNA\u2019s and googling a few things is that bad.",
          "sentiment": 0.0,
          "engagement": "2,618",
          "price_at_post": "1.35",
          "thread_title": "RE: Can",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=28165808-701F-48DA-95C7-867899DCB7C6"
        },
        "ingested_at": "2026-01-30T23:00:24.733578+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261653-Kikudi-24509645",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.118754",
        "source": "LSE_CHAT",
        "data": {
          "author": "Kikudi",
          "content": "Some please give me highlights of ROQ that will save me go through  RNS I want to invest. Thanks in advance",
          "sentiment": 0.0,
          "engagement": "15",
          "price_at_post": "1.35",
          "thread_title": "Can",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=28165808-701F-48DA-95C7-867899DCB7C6"
        },
        "ingested_at": "2026-01-30T23:00:24.733597+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261338-Downagai--6940241",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.119177",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "IYHO I take it \ud83d\ude03",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-30T23:00:24.733615+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261337-bbr391--4124307",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.119594",
        "source": "LSE_CHAT",
        "data": {
          "author": "bbr391",
          "content": "Come to Papa . We will all soon be very very pleased (possibly). Outstanding",
          "sentiment": 0.5,
          "engagement": "8,990",
          "price_at_post": "1.35",
          "thread_title": "Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-01-30T23:00:24.733633+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260911-SharePic-83394613",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.120004",
        "source": "LSE_CHAT",
        "data": {
          "author": "SharePicks",
          "content": "I've added this to portfolio. Lets see where it goes.",
          "sentiment": 0.0,
          "engagement": "1,198",
          "price_at_post": "1.30",
          "thread_title": "1.5p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=EC7A8D0C-531B-4D1D-A5F0-14D0049CD3D9"
        },
        "ingested_at": "2026-01-30T23:00:24.733651+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260903-davey50--2841902",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.120420",
        "source": "LSE_CHAT",
        "data": {
          "author": "davey50",
          "content": "Just need to clear the slack below 1.4p and then the herd will arrive, if trls can do 300% then roq is always good for a spike a few times a year",
          "sentiment": 0.0,
          "engagement": "7,037",
          "price_at_post": "1.30",
          "thread_title": "RE: ROQ",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=34D50F4B-4B38-438B-BCC4-912454A889E9"
        },
        "ingested_at": "2026-01-30T23:00:24.733669+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260813-SharePic-54904861",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.120830",
        "source": "LSE_CHAT",
        "data": {
          "author": "SharePicks",
          "content": "Good start so far today.",
          "sentiment": 0.0,
          "engagement": "1,198",
          "price_at_post": "1.15",
          "thread_title": "ROQ",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=34D50F4B-4B38-438B-BCC4-912454A889E9"
        },
        "ingested_at": "2026-01-30T23:00:24.733690+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20260756-Downagai--7493704",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.121244",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Interesting pre market spread today. I wish",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.60",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-30T23:00:24.733708+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260840-billy101-61466903",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.121680",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "We will get updates on deals when and if  they are complete. They can't keep doing a running commentary on progress of deals. We have been told the aims in the R/Note. We have split Mk(nearly) upon condition of Coil happening. We are in different phases in trials. Anything else is conjecture. Whilst this is happening its stalemate on all pathways.",
          "sentiment": 0.0,
          "engagement": "31,698",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-30T23:00:24.733726+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260834-Downagai-30220499",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.122092",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "About progess on the deals? What page please I missed that thanks",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-30T23:00:24.733744+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260810-billy101--8735694",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.122513",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "We had news last wek in R/note.",
          "sentiment": 0.0,
          "engagement": "31,698",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-30T23:00:24.733762+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260730-Downagai--8235168",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.122926",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "They need to provide an update, this radio silence is very poor",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-30T23:00:24.733781+00:00"
      },
      {
        "event_id": "SOCIAL-17Jan20260249-Escapeto--5889705",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.123352",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "I'm hopeful, but not convinced this team can build value. I'm not sure what it is but just look at the history for starters. Continual missed deadlines. At the very least don't make a rod for your back with deadlines you never keep.",
          "sentiment": 0.0,
          "engagement": "1,297",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-30T23:00:24.733799+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20262335-Downagai--6983264",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.123758",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "It's because they keep promising the earth and delivering nothing with no updates and just delays",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-01-30T23:00:24.733817+00:00"
      },
      {
        "event_id": "SOCIAL-Today1052-Escapeto--6734201",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.483596",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Education helps you know.",
          "sentiment": 0.0,
          "engagement": "1,339",
          "price_at_post": "1.20",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-06T22:55:43.302634+00:00"
      },
      {
        "event_id": "SOCIAL-Today1047-Escapeto--6209178",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.484024",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "In my role I was expected to deliver to time, yes sometimes it is very complicated, in those situations we tended to be more wooly with what we said.",
          "sentiment": 0.0,
          "engagement": "1,339",
          "price_at_post": "1.20",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-06T22:55:43.302681+00:00"
      },
      {
        "event_id": "SOCIAL-Today0946-billy101--1097475",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.484477",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Re post 0941hrs Its out of their hands. Its not an education level thingy",
          "sentiment": 0.0,
          "engagement": "31,754",
          "price_at_post": "1.20",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-06T22:55:43.302723+00:00"
      },
      {
        "event_id": "SOCIAL-Today0941-Escapeto--2675105",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.484881",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "For Oxford University level of education , we expect bod to meet deadlines they themselves set.",
          "sentiment": 0.0,
          "engagement": "1,339",
          "price_at_post": "1.20",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-06T22:55:43.302755+00:00"
      },
      {
        "event_id": "SOCIAL-Today0641-leew-79231814",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.485330",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Hamilton, they will at some stage, sometime funding takes time if you are doing more than a cheap placing for funding. If other companies are raising funding to buy some of our assets and it involves multiple parties the DD takes time and the same on the RTO side. This is a very small portion of my portfolio and if it takes 6 months extra / 1 year extra but happens I could not careless. I have a couple of Pharma\u2019s and I will stay in them for many many years not a trade. Therefore more view on hitting a timing date is not really relevant for this.",
          "sentiment": 0.0,
          "engagement": "2,659",
          "price_at_post": "1.20",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-06T22:55:43.302785+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261331-Gigontbs-77779254",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.485733",
        "source": "LSE_CHAT",
        "data": {
          "author": "Gigontbsaaa",
          "content": "FM pumping and dumping, was the 1st sign",
          "sentiment": 0.0,
          "engagement": "435",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-06T22:55:43.302821+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261328-Escapeto--7182592",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.486145",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "May have to put this one down to experience. All the warning signs present",
          "sentiment": 0.0,
          "engagement": "1,339",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-06T22:55:43.302861+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261220-pumpky-12484712",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.486552",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Caroline Fortier expected funding to be completed before January 31 also \ud83d\ude02 One thing for sure is Roq need to do something soon as must be running out of money",
          "sentiment": 0.0,
          "engagement": "17,738",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-06T22:55:43.302900+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261203-Escapeto-44458924",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.486959",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Cardiogeni's December annual stated :\" Advanced discussions for a funding agreement of $25M (~\u00a319M) for Cardiogeni (UAE) Limited expected to complete by the end of January 2026 where upon first tranche of funding is anticipated\". SURELY VERY CLOSE. CMon Roquefort get that funding.",
          "sentiment": 0.0,
          "engagement": "1,339",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-06T22:55:43.302939+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261150-Escapeto-99150649",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.487382",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Smelly cheese!",
          "sentiment": 0.0,
          "engagement": "1,339",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-06T22:55:43.302977+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261145-hamilton-67450422",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.487799",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "No doubt everyone has done their research and knows that the same people at ROQ are in CGNI also ? Have a look at their deal tha hasn\u2019t happened either !! https://www.investegate.co.uk/announcement/rns/cardiogeni-plc--cgni/details-of-advanced-subscription-company-update/8998882 Not sure what they actually do ! Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,563",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-06T22:55:43.303014+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261108-hamilton-89455075",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.488221",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "What makes you think they will hit the new deadline ? It\u2019s been going on over a year now. The communication is terrible. Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,563",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-06T22:55:43.303051+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20262326-leew--4576462",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.488635",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Hamilton, nothing is terminated, looks like the date was changed in the research note, which I have just noticed only as it was pointed out below. Stupid for me to have missed that, but had a huge amount going on. Not brilliant to have communicated it there but is what it is so we move on with 2 dates close together now :)",
          "sentiment": 0.0,
          "engagement": "2,659",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-06T22:55:43.303091+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261258-hamilton--8731537",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.489050",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "Looks like the deal has terminated then ? They did this last year with the Oncogeni sale. It had a deadline and they ended talks but we didn\u2019t find out till months later. If no rns then can only assume the worst ? Poor ! Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,563",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-06T22:55:43.303140+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260830-billy101--3627434",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.489492",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "The RN laid it all out. The bit we are interested in the financials etc  can get losted in the impress pathways we have. Lets hope it comes together.",
          "sentiment": 0.0,
          "engagement": "31,754",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-06T22:55:43.303177+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260823-Downagai-53456393",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.489897",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "If it is then to hide that in a research note is shockingly poor. Management are losing all credibility here for me I'm afraid",
          "sentiment": 0.0,
          "engagement": "939",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-06T22:55:43.303215+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260806-billy101--3057613",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.490315",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "March 16th it is then for now.",
          "sentiment": 0.0,
          "engagement": "31,754",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-06T22:55:43.303252+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260758-Downagai-44281453",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.490720",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "I seriously hope so but have my doubts",
          "sentiment": 0.0,
          "engagement": "939",
          "price_at_post": "1.60",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-06T22:55:43.303289+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260751-Dicko80--1254122",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.491148",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dicko80",
          "content": "Previously the extensions have come in advance of the date So with no ext announced Maybe they are closing their financing and close to completion Hence no RNS as of yet \ud83e\udd1e",
          "sentiment": 0.0,
          "engagement": "2,435",
          "price_at_post": "1.60",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-06T22:55:43.303327+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260737-Downagai--7610994",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.491552",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Tumbleweed \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "939",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-06T22:55:43.303365+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20260855-Dicko80--2821001",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.491952",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dicko80",
          "content": "Im sure we\u2019ll find out soon enough",
          "sentiment": 0.0,
          "engagement": "2,435",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-06T22:55:43.303401+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20260727-leew--9721015",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.492377",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Must admit I was expecting an RNA today. Unless it drops at 7.30 for various reasons :)",
          "sentiment": 0.0,
          "engagement": "2,659",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-06T22:55:43.303439+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20260720-hamilton--2180104",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.492790",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "No rns ? Not sure what\u2019s going on now. Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,563",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-06T22:55:43.303477+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260823-Downagai-54916907",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.493218",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "I started worrying when emails started being ignored tbh this os farcical now",
          "sentiment": 0.0,
          "engagement": "939",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-06T22:55:43.303517+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260742-pumpky-60523945",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.493624",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Monday then \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,738",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-06T22:55:43.303555+00:00"
      },
      {
        "event_id": "SOCIAL-Today0823-Downagai-54916907",
        "event_type": "social_post",
        "date": "2026-01-30T23:00:14.646540",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "I started worrying when emails started being ignored tbh this os farcical now",
          "sentiment": 0.0,
          "engagement": "920",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-06T22:55:43.303595+00:00"
      },
      {
        "event_id": "SOCIAL-Today0742-pumpky-60523945",
        "event_type": "social_post",
        "date": "2026-01-30T23:00:14.647111",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Monday then \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,680",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-06T22:55:43.303634+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260849-bbr391-67028680",
        "event_type": "social_post",
        "date": "2026-01-30T23:00:14.647545",
        "source": "LSE_CHAT",
        "data": {
          "author": "bbr391",
          "content": "Will this old dog ever have It`s day You Decide Outstanding  ( perhaps )",
          "sentiment": 0.0,
          "engagement": "8,994",
          "price_at_post": "1.30",
          "thread_title": "Old Dogs & Englishmen",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=CFBF3BDA-6A27-4675-B082-EFC47765863B"
        },
        "ingested_at": "2026-02-06T22:55:43.303673+00:00"
      },
      {
        "event_id": "SOCIAL-Today0849-bbr391-67028680",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.705516",
        "source": "LSE_CHAT",
        "data": {
          "author": "bbr391",
          "content": "Will this old dog ever have It`s day You Decide Outstanding  ( perhaps )",
          "sentiment": 0.0,
          "engagement": "8,993",
          "price_at_post": "1.30",
          "thread_title": "Old Dogs & Englishmen",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=CFBF3BDA-6A27-4675-B082-EFC47765863B"
        },
        "ingested_at": "2026-02-06T22:55:43.303711+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261815-Downagai--1629627",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.706052",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Says 8 trades but only 2 showing??",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-06T22:55:43.303749+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261357-billy101-69761240",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.706616",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Will either find out Friday or Monday",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-06T22:55:43.303788+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261350-Downagai-29272649",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.707168",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "I don't think the research note it right, the dates are nonsense tbh it's really poor.",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-06T22:55:43.303827+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261338-Merciama-81698024",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.707689",
        "source": "LSE_CHAT",
        "data": {
          "author": "Merciaman",
          "content": "Agreed downagain - I saw the section from the research note that Billy points out, and expected an official confirmation from the company regarding date for the deal. In the absence of that there is clearly some uncertainty - does the 31/1 date still apply, or is it indeed a case of both deals now having a longstop date of 16/3 ?",
          "sentiment": 0.0,
          "engagement": "286",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-06T22:55:43.303864+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261234-Downagai-13784582",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.708207",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Think they just need to update clearly and transparently",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-06T22:55:43.303901+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261206-billy101--2321762",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.708763",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Separately, the Company updated the status of the sale of its subsidiary Lyramid to Pleiades, a transaction worth up to $10.8m. Because Pleiades has not yet completed its fundraising with institutional and sovereign wealth fund investors in the GCC (Gulf Cooperation Council), the longstop date has been extended to 16 March 2026. The SPA has also been amended so that Midkine Investments, rather than Roquefort Therapeutics, is now the selling entity, and to acknowledge the scheduled termination of Lyramid\u2019s third-party licence to the Midkine antibody programme in November 2025.",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-06T22:55:43.303938+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261142-billy101--1074895",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.709296",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Didn\u2019t he take on a NED role. Maybe wrong due to information overload.",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-06T22:55:43.303977+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261139-hamilton--8124989",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.709808",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "The RTO and the carve out are not related at all apart from being ROQ assets. The thing worrying me is why did AR sell all his shares before the Carve out entitlement date when he was the one that introduced ROQ to Pleiades, apparently ? Another extension coming no doubt. Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,547",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-06T22:55:43.304016+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261056-Downagai-25221286",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.710353",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Oops Group Restructuring The Company intends to carve out the value of the Lyramid SPA and the MK Cell Out-License for the benefit of existing shareholders and convertible loan holders. In order to facilitate this, the Company has recently undertaken the following restructuring of the Group (the \"Group Restructuring\"): a) The entire issued shares of Lyramid have been acquired by Midkine Investments (a 100% owned subsidiary of Roquefort Therapeutics) such that Lyramid is now 100% owned by Midkine Investments; and b) The rights to the MK Cell program held by Oncogeni Ltd have been novated to Midkine Investments such that Midkine Investments now holds the underlying exclusive worldwide rights to the MK Cell program. It is the intention of the Company to issue new unlisted redeemable non-voting shares (\"Unlisted RNV Shares\") to the holders of Roquefort Therapeutics ordinary shares and convertible loan notes listed on the Company's registers as at 30 November 2025. The Unlisted RNV Shares will entitle holders to all commercial benefits from Midkine Investments with the ultimate aim of undertaking an in-specie distribution of the Midkine Investments shares once the balance sheet of the Company permits such an action under the Companies Act.",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-06T22:55:43.304054+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261054-Downagai--7772828",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.711148",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "London South East Check out our new Alternative Investment section.Click here Share PricesRoquefort Thera Share PriceRoquefort Thera Share Regulatory NewsMK Cell Out-License & Lyramid SPA Update Pin to quick picksRoquefort Thera Regulatory News (ROQ) ROQ Share Price ROQ Share Price ROQ Share News ROQ Share News ROQ Share Chat ROQ Share Chat 10 ROQ Share Trades ROQ Share Trades ROQ Live RNS ROQ Live RNS Sponsored Content Roquefort Thera Information Add ROQ to Timeline Add ROQ to Timeline Add ROQ to Watchlist Add ROQ to Watchlist Add ROQ to Alert Add ROQ to Alert Buy ROQ Shares Buy ROQ Shares Share Price Information for Roquefort Thera (ROQ) Share Price is delayed by 15 minutes Get Live Data 1.30 0.00 (0.00%) Bid: 1.20 Ask: 1.40 Spread: 0.20 (16.667%)Market Cap: \u00a32.13m ROQ Live PriceLast checked at 10:53:52London Stock Exchange Sponsored Content MK Cell Out-License & Lyramid SPA Update 3 Nov 2025 07:00 RNS Number : 8172F Roquefort Therapeutics PLC 03 November 2025 3 November 2025 Roquefort Therapeutics plc (\"Roquefort Therapeutics\" or the \"Company\") MK Cell Out-License & Lyramid SPA Update Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces it has entered into an agreement to out-license its MK Cell patents to Pleiades Pharma Ltd (\"Pleiades\") in return for up to US$25 million in milestone cash payments together and a royalty payment obligation (the \"MK Cell Out-License\"). Background As announced on 8 September 2025, the Company is proposing to acquire from A2A Pharmaceuticals, Inc. and Coiled Therapeutics, Inc. the exclusive licence rights to AO-252, a novel first-in-class, first-in-human new drug alternative targeting the TACC3 protein for the treatment of certain cancers (the \"Proposed Transaction\"), retain the STAT-6 program and has ceased discussions around the sale of its wholly owned subsidiary Oncogeni Ltd. Further details on the progress of the Proposed Transaction will be announced in due course. Following the announcement of the Proposed Transaction, the Company initiated discussions with Pleiades regarding the grant of an exclusive worldwide license for its MK Cell program, which has resulted in the signing of the MK Cell Out-License. MK Cell Out-License To accommodate the Group Restructuring (refer below) that was signalled in August 2025, the parties to the MK Cell Out-License are Roquefort Therapeutics' wholly owned subsidiary Midkine Investments Ltd (\"Midkine Investments\") and Pleiades. The consideration payable by Pleiades for the MK Cell Out-License is a combination of milestone cash payments and a royalty payment obligation of 1.5% perpetuity royalty on all global net sales of products derived from the licensed technology. The total milestone cash payments of up to US$25 million is payable by Pleiades as follows: a) US$500,000 upon Pleiades securing a minimum fundraising",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-06T22:55:43.304089+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261043-billy101--1351392",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.711670",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Sorry not RTO shares should have put  Unlisted RNV Shares",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-06T22:55:43.304142+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261026-billy101--1038786",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.712198",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Lets hope so. However MK will only happen up on condition of Coil happening otherwise there is no point. ROQ doesn't benefit only the RTO holders. Personally I want the RTO regardless of Coil. Compnaies House registers have all been updated we are just waiting for a completion of something (deal) otherwise we would have had our allocation of RTO shares of 10:1 by now.",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-06T22:55:43.304181+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261003-Downagai--7349593",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.712701",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "No that's not right, the deals are not linked, funding due this week",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-06T22:55:43.304221+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260947-billy101--7655382",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.713218",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Otherwsie no split required. ROQ will remain one entity with just Pleiades deal.",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-06T22:55:43.304259+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260943-billy101-85117238",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.713754",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "The research note has implied the deal(s) have been extended to 16th March. Surely MK will only happen if Coil completes.",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-06T22:55:43.304298+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260915-Escapeto--3194399",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.714286",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Delay... They never fail on that one.",
          "sentiment": 0.0,
          "engagement": "1,307",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-06T22:55:43.304339+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260810-Downagai-21531827",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.714786",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Tbh given this is carved off it shouldn't technically affect the Roq price anyway hut would be nice to conclude the free shares and understand what is actually going on",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-06T22:55:43.304380+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260753-Downagai-36032146",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.715339",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "No way I see this sorted this week. If funding was coming after a year they would not be this close to the wire injo",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.45",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-06T22:55:43.304419+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260751-mnsa--6068839",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.715754",
        "source": "LSE_CHAT",
        "data": {
          "author": "mnsa",
          "content": "Let\u2019s hope for once the deliver on the deadline given! If they do this should recover very well! Hoping for some +ve!",
          "sentiment": 0.0,
          "engagement": "311",
          "price_at_post": "1.60",
          "thread_title": "Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-06T22:55:43.304459+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260721-hamilton--4314232",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.716197",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "Anyone heard from the company or seen anything ? Literally can\u2019t be bothered with another extension. Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,547",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-06T22:55:43.304498+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261158-Downagai-49692244",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.716610",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "4 more days \ud83d\ude2c",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-06T22:55:43.304537+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20260858-pumpky--2707203",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.717023",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Billy Yes invested in January due to their RNS",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-06T22:55:43.304574+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20262322-Escapeto--3293627",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:27.301413",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Huge bull market for biotech , roq at all time low.",
          "sentiment": 0.0,
          "engagement": "1,307",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-06T22:55:43.304614+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261742-pumpky-41073567",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:27.301822",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Read them and what? SP Angel are the Brokers  for Roquefort \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-06T22:55:43.304654+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261447-billy101-34219418",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.001123",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Read pages 28 and 29",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-06T22:55:43.304693+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261350-Escapeto--4450824",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.001936",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "They'll miss it.",
          "sentiment": 0.0,
          "engagement": "1,307",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-06T22:55:43.304731+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261326-pumpky-58494756",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.002732",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Pileades deal 16  March ?",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-06T22:55:43.304770+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261315-billy101--5424606",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.003543",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Could go in until 16th March",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-06T22:55:43.304811+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261257-pumpky-14259620",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.004326",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "3rd November RNS Caroline Fortier  We anticipate the round of funding to be completed before the Long stop date of 31Januaey 2026",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-06T22:55:43.304849+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261256-Escapeto-43684112",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.005138",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Disappointed \ud83d\ude1e. DOWN.",
          "sentiment": 0.0,
          "engagement": "1,307",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-06T22:55:43.304889+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261253-pumpky-46347045",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.005910",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "IF being the operative word \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-06T22:55:43.304927+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261147-Downagai-19079801",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.006712",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Well with all the fanfare around this never thought I'd be able to buy under 1.2p. If the deal happens near 50% upside straight away. What not to like \ud83d\ude03\ud83d\ude80",
          "sentiment": 0.5,
          "engagement": "864",
          "price_at_post": "1.20",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-06T22:55:43.304967+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261029-Aklee--3376570",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.007517",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aklee",
          "content": "I see Davey is here peddling his usual nonsense. Be careful on any share he is in. Always sells into the smallest rise whilst claiming it's someone else",
          "sentiment": 0.0,
          "engagement": "3,597",
          "price_at_post": "1.25",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-06T22:55:43.305005+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261212-Downagai--2099384",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.008304",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Wow how to lose \u00a3730 in 3 hours. Unlucky trader Sam \ud83e\udd26\u200d\u2642\ufe0f",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "Loss",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=A17EF4D3-D0D3-4793-A674-53112286A2B2"
        },
        "ingested_at": "2026-02-06T22:55:43.305044+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260826-billy101--3948440",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.009089",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Only issue I have with todays RNS(RESEARCH NOTE) . It should have been released in November.",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-06T22:55:43.305083+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260806-billy101-58601024",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.009911",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Keeping this short and brief for us investors page 7 matters. And if they tick all the boxes with TACC3 Inhibitor thats mentioned on page 14 then were off to the moon. The rest of the read research note is for my daughters and son in law to translate to me!",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.20",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-06T22:55:43.305143+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260805-davey50--6060739",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.010700",
        "source": "LSE_CHAT",
        "data": {
          "author": "davey50",
          "content": "Just play the game, buy them when totally unloved and sell them when the shares are spiking and the herd arrives rinse and repeat. I took 500k more at the bell 1.23p ish...what a price...they were chasing this up to 2.5p not long ago",
          "sentiment": 0.0,
          "engagement": "7,050",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-06T22:55:43.305179+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260804-leew--1655753",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.011498",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Well digesting the financial pages was my first port of call and to be honest the purchase price we are paying is very reasonable and if the shares are issued at 1.7 as adv used then on the RTO I see some potential for immediate upside with no real news other than we have done the RTO and its purchase value. Add that to then normal news on progression in phase 1 and beyond we could see some very good gains. Will need to digest the technical aspect later but form investment strategy I am happy",
          "sentiment": 0.0,
          "engagement": "2,632",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-06T22:55:43.305214+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260756-bbr391--4334379",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.012391",
        "source": "LSE_CHAT",
        "data": {
          "author": "bbr391",
          "content": "Progress to date Roquefort has demonstrated significant anti-cancer activity with its STAT-6 siRNA therapeutics, as validated in in vivo models of breast and colon cancer. These results further reinforce the potential of STAT-6 targeting approaches in multiple tumour types and provide a strong foundation for advancing this programme towards clinical evaluation. STAT-6 targeting siRNA constructs have shown significant in vivo anti-cancer activity in validated models of colon cancer. STAT-6 siRNAs demonstrated a significant reduction in the proliferation of colorectal cancer with a ca.50% reduction in cell growth at seven days. This anti-cancer effect was replicated in a validated in vivo model of colorectal cancer with a significant reduction in cancer weight and volume over 28 days As usual . One feels the Americans are getting good research at a very very very low cost . Outstanding",
          "sentiment": 0.5,
          "engagement": "8,993",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-06T22:55:43.305248+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260751-billy101-89596759",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.013194",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "There is alot in there, so they have starteed the PR now. The Key milestone dates for 2025-2027 and Financial valuation on page 4 will keep investors happy. Its a long read",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-06T22:55:43.305284+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260739-Downagai--1040157",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.013953",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "That'd an easy read. Nothing new really though that I can see",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.20",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-06T22:55:43.305321+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261116-cassdav5-54409367",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.014729",
        "source": "LSE_CHAT",
        "data": {
          "author": "cassdav57",
          "content": "Yes pumpky your correct.  My bad, brain fog on different aspects of deal and moving targets. The deal requires ROQ's enlarged share capital to be admitted to trading on AIM by this new March 16, 2026 deadline to complete the transaction. So they have about 2 more months to finalize everything and get the AIM listing done.",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-02-06T22:55:43.305358+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261027-Merciama--1761256",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.015502",
        "source": "LSE_CHAT",
        "data": {
          "author": "Merciaman",
          "content": "It is Pumpky, 31/1 deadline for Pleiades to buy Lyramid from Midkine Investments. The reverse takeover of Roquefort to form Coiled Therapeutics has the 16th March deadline.",
          "sentiment": 0.0,
          "engagement": "286",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-02-06T22:55:43.305396+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260941-pumpky--3113321",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.016237",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Isnt the Pileades deal January?",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-02-06T22:55:43.305434+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260924-cassdav5--3702937",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.016655",
        "source": "LSE_CHAT",
        "data": {
          "author": "cassdav57",
          "content": "Sorry guys, Realise, The exclusivity period extended to March 16th but would still expect news by end of Jan.",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-02-06T22:55:43.305472+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260918-cassdav5--6181090",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.017066",
        "source": "LSE_CHAT",
        "data": {
          "author": "cassdav57",
          "content": "The exclusivity period should be ending soon (January 2026), so we might hear updates about whether the deal proceeds in the coming weeks. The  main hope for good news  for me was the director buy in November of 5 million shares (\u00a385k) and the calibre of the trails technology plus funding through A2A Pharmaceuticals.  So yes, definitely a waiting game, currently I am down about 50% and will be holding and making some small additions at these low or lower prices until things become clearer as upside could be considerable.",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "1.20",
          "thread_title": "News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-02-06T22:55:43.305511+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261743-Downagai--6877696",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.017500",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "True enough",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.20",
          "thread_title": "RE: Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-02-06T22:55:43.305549+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261714-pumpky--8217013",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.017906",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "What is there to say? Just waiting for news",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.20",
          "thread_title": "RE: Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-02-06T22:55:43.305587+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261649-Downagai--8937472",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.018342",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Quiet here \ud83d\ude34",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.20",
          "thread_title": "RE: Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-02-06T22:55:43.305626+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261617-Downagai--4658332",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.113544",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Big sell 3 big buys?",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-06T22:55:43.305664+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261505-billy101--3900955",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.113993",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "What\u2019s another few months. Have you been in since Jan 25?",
          "sentiment": 0.0,
          "engagement": "31,698",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-06T22:55:43.305701+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261504-pumpky--4615869",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.114430",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Deal  has been going on since January 2025",
          "sentiment": 0.0,
          "engagement": "17,626",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-06T22:55:43.305741+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261425-leew--4724218",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.114946",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Could be a delay or could happen on time, funding is never a simple process having been involved myself. The access to the data room and the DD questions from all parties is always significant. Just wait for the confirmation, because all that is needed is patience with ROQ in my view.",
          "sentiment": 0.0,
          "engagement": "2,618",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-06T22:55:43.305780+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260859-davey50-25316343",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.115405",
        "source": "LSE_CHAT",
        "data": {
          "author": "davey50",
          "content": "1.23-1.35p online so mid price to buy, not a bad price for a gamble given it's history of spikes",
          "sentiment": 0.0,
          "engagement": "7,037",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-06T22:55:43.305819+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260806-pumpky--6971382",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.115821",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Anticipate not expect \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,626",
          "price_at_post": "1.45",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-06T22:55:43.305858+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260726-Downagai-81907915",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.116249",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Apparently a couple of days is aay ahead \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-06T22:55:43.305898+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260725-pumpky--1195131",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.116661",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Caroline Fortier We expect to finalise before the 31 January date\" Expect\" Get out card ( maybe delayed due to Trump wanting Greenland \ud83d\ude02)",
          "sentiment": 0.0,
          "engagement": "17,626",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-06T22:55:43.306214+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260725-Downagai-59736925",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.117079",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "No Dicko after all \"Caroline Fortier, Pleiades CEO commented: \"Following the previously announced acquisition of Lyramid, we are delighted to build on our relationship with Roquefort Therapeutics and take an exclusive license of the MK Cell therapy asset which we plan to take into clinical studies targeting high value oncology indications of unmet need. The addition of these assets to our immunotherapy, late-stage pan-specific vaccine and cell therapy portfolio is an important part of our strategy to position ourselves as a material biotechnology company to institutional investors with whom we are currently working to close on a significant equity funding round. In alignment with the extension of the Lyramid SPA we anticipate our funding round to complete ahead of the new 31 January 2026 long stop date.\"",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-06T22:55:43.306254+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260720-Dicko80--2974946",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.117508",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dicko80",
          "content": "What\u2019s the betting they\u2019ll be another extension to us getting our shares ? 1 week deadline",
          "sentiment": 0.0,
          "engagement": "2,427",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-06T22:55:43.306292+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20262142-leew--3124286",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.117916",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Well there is a lot of news due bbr, would be great to get the RTO confirmed and initially just get the SP back to 1.7p and then see where the RTO then takes it as there is some potential for increasing in market cap after so fingers crossed. Would also be good on the back of that to then here about the spin off and the deals associated to that to see when some cash might come in from the free shares.",
          "sentiment": 0.0,
          "engagement": "2,618",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-06T22:55:43.306330+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20262130-leew-57527985",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.118340",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Honestly if you want to invest best check yourself. I don\u2019t think reading a few RNA\u2019s and googling a few things is that bad.",
          "sentiment": 0.0,
          "engagement": "2,618",
          "price_at_post": "1.35",
          "thread_title": "RE: Can",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=28165808-701F-48DA-95C7-867899DCB7C6"
        },
        "ingested_at": "2026-02-06T22:55:43.306369+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261653-Kikudi-18359913",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.118754",
        "source": "LSE_CHAT",
        "data": {
          "author": "Kikudi",
          "content": "Some please give me highlights of ROQ that will save me go through  RNS I want to invest. Thanks in advance",
          "sentiment": 0.0,
          "engagement": "15",
          "price_at_post": "1.35",
          "thread_title": "Can",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=28165808-701F-48DA-95C7-867899DCB7C6"
        },
        "ingested_at": "2026-02-06T22:55:43.306407+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261338-Downagai-21781381",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.119177",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "IYHO I take it \ud83d\ude03",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-06T22:55:43.306445+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261337-bbr391-67130928",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.119594",
        "source": "LSE_CHAT",
        "data": {
          "author": "bbr391",
          "content": "Come to Papa . We will all soon be very very pleased (possibly). Outstanding",
          "sentiment": 0.5,
          "engagement": "8,990",
          "price_at_post": "1.35",
          "thread_title": "Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-06T22:55:43.306483+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260911-SharePic-18612719",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.120004",
        "source": "LSE_CHAT",
        "data": {
          "author": "SharePicks",
          "content": "I've added this to portfolio. Lets see where it goes.",
          "sentiment": 0.0,
          "engagement": "1,198",
          "price_at_post": "1.30",
          "thread_title": "1.5p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=EC7A8D0C-531B-4D1D-A5F0-14D0049CD3D9"
        },
        "ingested_at": "2026-02-06T22:55:43.306521+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260903-davey50-19465916",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.120420",
        "source": "LSE_CHAT",
        "data": {
          "author": "davey50",
          "content": "Just need to clear the slack below 1.4p and then the herd will arrive, if trls can do 300% then roq is always good for a spike a few times a year",
          "sentiment": 0.0,
          "engagement": "7,037",
          "price_at_post": "1.30",
          "thread_title": "RE: ROQ",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=34D50F4B-4B38-438B-BCC4-912454A889E9"
        },
        "ingested_at": "2026-02-06T22:55:43.306559+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260813-SharePic-53391914",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.120830",
        "source": "LSE_CHAT",
        "data": {
          "author": "SharePicks",
          "content": "Good start so far today.",
          "sentiment": 0.0,
          "engagement": "1,198",
          "price_at_post": "1.15",
          "thread_title": "ROQ",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=34D50F4B-4B38-438B-BCC4-912454A889E9"
        },
        "ingested_at": "2026-02-06T22:55:43.306597+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20260756-Downagai-73875575",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.121244",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Interesting pre market spread today. I wish",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.60",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-06T22:55:43.306636+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260840-billy101-11862590",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.121680",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "We will get updates on deals when and if  they are complete. They can't keep doing a running commentary on progress of deals. We have been told the aims in the R/Note. We have split Mk(nearly) upon condition of Coil happening. We are in different phases in trials. Anything else is conjecture. Whilst this is happening its stalemate on all pathways.",
          "sentiment": 0.0,
          "engagement": "31,698",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-06T22:55:43.306673+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260834-Downagai--5863550",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.122092",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "About progess on the deals? What page please I missed that thanks",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-06T22:55:43.306711+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260810-billy101--1401139",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.122513",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "We had news last wek in R/note.",
          "sentiment": 0.0,
          "engagement": "31,698",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-06T22:55:43.306749+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260730-Downagai--7645848",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.122926",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "They need to provide an update, this radio silence is very poor",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-06T22:55:43.306788+00:00"
      },
      {
        "event_id": "SOCIAL-17Jan20260249-Escapeto--5658634",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.123352",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "I'm hopeful, but not convinced this team can build value. I'm not sure what it is but just look at the history for starters. Continual missed deadlines. At the very least don't make a rod for your back with deadlines you never keep.",
          "sentiment": 0.0,
          "engagement": "1,297",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-06T22:55:43.306827+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20262335-Downagai--6001386",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.123758",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "It's because they keep promising the earth and delivering nothing with no updates and just delays",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-06T22:55:43.306865+00:00"
      },
      {
        "event_id": "SOCIAL-Today1646-billy101--8710976",
        "event_type": "social_post",
        "date": "2026-02-09T23:04:53.945984",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "It will jump back up to 1.3",
          "sentiment": 0.0,
          "engagement": "31,760",
          "price_at_post": "1.10",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618233+00:00"
      },
      {
        "event_id": "SOCIAL-Today1526-Escapeto--3584262",
        "event_type": "social_post",
        "date": "2026-02-09T23:04:53.946429",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "DOWN.",
          "sentiment": 0.0,
          "engagement": "1,341",
          "price_at_post": "1.10",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618272+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261052-Escapeto--6669330",
        "event_type": "social_post",
        "date": "2026-02-09T23:04:53.946840",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Education helps you know.",
          "sentiment": 0.0,
          "engagement": "1,341",
          "price_at_post": "1.20",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618305+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261047-Escapeto-12330311",
        "event_type": "social_post",
        "date": "2026-02-09T23:04:53.947253",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "In my role I was expected to deliver to time, yes sometimes it is very complicated, in those situations we tended to be more wooly with what we said.",
          "sentiment": 0.0,
          "engagement": "1,341",
          "price_at_post": "1.20",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618330+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260946-billy101-79786920",
        "event_type": "social_post",
        "date": "2026-02-09T23:04:53.947666",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Re post 0941hrs Its out of their hands. Its not an education level thingy",
          "sentiment": 0.0,
          "engagement": "31,760",
          "price_at_post": "1.20",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618348+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260941-Escapeto--4939147",
        "event_type": "social_post",
        "date": "2026-02-09T23:04:53.948071",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "For Oxford University level of education , we expect bod to meet deadlines they themselves set.",
          "sentiment": 0.0,
          "engagement": "1,341",
          "price_at_post": "1.20",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618367+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260641-leew-71177925",
        "event_type": "social_post",
        "date": "2026-02-09T23:04:53.948495",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Hamilton, they will at some stage, sometime funding takes time if you are doing more than a cheap placing for funding. If other companies are raising funding to buy some of our assets and it involves multiple parties the DD takes time and the same on the RTO side. This is a very small portion of my portfolio and if it takes 6 months extra / 1 year extra but happens I could not careless. I have a couple of Pharma\u2019s and I will stay in them for many many years not a trade. Therefore more view on hitting a timing date is not really relevant for this.",
          "sentiment": 0.0,
          "engagement": "2,659",
          "price_at_post": "1.20",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618385+00:00"
      },
      {
        "event_id": "SOCIAL-Today1052-Escapeto--6669330",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.483596",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Education helps you know.",
          "sentiment": 0.0,
          "engagement": "1,339",
          "price_at_post": "1.20",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618405+00:00"
      },
      {
        "event_id": "SOCIAL-Today1047-Escapeto-12330311",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.484024",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "In my role I was expected to deliver to time, yes sometimes it is very complicated, in those situations we tended to be more wooly with what we said.",
          "sentiment": 0.0,
          "engagement": "1,339",
          "price_at_post": "1.20",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618423+00:00"
      },
      {
        "event_id": "SOCIAL-Today0946-billy101-79786920",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.484477",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Re post 0941hrs Its out of their hands. Its not an education level thingy",
          "sentiment": 0.0,
          "engagement": "31,754",
          "price_at_post": "1.20",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618441+00:00"
      },
      {
        "event_id": "SOCIAL-Today0941-Escapeto--4939147",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.484881",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "For Oxford University level of education , we expect bod to meet deadlines they themselves set.",
          "sentiment": 0.0,
          "engagement": "1,339",
          "price_at_post": "1.20",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618459+00:00"
      },
      {
        "event_id": "SOCIAL-Today0641-leew-71177925",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.485330",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Hamilton, they will at some stage, sometime funding takes time if you are doing more than a cheap placing for funding. If other companies are raising funding to buy some of our assets and it involves multiple parties the DD takes time and the same on the RTO side. This is a very small portion of my portfolio and if it takes 6 months extra / 1 year extra but happens I could not careless. I have a couple of Pharma\u2019s and I will stay in them for many many years not a trade. Therefore more view on hitting a timing date is not really relevant for this.",
          "sentiment": 0.0,
          "engagement": "2,659",
          "price_at_post": "1.20",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618477+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261331-Gigontbs--5057083",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.485733",
        "source": "LSE_CHAT",
        "data": {
          "author": "Gigontbsaaa",
          "content": "FM pumping and dumping, was the 1st sign",
          "sentiment": 0.0,
          "engagement": "435",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618495+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261328-Escapeto-21521231",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.486145",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "May have to put this one down to experience. All the warning signs present",
          "sentiment": 0.0,
          "engagement": "1,339",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618513+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261220-pumpky--5398569",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.486552",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Caroline Fortier expected funding to be completed before January 31 also \ud83d\ude02 One thing for sure is Roq need to do something soon as must be running out of money",
          "sentiment": 0.0,
          "engagement": "17,738",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618531+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261203-Escapeto--6718506",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.486959",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Cardiogeni's December annual stated :\" Advanced discussions for a funding agreement of $25M (~\u00a319M) for Cardiogeni (UAE) Limited expected to complete by the end of January 2026 where upon first tranche of funding is anticipated\". SURELY VERY CLOSE. CMon Roquefort get that funding.",
          "sentiment": 0.0,
          "engagement": "1,339",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618549+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261150-Escapeto--1559423",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.487382",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Smelly cheese!",
          "sentiment": 0.0,
          "engagement": "1,339",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618567+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261145-hamilton--8587518",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.487799",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "No doubt everyone has done their research and knows that the same people at ROQ are in CGNI also ? Have a look at their deal tha hasn\u2019t happened either !! https://www.investegate.co.uk/announcement/rns/cardiogeni-plc--cgni/details-of-advanced-subscription-company-update/8998882 Not sure what they actually do ! Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,563",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618584+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261108-hamilton--2040267",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.488221",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "What makes you think they will hit the new deadline ? It\u2019s been going on over a year now. The communication is terrible. Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,563",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618602+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20262326-leew-65620569",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.488635",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Hamilton, nothing is terminated, looks like the date was changed in the research note, which I have just noticed only as it was pointed out below. Stupid for me to have missed that, but had a huge amount going on. Not brilliant to have communicated it there but is what it is so we move on with 2 dates close together now :)",
          "sentiment": 0.0,
          "engagement": "2,659",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618620+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261258-hamilton--9389456",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.489050",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "Looks like the deal has terminated then ? They did this last year with the Oncogeni sale. It had a deadline and they ended talks but we didn\u2019t find out till months later. If no rns then can only assume the worst ? Poor ! Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,563",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618638+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260830-billy101-86572008",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.489492",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "The RN laid it all out. The bit we are interested in the financials etc  can get losted in the impress pathways we have. Lets hope it comes together.",
          "sentiment": 0.0,
          "engagement": "31,754",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618655+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260823-Downagai-80512017",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.489897",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "If it is then to hide that in a research note is shockingly poor. Management are losing all credibility here for me I'm afraid",
          "sentiment": 0.0,
          "engagement": "939",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618673+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260806-billy101-79542990",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.490315",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "March 16th it is then for now.",
          "sentiment": 0.0,
          "engagement": "31,754",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618691+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260758-Downagai-71222557",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.490720",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "I seriously hope so but have my doubts",
          "sentiment": 0.0,
          "engagement": "939",
          "price_at_post": "1.60",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618709+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260751-Dicko80-58378787",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.491148",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dicko80",
          "content": "Previously the extensions have come in advance of the date So with no ext announced Maybe they are closing their financing and close to completion Hence no RNS as of yet \ud83e\udd1e",
          "sentiment": 0.0,
          "engagement": "2,435",
          "price_at_post": "1.60",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618727+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260737-Downagai--5010909",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.491552",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Tumbleweed \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "939",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618745+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20260855-Dicko80--1862002",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.491952",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dicko80",
          "content": "Im sure we\u2019ll find out soon enough",
          "sentiment": 0.0,
          "engagement": "2,435",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618763+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20260727-leew-19899301",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.492377",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Must admit I was expecting an RNA today. Unless it drops at 7.30 for various reasons :)",
          "sentiment": 0.0,
          "engagement": "2,659",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618781+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20260720-hamilton--5659925",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.492790",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "No rns ? Not sure what\u2019s going on now. Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,563",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618799+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260823-Downagai-41079445",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.493218",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "I started worrying when emails started being ignored tbh this os farcical now",
          "sentiment": 0.0,
          "engagement": "939",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618817+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260742-pumpky-86267646",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.493624",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Monday then \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,738",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618835+00:00"
      },
      {
        "event_id": "SOCIAL-Today0823-Downagai-41079445",
        "event_type": "social_post",
        "date": "2026-01-30T23:00:14.646540",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "I started worrying when emails started being ignored tbh this os farcical now",
          "sentiment": 0.0,
          "engagement": "920",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618853+00:00"
      },
      {
        "event_id": "SOCIAL-Today0742-pumpky-86267646",
        "event_type": "social_post",
        "date": "2026-01-30T23:00:14.647111",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Monday then \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,680",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618870+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260849-bbr391-88660721",
        "event_type": "social_post",
        "date": "2026-01-30T23:00:14.647545",
        "source": "LSE_CHAT",
        "data": {
          "author": "bbr391",
          "content": "Will this old dog ever have It`s day You Decide Outstanding  ( perhaps )",
          "sentiment": 0.0,
          "engagement": "8,994",
          "price_at_post": "1.30",
          "thread_title": "Old Dogs & Englishmen",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=CFBF3BDA-6A27-4675-B082-EFC47765863B"
        },
        "ingested_at": "2026-02-09T23:05:02.618888+00:00"
      },
      {
        "event_id": "SOCIAL-Today0849-bbr391-88660721",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.705516",
        "source": "LSE_CHAT",
        "data": {
          "author": "bbr391",
          "content": "Will this old dog ever have It`s day You Decide Outstanding  ( perhaps )",
          "sentiment": 0.0,
          "engagement": "8,993",
          "price_at_post": "1.30",
          "thread_title": "Old Dogs & Englishmen",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=CFBF3BDA-6A27-4675-B082-EFC47765863B"
        },
        "ingested_at": "2026-02-09T23:05:02.618906+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261815-Downagai-37372185",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.706052",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Says 8 trades but only 2 showing??",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618923+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261357-billy101--1716563",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.706616",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Will either find out Friday or Monday",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618941+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261350-Downagai-38486430",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.707168",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "I don't think the research note it right, the dates are nonsense tbh it's really poor.",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618959+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261338-Merciama--7722255",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.707689",
        "source": "LSE_CHAT",
        "data": {
          "author": "Merciaman",
          "content": "Agreed downagain - I saw the section from the research note that Billy points out, and expected an official confirmation from the company regarding date for the deal. In the absence of that there is clearly some uncertainty - does the 31/1 date still apply, or is it indeed a case of both deals now having a longstop date of 16/3 ?",
          "sentiment": 0.0,
          "engagement": "286",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618977+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261234-Downagai--7968812",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.708207",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Think they just need to update clearly and transparently",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.618995+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261206-billy101--8406724",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.708763",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Separately, the Company updated the status of the sale of its subsidiary Lyramid to Pleiades, a transaction worth up to $10.8m. Because Pleiades has not yet completed its fundraising with institutional and sovereign wealth fund investors in the GCC (Gulf Cooperation Council), the longstop date has been extended to 16 March 2026. The SPA has also been amended so that Midkine Investments, rather than Roquefort Therapeutics, is now the selling entity, and to acknowledge the scheduled termination of Lyramid\u2019s third-party licence to the Midkine antibody programme in November 2025.",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-09T23:05:02.619020+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261142-billy101-84351343",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.709296",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Didn\u2019t he take on a NED role. Maybe wrong due to information overload.",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-09T23:05:02.619039+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261139-hamilton-56632401",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.709808",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "The RTO and the carve out are not related at all apart from being ROQ assets. The thing worrying me is why did AR sell all his shares before the Carve out entitlement date when he was the one that introduced ROQ to Pleiades, apparently ? Another extension coming no doubt. Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,547",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-09T23:05:02.619057+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261056-Downagai-34559803",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.710353",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Oops Group Restructuring The Company intends to carve out the value of the Lyramid SPA and the MK Cell Out-License for the benefit of existing shareholders and convertible loan holders. In order to facilitate this, the Company has recently undertaken the following restructuring of the Group (the \"Group Restructuring\"): a) The entire issued shares of Lyramid have been acquired by Midkine Investments (a 100% owned subsidiary of Roquefort Therapeutics) such that Lyramid is now 100% owned by Midkine Investments; and b) The rights to the MK Cell program held by Oncogeni Ltd have been novated to Midkine Investments such that Midkine Investments now holds the underlying exclusive worldwide rights to the MK Cell program. It is the intention of the Company to issue new unlisted redeemable non-voting shares (\"Unlisted RNV Shares\") to the holders of Roquefort Therapeutics ordinary shares and convertible loan notes listed on the Company's registers as at 30 November 2025. The Unlisted RNV Shares will entitle holders to all commercial benefits from Midkine Investments with the ultimate aim of undertaking an in-specie distribution of the Midkine Investments shares once the balance sheet of the Company permits such an action under the Companies Act.",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-09T23:05:02.619076+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261054-Downagai-25077049",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.711148",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "London South East Check out our new Alternative Investment section.Click here Share PricesRoquefort Thera Share PriceRoquefort Thera Share Regulatory NewsMK Cell Out-License & Lyramid SPA Update Pin to quick picksRoquefort Thera Regulatory News (ROQ) ROQ Share Price ROQ Share Price ROQ Share News ROQ Share News ROQ Share Chat ROQ Share Chat 10 ROQ Share Trades ROQ Share Trades ROQ Live RNS ROQ Live RNS Sponsored Content Roquefort Thera Information Add ROQ to Timeline Add ROQ to Timeline Add ROQ to Watchlist Add ROQ to Watchlist Add ROQ to Alert Add ROQ to Alert Buy ROQ Shares Buy ROQ Shares Share Price Information for Roquefort Thera (ROQ) Share Price is delayed by 15 minutes Get Live Data 1.30 0.00 (0.00%) Bid: 1.20 Ask: 1.40 Spread: 0.20 (16.667%)Market Cap: \u00a32.13m ROQ Live PriceLast checked at 10:53:52London Stock Exchange Sponsored Content MK Cell Out-License & Lyramid SPA Update 3 Nov 2025 07:00 RNS Number : 8172F Roquefort Therapeutics PLC 03 November 2025 3 November 2025 Roquefort Therapeutics plc (\"Roquefort Therapeutics\" or the \"Company\") MK Cell Out-License & Lyramid SPA Update Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces it has entered into an agreement to out-license its MK Cell patents to Pleiades Pharma Ltd (\"Pleiades\") in return for up to US$25 million in milestone cash payments together and a royalty payment obligation (the \"MK Cell Out-License\"). Background As announced on 8 September 2025, the Company is proposing to acquire from A2A Pharmaceuticals, Inc. and Coiled Therapeutics, Inc. the exclusive licence rights to AO-252, a novel first-in-class, first-in-human new drug alternative targeting the TACC3 protein for the treatment of certain cancers (the \"Proposed Transaction\"), retain the STAT-6 program and has ceased discussions around the sale of its wholly owned subsidiary Oncogeni Ltd. Further details on the progress of the Proposed Transaction will be announced in due course. Following the announcement of the Proposed Transaction, the Company initiated discussions with Pleiades regarding the grant of an exclusive worldwide license for its MK Cell program, which has resulted in the signing of the MK Cell Out-License. MK Cell Out-License To accommodate the Group Restructuring (refer below) that was signalled in August 2025, the parties to the MK Cell Out-License are Roquefort Therapeutics' wholly owned subsidiary Midkine Investments Ltd (\"Midkine Investments\") and Pleiades. The consideration payable by Pleiades for the MK Cell Out-License is a combination of milestone cash payments and a royalty payment obligation of 1.5% perpetuity royalty on all global net sales of products derived from the licensed technology. The total milestone cash payments of up to US$25 million is payable by Pleiades as follows: a) US$500,000 upon Pleiades securing a minimum fundraising",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-09T23:05:02.619094+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261043-billy101-60138080",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.711670",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Sorry not RTO shares should have put  Unlisted RNV Shares",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-09T23:05:02.619132+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261026-billy101--7175175",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.712198",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Lets hope so. However MK will only happen up on condition of Coil happening otherwise there is no point. ROQ doesn't benefit only the RTO holders. Personally I want the RTO regardless of Coil. Compnaies House registers have all been updated we are just waiting for a completion of something (deal) otherwise we would have had our allocation of RTO shares of 10:1 by now.",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-09T23:05:02.619150+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261003-Downagai-25455001",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.712701",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "No that's not right, the deals are not linked, funding due this week",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-09T23:05:02.619169+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260947-billy101--6816755",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.713218",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Otherwsie no split required. ROQ will remain one entity with just Pleiades deal.",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-09T23:05:02.619187+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260943-billy101-87728897",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.713754",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "The research note has implied the deal(s) have been extended to 16th March. Surely MK will only happen if Coil completes.",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-09T23:05:02.619205+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260915-Escapeto-76613183",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.714286",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Delay... They never fail on that one.",
          "sentiment": 0.0,
          "engagement": "1,307",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-09T23:05:02.619224+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260810-Downagai-76346598",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.714786",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Tbh given this is carved off it shouldn't technically affect the Roq price anyway hut would be nice to conclude the free shares and understand what is actually going on",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-09T23:05:02.619242+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260753-Downagai--2879031",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.715339",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "No way I see this sorted this week. If funding was coming after a year they would not be this close to the wire injo",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.45",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-09T23:05:02.619261+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260751-mnsa--5671574",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.715754",
        "source": "LSE_CHAT",
        "data": {
          "author": "mnsa",
          "content": "Let\u2019s hope for once the deliver on the deadline given! If they do this should recover very well! Hoping for some +ve!",
          "sentiment": 0.0,
          "engagement": "311",
          "price_at_post": "1.60",
          "thread_title": "Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-09T23:05:02.619279+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260721-hamilton-43025806",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.716197",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "Anyone heard from the company or seen anything ? Literally can\u2019t be bothered with another extension. Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,547",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-09T23:05:02.619298+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261158-Downagai-78504213",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.716610",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "4 more days \ud83d\ude2c",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-09T23:05:02.619315+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20260858-pumpky-32325660",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.717023",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Billy Yes invested in January due to their RNS",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-09T23:05:02.619334+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20262322-Escapeto--5613056",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:27.301413",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Huge bull market for biotech , roq at all time low.",
          "sentiment": 0.0,
          "engagement": "1,307",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-09T23:05:02.619352+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261742-pumpky-50994494",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:27.301822",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Read them and what? SP Angel are the Brokers  for Roquefort \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-09T23:05:02.619370+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261447-billy101-81358321",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.001123",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Read pages 28 and 29",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-09T23:05:02.619388+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261350-Escapeto-51972884",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.001936",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "They'll miss it.",
          "sentiment": 0.0,
          "engagement": "1,307",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-09T23:05:02.619406+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261326-pumpky--8328145",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.002732",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Pileades deal 16  March ?",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-09T23:05:02.619424+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261315-billy101-73569527",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.003543",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Could go in until 16th March",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-09T23:05:02.619442+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261257-pumpky-75072956",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.004326",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "3rd November RNS Caroline Fortier  We anticipate the round of funding to be completed before the Long stop date of 31Januaey 2026",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-09T23:05:02.619460+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261256-Escapeto--1655754",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.005138",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Disappointed \ud83d\ude1e. DOWN.",
          "sentiment": 0.0,
          "engagement": "1,307",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-09T23:05:02.619478+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261253-pumpky--3195891",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.005910",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "IF being the operative word \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-09T23:05:02.619496+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261147-Downagai--1529148",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.006712",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Well with all the fanfare around this never thought I'd be able to buy under 1.2p. If the deal happens near 50% upside straight away. What not to like \ud83d\ude03\ud83d\ude80",
          "sentiment": 0.5,
          "engagement": "864",
          "price_at_post": "1.20",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-09T23:05:02.619515+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261029-Aklee-22536549",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.007517",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aklee",
          "content": "I see Davey is here peddling his usual nonsense. Be careful on any share he is in. Always sells into the smallest rise whilst claiming it's someone else",
          "sentiment": 0.0,
          "engagement": "3,597",
          "price_at_post": "1.25",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-09T23:05:02.619533+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261212-Downagai-18108664",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.008304",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Wow how to lose \u00a3730 in 3 hours. Unlucky trader Sam \ud83e\udd26\u200d\u2642\ufe0f",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "Loss",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=A17EF4D3-D0D3-4793-A674-53112286A2B2"
        },
        "ingested_at": "2026-02-09T23:05:02.619552+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260826-billy101-78686890",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.009089",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Only issue I have with todays RNS(RESEARCH NOTE) . It should have been released in November.",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-09T23:05:02.619570+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260806-billy101--8787057",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.009911",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Keeping this short and brief for us investors page 7 matters. And if they tick all the boxes with TACC3 Inhibitor thats mentioned on page 14 then were off to the moon. The rest of the read research note is for my daughters and son in law to translate to me!",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.20",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-09T23:05:02.619588+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260805-davey50--8744523",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.010700",
        "source": "LSE_CHAT",
        "data": {
          "author": "davey50",
          "content": "Just play the game, buy them when totally unloved and sell them when the shares are spiking and the herd arrives rinse and repeat. I took 500k more at the bell 1.23p ish...what a price...they were chasing this up to 2.5p not long ago",
          "sentiment": 0.0,
          "engagement": "7,050",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-09T23:05:02.619606+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260804-leew-57070086",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.011498",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Well digesting the financial pages was my first port of call and to be honest the purchase price we are paying is very reasonable and if the shares are issued at 1.7 as adv used then on the RTO I see some potential for immediate upside with no real news other than we have done the RTO and its purchase value. Add that to then normal news on progression in phase 1 and beyond we could see some very good gains. Will need to digest the technical aspect later but form investment strategy I am happy",
          "sentiment": 0.0,
          "engagement": "2,632",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-09T23:05:02.619625+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260756-bbr391--6311130",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.012391",
        "source": "LSE_CHAT",
        "data": {
          "author": "bbr391",
          "content": "Progress to date Roquefort has demonstrated significant anti-cancer activity with its STAT-6 siRNA therapeutics, as validated in in vivo models of breast and colon cancer. These results further reinforce the potential of STAT-6 targeting approaches in multiple tumour types and provide a strong foundation for advancing this programme towards clinical evaluation. STAT-6 targeting siRNA constructs have shown significant in vivo anti-cancer activity in validated models of colon cancer. STAT-6 siRNAs demonstrated a significant reduction in the proliferation of colorectal cancer with a ca.50% reduction in cell growth at seven days. This anti-cancer effect was replicated in a validated in vivo model of colorectal cancer with a significant reduction in cancer weight and volume over 28 days As usual . One feels the Americans are getting good research at a very very very low cost . Outstanding",
          "sentiment": 0.5,
          "engagement": "8,993",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-09T23:05:02.619643+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260751-billy101-44950602",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.013194",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "There is alot in there, so they have starteed the PR now. The Key milestone dates for 2025-2027 and Financial valuation on page 4 will keep investors happy. Its a long read",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-09T23:05:02.619661+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260739-Downagai-88098081",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.013953",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "That'd an easy read. Nothing new really though that I can see",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.20",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-09T23:05:02.619680+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261116-cassdav5-89830486",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.014729",
        "source": "LSE_CHAT",
        "data": {
          "author": "cassdav57",
          "content": "Yes pumpky your correct.  My bad, brain fog on different aspects of deal and moving targets. The deal requires ROQ's enlarged share capital to be admitted to trading on AIM by this new March 16, 2026 deadline to complete the transaction. So they have about 2 more months to finalize everything and get the AIM listing done.",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-02-09T23:05:02.619698+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261027-Merciama-28683572",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.015502",
        "source": "LSE_CHAT",
        "data": {
          "author": "Merciaman",
          "content": "It is Pumpky, 31/1 deadline for Pleiades to buy Lyramid from Midkine Investments. The reverse takeover of Roquefort to form Coiled Therapeutics has the 16th March deadline.",
          "sentiment": 0.0,
          "engagement": "286",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-02-09T23:05:02.619716+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260941-pumpky--5664904",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.016237",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Isnt the Pileades deal January?",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-02-09T23:05:02.619733+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260924-cassdav5--8429787",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.016655",
        "source": "LSE_CHAT",
        "data": {
          "author": "cassdav57",
          "content": "Sorry guys, Realise, The exclusivity period extended to March 16th but would still expect news by end of Jan.",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-02-09T23:05:02.619751+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260918-cassdav5-24408914",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.017066",
        "source": "LSE_CHAT",
        "data": {
          "author": "cassdav57",
          "content": "The exclusivity period should be ending soon (January 2026), so we might hear updates about whether the deal proceeds in the coming weeks. The  main hope for good news  for me was the director buy in November of 5 million shares (\u00a385k) and the calibre of the trails technology plus funding through A2A Pharmaceuticals.  So yes, definitely a waiting game, currently I am down about 50% and will be holding and making some small additions at these low or lower prices until things become clearer as upside could be considerable.",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "1.20",
          "thread_title": "News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-02-09T23:05:02.619769+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261743-Downagai-17756056",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.017500",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "True enough",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.20",
          "thread_title": "RE: Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-02-09T23:05:02.619787+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261714-pumpky--3292189",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.017906",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "What is there to say? Just waiting for news",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.20",
          "thread_title": "RE: Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-02-09T23:05:02.619806+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261649-Downagai--6105944",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.018342",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Quiet here \ud83d\ude34",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.20",
          "thread_title": "RE: Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-02-09T23:05:02.619824+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261617-Downagai--1953233",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.113544",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Big sell 3 big buys?",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-09T23:05:02.619842+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261505-billy101--5745374",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.113993",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "What\u2019s another few months. Have you been in since Jan 25?",
          "sentiment": 0.0,
          "engagement": "31,698",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-09T23:05:02.619860+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261504-pumpky-63542325",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.114430",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Deal  has been going on since January 2025",
          "sentiment": 0.0,
          "engagement": "17,626",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-09T23:05:02.619879+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261425-leew--8236854",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.114946",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Could be a delay or could happen on time, funding is never a simple process having been involved myself. The access to the data room and the DD questions from all parties is always significant. Just wait for the confirmation, because all that is needed is patience with ROQ in my view.",
          "sentiment": 0.0,
          "engagement": "2,618",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-09T23:05:02.619897+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260859-davey50-27014487",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.115405",
        "source": "LSE_CHAT",
        "data": {
          "author": "davey50",
          "content": "1.23-1.35p online so mid price to buy, not a bad price for a gamble given it's history of spikes",
          "sentiment": 0.0,
          "engagement": "7,037",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-09T23:05:02.619915+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260806-pumpky-63398998",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.115821",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Anticipate not expect \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,626",
          "price_at_post": "1.45",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-09T23:05:02.619933+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260726-Downagai-11925712",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.116249",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Apparently a couple of days is aay ahead \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-09T23:05:02.619951+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260725-pumpky--7480585",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.116661",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Caroline Fortier We expect to finalise before the 31 January date\" Expect\" Get out card ( maybe delayed due to Trump wanting Greenland \ud83d\ude02)",
          "sentiment": 0.0,
          "engagement": "17,626",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-09T23:05:02.619969+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260725-Downagai--5833407",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.117079",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "No Dicko after all \"Caroline Fortier, Pleiades CEO commented: \"Following the previously announced acquisition of Lyramid, we are delighted to build on our relationship with Roquefort Therapeutics and take an exclusive license of the MK Cell therapy asset which we plan to take into clinical studies targeting high value oncology indications of unmet need. The addition of these assets to our immunotherapy, late-stage pan-specific vaccine and cell therapy portfolio is an important part of our strategy to position ourselves as a material biotechnology company to institutional investors with whom we are currently working to close on a significant equity funding round. In alignment with the extension of the Lyramid SPA we anticipate our funding round to complete ahead of the new 31 January 2026 long stop date.\"",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-09T23:05:02.619987+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260720-Dicko80--3243853",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.117508",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dicko80",
          "content": "What\u2019s the betting they\u2019ll be another extension to us getting our shares ? 1 week deadline",
          "sentiment": 0.0,
          "engagement": "2,427",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-09T23:05:02.620005+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20262142-leew--8316977",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.117916",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Well there is a lot of news due bbr, would be great to get the RTO confirmed and initially just get the SP back to 1.7p and then see where the RTO then takes it as there is some potential for increasing in market cap after so fingers crossed. Would also be good on the back of that to then here about the spin off and the deals associated to that to see when some cash might come in from the free shares.",
          "sentiment": 0.0,
          "engagement": "2,618",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-09T23:05:02.620023+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20262130-leew-83086492",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.118340",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Honestly if you want to invest best check yourself. I don\u2019t think reading a few RNA\u2019s and googling a few things is that bad.",
          "sentiment": 0.0,
          "engagement": "2,618",
          "price_at_post": "1.35",
          "thread_title": "RE: Can",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=28165808-701F-48DA-95C7-867899DCB7C6"
        },
        "ingested_at": "2026-02-09T23:05:02.620041+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261653-Kikudi-73222807",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.118754",
        "source": "LSE_CHAT",
        "data": {
          "author": "Kikudi",
          "content": "Some please give me highlights of ROQ that will save me go through  RNS I want to invest. Thanks in advance",
          "sentiment": 0.0,
          "engagement": "15",
          "price_at_post": "1.35",
          "thread_title": "Can",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=28165808-701F-48DA-95C7-867899DCB7C6"
        },
        "ingested_at": "2026-02-09T23:05:02.620059+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261338-Downagai-32659647",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.119177",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "IYHO I take it \ud83d\ude03",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-09T23:05:02.620078+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261337-bbr391--5861679",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.119594",
        "source": "LSE_CHAT",
        "data": {
          "author": "bbr391",
          "content": "Come to Papa . We will all soon be very very pleased (possibly). Outstanding",
          "sentiment": 0.5,
          "engagement": "8,990",
          "price_at_post": "1.35",
          "thread_title": "Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-09T23:05:02.620095+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260911-SharePic--3355607",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.120004",
        "source": "LSE_CHAT",
        "data": {
          "author": "SharePicks",
          "content": "I've added this to portfolio. Lets see where it goes.",
          "sentiment": 0.0,
          "engagement": "1,198",
          "price_at_post": "1.30",
          "thread_title": "1.5p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=EC7A8D0C-531B-4D1D-A5F0-14D0049CD3D9"
        },
        "ingested_at": "2026-02-09T23:05:02.620132+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260903-davey50-57861898",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.120420",
        "source": "LSE_CHAT",
        "data": {
          "author": "davey50",
          "content": "Just need to clear the slack below 1.4p and then the herd will arrive, if trls can do 300% then roq is always good for a spike a few times a year",
          "sentiment": 0.0,
          "engagement": "7,037",
          "price_at_post": "1.30",
          "thread_title": "RE: ROQ",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=34D50F4B-4B38-438B-BCC4-912454A889E9"
        },
        "ingested_at": "2026-02-09T23:05:02.620151+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260813-SharePic-82413844",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.120830",
        "source": "LSE_CHAT",
        "data": {
          "author": "SharePicks",
          "content": "Good start so far today.",
          "sentiment": 0.0,
          "engagement": "1,198",
          "price_at_post": "1.15",
          "thread_title": "ROQ",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=34D50F4B-4B38-438B-BCC4-912454A889E9"
        },
        "ingested_at": "2026-02-09T23:05:02.620169+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20260756-Downagai--2429829",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.121244",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Interesting pre market spread today. I wish",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.60",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-09T23:05:02.620187+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260840-billy101-84685528",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.121680",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "We will get updates on deals when and if  they are complete. They can't keep doing a running commentary on progress of deals. We have been told the aims in the R/Note. We have split Mk(nearly) upon condition of Coil happening. We are in different phases in trials. Anything else is conjecture. Whilst this is happening its stalemate on all pathways.",
          "sentiment": 0.0,
          "engagement": "31,698",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-09T23:05:02.620205+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260834-Downagai-11365165",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.122092",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "About progess on the deals? What page please I missed that thanks",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-09T23:05:02.620223+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260810-billy101--5258073",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.122513",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "We had news last wek in R/note.",
          "sentiment": 0.0,
          "engagement": "31,698",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-09T23:05:02.620242+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260730-Downagai-56385026",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.122926",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "They need to provide an update, this radio silence is very poor",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-09T23:05:02.620260+00:00"
      },
      {
        "event_id": "SOCIAL-17Jan20260249-Escapeto-46178839",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.123352",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "I'm hopeful, but not convinced this team can build value. I'm not sure what it is but just look at the history for starters. Continual missed deadlines. At the very least don't make a rod for your back with deadlines you never keep.",
          "sentiment": 0.0,
          "engagement": "1,297",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-09T23:05:02.620278+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20262335-Downagai-12094526",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.123758",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "It's because they keep promising the earth and delivering nothing with no updates and just delays",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-09T23:05:02.620296+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261646-billy101-20948296",
        "event_type": "social_post",
        "date": "2026-02-10T22:37:10.566395",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "It will jump back up to 1.3",
          "sentiment": 0.0,
          "engagement": "31,770",
          "price_at_post": "1.10",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.407203+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261526-Escapeto--4762714",
        "event_type": "social_post",
        "date": "2026-02-10T22:37:10.566823",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "DOWN.",
          "sentiment": 0.0,
          "engagement": "1,345",
          "price_at_post": "1.10",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.407240+00:00"
      },
      {
        "event_id": "SOCIAL-Today1646-billy101-20948296",
        "event_type": "social_post",
        "date": "2026-02-09T23:04:53.945984",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "It will jump back up to 1.3",
          "sentiment": 0.0,
          "engagement": "31,760",
          "price_at_post": "1.10",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.407281+00:00"
      },
      {
        "event_id": "SOCIAL-Today1526-Escapeto--4762714",
        "event_type": "social_post",
        "date": "2026-02-09T23:04:53.946429",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "DOWN.",
          "sentiment": 0.0,
          "engagement": "1,341",
          "price_at_post": "1.10",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.407320+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261052-Escapeto--1491029",
        "event_type": "social_post",
        "date": "2026-02-09T23:04:53.946840",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Education helps you know.",
          "sentiment": 0.0,
          "engagement": "1,341",
          "price_at_post": "1.20",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.407359+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261047-Escapeto--8373594",
        "event_type": "social_post",
        "date": "2026-02-09T23:04:53.947253",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "In my role I was expected to deliver to time, yes sometimes it is very complicated, in those situations we tended to be more wooly with what we said.",
          "sentiment": 0.0,
          "engagement": "1,341",
          "price_at_post": "1.20",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.407399+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260946-billy101-51759639",
        "event_type": "social_post",
        "date": "2026-02-09T23:04:53.947666",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Re post 0941hrs Its out of their hands. Its not an education level thingy",
          "sentiment": 0.0,
          "engagement": "31,760",
          "price_at_post": "1.20",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.407439+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260941-Escapeto--4559189",
        "event_type": "social_post",
        "date": "2026-02-09T23:04:53.948071",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "For Oxford University level of education , we expect bod to meet deadlines they themselves set.",
          "sentiment": 0.0,
          "engagement": "1,341",
          "price_at_post": "1.20",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.407478+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260641-leew-62989538",
        "event_type": "social_post",
        "date": "2026-02-09T23:04:53.948495",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Hamilton, they will at some stage, sometime funding takes time if you are doing more than a cheap placing for funding. If other companies are raising funding to buy some of our assets and it involves multiple parties the DD takes time and the same on the RTO side. This is a very small portion of my portfolio and if it takes 6 months extra / 1 year extra but happens I could not careless. I have a couple of Pharma\u2019s and I will stay in them for many many years not a trade. Therefore more view on hitting a timing date is not really relevant for this.",
          "sentiment": 0.0,
          "engagement": "2,659",
          "price_at_post": "1.20",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.407518+00:00"
      },
      {
        "event_id": "SOCIAL-Today1052-Escapeto--1491029",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.483596",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Education helps you know.",
          "sentiment": 0.0,
          "engagement": "1,339",
          "price_at_post": "1.20",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.407557+00:00"
      },
      {
        "event_id": "SOCIAL-Today1047-Escapeto--8373594",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.484024",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "In my role I was expected to deliver to time, yes sometimes it is very complicated, in those situations we tended to be more wooly with what we said.",
          "sentiment": 0.0,
          "engagement": "1,339",
          "price_at_post": "1.20",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.407593+00:00"
      },
      {
        "event_id": "SOCIAL-Today0946-billy101-51759639",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.484477",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Re post 0941hrs Its out of their hands. Its not an education level thingy",
          "sentiment": 0.0,
          "engagement": "31,754",
          "price_at_post": "1.20",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.407630+00:00"
      },
      {
        "event_id": "SOCIAL-Today0941-Escapeto--4559189",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.484881",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "For Oxford University level of education , we expect bod to meet deadlines they themselves set.",
          "sentiment": 0.0,
          "engagement": "1,339",
          "price_at_post": "1.20",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.407667+00:00"
      },
      {
        "event_id": "SOCIAL-Today0641-leew-62989538",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.485330",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Hamilton, they will at some stage, sometime funding takes time if you are doing more than a cheap placing for funding. If other companies are raising funding to buy some of our assets and it involves multiple parties the DD takes time and the same on the RTO side. This is a very small portion of my portfolio and if it takes 6 months extra / 1 year extra but happens I could not careless. I have a couple of Pharma\u2019s and I will stay in them for many many years not a trade. Therefore more view on hitting a timing date is not really relevant for this.",
          "sentiment": 0.0,
          "engagement": "2,659",
          "price_at_post": "1.20",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.407704+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261331-Gigontbs-48784147",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.485733",
        "source": "LSE_CHAT",
        "data": {
          "author": "Gigontbsaaa",
          "content": "FM pumping and dumping, was the 1st sign",
          "sentiment": 0.0,
          "engagement": "435",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.407743+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261328-Escapeto--8611966",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.486145",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "May have to put this one down to experience. All the warning signs present",
          "sentiment": 0.0,
          "engagement": "1,339",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.407782+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261220-pumpky--6110365",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.486552",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Caroline Fortier expected funding to be completed before January 31 also \ud83d\ude02 One thing for sure is Roq need to do something soon as must be running out of money",
          "sentiment": 0.0,
          "engagement": "17,738",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.407820+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261203-Escapeto--3834158",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.486959",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Cardiogeni's December annual stated :\" Advanced discussions for a funding agreement of $25M (~\u00a319M) for Cardiogeni (UAE) Limited expected to complete by the end of January 2026 where upon first tranche of funding is anticipated\". SURELY VERY CLOSE. CMon Roquefort get that funding.",
          "sentiment": 0.0,
          "engagement": "1,339",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.407858+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261150-Escapeto-55819530",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.487382",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Smelly cheese!",
          "sentiment": 0.0,
          "engagement": "1,339",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.407895+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261145-hamilton-48510926",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.487799",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "No doubt everyone has done their research and knows that the same people at ROQ are in CGNI also ? Have a look at their deal tha hasn\u2019t happened either !! https://www.investegate.co.uk/announcement/rns/cardiogeni-plc--cgni/details-of-advanced-subscription-company-update/8998882 Not sure what they actually do ! Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,563",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.407942+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261108-hamilton-20506684",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.488221",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "What makes you think they will hit the new deadline ? It\u2019s been going on over a year now. The communication is terrible. Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,563",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.407981+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20262326-leew--3000054",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.488635",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Hamilton, nothing is terminated, looks like the date was changed in the research note, which I have just noticed only as it was pointed out below. Stupid for me to have missed that, but had a huge amount going on. Not brilliant to have communicated it there but is what it is so we move on with 2 dates close together now :)",
          "sentiment": 0.0,
          "engagement": "2,659",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.408019+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261258-hamilton--2119615",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.489050",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "Looks like the deal has terminated then ? They did this last year with the Oncogeni sale. It had a deadline and they ended talks but we didn\u2019t find out till months later. If no rns then can only assume the worst ? Poor ! Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,563",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.408057+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260830-billy101-38875846",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.489492",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "The RN laid it all out. The bit we are interested in the financials etc  can get losted in the impress pathways we have. Lets hope it comes together.",
          "sentiment": 0.0,
          "engagement": "31,754",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.408093+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260823-Downagai-48969007",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.489897",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "If it is then to hide that in a research note is shockingly poor. Management are losing all credibility here for me I'm afraid",
          "sentiment": 0.0,
          "engagement": "939",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.408147+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260806-billy101--7246234",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.490315",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "March 16th it is then for now.",
          "sentiment": 0.0,
          "engagement": "31,754",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.408184+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260758-Downagai-42400921",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.490720",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "I seriously hope so but have my doubts",
          "sentiment": 0.0,
          "engagement": "939",
          "price_at_post": "1.60",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.408223+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260751-Dicko80-17602774",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.491148",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dicko80",
          "content": "Previously the extensions have come in advance of the date So with no ext announced Maybe they are closing their financing and close to completion Hence no RNS as of yet \ud83e\udd1e",
          "sentiment": 0.0,
          "engagement": "2,435",
          "price_at_post": "1.60",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.408260+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260737-Downagai-20719754",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.491552",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Tumbleweed \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "939",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.408298+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20260855-Dicko80--6546313",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.491952",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dicko80",
          "content": "Im sure we\u2019ll find out soon enough",
          "sentiment": 0.0,
          "engagement": "2,435",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.408334+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20260727-leew-51184992",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.492377",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Must admit I was expecting an RNA today. Unless it drops at 7.30 for various reasons :)",
          "sentiment": 0.0,
          "engagement": "2,659",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.408371+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20260720-hamilton-95219117",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.492790",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "No rns ? Not sure what\u2019s going on now. Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,563",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.408408+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260823-Downagai-13271793",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.493218",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "I started worrying when emails started being ignored tbh this os farcical now",
          "sentiment": 0.0,
          "engagement": "939",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.408447+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260742-pumpky-62053052",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.493624",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Monday then \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,738",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.408485+00:00"
      },
      {
        "event_id": "SOCIAL-Today0823-Downagai-13271793",
        "event_type": "social_post",
        "date": "2026-01-30T23:00:14.646540",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "I started worrying when emails started being ignored tbh this os farcical now",
          "sentiment": 0.0,
          "engagement": "920",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.408521+00:00"
      },
      {
        "event_id": "SOCIAL-Today0742-pumpky-62053052",
        "event_type": "social_post",
        "date": "2026-01-30T23:00:14.647111",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Monday then \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,680",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.408558+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260849-bbr391--6230283",
        "event_type": "social_post",
        "date": "2026-01-30T23:00:14.647545",
        "source": "LSE_CHAT",
        "data": {
          "author": "bbr391",
          "content": "Will this old dog ever have It`s day You Decide Outstanding  ( perhaps )",
          "sentiment": 0.0,
          "engagement": "8,994",
          "price_at_post": "1.30",
          "thread_title": "Old Dogs & Englishmen",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=CFBF3BDA-6A27-4675-B082-EFC47765863B"
        },
        "ingested_at": "2026-02-10T22:37:17.408596+00:00"
      },
      {
        "event_id": "SOCIAL-Today0849-bbr391--6230283",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.705516",
        "source": "LSE_CHAT",
        "data": {
          "author": "bbr391",
          "content": "Will this old dog ever have It`s day You Decide Outstanding  ( perhaps )",
          "sentiment": 0.0,
          "engagement": "8,993",
          "price_at_post": "1.30",
          "thread_title": "Old Dogs & Englishmen",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=CFBF3BDA-6A27-4675-B082-EFC47765863B"
        },
        "ingested_at": "2026-02-10T22:37:17.408633+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261815-Downagai--1568261",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.706052",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Says 8 trades but only 2 showing??",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.408672+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261357-billy101-14547065",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.706616",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Will either find out Friday or Monday",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.408708+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261350-Downagai--6447770",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.707168",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "I don't think the research note it right, the dates are nonsense tbh it's really poor.",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.408745+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261338-Merciama--4324280",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.707689",
        "source": "LSE_CHAT",
        "data": {
          "author": "Merciaman",
          "content": "Agreed downagain - I saw the section from the research note that Billy points out, and expected an official confirmation from the company regarding date for the deal. In the absence of that there is clearly some uncertainty - does the 31/1 date still apply, or is it indeed a case of both deals now having a longstop date of 16/3 ?",
          "sentiment": 0.0,
          "engagement": "286",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.408782+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261234-Downagai--2965539",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.708207",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Think they just need to update clearly and transparently",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.408819+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261206-billy101-20465125",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.708763",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Separately, the Company updated the status of the sale of its subsidiary Lyramid to Pleiades, a transaction worth up to $10.8m. Because Pleiades has not yet completed its fundraising with institutional and sovereign wealth fund investors in the GCC (Gulf Cooperation Council), the longstop date has been extended to 16 March 2026. The SPA has also been amended so that Midkine Investments, rather than Roquefort Therapeutics, is now the selling entity, and to acknowledge the scheduled termination of Lyramid\u2019s third-party licence to the Midkine antibody programme in November 2025.",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-10T22:37:17.408857+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261142-billy101-70417694",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.709296",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Didn\u2019t he take on a NED role. Maybe wrong due to information overload.",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-10T22:37:17.408896+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261139-hamilton-83188830",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.709808",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "The RTO and the carve out are not related at all apart from being ROQ assets. The thing worrying me is why did AR sell all his shares before the Carve out entitlement date when he was the one that introduced ROQ to Pleiades, apparently ? Another extension coming no doubt. Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,547",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-10T22:37:17.408934+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261056-Downagai-49883618",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.710353",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Oops Group Restructuring The Company intends to carve out the value of the Lyramid SPA and the MK Cell Out-License for the benefit of existing shareholders and convertible loan holders. In order to facilitate this, the Company has recently undertaken the following restructuring of the Group (the \"Group Restructuring\"): a) The entire issued shares of Lyramid have been acquired by Midkine Investments (a 100% owned subsidiary of Roquefort Therapeutics) such that Lyramid is now 100% owned by Midkine Investments; and b) The rights to the MK Cell program held by Oncogeni Ltd have been novated to Midkine Investments such that Midkine Investments now holds the underlying exclusive worldwide rights to the MK Cell program. It is the intention of the Company to issue new unlisted redeemable non-voting shares (\"Unlisted RNV Shares\") to the holders of Roquefort Therapeutics ordinary shares and convertible loan notes listed on the Company's registers as at 30 November 2025. The Unlisted RNV Shares will entitle holders to all commercial benefits from Midkine Investments with the ultimate aim of undertaking an in-specie distribution of the Midkine Investments shares once the balance sheet of the Company permits such an action under the Companies Act.",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-10T22:37:17.408972+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261054-Downagai--5108044",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.711148",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "London South East Check out our new Alternative Investment section.Click here Share PricesRoquefort Thera Share PriceRoquefort Thera Share Regulatory NewsMK Cell Out-License & Lyramid SPA Update Pin to quick picksRoquefort Thera Regulatory News (ROQ) ROQ Share Price ROQ Share Price ROQ Share News ROQ Share News ROQ Share Chat ROQ Share Chat 10 ROQ Share Trades ROQ Share Trades ROQ Live RNS ROQ Live RNS Sponsored Content Roquefort Thera Information Add ROQ to Timeline Add ROQ to Timeline Add ROQ to Watchlist Add ROQ to Watchlist Add ROQ to Alert Add ROQ to Alert Buy ROQ Shares Buy ROQ Shares Share Price Information for Roquefort Thera (ROQ) Share Price is delayed by 15 minutes Get Live Data 1.30 0.00 (0.00%) Bid: 1.20 Ask: 1.40 Spread: 0.20 (16.667%)Market Cap: \u00a32.13m ROQ Live PriceLast checked at 10:53:52London Stock Exchange Sponsored Content MK Cell Out-License & Lyramid SPA Update 3 Nov 2025 07:00 RNS Number : 8172F Roquefort Therapeutics PLC 03 November 2025 3 November 2025 Roquefort Therapeutics plc (\"Roquefort Therapeutics\" or the \"Company\") MK Cell Out-License & Lyramid SPA Update Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces it has entered into an agreement to out-license its MK Cell patents to Pleiades Pharma Ltd (\"Pleiades\") in return for up to US$25 million in milestone cash payments together and a royalty payment obligation (the \"MK Cell Out-License\"). Background As announced on 8 September 2025, the Company is proposing to acquire from A2A Pharmaceuticals, Inc. and Coiled Therapeutics, Inc. the exclusive licence rights to AO-252, a novel first-in-class, first-in-human new drug alternative targeting the TACC3 protein for the treatment of certain cancers (the \"Proposed Transaction\"), retain the STAT-6 program and has ceased discussions around the sale of its wholly owned subsidiary Oncogeni Ltd. Further details on the progress of the Proposed Transaction will be announced in due course. Following the announcement of the Proposed Transaction, the Company initiated discussions with Pleiades regarding the grant of an exclusive worldwide license for its MK Cell program, which has resulted in the signing of the MK Cell Out-License. MK Cell Out-License To accommodate the Group Restructuring (refer below) that was signalled in August 2025, the parties to the MK Cell Out-License are Roquefort Therapeutics' wholly owned subsidiary Midkine Investments Ltd (\"Midkine Investments\") and Pleiades. The consideration payable by Pleiades for the MK Cell Out-License is a combination of milestone cash payments and a royalty payment obligation of 1.5% perpetuity royalty on all global net sales of products derived from the licensed technology. The total milestone cash payments of up to US$25 million is payable by Pleiades as follows: a) US$500,000 upon Pleiades securing a minimum fundraising",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-10T22:37:17.409010+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261043-billy101--3131313",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.711670",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Sorry not RTO shares should have put  Unlisted RNV Shares",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-10T22:37:17.409050+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261026-billy101--7871031",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.712198",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Lets hope so. However MK will only happen up on condition of Coil happening otherwise there is no point. ROQ doesn't benefit only the RTO holders. Personally I want the RTO regardless of Coil. Compnaies House registers have all been updated we are just waiting for a completion of something (deal) otherwise we would have had our allocation of RTO shares of 10:1 by now.",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-10T22:37:17.409088+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261003-Downagai-18344120",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.712701",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "No that's not right, the deals are not linked, funding due this week",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-10T22:37:17.409140+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260947-billy101-81840711",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.713218",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Otherwsie no split required. ROQ will remain one entity with just Pleiades deal.",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-10T22:37:17.409178+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260943-billy101--8924443",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.713754",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "The research note has implied the deal(s) have been extended to 16th March. Surely MK will only happen if Coil completes.",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-10T22:37:17.409216+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260915-Escapeto--9015780",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.714286",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Delay... They never fail on that one.",
          "sentiment": 0.0,
          "engagement": "1,307",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-10T22:37:17.409254+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260810-Downagai--3564128",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.714786",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Tbh given this is carved off it shouldn't technically affect the Roq price anyway hut would be nice to conclude the free shares and understand what is actually going on",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-10T22:37:17.409292+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260753-Downagai-43772325",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.715339",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "No way I see this sorted this week. If funding was coming after a year they would not be this close to the wire injo",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.45",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-10T22:37:17.409331+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260751-mnsa-32077201",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.715754",
        "source": "LSE_CHAT",
        "data": {
          "author": "mnsa",
          "content": "Let\u2019s hope for once the deliver on the deadline given! If they do this should recover very well! Hoping for some +ve!",
          "sentiment": 0.0,
          "engagement": "311",
          "price_at_post": "1.60",
          "thread_title": "Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-10T22:37:17.409368+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260721-hamilton--3889660",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.716197",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "Anyone heard from the company or seen anything ? Literally can\u2019t be bothered with another extension. Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,547",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-10T22:37:17.409406+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261158-Downagai-31986859",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.716610",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "4 more days \ud83d\ude2c",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-10T22:37:17.409443+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20260858-pumpky-77642307",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.717023",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Billy Yes invested in January due to their RNS",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-10T22:37:17.409480+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20262322-Escapeto--6788153",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:27.301413",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Huge bull market for biotech , roq at all time low.",
          "sentiment": 0.0,
          "engagement": "1,307",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-10T22:37:17.409517+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261742-pumpky-16624302",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:27.301822",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Read them and what? SP Angel are the Brokers  for Roquefort \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-10T22:37:17.409555+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261447-billy101--7880761",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.001123",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Read pages 28 and 29",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-10T22:37:17.409593+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261350-Escapeto-72178215",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.001936",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "They'll miss it.",
          "sentiment": 0.0,
          "engagement": "1,307",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-10T22:37:17.409633+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261326-pumpky-48608838",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.002732",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Pileades deal 16  March ?",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-10T22:37:17.409670+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261315-billy101-16589774",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.003543",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Could go in until 16th March",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-10T22:37:17.409709+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261257-pumpky--6021928",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.004326",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "3rd November RNS Caroline Fortier  We anticipate the round of funding to be completed before the Long stop date of 31Januaey 2026",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-10T22:37:17.409747+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261256-Escapeto-13561360",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.005138",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Disappointed \ud83d\ude1e. DOWN.",
          "sentiment": 0.0,
          "engagement": "1,307",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-10T22:37:17.409784+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261253-pumpky--9379329",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.005910",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "IF being the operative word \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-10T22:37:17.409821+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261147-Downagai--6218061",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.006712",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Well with all the fanfare around this never thought I'd be able to buy under 1.2p. If the deal happens near 50% upside straight away. What not to like \ud83d\ude03\ud83d\ude80",
          "sentiment": 0.5,
          "engagement": "864",
          "price_at_post": "1.20",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-10T22:37:17.409860+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261029-Aklee-35532858",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.007517",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aklee",
          "content": "I see Davey is here peddling his usual nonsense. Be careful on any share he is in. Always sells into the smallest rise whilst claiming it's someone else",
          "sentiment": 0.0,
          "engagement": "3,597",
          "price_at_post": "1.25",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-10T22:37:17.409898+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261212-Downagai--2247619",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.008304",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Wow how to lose \u00a3730 in 3 hours. Unlucky trader Sam \ud83e\udd26\u200d\u2642\ufe0f",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "Loss",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=A17EF4D3-D0D3-4793-A674-53112286A2B2"
        },
        "ingested_at": "2026-02-10T22:37:17.409937+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260826-billy101-26141264",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.009089",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Only issue I have with todays RNS(RESEARCH NOTE) . It should have been released in November.",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-10T22:37:17.409976+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260806-billy101--3910829",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.009911",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Keeping this short and brief for us investors page 7 matters. And if they tick all the boxes with TACC3 Inhibitor thats mentioned on page 14 then were off to the moon. The rest of the read research note is for my daughters and son in law to translate to me!",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.20",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-10T22:37:17.410014+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260805-davey50-50440252",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.010700",
        "source": "LSE_CHAT",
        "data": {
          "author": "davey50",
          "content": "Just play the game, buy them when totally unloved and sell them when the shares are spiking and the herd arrives rinse and repeat. I took 500k more at the bell 1.23p ish...what a price...they were chasing this up to 2.5p not long ago",
          "sentiment": 0.0,
          "engagement": "7,050",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-10T22:37:17.410052+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260804-leew-32937360",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.011498",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Well digesting the financial pages was my first port of call and to be honest the purchase price we are paying is very reasonable and if the shares are issued at 1.7 as adv used then on the RTO I see some potential for immediate upside with no real news other than we have done the RTO and its purchase value. Add that to then normal news on progression in phase 1 and beyond we could see some very good gains. Will need to digest the technical aspect later but form investment strategy I am happy",
          "sentiment": 0.0,
          "engagement": "2,632",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-10T22:37:17.410088+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260756-bbr391--8877560",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.012391",
        "source": "LSE_CHAT",
        "data": {
          "author": "bbr391",
          "content": "Progress to date Roquefort has demonstrated significant anti-cancer activity with its STAT-6 siRNA therapeutics, as validated in in vivo models of breast and colon cancer. These results further reinforce the potential of STAT-6 targeting approaches in multiple tumour types and provide a strong foundation for advancing this programme towards clinical evaluation. STAT-6 targeting siRNA constructs have shown significant in vivo anti-cancer activity in validated models of colon cancer. STAT-6 siRNAs demonstrated a significant reduction in the proliferation of colorectal cancer with a ca.50% reduction in cell growth at seven days. This anti-cancer effect was replicated in a validated in vivo model of colorectal cancer with a significant reduction in cancer weight and volume over 28 days As usual . One feels the Americans are getting good research at a very very very low cost . Outstanding",
          "sentiment": 0.5,
          "engagement": "8,993",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-10T22:37:17.410139+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260751-billy101--2834827",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.013194",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "There is alot in there, so they have starteed the PR now. The Key milestone dates for 2025-2027 and Financial valuation on page 4 will keep investors happy. Its a long read",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-10T22:37:17.410177+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260739-Downagai-79389568",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.013953",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "That'd an easy read. Nothing new really though that I can see",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.20",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-10T22:37:17.410215+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261116-cassdav5--8624889",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.014729",
        "source": "LSE_CHAT",
        "data": {
          "author": "cassdav57",
          "content": "Yes pumpky your correct.  My bad, brain fog on different aspects of deal and moving targets. The deal requires ROQ's enlarged share capital to be admitted to trading on AIM by this new March 16, 2026 deadline to complete the transaction. So they have about 2 more months to finalize everything and get the AIM listing done.",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-02-10T22:37:17.410254+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261027-Merciama-66171853",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.015502",
        "source": "LSE_CHAT",
        "data": {
          "author": "Merciaman",
          "content": "It is Pumpky, 31/1 deadline for Pleiades to buy Lyramid from Midkine Investments. The reverse takeover of Roquefort to form Coiled Therapeutics has the 16th March deadline.",
          "sentiment": 0.0,
          "engagement": "286",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-02-10T22:37:17.410292+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260941-pumpky--8170554",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.016237",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Isnt the Pileades deal January?",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-02-10T22:37:17.410328+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260924-cassdav5--3658723",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.016655",
        "source": "LSE_CHAT",
        "data": {
          "author": "cassdav57",
          "content": "Sorry guys, Realise, The exclusivity period extended to March 16th but would still expect news by end of Jan.",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-02-10T22:37:17.410366+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260918-cassdav5--2545967",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.017066",
        "source": "LSE_CHAT",
        "data": {
          "author": "cassdav57",
          "content": "The exclusivity period should be ending soon (January 2026), so we might hear updates about whether the deal proceeds in the coming weeks. The  main hope for good news  for me was the director buy in November of 5 million shares (\u00a385k) and the calibre of the trails technology plus funding through A2A Pharmaceuticals.  So yes, definitely a waiting game, currently I am down about 50% and will be holding and making some small additions at these low or lower prices until things become clearer as upside could be considerable.",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "1.20",
          "thread_title": "News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-02-10T22:37:17.410404+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261743-Downagai-19873603",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.017500",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "True enough",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.20",
          "thread_title": "RE: Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-02-10T22:37:17.410442+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261714-pumpky-88422686",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.017906",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "What is there to say? Just waiting for news",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.20",
          "thread_title": "RE: Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-02-10T22:37:17.410479+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261649-Downagai-80754783",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.018342",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Quiet here \ud83d\ude34",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.20",
          "thread_title": "RE: Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-02-10T22:37:17.410517+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261617-Downagai--6329246",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.113544",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Big sell 3 big buys?",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-10T22:37:17.410554+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261505-billy101--5349724",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.113993",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "What\u2019s another few months. Have you been in since Jan 25?",
          "sentiment": 0.0,
          "engagement": "31,698",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-10T22:37:17.410591+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261504-pumpky-35260061",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.114430",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Deal  has been going on since January 2025",
          "sentiment": 0.0,
          "engagement": "17,626",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-10T22:37:17.410628+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261425-leew--4375443",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.114946",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Could be a delay or could happen on time, funding is never a simple process having been involved myself. The access to the data room and the DD questions from all parties is always significant. Just wait for the confirmation, because all that is needed is patience with ROQ in my view.",
          "sentiment": 0.0,
          "engagement": "2,618",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-10T22:37:17.410666+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260859-davey50-47867513",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.115405",
        "source": "LSE_CHAT",
        "data": {
          "author": "davey50",
          "content": "1.23-1.35p online so mid price to buy, not a bad price for a gamble given it's history of spikes",
          "sentiment": 0.0,
          "engagement": "7,037",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-10T22:37:17.410703+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260806-pumpky-63192750",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.115821",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Anticipate not expect \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,626",
          "price_at_post": "1.45",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-10T22:37:17.410741+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260726-Downagai--5955689",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.116249",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Apparently a couple of days is aay ahead \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-10T22:37:17.410779+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260725-pumpky-34914053",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.116661",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Caroline Fortier We expect to finalise before the 31 January date\" Expect\" Get out card ( maybe delayed due to Trump wanting Greenland \ud83d\ude02)",
          "sentiment": 0.0,
          "engagement": "17,626",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-10T22:37:17.410817+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260725-Downagai--6601440",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.117079",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "No Dicko after all \"Caroline Fortier, Pleiades CEO commented: \"Following the previously announced acquisition of Lyramid, we are delighted to build on our relationship with Roquefort Therapeutics and take an exclusive license of the MK Cell therapy asset which we plan to take into clinical studies targeting high value oncology indications of unmet need. The addition of these assets to our immunotherapy, late-stage pan-specific vaccine and cell therapy portfolio is an important part of our strategy to position ourselves as a material biotechnology company to institutional investors with whom we are currently working to close on a significant equity funding round. In alignment with the extension of the Lyramid SPA we anticipate our funding round to complete ahead of the new 31 January 2026 long stop date.\"",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-10T22:37:17.410856+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260720-Dicko80-31315016",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.117508",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dicko80",
          "content": "What\u2019s the betting they\u2019ll be another extension to us getting our shares ? 1 week deadline",
          "sentiment": 0.0,
          "engagement": "2,427",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-10T22:37:17.410895+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20262142-leew--3195954",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.117916",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Well there is a lot of news due bbr, would be great to get the RTO confirmed and initially just get the SP back to 1.7p and then see where the RTO then takes it as there is some potential for increasing in market cap after so fingers crossed. Would also be good on the back of that to then here about the spin off and the deals associated to that to see when some cash might come in from the free shares.",
          "sentiment": 0.0,
          "engagement": "2,618",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-10T22:37:17.410932+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20262130-leew--5917781",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.118340",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Honestly if you want to invest best check yourself. I don\u2019t think reading a few RNA\u2019s and googling a few things is that bad.",
          "sentiment": 0.0,
          "engagement": "2,618",
          "price_at_post": "1.35",
          "thread_title": "RE: Can",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=28165808-701F-48DA-95C7-867899DCB7C6"
        },
        "ingested_at": "2026-02-10T22:37:17.410969+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261653-Kikudi-54005019",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.118754",
        "source": "LSE_CHAT",
        "data": {
          "author": "Kikudi",
          "content": "Some please give me highlights of ROQ that will save me go through  RNS I want to invest. Thanks in advance",
          "sentiment": 0.0,
          "engagement": "15",
          "price_at_post": "1.35",
          "thread_title": "Can",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=28165808-701F-48DA-95C7-867899DCB7C6"
        },
        "ingested_at": "2026-02-10T22:37:17.411007+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261338-Downagai-53682436",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.119177",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "IYHO I take it \ud83d\ude03",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-10T22:37:17.411045+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261337-bbr391--7125627",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.119594",
        "source": "LSE_CHAT",
        "data": {
          "author": "bbr391",
          "content": "Come to Papa . We will all soon be very very pleased (possibly). Outstanding",
          "sentiment": 0.5,
          "engagement": "8,990",
          "price_at_post": "1.35",
          "thread_title": "Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-10T22:37:17.411083+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260911-SharePic--6836521",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.120004",
        "source": "LSE_CHAT",
        "data": {
          "author": "SharePicks",
          "content": "I've added this to portfolio. Lets see where it goes.",
          "sentiment": 0.0,
          "engagement": "1,198",
          "price_at_post": "1.30",
          "thread_title": "1.5p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=EC7A8D0C-531B-4D1D-A5F0-14D0049CD3D9"
        },
        "ingested_at": "2026-02-10T22:37:17.411161+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260903-davey50--7357069",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.120420",
        "source": "LSE_CHAT",
        "data": {
          "author": "davey50",
          "content": "Just need to clear the slack below 1.4p and then the herd will arrive, if trls can do 300% then roq is always good for a spike a few times a year",
          "sentiment": 0.0,
          "engagement": "7,037",
          "price_at_post": "1.30",
          "thread_title": "RE: ROQ",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=34D50F4B-4B38-438B-BCC4-912454A889E9"
        },
        "ingested_at": "2026-02-10T22:37:17.411199+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260813-SharePic--4324095",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.120830",
        "source": "LSE_CHAT",
        "data": {
          "author": "SharePicks",
          "content": "Good start so far today.",
          "sentiment": 0.0,
          "engagement": "1,198",
          "price_at_post": "1.15",
          "thread_title": "ROQ",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=34D50F4B-4B38-438B-BCC4-912454A889E9"
        },
        "ingested_at": "2026-02-10T22:37:17.411237+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20260756-Downagai-10251351",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.121244",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Interesting pre market spread today. I wish",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.60",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-10T22:37:17.411274+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260840-billy101-74563137",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.121680",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "We will get updates on deals when and if  they are complete. They can't keep doing a running commentary on progress of deals. We have been told the aims in the R/Note. We have split Mk(nearly) upon condition of Coil happening. We are in different phases in trials. Anything else is conjecture. Whilst this is happening its stalemate on all pathways.",
          "sentiment": 0.0,
          "engagement": "31,698",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-10T22:37:17.411311+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260834-Downagai--8290462",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.122092",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "About progess on the deals? What page please I missed that thanks",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-10T22:37:17.411349+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260810-billy101--8057432",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.122513",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "We had news last wek in R/note.",
          "sentiment": 0.0,
          "engagement": "31,698",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-10T22:37:17.411386+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260730-Downagai--4240760",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.122926",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "They need to provide an update, this radio silence is very poor",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-10T22:37:17.411424+00:00"
      },
      {
        "event_id": "SOCIAL-17Jan20260249-Escapeto--6043089",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.123352",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "I'm hopeful, but not convinced this team can build value. I'm not sure what it is but just look at the history for starters. Continual missed deadlines. At the very least don't make a rod for your back with deadlines you never keep.",
          "sentiment": 0.0,
          "engagement": "1,297",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-10T22:37:17.411463+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20262335-Downagai-90575271",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.123758",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "It's because they keep promising the earth and delivering nothing with no updates and just delays",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-10T22:37:17.411500+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261646-billy101-82361913",
        "event_type": "social_post",
        "date": "2026-02-10T22:37:10.566395",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "It will jump back up to 1.3",
          "sentiment": 0.0,
          "engagement": "31,770",
          "price_at_post": "1.10",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.310485+00:00"
      },
      {
        "event_id": "SOCIAL-9Feb20261526-Escapeto-47380271",
        "event_type": "social_post",
        "date": "2026-02-10T22:37:10.566823",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "DOWN.",
          "sentiment": 0.0,
          "engagement": "1,345",
          "price_at_post": "1.10",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.310509+00:00"
      },
      {
        "event_id": "SOCIAL-Today1646-billy101-82361913",
        "event_type": "social_post",
        "date": "2026-02-09T23:04:53.945984",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "It will jump back up to 1.3",
          "sentiment": 0.0,
          "engagement": "31,760",
          "price_at_post": "1.10",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.310528+00:00"
      },
      {
        "event_id": "SOCIAL-Today1526-Escapeto-47380271",
        "event_type": "social_post",
        "date": "2026-02-09T23:04:53.946429",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "DOWN.",
          "sentiment": 0.0,
          "engagement": "1,341",
          "price_at_post": "1.10",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.310547+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261052-Escapeto-16757001",
        "event_type": "social_post",
        "date": "2026-02-09T23:04:53.946840",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Education helps you know.",
          "sentiment": 0.0,
          "engagement": "1,341",
          "price_at_post": "1.20",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.310565+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20261047-Escapeto--8232826",
        "event_type": "social_post",
        "date": "2026-02-09T23:04:53.947253",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "In my role I was expected to deliver to time, yes sometimes it is very complicated, in those situations we tended to be more wooly with what we said.",
          "sentiment": 0.0,
          "engagement": "1,341",
          "price_at_post": "1.20",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.310583+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260946-billy101--1776128",
        "event_type": "social_post",
        "date": "2026-02-09T23:04:53.947666",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Re post 0941hrs Its out of their hands. Its not an education level thingy",
          "sentiment": 0.0,
          "engagement": "31,760",
          "price_at_post": "1.20",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.310601+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260941-Escapeto-24028957",
        "event_type": "social_post",
        "date": "2026-02-09T23:04:53.948071",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "For Oxford University level of education , we expect bod to meet deadlines they themselves set.",
          "sentiment": 0.0,
          "engagement": "1,341",
          "price_at_post": "1.20",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.310625+00:00"
      },
      {
        "event_id": "SOCIAL-6Feb20260641-leew--7182977",
        "event_type": "social_post",
        "date": "2026-02-09T23:04:53.948495",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Hamilton, they will at some stage, sometime funding takes time if you are doing more than a cheap placing for funding. If other companies are raising funding to buy some of our assets and it involves multiple parties the DD takes time and the same on the RTO side. This is a very small portion of my portfolio and if it takes 6 months extra / 1 year extra but happens I could not careless. I have a couple of Pharma\u2019s and I will stay in them for many many years not a trade. Therefore more view on hitting a timing date is not really relevant for this.",
          "sentiment": 0.0,
          "engagement": "2,659",
          "price_at_post": "1.20",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.310644+00:00"
      },
      {
        "event_id": "SOCIAL-Today1052-Escapeto-16757001",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.483596",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Education helps you know.",
          "sentiment": 0.0,
          "engagement": "1,339",
          "price_at_post": "1.20",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.310662+00:00"
      },
      {
        "event_id": "SOCIAL-Today1047-Escapeto--8232826",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.484024",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "In my role I was expected to deliver to time, yes sometimes it is very complicated, in those situations we tended to be more wooly with what we said.",
          "sentiment": 0.0,
          "engagement": "1,339",
          "price_at_post": "1.20",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.310679+00:00"
      },
      {
        "event_id": "SOCIAL-Today0946-billy101--1776128",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.484477",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Re post 0941hrs Its out of their hands. Its not an education level thingy",
          "sentiment": 0.0,
          "engagement": "31,754",
          "price_at_post": "1.20",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.310697+00:00"
      },
      {
        "event_id": "SOCIAL-Today0941-Escapeto-24028957",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.484881",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "For Oxford University level of education , we expect bod to meet deadlines they themselves set.",
          "sentiment": 0.0,
          "engagement": "1,339",
          "price_at_post": "1.20",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.310714+00:00"
      },
      {
        "event_id": "SOCIAL-Today0641-leew--7182977",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.485330",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Hamilton, they will at some stage, sometime funding takes time if you are doing more than a cheap placing for funding. If other companies are raising funding to buy some of our assets and it involves multiple parties the DD takes time and the same on the RTO side. This is a very small portion of my portfolio and if it takes 6 months extra / 1 year extra but happens I could not careless. I have a couple of Pharma\u2019s and I will stay in them for many many years not a trade. Therefore more view on hitting a timing date is not really relevant for this.",
          "sentiment": 0.0,
          "engagement": "2,659",
          "price_at_post": "1.20",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.310732+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261331-Gigontbs-89930100",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.485733",
        "source": "LSE_CHAT",
        "data": {
          "author": "Gigontbsaaa",
          "content": "FM pumping and dumping, was the 1st sign",
          "sentiment": 0.0,
          "engagement": "435",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.310749+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261328-Escapeto--2035597",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.486145",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "May have to put this one down to experience. All the warning signs present",
          "sentiment": 0.0,
          "engagement": "1,339",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.310767+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261220-pumpky--6718755",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.486552",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Caroline Fortier expected funding to be completed before January 31 also \ud83d\ude02 One thing for sure is Roq need to do something soon as must be running out of money",
          "sentiment": 0.0,
          "engagement": "17,738",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.310785+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261203-Escapeto--4621738",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.486959",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Cardiogeni's December annual stated :\" Advanced discussions for a funding agreement of $25M (~\u00a319M) for Cardiogeni (UAE) Limited expected to complete by the end of January 2026 where upon first tranche of funding is anticipated\". SURELY VERY CLOSE. CMon Roquefort get that funding.",
          "sentiment": 0.0,
          "engagement": "1,339",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.310803+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261150-Escapeto-85651406",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.487382",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Smelly cheese!",
          "sentiment": 0.0,
          "engagement": "1,339",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.310821+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261145-hamilton--7295564",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.487799",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "No doubt everyone has done their research and knows that the same people at ROQ are in CGNI also ? Have a look at their deal tha hasn\u2019t happened either !! https://www.investegate.co.uk/announcement/rns/cardiogeni-plc--cgni/details-of-advanced-subscription-company-update/8998882 Not sure what they actually do ! Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,563",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.310838+00:00"
      },
      {
        "event_id": "SOCIAL-5Feb20261108-hamilton-64238068",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.488221",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "What makes you think they will hit the new deadline ? It\u2019s been going on over a year now. The communication is terrible. Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,563",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.310856+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20262326-leew--7041042",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.488635",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Hamilton, nothing is terminated, looks like the date was changed in the research note, which I have just noticed only as it was pointed out below. Stupid for me to have missed that, but had a huge amount going on. Not brilliant to have communicated it there but is what it is so we move on with 2 dates close together now :)",
          "sentiment": 0.0,
          "engagement": "2,659",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.310873+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20261258-hamilton--6638416",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.489050",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "Looks like the deal has terminated then ? They did this last year with the Oncogeni sale. It had a deadline and they ended talks but we didn\u2019t find out till months later. If no rns then can only assume the worst ? Poor ! Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,563",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.310891+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260830-billy101--7571436",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.489492",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "The RN laid it all out. The bit we are interested in the financials etc  can get losted in the impress pathways we have. Lets hope it comes together.",
          "sentiment": 0.0,
          "engagement": "31,754",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.310908+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260823-Downagai--3215409",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.489897",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "If it is then to hide that in a research note is shockingly poor. Management are losing all credibility here for me I'm afraid",
          "sentiment": 0.0,
          "engagement": "939",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.310926+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260806-billy101-80529665",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.490315",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "March 16th it is then for now.",
          "sentiment": 0.0,
          "engagement": "31,754",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.310944+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260758-Downagai--3003082",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.490720",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "I seriously hope so but have my doubts",
          "sentiment": 0.0,
          "engagement": "939",
          "price_at_post": "1.60",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.310962+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260751-Dicko80-66911661",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.491148",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dicko80",
          "content": "Previously the extensions have come in advance of the date So with no ext announced Maybe they are closing their financing and close to completion Hence no RNS as of yet \ud83e\udd1e",
          "sentiment": 0.0,
          "engagement": "2,435",
          "price_at_post": "1.60",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.310979+00:00"
      },
      {
        "event_id": "SOCIAL-3Feb20260737-Downagai-70141339",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.491552",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Tumbleweed \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "939",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.310997+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20260855-Dicko80-91102043",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.491952",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dicko80",
          "content": "Im sure we\u2019ll find out soon enough",
          "sentiment": 0.0,
          "engagement": "2,435",
          "price_at_post": "1.25",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.311015+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20260727-leew--3591935",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.492377",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Must admit I was expecting an RNA today. Unless it drops at 7.30 for various reasons :)",
          "sentiment": 0.0,
          "engagement": "2,659",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.311033+00:00"
      },
      {
        "event_id": "SOCIAL-2Feb20260720-hamilton-21221135",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.492790",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "No rns ? Not sure what\u2019s going on now. Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,563",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.311050+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260823-Downagai--2912607",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.493218",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "I started worrying when emails started being ignored tbh this os farcical now",
          "sentiment": 0.0,
          "engagement": "939",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.311068+00:00"
      },
      {
        "event_id": "SOCIAL-30Jan20260742-pumpky--4019258",
        "event_type": "social_post",
        "date": "2026-02-06T22:55:35.493624",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Monday then \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,738",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.311086+00:00"
      },
      {
        "event_id": "SOCIAL-Today0823-Downagai--2912607",
        "event_type": "social_post",
        "date": "2026-01-30T23:00:14.646540",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "I started worrying when emails started being ignored tbh this os farcical now",
          "sentiment": 0.0,
          "engagement": "920",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.311121+00:00"
      },
      {
        "event_id": "SOCIAL-Today0742-pumpky--4019258",
        "event_type": "social_post",
        "date": "2026-01-30T23:00:14.647111",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Monday then \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,680",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.311141+00:00"
      },
      {
        "event_id": "SOCIAL-29Jan20260849-bbr391-59351124",
        "event_type": "social_post",
        "date": "2026-01-30T23:00:14.647545",
        "source": "LSE_CHAT",
        "data": {
          "author": "bbr391",
          "content": "Will this old dog ever have It`s day You Decide Outstanding  ( perhaps )",
          "sentiment": 0.0,
          "engagement": "8,994",
          "price_at_post": "1.30",
          "thread_title": "Old Dogs & Englishmen",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=CFBF3BDA-6A27-4675-B082-EFC47765863B"
        },
        "ingested_at": "2026-02-11T16:56:25.311159+00:00"
      },
      {
        "event_id": "SOCIAL-Today0849-bbr391-59351124",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.705516",
        "source": "LSE_CHAT",
        "data": {
          "author": "bbr391",
          "content": "Will this old dog ever have It`s day You Decide Outstanding  ( perhaps )",
          "sentiment": 0.0,
          "engagement": "8,993",
          "price_at_post": "1.30",
          "thread_title": "Old Dogs & Englishmen",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=CFBF3BDA-6A27-4675-B082-EFC47765863B"
        },
        "ingested_at": "2026-02-11T16:56:25.311176+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261815-Downagai--1399640",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.706052",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Says 8 trades but only 2 showing??",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.311194+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261357-billy101-33430666",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.706616",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Will either find out Friday or Monday",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.311211+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261350-Downagai--3520548",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.707168",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "I don't think the research note it right, the dates are nonsense tbh it's really poor.",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.311229+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261338-Merciama-59168687",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.707689",
        "source": "LSE_CHAT",
        "data": {
          "author": "Merciaman",
          "content": "Agreed downagain - I saw the section from the research note that Billy points out, and expected an official confirmation from the company regarding date for the deal. In the absence of that there is clearly some uncertainty - does the 31/1 date still apply, or is it indeed a case of both deals now having a longstop date of 16/3 ?",
          "sentiment": 0.0,
          "engagement": "286",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.311248+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261234-Downagai--2943550",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.708207",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Think they just need to update clearly and transparently",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.311267+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261206-billy101-37341742",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.708763",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Separately, the Company updated the status of the sale of its subsidiary Lyramid to Pleiades, a transaction worth up to $10.8m. Because Pleiades has not yet completed its fundraising with institutional and sovereign wealth fund investors in the GCC (Gulf Cooperation Council), the longstop date has been extended to 16 March 2026. The SPA has also been amended so that Midkine Investments, rather than Roquefort Therapeutics, is now the selling entity, and to acknowledge the scheduled termination of Lyramid\u2019s third-party licence to the Midkine antibody programme in November 2025.",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "Page 7 on Research Note",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=C2F1110E-A080-4B30-BCEE-97FDD7240591"
        },
        "ingested_at": "2026-02-11T16:56:25.311285+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261142-billy101--3073334",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.709296",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Didn\u2019t he take on a NED role. Maybe wrong due to information overload.",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-11T16:56:25.311303+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261139-hamilton-58911317",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.709808",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "The RTO and the carve out are not related at all apart from being ROQ assets. The thing worrying me is why did AR sell all his shares before the Carve out entitlement date when he was the one that introduced ROQ to Pleiades, apparently ? Another extension coming no doubt. Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,547",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-11T16:56:25.311321+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261056-Downagai-57299911",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.710353",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Oops Group Restructuring The Company intends to carve out the value of the Lyramid SPA and the MK Cell Out-License for the benefit of existing shareholders and convertible loan holders. In order to facilitate this, the Company has recently undertaken the following restructuring of the Group (the \"Group Restructuring\"): a) The entire issued shares of Lyramid have been acquired by Midkine Investments (a 100% owned subsidiary of Roquefort Therapeutics) such that Lyramid is now 100% owned by Midkine Investments; and b) The rights to the MK Cell program held by Oncogeni Ltd have been novated to Midkine Investments such that Midkine Investments now holds the underlying exclusive worldwide rights to the MK Cell program. It is the intention of the Company to issue new unlisted redeemable non-voting shares (\"Unlisted RNV Shares\") to the holders of Roquefort Therapeutics ordinary shares and convertible loan notes listed on the Company's registers as at 30 November 2025. The Unlisted RNV Shares will entitle holders to all commercial benefits from Midkine Investments with the ultimate aim of undertaking an in-specie distribution of the Midkine Investments shares once the balance sheet of the Company permits such an action under the Companies Act.",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-11T16:56:25.311339+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261054-Downagai--2681729",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.711148",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "London South East Check out our new Alternative Investment section.Click here Share PricesRoquefort Thera Share PriceRoquefort Thera Share Regulatory NewsMK Cell Out-License & Lyramid SPA Update Pin to quick picksRoquefort Thera Regulatory News (ROQ) ROQ Share Price ROQ Share Price ROQ Share News ROQ Share News ROQ Share Chat ROQ Share Chat 10 ROQ Share Trades ROQ Share Trades ROQ Live RNS ROQ Live RNS Sponsored Content Roquefort Thera Information Add ROQ to Timeline Add ROQ to Timeline Add ROQ to Watchlist Add ROQ to Watchlist Add ROQ to Alert Add ROQ to Alert Buy ROQ Shares Buy ROQ Shares Share Price Information for Roquefort Thera (ROQ) Share Price is delayed by 15 minutes Get Live Data 1.30 0.00 (0.00%) Bid: 1.20 Ask: 1.40 Spread: 0.20 (16.667%)Market Cap: \u00a32.13m ROQ Live PriceLast checked at 10:53:52London Stock Exchange Sponsored Content MK Cell Out-License & Lyramid SPA Update 3 Nov 2025 07:00 RNS Number : 8172F Roquefort Therapeutics PLC 03 November 2025 3 November 2025 Roquefort Therapeutics plc (\"Roquefort Therapeutics\" or the \"Company\") MK Cell Out-License & Lyramid SPA Update Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces it has entered into an agreement to out-license its MK Cell patents to Pleiades Pharma Ltd (\"Pleiades\") in return for up to US$25 million in milestone cash payments together and a royalty payment obligation (the \"MK Cell Out-License\"). Background As announced on 8 September 2025, the Company is proposing to acquire from A2A Pharmaceuticals, Inc. and Coiled Therapeutics, Inc. the exclusive licence rights to AO-252, a novel first-in-class, first-in-human new drug alternative targeting the TACC3 protein for the treatment of certain cancers (the \"Proposed Transaction\"), retain the STAT-6 program and has ceased discussions around the sale of its wholly owned subsidiary Oncogeni Ltd. Further details on the progress of the Proposed Transaction will be announced in due course. Following the announcement of the Proposed Transaction, the Company initiated discussions with Pleiades regarding the grant of an exclusive worldwide license for its MK Cell program, which has resulted in the signing of the MK Cell Out-License. MK Cell Out-License To accommodate the Group Restructuring (refer below) that was signalled in August 2025, the parties to the MK Cell Out-License are Roquefort Therapeutics' wholly owned subsidiary Midkine Investments Ltd (\"Midkine Investments\") and Pleiades. The consideration payable by Pleiades for the MK Cell Out-License is a combination of milestone cash payments and a royalty payment obligation of 1.5% perpetuity royalty on all global net sales of products derived from the licensed technology. The total milestone cash payments of up to US$25 million is payable by Pleiades as follows: a) US$500,000 upon Pleiades securing a minimum fundraising",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-11T16:56:25.311357+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261043-billy101-51688663",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.711670",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Sorry not RTO shares should have put  Unlisted RNV Shares",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-11T16:56:25.311375+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261026-billy101-77939088",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.712198",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Lets hope so. However MK will only happen up on condition of Coil happening otherwise there is no point. ROQ doesn't benefit only the RTO holders. Personally I want the RTO regardless of Coil. Compnaies House registers have all been updated we are just waiting for a completion of something (deal) otherwise we would have had our allocation of RTO shares of 10:1 by now.",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-11T16:56:25.311392+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20261003-Downagai--6115626",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.712701",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "No that's not right, the deals are not linked, funding due this week",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-11T16:56:25.311410+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260947-billy101-59928386",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.713218",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Otherwsie no split required. ROQ will remain one entity with just Pleiades deal.",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-11T16:56:25.311428+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260943-billy101-63252102",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.713754",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "The research note has implied the deal(s) have been extended to 16th March. Surely MK will only happen if Coil completes.",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-11T16:56:25.311445+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260915-Escapeto--6153352",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.714286",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Delay... They never fail on that one.",
          "sentiment": 0.0,
          "engagement": "1,307",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-11T16:56:25.311463+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260810-Downagai-62498570",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.714786",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Tbh given this is carved off it shouldn't technically affect the Roq price anyway hut would be nice to conclude the free shares and understand what is actually going on",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-11T16:56:25.311481+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260753-Downagai-32456598",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.715339",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "No way I see this sorted this week. If funding was coming after a year they would not be this close to the wire injo",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.45",
          "thread_title": "RE: Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-11T16:56:25.311499+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260751-mnsa--4018455",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.715754",
        "source": "LSE_CHAT",
        "data": {
          "author": "mnsa",
          "content": "Let\u2019s hope for once the deliver on the deadline given! If they do this should recover very well! Hoping for some +ve!",
          "sentiment": 0.0,
          "engagement": "311",
          "price_at_post": "1.60",
          "thread_title": "Hoping for some good news it\u2019s been a long grind!",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=B7DEA3B8-EFC3-4161-85C0-B8FCA614D2A2"
        },
        "ingested_at": "2026-02-11T16:56:25.311516+00:00"
      },
      {
        "event_id": "SOCIAL-28Jan20260721-hamilton--8075292",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.716197",
        "source": "LSE_CHAT",
        "data": {
          "author": "hamiltonbro",
          "content": "Anyone heard from the company or seen anything ? Literally can\u2019t be bothered with another extension. Nai/DYOR",
          "sentiment": 0.0,
          "engagement": "3,547",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-11T16:56:25.311534+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20261158-Downagai-64292315",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.716610",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "4 more days \ud83d\ude2c",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-11T16:56:25.311552+00:00"
      },
      {
        "event_id": "SOCIAL-26Jan20260858-pumpky--5230801",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:24.717023",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Billy Yes invested in January due to their RNS",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-11T16:56:25.311570+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20262322-Escapeto--7979366",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:27.301413",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Huge bull market for biotech , roq at all time low.",
          "sentiment": 0.0,
          "engagement": "1,307",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-11T16:56:25.311588+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261742-pumpky-68149946",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:27.301822",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Read them and what? SP Angel are the Brokers  for Roquefort \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-11T16:56:25.311605+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261447-billy101-80499683",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.001123",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Read pages 28 and 29",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-11T16:56:25.311623+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261350-Escapeto-90260780",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.001936",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "They'll miss it.",
          "sentiment": 0.0,
          "engagement": "1,307",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-11T16:56:25.311641+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261326-pumpky-12793342",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.002732",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Pileades deal 16  March ?",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-11T16:56:25.311659+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261315-billy101--9216936",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.003543",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Could go in until 16th March",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-11T16:56:25.311676+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261257-pumpky--8295994",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.004326",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "3rd November RNS Caroline Fortier  We anticipate the round of funding to be completed before the Long stop date of 31Januaey 2026",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-11T16:56:25.311694+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261256-Escapeto--2180566",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.005138",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "Disappointed \ud83d\ude1e. DOWN.",
          "sentiment": 0.0,
          "engagement": "1,307",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-11T16:56:25.311712+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261253-pumpky--2070313",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.005910",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "IF being the operative word \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-11T16:56:25.311730+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261147-Downagai--4567954",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.006712",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Well with all the fanfare around this never thought I'd be able to buy under 1.2p. If the deal happens near 50% upside straight away. What not to like \ud83d\ude03\ud83d\ude80",
          "sentiment": 0.5,
          "engagement": "864",
          "price_at_post": "1.20",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-11T16:56:25.311747+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20261029-Aklee--7961277",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.007517",
        "source": "LSE_CHAT",
        "data": {
          "author": "Aklee",
          "content": "I see Davey is here peddling his usual nonsense. Be careful on any share he is in. Always sells into the smallest rise whilst claiming it's someone else",
          "sentiment": 0.0,
          "engagement": "3,597",
          "price_at_post": "1.25",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-11T16:56:25.311765+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20261212-Downagai--7964540",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.008304",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Wow how to lose \u00a3730 in 3 hours. Unlucky trader Sam \ud83e\udd26\u200d\u2642\ufe0f",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.30",
          "thread_title": "Loss",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=A17EF4D3-D0D3-4793-A674-53112286A2B2"
        },
        "ingested_at": "2026-02-11T16:56:25.311783+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260826-billy101-28590106",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.009089",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Only issue I have with todays RNS(RESEARCH NOTE) . It should have been released in November.",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.30",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-11T16:56:25.311800+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260806-billy101-11720944",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.009911",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "Keeping this short and brief for us investors page 7 matters. And if they tick all the boxes with TACC3 Inhibitor thats mentioned on page 14 then were off to the moon. The rest of the read research note is for my daughters and son in law to translate to me!",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.20",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-11T16:56:25.311818+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260805-davey50-76557900",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.010700",
        "source": "LSE_CHAT",
        "data": {
          "author": "davey50",
          "content": "Just play the game, buy them when totally unloved and sell them when the shares are spiking and the herd arrives rinse and repeat. I took 500k more at the bell 1.23p ish...what a price...they were chasing this up to 2.5p not long ago",
          "sentiment": 0.0,
          "engagement": "7,050",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-11T16:56:25.311835+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260804-leew--6689312",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.011498",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Well digesting the financial pages was my first port of call and to be honest the purchase price we are paying is very reasonable and if the shares are issued at 1.7 as adv used then on the RTO I see some potential for immediate upside with no real news other than we have done the RTO and its purchase value. Add that to then normal news on progression in phase 1 and beyond we could see some very good gains. Will need to digest the technical aspect later but form investment strategy I am happy",
          "sentiment": 0.0,
          "engagement": "2,632",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-11T16:56:25.311853+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260756-bbr391--1006819",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.012391",
        "source": "LSE_CHAT",
        "data": {
          "author": "bbr391",
          "content": "Progress to date Roquefort has demonstrated significant anti-cancer activity with its STAT-6 siRNA therapeutics, as validated in in vivo models of breast and colon cancer. These results further reinforce the potential of STAT-6 targeting approaches in multiple tumour types and provide a strong foundation for advancing this programme towards clinical evaluation. STAT-6 targeting siRNA constructs have shown significant in vivo anti-cancer activity in validated models of colon cancer. STAT-6 siRNAs demonstrated a significant reduction in the proliferation of colorectal cancer with a ca.50% reduction in cell growth at seven days. This anti-cancer effect was replicated in a validated in vivo model of colorectal cancer with a significant reduction in cancer weight and volume over 28 days As usual . One feels the Americans are getting good research at a very very very low cost . Outstanding",
          "sentiment": 0.5,
          "engagement": "8,993",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-11T16:56:25.311870+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260751-billy101--4190574",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.013194",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "There is alot in there, so they have starteed the PR now. The Key milestone dates for 2025-2027 and Financial valuation on page 4 will keep investors happy. Its a long read",
          "sentiment": 0.0,
          "engagement": "31,718",
          "price_at_post": "1.00",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-11T16:56:25.311888+00:00"
      },
      {
        "event_id": "SOCIAL-15Jan20260739-Downagai-40591886",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.013953",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "That'd an easy read. Nothing new really though that I can see",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.20",
          "thread_title": "RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-11T16:56:25.311906+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261116-cassdav5-96212637",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.014729",
        "source": "LSE_CHAT",
        "data": {
          "author": "cassdav57",
          "content": "Yes pumpky your correct.  My bad, brain fog on different aspects of deal and moving targets. The deal requires ROQ's enlarged share capital to be admitted to trading on AIM by this new March 16, 2026 deadline to complete the transaction. So they have about 2 more months to finalize everything and get the AIM listing done.",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-02-11T16:56:25.311924+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20261027-Merciama-78264951",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.015502",
        "source": "LSE_CHAT",
        "data": {
          "author": "Merciaman",
          "content": "It is Pumpky, 31/1 deadline for Pleiades to buy Lyramid from Midkine Investments. The reverse takeover of Roquefort to form Coiled Therapeutics has the 16th March deadline.",
          "sentiment": 0.0,
          "engagement": "286",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-02-11T16:56:25.311942+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260941-pumpky--5481079",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.016237",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Isnt the Pileades deal January?",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-02-11T16:56:25.311959+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260924-cassdav5--7875198",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.016655",
        "source": "LSE_CHAT",
        "data": {
          "author": "cassdav57",
          "content": "Sorry guys, Realise, The exclusivity period extended to March 16th but would still expect news by end of Jan.",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "1.20",
          "thread_title": "RE: News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-02-11T16:56:25.311977+00:00"
      },
      {
        "event_id": "SOCIAL-14Jan20260918-cassdav5--7780777",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.017066",
        "source": "LSE_CHAT",
        "data": {
          "author": "cassdav57",
          "content": "The exclusivity period should be ending soon (January 2026), so we might hear updates about whether the deal proceeds in the coming weeks. The  main hope for good news  for me was the director buy in November of 5 million shares (\u00a385k) and the calibre of the trails technology plus funding through A2A Pharmaceuticals.  So yes, definitely a waiting game, currently I am down about 50% and will be holding and making some small additions at these low or lower prices until things become clearer as upside could be considerable.",
          "sentiment": 0.0,
          "engagement": "36",
          "price_at_post": "1.20",
          "thread_title": "News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=3B6DA647-3006-47E9-8E32-7519552A1ECB"
        },
        "ingested_at": "2026-02-11T16:56:25.311994+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261743-Downagai-57846849",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.017500",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "True enough",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.20",
          "thread_title": "RE: Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-02-11T16:56:25.312012+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261714-pumpky--5366429",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.017906",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "What is there to say? Just waiting for news",
          "sentiment": 0.0,
          "engagement": "17,655",
          "price_at_post": "1.20",
          "thread_title": "RE: Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-02-11T16:56:25.312030+00:00"
      },
      {
        "event_id": "SOCIAL-13Jan20261649-Downagai--4021538",
        "event_type": "social_post",
        "date": "2026-01-29T09:59:32.018342",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Quiet here \ud83d\ude34",
          "sentiment": 0.0,
          "engagement": "864",
          "price_at_post": "1.20",
          "thread_title": "RE: Uptick",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&share=ROQ&thread=601148D8-ABF5-4F66-88CC-388368E1BBD0"
        },
        "ingested_at": "2026-02-11T16:56:25.312047+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261617-Downagai-87446471",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.113544",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Big sell 3 big buys?",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-11T16:56:25.312065+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261505-billy101-88147435",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.113993",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "What\u2019s another few months. Have you been in since Jan 25?",
          "sentiment": 0.0,
          "engagement": "31,698",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-11T16:56:25.312082+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261504-pumpky-40404794",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.114430",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Deal  has been going on since January 2025",
          "sentiment": 0.0,
          "engagement": "17,626",
          "price_at_post": "1.30",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-11T16:56:25.312122+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20261425-leew-62647113",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.114946",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Could be a delay or could happen on time, funding is never a simple process having been involved myself. The access to the data room and the DD questions from all parties is always significant. Just wait for the confirmation, because all that is needed is patience with ROQ in my view.",
          "sentiment": 0.0,
          "engagement": "2,618",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-11T16:56:25.312144+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260859-davey50--2270441",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.115405",
        "source": "LSE_CHAT",
        "data": {
          "author": "davey50",
          "content": "1.23-1.35p online so mid price to buy, not a bad price for a gamble given it's history of spikes",
          "sentiment": 0.0,
          "engagement": "7,037",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-11T16:56:25.312162+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260806-pumpky-26025056",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.115821",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Anticipate not expect \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "17,626",
          "price_at_post": "1.45",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-11T16:56:25.312179+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260726-Downagai--5272966",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.116249",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Apparently a couple of days is aay ahead \ud83d\ude02",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-11T16:56:25.312197+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260725-pumpky-25590036",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.116661",
        "source": "LSE_CHAT",
        "data": {
          "author": "pumpky",
          "content": "Caroline Fortier We expect to finalise before the 31 January date\" Expect\" Get out card ( maybe delayed due to Trump wanting Greenland \ud83d\ude02)",
          "sentiment": 0.0,
          "engagement": "17,626",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-11T16:56:25.312215+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260725-Downagai-37703945",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.117079",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "No Dicko after all \"Caroline Fortier, Pleiades CEO commented: \"Following the previously announced acquisition of Lyramid, we are delighted to build on our relationship with Roquefort Therapeutics and take an exclusive license of the MK Cell therapy asset which we plan to take into clinical studies targeting high value oncology indications of unmet need. The addition of these assets to our immunotherapy, late-stage pan-specific vaccine and cell therapy portfolio is an important part of our strategy to position ourselves as a material biotechnology company to institutional investors with whom we are currently working to close on a significant equity funding round. In alignment with the extension of the Lyramid SPA we anticipate our funding round to complete ahead of the new 31 January 2026 long stop date.\"",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-11T16:56:25.312233+00:00"
      },
      {
        "event_id": "SOCIAL-23Jan20260720-Dicko80--6278826",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.117508",
        "source": "LSE_CHAT",
        "data": {
          "author": "Dicko80",
          "content": "What\u2019s the betting they\u2019ll be another extension to us getting our shares ? 1 week deadline",
          "sentiment": 0.0,
          "engagement": "2,427",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-11T16:56:25.312250+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20262142-leew--2299209",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.117916",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Well there is a lot of news due bbr, would be great to get the RTO confirmed and initially just get the SP back to 1.7p and then see where the RTO then takes it as there is some potential for increasing in market cap after so fingers crossed. Would also be good on the back of that to then here about the spin off and the deals associated to that to see when some cash might come in from the free shares.",
          "sentiment": 0.0,
          "engagement": "2,618",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-11T16:56:25.312267+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20262130-leew--8017815",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.118340",
        "source": "LSE_CHAT",
        "data": {
          "author": "leew",
          "content": "Honestly if you want to invest best check yourself. I don\u2019t think reading a few RNA\u2019s and googling a few things is that bad.",
          "sentiment": 0.0,
          "engagement": "2,618",
          "price_at_post": "1.35",
          "thread_title": "RE: Can",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=28165808-701F-48DA-95C7-867899DCB7C6"
        },
        "ingested_at": "2026-02-11T16:56:25.312285+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261653-Kikudi-62653887",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.118754",
        "source": "LSE_CHAT",
        "data": {
          "author": "Kikudi",
          "content": "Some please give me highlights of ROQ that will save me go through  RNS I want to invest. Thanks in advance",
          "sentiment": 0.0,
          "engagement": "15",
          "price_at_post": "1.35",
          "thread_title": "Can",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=28165808-701F-48DA-95C7-867899DCB7C6"
        },
        "ingested_at": "2026-02-11T16:56:25.312302+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261338-Downagai--6783475",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.119177",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "IYHO I take it \ud83d\ude03",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.35",
          "thread_title": "RE: Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-11T16:56:25.312319+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20261337-bbr391-74492291",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.119594",
        "source": "LSE_CHAT",
        "data": {
          "author": "bbr391",
          "content": "Come to Papa . We will all soon be very very pleased (possibly). Outstanding",
          "sentiment": 0.5,
          "engagement": "8,990",
          "price_at_post": "1.35",
          "thread_title": "Good News",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=3E9F2776-6B87-484F-A3BD-52B5D8F1F6EE"
        },
        "ingested_at": "2026-02-11T16:56:25.312336+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260911-SharePic--5007555",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.120004",
        "source": "LSE_CHAT",
        "data": {
          "author": "SharePicks",
          "content": "I've added this to portfolio. Lets see where it goes.",
          "sentiment": 0.0,
          "engagement": "1,198",
          "price_at_post": "1.30",
          "thread_title": "1.5p",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=EC7A8D0C-531B-4D1D-A5F0-14D0049CD3D9"
        },
        "ingested_at": "2026-02-11T16:56:25.312354+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260903-davey50--9145800",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.120420",
        "source": "LSE_CHAT",
        "data": {
          "author": "davey50",
          "content": "Just need to clear the slack below 1.4p and then the herd will arrive, if trls can do 300% then roq is always good for a spike a few times a year",
          "sentiment": 0.0,
          "engagement": "7,037",
          "price_at_post": "1.30",
          "thread_title": "RE: ROQ",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=34D50F4B-4B38-438B-BCC4-912454A889E9"
        },
        "ingested_at": "2026-02-11T16:56:25.312372+00:00"
      },
      {
        "event_id": "SOCIAL-21Jan20260813-SharePic--2028729",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.120830",
        "source": "LSE_CHAT",
        "data": {
          "author": "SharePicks",
          "content": "Good start so far today.",
          "sentiment": 0.0,
          "engagement": "1,198",
          "price_at_post": "1.15",
          "thread_title": "ROQ",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=34D50F4B-4B38-438B-BCC4-912454A889E9"
        },
        "ingested_at": "2026-02-11T16:56:25.312389+00:00"
      },
      {
        "event_id": "SOCIAL-20Jan20260756-Downagai--1717479",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.121244",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "Interesting pre market spread today. I wish",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.60",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-11T16:56:25.312407+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260840-billy101-83183638",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.121680",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "We will get updates on deals when and if  they are complete. They can't keep doing a running commentary on progress of deals. We have been told the aims in the R/Note. We have split Mk(nearly) upon condition of Coil happening. We are in different phases in trials. Anything else is conjecture. Whilst this is happening its stalemate on all pathways.",
          "sentiment": 0.0,
          "engagement": "31,698",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-11T16:56:25.312424+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260834-Downagai-89480453",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.122092",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "About progess on the deals? What page please I missed that thanks",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-11T16:56:25.312442+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260810-billy101-27566967",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.122513",
        "source": "LSE_CHAT",
        "data": {
          "author": "billy101203",
          "content": "We had news last wek in R/note.",
          "sentiment": 0.0,
          "engagement": "31,698",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-11T16:56:25.312460+00:00"
      },
      {
        "event_id": "SOCIAL-19Jan20260730-Downagai-34822180",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.122926",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "They need to provide an update, this radio silence is very poor",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-11T16:56:25.312477+00:00"
      },
      {
        "event_id": "SOCIAL-17Jan20260249-Escapeto--4059118",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.123352",
        "source": "LSE_CHAT",
        "data": {
          "author": "Escapetohome",
          "content": "I'm hopeful, but not convinced this team can build value. I'm not sure what it is but just look at the history for starters. Continual missed deadlines. At the very least don't make a rod for your back with deadlines you never keep.",
          "sentiment": 0.0,
          "engagement": "1,297",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-11T16:56:25.312495+00:00"
      },
      {
        "event_id": "SOCIAL-16Jan20262335-Downagai-25524014",
        "event_type": "social_post",
        "date": "2026-01-24T01:40:09.123758",
        "source": "LSE_CHAT",
        "data": {
          "author": "Downagain",
          "content": "It's because they keep promising the earth and delivering nothing with no updates and just delays",
          "sentiment": 0.0,
          "engagement": "788",
          "price_at_post": "1.15",
          "thread_title": "RE: RNS",
          "thread_url": "https://www.lse.co.uk/ShareChat.html?ShareTicker=ROQ&thread=091D7014-CFFA-4FA8-9F90-B158D432ECBF"
        },
        "ingested_at": "2026-02-11T16:56:25.312512+00:00"
      }
    ],
    "catalyst_dates": {
      "proxy_date": "2025-11-27"
    }
  },
  "ai_insights": {
    "key_insights": [],
    "hidden_patterns": [],
    "contrarian_signals": [],
    "risk_warnings": [],
    "opportunity_flags": [],
    "narrative_summary": "ROQ.L presents a standard crash recovery setup without unusual patterns detected. Monitor for catalyst developments and trend shifts.",
    "_is_real": false
  },
  "crashdash": {
    "industry_intelligence": {
      "category": "BIOTECH_PHARMA",
      "name": "Biotech & Pharma",
      "icon": "\ud83e\uddec",
      "color": "#10b981",
      "crash_patterns": [
        "Clinical trial failures (Phase 1/2/3)",
        "FDA/EMA rejection or delay",
        "Safety concerns or adverse events",
        "Patent expiry or IP challenges",
        "Funding gaps (cash runway concerns)"
      ],
      "recovery_paths": [
        "Positive trial data (efficacy endpoints met)",
        "Regulatory approvals (FDA/EMA)",
        "Partnership deals (big pharma licensing)",
        "Orphan drug designation or fast track",
        "New trial initiations (pipeline expansion)"
      ],
      "active_patterns": [
        "Clinical trial failures (Phase 1/2/3)",
        "FDA/EMA rejection or delay"
      ],
      "relevant_rns_count": 1,
      "key_metrics": [
        "Clinical stage (preclinical, Phase 1/2/3, commercialized)",
        "Cash runway (months until next funding)",
        "Addressable market size (indication)",
        "Trial enrollment progress",
        "Intellectual property strength"
      ]
    },
    "panic_analysis": {
      "panic_score": 45.2,
      "signal": "MODERATE_FEAR",
      "interpretation": "\ud83d\udfe1 Cautious sentiment - assess risk/reward",
      "breakdown": {
        "price_destruction": 11.2,
        "volume_death": 18,
        "social_silence": 6,
        "news_sentiment": 10
      },
      "is_opportunity": false,
      "opportunity_reason": "\ud83d\udcca Moderate fear detected - monitor for escalation"
    },
    "fear_vs_facts": {
      "fear_points": [
        "\ud83d\udcc9 Volume death: 18/20 points"
      ],
      "facts_points": [
        "\ud83d\udcc8 Historical upside: 104% proven capacity"
      ],
      "verdict": "\u2696\ufe0f Mixed signals - Fear and facts balanced, wait for clarity"
    },
    "crashhunter_signals": [
      {
        "type": "EARLY",
        "icon": "\u23f0",
        "text": "Too Early",
        "color": "#3b82f6"
      },
      {
        "type": "MODERATE_QUALITY",
        "icon": "\ud83c\udf1f",
        "text": "APEX 50",
        "color": "#3b82f6"
      }
    ],
    "catalyst_pipeline": [
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Research Note Published",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Clinical Trial & License Agreement Update",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Conversion of CLNs",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Ex-Entitlement Date - Unlisted RNV Shares",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "Unknown",
        "title": "Determination of Record Date and Entitlement",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "expected",
        "date": "Expected soon",
        "title": "Watch for: Funding announcement or operational update",
        "status": "pending",
        "icon": "\ud83d\udd2e"
      },
      {
        "type": "expected",
        "date": "Expected soon",
        "title": "Watch for: Volume expansion confirmation",
        "status": "pending",
        "icon": "\ud83d\udd2e"
      }
    ],
    "decision_matrix": {
      "decision": "WATCH",
      "reason": "\u23f3 Monitor for timing regime change or panic escalation",
      "checklist": [
        {
          "criterion": "Panic Score",
          "value": "45/100",
          "pass": false,
          "icon": "\ud83d\udfe2"
        },
        {
          "criterion": "Timing Regime",
          "value": "TOO_EARLY",
          "pass": true,
          "icon": "\u2705"
        },
        {
          "criterion": "APEX Quality",
          "value": "50/100",
          "pass": true,
          "icon": "\u2b50"
        },
        {
          "criterion": "Data Confidence",
          "value": "40/100",
          "pass": true,
          "icon": "\ud83c\udfaf"
        },
        {
          "criterion": "Industry Pattern",
          "value": "2 active",
          "pass": true,
          "icon": "\ud83e\uddec"
        }
      ],
      "pass_rate": "4/5"
    },
    "contrarian_panic": {
      "total_score": 27,
      "band": "\u26aa LOW COMPRESSION (Early/Weak)",
      "components": {
        "compression": {
          "score": 10,
          "max": 40,
          "signals_30d": 3,
          "signals_60d": 3,
          "signals_90d": 4,
          "signals_per_week": 0.31,
          "total_signals": 5,
          "rsi_extreme_count": 4,
          "rsi_ultra_count": 1,
          "escalation_count": 0,
          "density_score": 3,
          "rsi_score": 7,
          "escalation_score": 0,
          "description": "0.3 signals/week | 4 RSI<20 | \ud83c\udfaf MILD COMPRESSION"
        },
        "intensification": {
          "score": 5,
          "max": 20,
          "recent_types": [
            "CRASH ZONE BOTTOM",
            "CRASH ZONE BOTTOM",
            "CRASH ZONE BOTTOM"
          ],
          "escalating": false,
          "sustained": false,
          "current_intensity": 1,
          "pattern": "NORMAL CRASH LEVEL"
        },
        "volume_death": {
          "score": 8,
          "max": 15,
          "relative_volume": 6.94,
          "description": "High volume - Panic spike or interest"
        },
        "pop_potential": {
          "score": 4,
          "max": 15,
          "best_historical_rally": 112.0,
          "avg_rally": 94.4,
          "signal_count": 5,
          "description": "Baseline mover (112%)"
        },
        "accumulation": {
          "score": 0,
          "max": 10,
          "has_accumulation": false,
          "bars_since_accum": 0,
          "description": "No accumulation detected"
        }
      },
      "ticker": "ROQ.L",
      "signal_date": "2025-08-28",
      "total_signals_history": 5
    }
  },
  "scoring_breakdown": {
    "apex_factors": [
      "Technical quality: +11 (AI_Technical_Score=9.0/20)",
      "Drawdown reversion potential: +16 (Drawdown_Pct=80.8%)",
      "Volume confirmation: +10 (Relative_Volume=6.9)",
      "Pattern reliability: +5 (Rally_Count=1.0)",
      "Upside history: +8 (best_rally_pct=104%)"
    ],
    "technical_score": {
      "points": 11,
      "ai_score": 9.0,
      "reason": "AI Technical Score 9.0/20 translates to 11/25 points"
    },
    "drawdown_score": {
      "points": 16,
      "drawdown_pct": 80.81,
      "reason": "Drawdown of 80.8% gives 16/20 points"
    },
    "volume_score": {
      "points": 10,
      "rel_volume": 6.94,
      "reason": "Relative volume 6.94x gives 10 points"
    },
    "pattern_score": {
      "points": 5,
      "rally_count": 1.0,
      "reason": "1.0 historical rallies gives 5/15 points"
    },
    "upside_score": {
      "points": 8,
      "best_rally_pct": 103.85,
      "reason": "Best rally of 104% gives 8/20 points"
    },
    "penalties": {
      "total": 0,
      "items": []
    }
  },
  "reasons_buy_sell": {
    "reasons_to_buy": [
      {
        "reason": "Early stage positioning offers best R:R if catalysts appear",
        "tag": "MED",
        "evidence": [
          "timing_regime=TOO_EARLY",
          "current_return_pct=-5.8%"
        ]
      },
      {
        "reason": "Proven winner - previously hit lock-in target",
        "tag": "MED",
        "evidence": [
          "lock_in_reached=True"
        ]
      }
    ],
    "reasons_to_sell": [
      {
        "reason": "Stale signal - not for active trading",
        "tag": "HIGH",
        "evidence": [
          "status=historical",
          "signal_date=2025-08-28"
        ]
      }
    ]
  },
  "trade_plan": {
    "trader_plan": {
      "style": "Watch / Starter",
      "action": "Wait for base + catalyst confirmation; starter position only",
      "sizing": "0-1% until CONFIRMED",
      "risk": "Invalidation = breaks recent lows / dilution / suspension",
      "profit_taking": "Scale out 25% at +15%, 25% at +50%, runner above"
    },
    "investor_plan": {
      "allowed": false,
      "thesis_conditions": "Unlock after AI triangulation + CONFIRMED timing",
      "hold_window": "N/A",
      "risk_management": "N/A"
    }
  },
  "exhaustion": {
    "regime": "TOO_EARLY",
    "run_multiple": -0.06,
    "current_run_pct": -5.77,
    "avg_historical_run_pct": 103.85
  },
  "history_snapshot": {
    "previous_report_date": null,
    "score_change": null,
    "confidence_change": null,
    "new_events_count": 0,
    "new_rns_titles": []
  },
  "commentary": {
    "executive_summary": "This report runs in HISTORICAL-ONLY mode: triangulation (RNS/social/trends) not loaded. The setup shows TOO_EARLY timing with 50/100 APEX score. Historical data shows 1 rallies averaging 104% upside. Current position: -5.8%. Your edge comes from waiting for AI Engine confirmation instead of blind entry.",
    "bull_case": [
      "Early regime often offers best risk/reward"
    ],
    "bear_case": [
      "TOO_EARLY means you can get chopped before real move"
    ],
    "timing_translation": "It might be starting, but not proven yet. Wait for base + volume + catalysts.",
    "confidence_explained": "Confidence 40/100 reflects full data quality with triangulation loaded."
  },
  "data_quality": {
    "sources_present": {
      "snapshot_json": false,
      "daily_enrichment_row": true,
      "historical_profile": true,
      "metadata": true,
      "triangulation_events": true,
      "ai_insights": true
    },
    "missing_data": [
      "AI insights from Groq LLM"
    ],
    "confidence_impact": "HIGH",
    "disclaimer": "Data provided as-is. Not financial advice. AIM micro-caps carry significant volatility risk."
  },
  "report_version": "5.0",
  "comprehensive_apex": {
    "score": 50,
    "rating": "MODERATE",
    "color": "#f59e0b",
    "calculation": "APEX Score: 50/100",
    "components": {
      "setup": {
        "score": 44,
        "weight": 0.25
      },
      "trust": {
        "score": 40,
        "weight": 0.2
      },
      "panic": {
        "score": 45.2,
        "weight": 0.3
      },
      "compression": {
        "score": 27,
        "weight": 0.25
      }
    },
    "timing": {
      "regime": "TOO_EARLY",
      "multiplier": 1.0
    }
  }
};</script>
  <script src="../../apex_trust_panel.js"></script>
</body>
</html>
